Asymmetric Synthesis of Bioactive Molecules and Methodologies Involving Oxidative Functionalization of Alkanes, Alkenes and Hydrosilylation of Ketones

A THESIS

SUBMITTED FOR THE DEGREE OF

DOCTOR OF PHILOSOPHY

(IN CHEMISTRY)

To UNIVERSITY OF PUNE

By

Pandurang Vilasrao Chouthaiwale

UNDER THE GUIDANCE OF Dr. A. Sudalai

Chemical Engineering and Process Development Division National Chemical Laboratory Pune- 411008, INDIA

March 2011



DEDICATED TO MY BELOVED FAMILY MEMBERS AND FRIENDS



NATIONAL CHEMICAL LABOATORY Dr. A. Sudalai Scientist Chemical Engineering & Process Development Division, Pune – 411 008, India Phone (O) : 0091-20-25902174, Fax: 0091-20-25902676, e-mail: a.sudalai@ncl.res.in

CERTIFICATE

Certified that the work incorporated in the thesis entitled "Asymmetric Synthesis of Bioactive Molecules and Methodologies Involving Oxidative Functionalization of Alkanes, Alkenes and Hydrosilylation of Ketones" was carried out by the candidate under my supervision. Such material as had been obtained from other sources has been duly acknowledged in the thesis.

March 2011 Pune

(**Dr. A. Sudalai**) Research Supervisor



NATIONAL CHEMICAL LABORATORY

DECLARATION

I here by declare that the thesis entitled "Asymmetric Synthesis of Bioactive Molecules and Methodologies Involving Oxidative Functionalization of Alkanes, Alkenes and Hydrosilylation of Ketones" submitted for the degree of Doctor of Philosophy in Chemistry to the University of Pune, has not been submitted by me to any other university or institution. This work was carried out at the National Chemical Laboratory, Pune, India.

March 2011 Pune Pandurang Vilasrao Chouthaiwale CE & PD Division National Chemical Laboratory Pune – 411 008

CONTENTS

	Page No.
Acknowledgements	i
Abbreviations	iii
General Remarks	V
Abstract	vi

Epoxides: A Short Enantioselective Synthesis of (+)-Epi- cytoxazone, (-)-Cytoxazone and (+)-2-OxazolidoneSection ICobalt-catalyzed hydrolytic kinetic resolution of azido epoxides1.1.1Introduction11.1.2Hydrolytic kinetic resolution (HKR)11.1.3Review of Literature41.1.4Present Work81.1.5Results and Discussion81.1.5.1Synthesis of racemic azido epoxide91.1.5.2HKR of racemic azido epoxide131.1.6Conclusion181.1.7Experimental Section18Section IIEnantioselective synthesis of (+)-epi-Cytoxazone and (-)- Cytoxazone via hydrolytic kinetic resolution of azido epoxides251.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.5Results and Discussion361.2.6Conclusion45	Chapter I	Cobalt-catalyzed Hydrolytic Kinetic Resol	ution of Azido
Section ICobalt-catalyzed hydrolytic kinetic resolution of azido epoxides1.1.1Introduction11.1.2Hydrolytic kinetic resolution (HKR)11.1.3Review of Literature41.1.4Present Work81.1.5Results and Discussion81.1.5.1Synthesis of racemic azido epoxide91.1.5.2HKR of racemic azido epoxide131.1.6Conclusion181.1.7Experimental Section18Section IIEnantioselective synthesis of (+)-epi-Cytoxazone and (-)- Cytoxazone via hydrolytic kinetic resolution of azido epoxides1.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.5Results and Discussion361.2.6Conclusion45		Epoxides: A Short Enantioselective Synth	esis of (+)- <i>Epi</i> -
epoxides1.1.1Introduction11.1.2Hydrolytic kinetic resolution (HKR)11.1.3Review of Literature41.1.4Present Work81.1.5Results and Discussion81.1.5.1Synthesis of racemic azido epoxide91.1.5.2HKR of racemic azido epoxide91.1.5.2HKR of racemic azido epoxide131.1.6Conclusion181.1.7Experimental Section18Section IIEnantioselective synthesis of (+)-epi-Cytoxazone and (-)- Cytoxazone via hydrolytic kinetic resolution of azido epoxides251.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.5Results and Discussion361.2.6Conclusion45		cytoxazone, (-)-Cytoxazone and (+)-2-Oxazoli	done
1.1.1Introduction11.1.2Hydrolytic kinetic resolution (HKR)11.1.3Review of Literature41.1.4Present Work81.1.4.1Objective81.1.5Results and Discussion81.1.5.1Synthesis of racemic azido epoxide91.1.5.2HKR of racemic azido epoxide131.1.6Conclusion181.1.7Experimental Section18Section IIEnantioselective synthesis of (+)-epi-Cytoxazone and (-)-Cytoxazone via hydrolytic kinetic resolution of azido epoxides1.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.5Results and Discussion361.2.6Conclusion45	Section I	Cobalt-catalyzed hydrolytic kinetic resolu	ution of azido
1.1.2Hydrolytic kinetic resolution (HKR)11.1.3Review of Literature41.1.4Present Work81.1.4Objective81.1.5Results and Discussion81.1.5.1Synthesis of racemic azido epoxide91.1.5.2HKR of racemic azido epoxide91.1.6Conclusion181.1.7Experimental Section18Section IIEnantioselective synthesis of (+)-epi-Cytoxazone and (-)-Cytoxazone via hydrolytic kinetic resolution of azido epoxides1.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.5Results and Discussion361.2.6Conclusion45		epoxides	
1.1.3Review of Literature41.1.4Present Work81.1.4Objective81.1.5Results and Discussion81.1.5Results and Discussion81.1.5.1Synthesis of racemic azido epoxide91.1.5.2HKR of racemic azido epoxide131.1.6Conclusion181.1.7Experimental Section18Section IIEnantioselective synthesis of (+)-epi-Cytoxazone and (-)-Cytoxazone via hydrolytic kinetic resolution of azido epoxides1.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.5Results and Discussion361.2.6Conclusion45	1.1.1	Introduction	1
1.1.4Present Work81.1.4.1Objective81.1.5.1Results and Discussion81.1.5.1Synthesis of racemic azido epoxide91.1.5.2HKR of racemic azido epoxide131.1.6Conclusion181.1.7Experimental Section18Section IIEnantioselective synthesis of (+)-epi-Cytoxazone and (-)-Cytoxazone via hydrolytic kinetic resolution of azido epoxides1.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.5Results and Discussion361.2.6Conclusion45	1.1.2	Hydrolytic kinetic resolution (HKR)	1
1.1.4.1Objective81.1.5Results and Discussion81.1.5Synthesis of racemic azido epoxide91.1.5.1Synthesis of racemic azido epoxide131.1.5.2HKR of racemic azido epoxide131.1.6Conclusion181.1.7Experimental Section18Section IIEnantioselective synthesis of (+)-epi-Cytoxazone and (-)- Cytoxazone via hydrolytic kinetic resolution of azido epoxides1.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.5Results and Discussion361.2.6Conclusion45	1.1.3	Review of Literature	4
1.1.5Results and Discussion81.1.5.1Synthesis of racemic azido epoxide91.1.5.2HKR of racemic azido epoxide131.1.6Conclusion181.1.7Experimental Section18Section IIEnantioselective synthesis of (+)-epi-Cytoxazone and (-)- Cytoxazone via hydrolytic kinetic resolution of azido epoxides1.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.5Results and Discussion361.2.6Conclusion45	1.1.4	Present Work	8
1.1.5.1Synthesis of racemic azido epoxide91.1.5.2HKR of racemic azido epoxide131.1.6Conclusion181.1.7Experimental Section18Section IIEnantioselective synthesis of (+)-epi-Cytoxazone and (-)- Cytoxazone via hydrolytic kinetic resolution of azido epoxides1.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.5Results and Discussion361.2.6Conclusion45	1.1.4.1	Objective	8
1.1.5.2HKR of racemic azido epoxide131.1.6Conclusion181.1.7Experimental Section18Section IIEnantioselective synthesis of (+)-epi-Cytoxazone and (-)- Cytoxazone via hydrolytic kinetic resolution of azido epoxides1.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.5Results and Discussion361.2.6Conclusion45	1.1.5	Results and Discussion	8
1.1.6Conclusion181.1.7Experimental Section18Section IIEnantioselective synthesis of (+)-epi-Cytoxazone and (-)- Cytoxazone via hydrolytic kinetic resolution of azido epoxidesadd (-)-1.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.5Results and Discussion361.2.6Conclusion45	1.1.5.1	Synthesis of racemic azido epoxide	9
1.1.7Experimental Section18Section IIEnantioselective synthesis of (+)-epi-Cytoxazone and (-)- Cytoxazone via hydrolytic kinetic resolution of azido epoxides1.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.5Results and Discussion361.2.6Conclusion45	1.1.5.2	HKR of racemic azido epoxide	13
Section IIEnantioselective synthesis of (+)-epi-Cytoxazone and (-)- Cytoxazone via hydrolytic kinetic resolution of azido epoxides1.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.5Results and Discussion361.2.6Conclusion45	1.1.6	Conclusion	18
Cytoxazoneviahydrolytickineticresolutionofazidoepoxides1.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.5Results and Discussion361.2.6Conclusion45	1.1.7	Experimental Section	18
epoxides1.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.4.1Objective361.2.5Results and Discussion361.2.6Conclusion45	Section II	Enantioselective synthesis of (+)-epi-Cytox	azone and (-)-
1.2.1Introduction251.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.4.1Objective361.2.5Results and Discussion361.2.6Conclusion45		Cytoxazone <i>via</i> hydrolytic kinetic resolu	ution of azido
1.2.2Pharmacology of cytoxazone251.2.3Review of Literature261.2.4Present Work361.2.4.1Objective361.2.5Results and Discussion361.2.6Conclusion45		epoxides	
1.2.3Review of Literature261.2.4Present Work361.2.4.1Objective361.2.5Results and Discussion361.2.6Conclusion45	1.2.1	Introduction	25
1.2.4Present Work361.2.4.1Objective361.2.5Results and Discussion361.2.6Conclusion45	1.2.2	Pharmacology of cytoxazone	25
1.2.4.1 Objective 36 1.2.5 Results and Discussion 36 1.2.6 Conclusion 45	1.2.3	Review of Literature	26
1.2.5Results and Discussion361.2.6Conclusion45	1.2.4	Present Work	36
1.2.6 Conclusion 45	1.2.4.1	Objective	36
	1.2.5	Results and Discussion	36
1.2.7Experimental Section45	1.2.6	Conclusion	45
	1.2.7	Experimental Section	45

Section III	Formal synthesis of <i>N</i> -thiolated 2-oxazolidone	
1.3.1	Introduction	49
1.3.2	Pharmacology of <i>N</i> -thiolated 2-oxazolidinone	49
1.3.3	Review of Literature	50
1.3.4	Present Work	51
1.3.4.1	Objective	51
1.3.5	Results and Discussion	51
1.3.6	Conclusion	56
1.3.7	Experimental Section	56
1.3.8	References	58
Chapter II	Enantioselective Synthesis of (+)-L-733,060 via	Hydrolytic
	Kinetic Resolution of Azido epoxide and Synth	esis of (S)-
	Dapoxetine via Sharpless Asymmetric Epoxidation	on
Section I	A short enantioselective synthesis of (+)-L-	733,060 <i>via</i>
	hydrolytic kinetic resolution of azido epoxide	
2.1.1	Introduction	61
2.1.2	Review of Literature	62
2.1.3	Present Work	70
2.1.3.1	Objective	70
2.1.4	Results and Discussion	71
2.1.5	Conclusion	78
2.1.6	Experimental Section	79
Section II	Enantioselective synthesis of (S)-dapoxetine vi	a Sharpless
	asymmetric epoxidation	
2.2.1	Introduction	87
2.2.2	Dapoxetine and Pharmacology	87
2.2.3	Review of Literature	88
2.2.4.	Present Work	93
2.2.4.1	Objective	93
2.2.4.2	Sharpless asymmetric epoxidation	94
2.2.5	Results and Discussion	96
2.2.6	Conclusion	102
2.2.7	Experimental Section	102

2.2.8	References	107
Chapter III	NalO ₄ -mediated Azidoiodination of Olefins, 1,2-	Diazidatior
	of Olefins and α, α -Diazidation of Aryl Ketone	s and C-H
	Functionalization of Hydrocarbons	
Section I	NalO ₄ –KI-NaN ₃ –mediated regioselective azidoio	dination of
	alkenes	
3.1.1	Introduction	110
3.1.2	Review of Literature	110
3.1.3	Present Work	114
3.1.3.1	Objective	114
3.1.4	Results and Discussion	114
3.1.5	Mechanism	118
3.1.6	Conclusion	118
3.1.7	Experimental Section	119
Section II	NalO ₄ –NaN ₃ –mediated diazidation of olefins	and α,α
	diazidation of aryl ketones	
3.2.1	Introduction	123
3.2.2	Review of Literature	123
3.2.3	Present Work	126
3.2.3.1	Objective	126
3.2.4	Results and Discussion	126
3.2.4.1	1,2-Diazidation of alkenes	126
3.2.4.2	α, α -Diazidation of aryl ketones	129
3.2.5	Conclusion	132
3.2.6	Experimental Section	132
Section III	NalO ₄ –KI-NaN ₃ –mediated C-H functionalization	ation of
	hydrocarbons	
3.3.1	Introduction	137
3.3.2	Review of Literature	137
3.3.3	Present Work	142
3.3.3.1	Objective	142
3.3.4	Results and Discussion	142

3.3.4.2	Direct azidation at benzylic position	147		
3.3.5	Mechanism	150		
3.3.6	Conclusion			
3.3.7	Experimental Section	152		
3.3.8	References	158		
Chapter IV	Palladium-catalyzed Hydrosilylation of Aryl Keton	es and		
	Enantioselective Rearrangement of 2-Alkyl Pyrid	line <i>N</i> -		
	oxides and Synthesis of 4-Substituted Chromanes vi	a Gold-		
	catalyzed Intramolecular Friedel-Crafts Reaction			
Section I	Palladium catalyzed hydrosilylation of aryl ketones w	ith		
	triethylsilane			
4.1.1	Introduction	161		
4.1.2	Review of Literature	161		
4.1.3	Present Work	167		
4.1.3.1	Objective	167		
4.1.4	Results and Discussion	168		
4.1.5	Mechanism 17			
4.1.6	Conclusion	175		
4.1.7	Experimental Section	175		
Section II	Enantioselective rearrangement of 2-alkyl pyridine N-	oxides		
4.2.1	Introduction	181		
4.2.2	Review of Literature	181		
4.2.3	Present Work	187		
4.2.3.1	Objective	187		
4.2.4	Results and Discussions	187		
4.2.5	Mechanism	191		
4.2.6	Conclusion	192		
4.2.7	Experimental Section	192		
Section III	Synthesis of 4-substituted chromanes via gold-catalyzed			
	intramolecular Friedel-Crafts reaction of 3-aryloxy	benzyl		
	alcohols			
4.3.1	Introduction	195		
4.3.2	Review of Literature	195		

4.3.3	Present Work	199
4.3.3.1	Objective	199
4.3.4	Results and Discussions	199
4.3.5	Mechanism	203
4.3.6	Conclusion	204
4.3.7	Experimental Section	204
4.3.8	References	210
	List of Publications	213

ACKNOWLEDGEMENT

I wish to express my sincere gratitude towards my research guide, Dr. A. Sudalai sir. I will be always obliged to him for his suggestions, criticisms and constant encouragement. I sincerely thank him for his splendid guidance, constant support, inspiration and personal freedom rendered to me during my research period. His endless enthusiasm and receptive attitude will always remain a source of inspiration for me.

I thank Dr. B. D. Kulkarni sir, Deputy Director and Head, CE-PD division, for his help and support. My special thanks go to Dr. S. Gurunath for his constant encouragement and moral support. I also want to thank Dr. Bhaval, Dr. V.G. Kulkarni Dr. G. Pandey, Dr. S. P. Chavan, Dr. Thulasiram, Dr. Kalkote, Dr. Mulla, and Dr. Ramana for their help and encouragement. I am immensely thankful to my seniors Drs. Milind, Gajanan, Vinay, Iliyas, Abhimanyu, Shriram, Sivakumar, Srinu, Ramesh, Arun and Victor, for useful training in the initial phase of my career which made me what I am today.

I am very thankful to Dr. Vilas Chavan for his help in the HPLC analysis. I thank NMR group and CMC group for their help in obtaining the analytical data. I thank PD office staff Mr. Bhosale, Mrs. Puranik and Mr. Kakade, Chavan, Suresh, for their cooperation. I also thank Student academic section in NCL and PG section of Pune University for their cooperation and help. It's my privilege to thank the Director, NCL for giving me this opportunity and providing all necessary infrastructure and facilities. Financial assistance from CSIR, New Delhi is greatly acknowledged.

I wish to thank my friendly and cooperative lab mates Drs. Emmanuvel, Tanveer, and Shyla, Santhosh, Pratibha, Varun, Dayanand, Chaithanya, Senthil, Dattatraya, Venkat, Brij, Souman, Sunita, Ravindra, Anil, Komal, Deepak, Ravi, Asif, Ramchandra, Sawant, Balaji, Prakash, Vijay, Hari, Kuppu, Amol, Satish, Santosh, Shobhana, Vandana, Geetanjali, Shaheen, Deepali, Nagesh, Nana, Rana, Baba, sandeep, Arvind and pramod for providing a cheerful atmosphere in the lab. I am also thankful to project students Rohini and Nilesh for helping me in this work.

My special thanks go to friends-cum-family Vinod (Dada), Awadut (Maharaj), Amol, Laxman, Namdev, Kulbhushan, Nagendra, Ram, Shital, Archana, Sharda, Prerna, Pallavi, Sonali, Kalpana, Sphurti, Priya and Chotu gang Adi, Shravu, Shreya, Sharayu, Shivam, Sarthak, Arnav, Astha, Kshitija, Keya for making Home away from Home.

I am deeply indebted to my friends Deepak, Anand, Sharad, Kishan (Anna), Kiran, Bapu, Lalita, Sofia, Nitin, manmat, Nilkanth, Deepak, Sudhir, Shafi, Tatya, Satendra, Sambhaji, Dushant, Ramdas, Bhargav, Raghupati, Vasu, Aaba, Ganesh, Sulemaan, Amit, Jayprakash, wasif, Panjab, Mahesh, Bhuvan, Sunil, Umesh, Prasad, Mahesh, Majid, Kishor, Dharmedra, Pinak, Sangram, Tukaram, Sachin, Ravi, Mangesh, Pushpesh, Abhishek, Divya, Sijo, Aarif, Pranjal, Srinivas, Panchami, Kishor, Baag, Bhalchandra, Bhaskar, Prassana, Ravindra, Rajedra, Debashis, Swarup, Bharat, Om, Harish, vivek, Indu, Sitaram, Sabita, Srinivas, Venkatesh, Palimkar, Suresh, Chopade, Vijay, Shailesh, Pankaj, Sangmesh, Mahendra, Abhijeet.

I acknowledge all my college teachers Drs. Despande, Sharma, Kuberkar, Gurav, Vibhute, Kulkarni, Dawne, Shaikh, Wartale and friends Drs. Bhosale, Badne and Madje, Bharat, Prasad, Bhagwat. I am greatly indebted to my school teacher Dr. Bhramane sir for igniting the spark of science in me.

Without understanding what I am doing, my beloved parents have supported me through out my career with lots of patience. I am indeed very grateful to them whose constant love, care, support and encouragement have been the main force and motivation so far and will continue so in the days to come. The best wishes of my Late.brother Dnyanoba, sisters and nephews have made me what I am and I owe much to them. I also thank my uncle, brothers Tukaram, and Pundalik for their support, also, my in-laws for their best wishes. Special thanks to my Grandmother and Mamas for their blessings.

I wish to thank Shital, my wife, for her love, affection and support extended to me during this work

Finally, I wish to thank great scientific community whose achievements are constant source of inspiration for me.

Pandurang V. Chouthaiwale

ii

ABBREVATIONS

Ar Bn Boc $(Boc)_2O$ n-Bu n-BuLi CAN Cbz CH_2Cl_2 CHCl ₃ CH ₂ Cl ₂ CHCl ₃ CH ₃ CN CuSO ₄ DBU DIBAL-H DET DMF DMSO DMAP ee Et Et Et ₃ N Et ₂ O EtOAc EtOH g h HCI HPLC H ₂ SO ₄ IR IBX KHMDS K ₂ CO ₃ KOH LiAIH ₄ LDA LiHMDS M+	Aryl Benzyl <i>N-tert</i> -Butoxycarbonyl Ditert-butyl dicarbonate <i>n</i> -Butyl <i>n</i> -Butyl Lithium Cerric ammonium nitrate Benzyloxy carbonyl Methylene chloride Chloroform Acetonitrile Copper(II) sulfate 1,8-Diazabicyclo[5.4.0]undecene-7 Diisobutyl alulinum hydride Diethyl Tartarate Dimethyl formamide Dimethyl sulphoxide <i>N,N</i> -dimethyl-4-aminopyridine Enantiomeric excess Ethyl Triethylamine Diethyl ether Ethyl acetate Ethyl acetate Ethyl alcohol Grams Hours Hydrochloric acid High pressure liquid chromatography Sulfuric acid Infra red 2-lodoxybenzoic acid potassium hexamethyl disilazide Potassium carbonate Potassium hydroxide Lithium aluminum hydride Lithium diisopropyl amide Lithium hexamethyl disilazide Molecular ion

MOM min mL mp MS MS Ms NaBH $_4$ NaHCO $_3$ NaOH Na $_2$ SO $_4$ NH $_4$ Cl NH $_4$ OH NBS NMR NMO Pd/C Pet. ether Ph ρ -TSA PhNO Py Red-Al TBS TBHP TEMPO THF TLC TBAF TBDMSCI TBDPSCI	Methoxymethyl Minutes Milliliter Melting point Mass spectrum Mesyl Sodium borohydride Sodium bicarbonate Sodium bicarbonate Sodium bicarbonate Sodium sulfate Ammonium chloride Ammonium chloride Ammonium hydroxide <i>N-Bromosuccinimide</i> Nuclear Magnetic Resonance <i>N-Bromosuccinimide</i> Nuclear Magnetic Resonance <i>N-Methyl morpholine N-oxide</i> Palladium on activated charcoal Petroleum ether Phenyl <i>p</i> -Toluene sulfonic acid Nitrosobenzene Pyridine Bis(2-methoxyethoxy)aluminum hydride <i>tert</i> -Butyldimethylsilyl <i>tert</i> -Butyl hydroperoxide 2,2,6,6-tetramethyl-1-piperidinyloxy Tetrahydrofuran Thin layer chromatography Tetrabutylammonium fluoride <i>tert</i> -Butyldimethylsilyl chloride <i>tert</i> -Butyldiphenylsilyl chloride
TBDMSCI TBDPSCI TFA TMSCN	<i>tert</i> -Butyldimethylsilyl chloride <i>tert</i> -Butyldiphenylsilyl chloride Trifluoroacetic acid Trimethylsilyl cyanide
Ts	Tosyl

GENERAL REMARKS

1. All solvents were distilled and dried before use.

2. Petroleum ether refers to the fraction collected in the boiling range 60-80 °C.

3. Organic layers after every extraction were dried over anhydrous sodium sulfate.

4. Column Chromatography was performed over silica gel (60-120 mesh).

5. TLC analyses were performed over aluminum plates coated with silica gel (5-25 m) containing UV active G-254 additive.

6. IR spectra were recorded on a Perkin-Elmer model 683 B or 1605 FT-IR and absorptions were expressed in cm⁻¹.

7. ¹H and ¹³C NMR spectra were recorded on Brucker FT AC-200 and MSL-300 MHz instruments using TMS as an internal standard. The following abbreviations were used: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, brs = broad singlet, dd = doublet of doublet, dt = doublet of triplet and ddd = doublet of doublet.

8. Mass spectra (MS) were recorded on an automated finnigan MAT 1020C mass spectrometer using ionization energy of 70eV.

9. Optical rotations were carried out on JASCO-181 digital polarimeter at 25 °C using sodium D light.

10. All melting points and boiling points are uncorrected and the temperatures are in centigrade scale.

11. Elemental analysis was done on Carlo ERBA EA 110B instrument.

12. The compounds, scheme and reference numbers given in each chapter refers to that particular chapter only.

13 Chiral Cobalt (Salen) complexes were purchased from Aldrich

ABSTRACT

The thesis entitled "Asymmetric Synthesis of Bioactive Molecules and Methodologies Involving Oxidative Functionalization of Alkanes, Alkenes and Hydrosilylation of Ketones" is divided into four chapters.

The title of the thesis clearly reflects the objective, which is to synthesize enantiomerically pure bioactive molecules and to develop useful synthetic methodologies. **Chapter 1** describes the cobalt-catalyzed hydrolytic kinetic resolution of azido epoxides and their application in the asymmetric synthesis of (+)-*epi*-cytoxazone, (-)-cytoxazone and (+)-2-oxazolidone. **Chapter 2** deals with the synthesis of two bioactive molecules namely (+)-L-733,060 *via* hydrolytic kinetic resolution of azido epoxide and (*S*)-dapoxetine *via* asymmetric epoxidation of cinnamyl alcohol. **Chapter 3** presents NaIO₄-mediated synthetic transformations involving regioselective azido iodination and diazidation of olefins, α, α -diazidation of aryl ketones and C-H functionalization of hydrocarbons. **Chapter 4** describes synthetic transformations involving palladium-catalyzed hydrosilylation of aryl ketones, enantioselective rearrangement of 2-alkyl pyridine N-oxides (Boekelheide reaction) and synthesis of 4-substituted chromanes *via* gold-catalyzed intramolecular Friedel-Crafts reaction.

CHAPTER I

Cobalt-catalyzed Hydrolytic Kinetic Resolution of Azido Epoxides: A Short Enantioselective Synthesis of (+)-*Epi*-cytoxazone, (-)-Cytoxazone and (+)-2-Oxazolidone

Hydrolytic kinetic resolution (HKR) developed by Jacobsen *et al.* has emerged as a powerful tool to obtain terminal epoxides as well as their corresponding diols in enantiomerically pure form.¹ These compounds are important intermediates for the synthesis of various bioactive molecules.² The enantiomerically pure *syn-* or *anti-*azido epoxides and the corresponding diols are also valuable 'building blocks' for the asymmetric synthesis of bioactive molecules and as chiral auxiliaries and ligands.³ This chapter deals with the development of a novel method in which HKR of azido epoxides catalyzed by chiral (salen)Co(III)-OAc complex was employed, for the first time to produce chiral azido epoxides and azido diols, followed by its application in the


vi

asymmetric synthesis of (+)-*epi*-cytoxazone, (-)-cytoxazone and (+)-2-oxazolidone. It is divided into three sections.

Section 1: Cobalt-catalyzed hydrolytic kinetic resolution of azido epoxides

The hydrolytic kinetic resolution of racemic *syn-* or *anti-*azido epoxide derivatives was carried out. In this strategy, the relative stereochemistry between the azide and the epoxide functions is established prior to the HKR step and thus a single asymmetric reaction is employed to form compounds with two asymmetric centers.⁴ The racemic *syn-* and *anti-* azido epoxides, the substrates for HKR, were efficiently prepared in highly diastereoselective manner⁵ from the corresponding (E)- and (Z)- allylic alcohols respectively, involving essentially a two-step reaction sequence of NBS-bromination in the presence of azide, as the case may be, followed by treatment with base to form the corresponding racemic epoxides. In this section, we have described a flexible, novel method that employs HKR of racemic azido epoxides to generate two stereocentres of high optical purities in a single step. When HKR of racemic *syn-*azido epoxide (\pm)-**1a-b** was performed with (*R*,*R*)-Salen Co(III)(OAc) complex (0.5 mol%) and H₂O (0.5 equiv.), the corresponding chiral epoxides **1a-b** and diols **2a-b** were isolated in high yields and optical purity (**Table 1**).





^a Isolated yield after column chromatographic purification. ^bee determined by chiral HPLC Chiralpak

OD-H

Similarly, *anti* azido epoxides (\pm) -**3a-c**, when subjected to (S,S)-SalenCo(III)OAccatalyzed HKR, produced chiral *anti*-azido epoxides (+)-**3a-c** and the corresponding *anti* diols **4a-c** with high enantio purity (**Table 2**).

R O		(<i>S,S</i>)-SalenCo(III)((0.5 mol%), 	→	$R \xrightarrow{N_3}_{O}$	+ R	N ₃	ОН
3a (2 <i>RS</i> , 3 <i>RS</i>))	0 °C, 14 h		3a (2 <i>R</i> , 3 <i>R</i>)		4a-c	
3b-c (2 <i>R</i> S, 3S	SR)			3a-c (2 <i>R</i> , 3 <i>S</i>)			
Azido epoxides Azido diols							
R		Yield (%) ^a	ee (%	b) 4a-c	Yield	l (%) ^a	ee (%)
CH ₂ OTBS	3 a	48	96	4 a	4	6	98 ^b
Ph	3b	48	97	4b	4	7	98 ^c
<i>p</i> -OMe- C ₆ H ₄	3c	47	96	4 c	4	7	97


Table 2: Co-catalyzed HKR of anti-azido epoxides

^{*a*} Isolated yield after column chromatographic purification. ^{*b*} ee determined by Mosher's ester analysis. ^{*c*} ee determined by chiral HPLC analysis (see the ESI).

Section 2: Enantioselective synthesis of (+)-*epi*-Cytoxazone and (-)- Cytoxazone *via* hydrolytic kinetic resolution of azido epoxides


(-)-Cytoxazone and (+)-*epi*-cytoxazone, both containing a novel 4,5-disubstituted-2-oxazolidinone moiety were isolated from *Streptomyces* sp.⁶ and found to exhibit cytokine-modulating activity by inhibiting the signaling pathway of Th2 cells. Inhibitors of Th2-dependant cytokine production would be a potent chemotherapeutic agent in the field of immunotherapy. In this section, we describe a concise enantioselective synthesis of (+)-*epi*-cytoxazone **5** and (-)-cytoxazone **9** using HKR of azido epoxides.

Our synthesis of (+)-*epi*-cytoxazone **5** started with the azido bromination of 4-methoxycinnamyl alcohol **6** using NBS and NaN₃ to give azido bromoalcohol **7** in 76% yield. Azido bromoalcohol **7** on treatment with LiOH, in THF: water (4:1) at 0 °C afforded racemic azido epoxide (\pm)-**1b** in 70% yield, which was then subjected to HKR using (*R*,*R*)-Co(salen)OAc to furnish the chiral azido diol **2b** in 48% chemical yield and 97% ee along with the corresponding azido epoxide (+)-**1b** in 48% yield and 98% ee. Both chiral azido diol **2b** and azido epoxide (+)-**1b** could be readily separated by column chromatographic purification. Azido diol **2b** was then subjected to azide reduction and Boc protection [10% Pd/C, polymethylhydrosiloxane (PMHS), (Boc)₂O, EtOH] to give *N*-Boc amino diol **8** in 95 % yield. Finally, the regioselective intramolecular cyclization of **8** using NaH in THF gave (+)-*epi*-cytoxazone **5** in 96 % yield and 97% ee (**Scheme 1**).



Scheme 1: (i) NBS, NaN₃, CH₃CN: H₂O (4:1), 0 °C, 75%; (ii) LiOH, THF: water (4: 1), 0- 25 °C, 3 h 76%; (iii) (R,R)-Co(salen)OAc (0.5 mol%), THF, H₂O (0.5 equiv), 0 °C, 12 h; (iv) polymethylhydrosiloxane (PMHS), 10% Pd/C, (Boc)₂O, EtOH, 25 °C, 4 h, 95%; (v) NaH, dry THF, 25 °C, 3 h, 96%.

For (-)-cytoxazone 9, the racemic azido epoxide (\pm)-1b was subjected to epoxide opening with 0.5M aq. NaOH, *tert*-BuOH to furnish racemic azido diol 2b. The selective protection of primary alcohol as pivolyl ester and the secondary alcohol as mesylate in 10 was carried out to give 11 in 95% yield. The subsequent hydrolysis of 11 with K₂CO₃, in methanol gave the racemic azido epoxide (\pm)-3c in 81% yield. Recemic azido epoxide (\pm)-3c was then subjected to HKR using (*S*,*S*)-Co(salen)OAc to furnish the required chiral azido diol 4c in 47% chemical yield and 97% ee along with azido epoxide (+)-3c in 47% yield and 96% ee. Azido diol 4c was transformed to (-)-cytoxazone 9 using standard sequence of reactions *via* azide reduction, amine protection followed by base-mediated cyclization (Scheme 2).




Scheme 2: (i) 0.5N aq. NaOH, *tert*-BuOH, 12 h, 70 °C, 90%; (ii) PivCl, Pyridine/CH₂Cl₂(1: 1), 0 °C, 5 h, 96%; (iii) MsCl, Et₃N, DMAP, CH₂Cl₂, 25 °C, 10 h, 90%; (iv) K₂CO₃, MeOH, 25 °C, 6 h, 81% over two step; (v) (*S,S*)-Co(salen)OAc (0.5 mol%), THF, H₂O (0.5 equiv.), 0 °C, 14 h; (vi) poly(methylhydrosiloxane) (PMHS), 10% Pd/C, (Boc)₂O, EtOH, 25 °C, 4 h, 90%; (vii) NaH, dry THF, 25 °C, 3 h.

Section 3: Formal synthesis of N-thiolated 2-oxazolidone

Recent studies have shown that N-thiolated 2-oxazolidinone **13** possesses antibacterial activity against methicillin-resistant *Staphylococcus aureus* and *Bacillus anthracis*.⁷ This section deals with the synthesis of (+)-2-oxazolidone **14**, precursor to **13**, Our synthesis starts with commercially available cinnamyl alcohol **15**, which was transformed into the *syn*-azido epoxiode (\pm)-**1a** in two steps: (i) azidobromination of cinnamyl alcohol and (ii) formation of epoxide from **16** to give racemic *syn*-azido epoxiode (\pm)-**1a** in 70% yield. The *syn*-azido epoxiode (\pm)-**1a** was then subjected to HKR using (*R*,*R*)-Co(salen)OAc to give the chiral *syn*-azido diol **2a** in 47% yield with 98% ee along with chiral *syn*-azido epoxide **1a** in 48% yield with 96% ee. Azido diol **2a** was subjected to azide reduction as well as Boc protection [10% Pd/C, polymethylhydrosiloxane (PMHS), (Boc)₂O, EtOH] to give *N*-Boc amino diol **17** using NaH in THF gave (+)-2-oxazolidone **18** in 96% yield.

Finally, mesylation of primary alcohol in oxazolidone **18** gave the mesylate **19**, which on subsequent treatment with NaN₃ in DMF at 60 °C afforded (+)-2-oxazolidone **14** in 80% yield. The conversion of (+)-2-oxazolidone **14** to *N*-thiolated 2-oxazolidinone **14** has been reported in the literature⁷ (**Scheme 3**).



Scheme 3: (i) NBS, NaN₃, CH₃CN: H₂O (4:1),0 °C, 70%; (ii) *tert*-BuOK, THF, 0 °C, 3 h; (iii) (*R*,*R*)-Co(salen)OAc (0.5 mol%), H₂O (0.5 equiv), 0 °C, 14 h; (iv) poly(methylhydrosiloxane), 10% Pd/C, (Boc)₂O, EtOH, 25 °C, 4 h, 96%; (v) NaH, dry THF, 25 °C, 3 h, 96%; (vi) (a) MsCl, Et₃N, CH₂Cl₂, 0 °C, 1 h then; (b) NaN₃, DMF, 60 °C, 12 h, 80%.


CHAPTER II

Enantioselective Synthesis of (+)-L-733,060 *via* Hydrolytic Kinetic Resolution of Azido epoxide and Synthesis of (S)-Dapoxetine *via* Sharpless Asymmetric Epoxidation

Chapter II is divided into two sections. **Section 1** presents the enantioselective synthesis of (+)-L-733,060 *via* HKR of azido epoxide while **Section 2** describes the asymmetric synthesis of (*S*)-dapoxetine *via* Sharpless asymmetric epoxidation.

Section 1: A short enantioselective synthesis of (+)-L-733,060 *via* hydrolytic kinetic resolution of azido epoxide

(+)-L-733,060 (**20**) possessing 2-alkyl-3-hydroxypiperidine structural unit has proven to be selective and potent non-peptide neurokinin substance P receptor antagonist.⁸ Recent studies have shown that (+)-L-733,060 (**20**) can act both as an antitumor agent and as a promising new target for the treatment of retinoblastoma. This section describes a practical, enantioselective synthesis of (+)-L-733,060 (**20**) by employing hydrolytic kinetic resolution of azido epoxide as a key reaction (**Scheme 4**).



Scheme 4: (i) (*S*,*S*)-salen-Co(III)OAc (0.5 mol%), H₂O (0.5 equiv), 0 °C, 14 h; (ii) TBSCl, imid, CH₂Cl₂, 25 °C, 98%; (iii) CSA, MeOH:CH₂Cl₂ (1:1), 0 °C 6 h, 95%; (iv) Dess-Martin periodinane, CH₂Cl₂, 25 °C, 98%;v) PPh₃=CHCO₂Et, THF, 25 °C, 14 h, 94%; (vi) 10% Pd/C, H₂, MeOH, 25 °C, than reflux in EtOH, 85%; (vii) TBAF, THF, 25 °C, 96%; (viii) a) Me₂S. BH₃, THF, reflux, 10 h; b) (Boc)₂O, Et₃N, cat. DMAP, CH₂Cl₂, $0 - 25^{\circ}$ C, 73% over two steps; (ix) 3, 5-bis (trifluoromethyl)benzyl bromide, NaH, DMF: THF (3:1), 0 °C, 6 h; (x) TFA, CH₂Cl₂, 18 h, 82% over two steps.

Our approach to the synthesis of L-733,060 (20) commenced with *syn* azido epoxide (\pm) -**1a**, which was subjected to HKR using (*S*,*S*)-Co(salen)OAc to furnish the required chiral


azido diol, (+)-**2a** in 48% chemical yield and 97% ee. It was then converted into *bis*-TBS ether (TBS chloride and imid.) to get **21** in 98% yield. The selective deprotection of TBS group in **22** was achieved using camphor sulfonic acid (CSA) in MeOH to produce azido alcohol **23** in 95% yield. Azido alcohol **22** on oxidation with Dess-Martin periodinane condition followed by Wittig olefination gave (*E*)- α , β -unsaturated azido ester **23** in 94% yield. Reduction of azide group along with C=C double bond was achieved under hydrogenation condition (H₂ and 10% Pd/C). Subsequently on reflux with EtOH, it gave TBS protected lactam **24** in 85% yield. Deprotection of TBS group in **24** was achieved using TBAF in THF to produce hydroxy lactam **25** in 96% yield. Reduction of lactam **25** with BH₃.SMe₂ in THF followed by the protection of the secondary amine with (Boc)₂O gave the *syn* amino alcohol **26** in 73% yield over two steps. *O*-Alkylation of **26** with 3,5-bis(trifluoromethyl)benzyl bromide in the presence of NaH furnished **27**, which underwent deprotection under acidic conditions affording L-733,060 (**20**) in 82% yield and 97% ee.

Section 2: Enantioselective synthesis of (S)-dapoxetine *via* Sharpless asymmetric epoxidation

Depression, a common psychiatric disorder, is one of the most frequent illnesses in the World affecting people of all genders, ages and backgrounds. Dapoxetine **29** is structurally related to fluoxetine with anti-depressant activity.⁹ Also, (*S*)-dapoxetine **29** is currently being tested as a treatment for premature ejaculation in men. Phase 3 clinical trials in patients with premature ejaculation have shown (*S*)-dapoxetine to be effective in improving the time of ejaculation, without any adverse effects.¹⁰

The synthesis of (*S*)-dapoxetine **29** starts with commercially available cinnamyl alcohol **15** which was subjected to the Sharpless asymmetric epoxidation¹¹ using Ti(OiPr)₄ and (+)-DET as ligand to give the epoxy alcohol **30** in 83% yield and 98% ee. Regioselective reductive ring opening of chiral epoxide **30** using Red-Al[®] gave 1,3-diol **31** in 88% yield, which on selective mono benzyl protection using benzyl bromide furnished OBn protected alcohol **32** in 80% yield. Mesylation of free alcohol **32** followed by subsequent displacement of the mesyl group with NaN₃ afforded azido benzyl ether **33** in 99% yield. The reduction of azide group coupled with the benzyl deprotection [10% Pd/C, H₂, (40 psi)] gave amino alcohol **34**, which was then condensed with formaldehyde and formic

acid as hydrogen source to give **35** in 80% yield. Finally, coupling of alcohol **36** with 1-naphthol was achieved *via* Mitsunobu reaction that afforded (*S*)-dapoxetine **29** in 71% yield and 98% ee (Scheme 5).



Scheme 5: (i) (+)-Diethyl tartarate, Ti(OⁱPr)₄, anhyd. TBHP, CH₂Cl₂, -33 °C, 83%; (ii) Red Al[®], DME, 0 -25 °C; (iii) NaH, benzyl bromide, DMF, -70 °C, 80%. (iv) a) MsCl, Et₃N, CH₂Cl₂, 0 °C, 1h ; (b) NaN₃, DMF, 60 °C, 5 h, 98%; (v) 10% Pd/C, H₂, MeOH, AcOH, 25 °C ; (vi) HCHO, HCO₂H, reflux, 8 h, 80%; (vii) PPh₃, DEAD, 1-naphthol, THF, 25 °C, 71%.

CHAPTER III


NaIO₄-mediated Azidoiodination of Olefins, 1,2-Diazidation of Olefins and α,α-Diazidation of Aryl Ketones and C-H Functionalization of Hydrocarbons

Chapter III is divided into three sections. Section 1 deals with NaIO₄-mediated synthetic transformation involving regioselective azido iodination of olefins; Section 2 describes 1,2-diazidation of olefins as well as α,α -diazidation of aryl ketones and Section 3 deals with C-H functionalization of hydrocarbons.

Section I: NaIO₄-KI-NaN₃-mediated regioselective azidoiodination of alkenes

Azido iodination of alkenes constitutes an important method for introducing nitrogen functionality into a carbon skeleton leading to vinyl azides, amines and heterocycles, particularly aziridines.¹² The conventional method for synthesis of azido iodides involves the use of iodine azide reagent, which is prepared *in situ* from sodium azide and iodine chloride in polar solvent. During the course of our study on NaIO₄-mediated oxidative

halogenations,¹³ We noticed that NaIO₄-KI-NaN₃ combination was found to be excellent for regiospecific azidoiodination of styrene in acetic acid as solvent. This prompted us to explore the effectiveness of the NaIO₄-KI-NaN₃ combination in the azidoiodination of alkenes. Several alkenes **36a-I** (aliphatic, styrenic, allylic and disubstituted) underwent azidoiodinations to give the corresponding β -iodoazides **37a-I** in excellent yields. It is interesting to note that the regiochemistry of the addition, for all the cases examined, proceeded in an *anti*-Markovnikov fashion, indicating a possible radical pathway. Internal olefins such as β -methylstyrene, cyclohexene and cinnamyl alcohol have proceeded to give products in excellent yields with diastereoselectivities reaching up to 1:4 as confirmed by their ¹H-NMR spectra. Terminal functionalized olefin such as allyl acetate also underwent regiospecific azidoiodination in 92% yield. However, no reactions took place in the case of conjugated alkenes with electron-withdrawing groups, which may be a limitation of this method (**Scheme 6**).




<u>Scheme 6</u>: alkenes (1 equiv.), KI (1 equiv.), NaIO₄ (1 equiv.), NaN₃ (3 equiv.), glacial AcOH, 25 °C.

Section 2: NaIO₄–NaN₃–mediated diazidation of olefins and α,α-diazidation of aryl ketones


(a) 1,2-Diazidation of alkenes:

Vicinal diazides are important precursors for the synthesis of 1,2-diamines, which have become important synthetic targets, in variety of natural products, various biologically active molecules, and are also used as ligands or catalysts in organo- and transition – metal catalyzed reaction.¹⁴ During the course of this study of NaIO₄-mediated oxidative functionalization of alkenes, we observed that treatment of alkenes **38a-h** with stochiometric amount NaIO₄ and sodium azide in AcOH : DMSO (1: 4) as a solvent at 75 °C, gave 1,2-diazides **39a-h** in good yields (**Scheme 7**).



(b) α,α-Diazidation of aryl ketones:

Under the similar reaction condition, we have observed that aryl ketones **40** with α methylene group (-CO-CH₂-) underwent oxidative diazidation with NaIO₄ and sodium azide in AcOH: DMSO (1:4) as a solvent at 75 °C, to give α,α -diazido aryl ketones **41** in 91-95% yields. Surprisingly, when benzylic alcohols **42** were subjected to α,α -diazidation condition. The corresponding α,α -diazido aryl ketones were obtained in good yields probably *via* oxidation followed by diazidation (**Scheme 8**).



Section 3: NaIO₄–KI-NaN₃–mediated C-H functionalization of hydrocarbons (a) Direct iodination of alkanes:


Direct and selective replacement of C-H bonds in hydrocarbons with C-C, C-O, C-N and C-X groups is an important and long-standing goal in chemistry.¹⁵ In particular, a new, effective method for 1,2-functionalization of unactivated C-H bonds in a single step represents a major challenge for chemists. During the course of our study on NaIO₄-mediated regiospecific aziodo iodination, we noticed that IN₃ generated *in situ*, undergoes addition onto olefins in an *anti* Markovnikov fashion, suggesting probably a radical

pathway. This prompted us to explore the effectiveness of the $NaIO_4$ -KI-NaN₃ combination in radical induced C-H activation of alkane. We thus observed that alkanes **43**, when treated with $NaIO_4$ -KI-NaN₃ in acetic acid at 25 °C, produced iodoalkanes **44** in excellent yields (Scheme 9).

 $R-H \xrightarrow{i} R-I$ $43 \qquad 44$ $R = alkyl, cycloalkyl \qquad yield: 97-99\%$ 7 example

<u>Scheme 9</u>: (i) alkane (5mL), NaIO₄ (5 mmol), KI (5 mmol), NaN₃ (15 mmol), AcOH (15 mL), 25 °C; yield (%) was calculated based on KI.

With a simple variation in temperature, we have observed that cycloalkane **45** was smoothly converted to either 1-acetoxy- or 1-azido-2-iodocycloalkane **46** (Scheme 10).




Scheme 10: (i) cycloalkane (5 mL), NaIO₄ (5 mmol), KI (5 mmol), NaN₃ (5-15 mmol), glacial AcOH (15 mL), 45-75 °C.

(b) Direct azidation at benzylic position:

The direct azidation of alkyl arene C-H bond is one of the challenging areas in organic synthesis.¹⁶ During the course of substrate study with NaIO₄-KI-NaN₃ system (1:1:3 molar ratio), we found that alkyl arenes **47** are functionalized smoothly at the benzylic position to give benzyl azides **48** along with benzyl acetates **49** (10%). Further, on increasing the concentration of azide (6 equiv), exclusive formation of monobenzyl azides **48** were realized in excellent yields (**Scheme 11**). However, in similar reaction condition no reactions took place in the case of secondary alkyl arene such as ethyl benzene and indane. However, when ethyl benzene and indane were subjected to oxidative functionalization in the absence of KI, with NaIO₄ (1 equiv) in the presence

 NaN_3 (3 equiv) in AcOH: DMSO (1: 4) as a solvent at 75 °C, the corresponding secondary benzyl azides were produced in 20% and 50% yields respectively.



mmol), KI (5 mmol), NaN₃ (30 mmol), AcOH (20 mL), 25 °C.

CHAPTER IV


Palladium-catalyzed Hydrosilylation of Aryl Ketones and Enantioselective Rearrangement of 2-Alkyl Pyridine *N*-oxides and Synthesis of 4-Substituted Chromanes *via* Gold-catalyzed Intramolecular Friedel-Crafts Reaction

Chapter IV is divided into three sections. Section 1 deals with Pd-catalyzed hydrosilylation of aryl ketones using triethylsilane while Section 2 describes an enantioselective rearrangement of 2-alkyl pyridine N-oxides. Section 3 deals with the synthesis of 4-substituted chromanes *via* AuCl₃-catalyzed intramolecular Friedel-Crafts reaction.

Section: 1 Palladium catalyzed hydrosilylation of aryl ketones with triethylsilane

In recent years hydrosilylation of various organic carbonyl compounds has made considerable progress and became a major tool of synthetic organic chemistry and organosilicon chemistry as well as providing efficient and versatile access to new organo silicon compounds.¹⁷ There are many methods available in the literature for hydrosilylation of carbonyl compounds using a variety of metal catalysts and hydrosilylation of ketones.¹⁸ In this section, we describe an efficient and selective method for the hydrosilylation of various aryl ketones catalyzed by palladium using triethylsilane as hydride source. We found that palladium catalysts were more effective for hydrosilylation of ketones **50** in DMF at room temperature using triethylsilane as a hydride source to produce silyl ethers **51** in 88-98% yield (**Scheme 12**). All the palladium catalysts gave excellent yield of hydrosilylated products **51**. The maximum yield of

silvlether obtained was with $Pd(OAc)_2$ (98%) whereas $Pd(dba)_2$ (60%) gave the lowest yield.





<u>Scheme 12</u>: aryl ketones (1 mmol), 10% Pd(OAc)₂ (0.5 mol%), Et₃SiH (1.2 mmol), DMF (2 ml), 25 °C, 1 h.

A noteworthy feature of this protocol is that when the reaction was carried out in DMFwater (4:1) solvent system, the corresponding alcohols were produced in high yields. Thus, both hydrosilylation and deprotection of the silyl ether were achieved in a single step by using a simple modification of solvent systems.

Section: 2 Enantioselective rearrangement of 2-alkyl pyridine N-oxides

Optically active pyridyl alcohols are useful key compounds, not only as pharmaceutical intermediates, but also as useful chiral ligands and auxiliaries in asymmetric synthesis.¹⁹ Although there have been many reports on the synthesis of this important class of compounds by means of asymmetric alkylation to pyridyl aldehydes, stoichiometric or catalytic asymmetric reduction of acetyl pyridines and enzymatic resolution of racemic pyridyl alcohols. As an alternative to these methods, We have developed an enantioselective rearrangement of 2-alkyl pyridine *N*-oxide **52** (Boekelheide reaction)²⁰ using acid chlorides and chiral bases that afforded 2-alkyl pyridyl ester, which on subsequent hydrolysis produced chiral 2-alkyl pyridyl alcohols **53**, in 70-80% yields and up to 50% ee (**Scheme 13**).






Lewis acid (20 mol%), CH_2Cl_2 (4 mL) -78 °C; (ii) LiOH (2.0 mmol) THF: water (4 :1), 25 °C, 4 h.

Section: 3 Synthesis of 4-substituted chromanes *via* gold-catalyzed intramolecular Friedel-Crafts reaction of 3-aryloxy benzyl alcohols

The chromane and benzopyran structures are abundant in natural products that possess a broad array of biological activities such as antimicrobial, antiviral, mutagenicity, antiproliferative, sex pheromone, antitumor, and central nervous system activity.²¹ Organic transformations catalyzed by gold have been a focus of attention recently.²² In contrast, gold-catalyzed arene functionalization has been less developed. Such processes could provide efficient ways to construct C-C bonds from simple arene substrates. Alkylation of aromatic groups is typically achieved with Friedel-Crafts reactions.²³ During the course of our study, we observed that 3-aryloxy benzyl alcohols **54** when subjected to intramolecular Friedel-Crafts reaction using gold(III) chloride as a catalyst, gave 4-aryl substituted chromanes **55** in 90-98% yields (**Scheme 14**). Substrate such as 3-phenoxy benzyl alcohols as well as 3-naphthoxy benzyl alcohols gave good yields. In the case of both electron-donating as well as electron-withdrawing substituted 3-aryloxy benzyl alcohols gave the corresponding chromanes in excellent yield.



AuCl₃ (1 mol%), CH₂Cl₂ (5 mL) 25 °C, 5 h.

References:

- 1 Tokunaga, M.; Larrow, J. F.; Kakiuchi, F.; Jacobsen, E. N. Science 1997, 277, 936.
- 2 (a) Yu, Q.; Wu, Y.; Xia, L. J.; Tang, M. H.; Wu, Y. L. J. Chem. Soc. Chem. Commun., 1999, 129; (b) Kumar, P.; Naidu, S. V.; and Gupta, P. Tetrahedron, 2007, 63, 2745.
- 3 (a) Grajewska, A.; Rozwadowska, M. D.; Tetrahedron: Asymmetry, 2007, 18, 803; (b) Gravier-

Pelletier, C.; Milla, M.; Merrer, Y. L.; Depezay, J-C. Eur. J. Org. Chem. 2001, 3089.

- 4 Kim, Y.-J.; Tae, J. Synlett 2006, 61.
- 5 Van Ende, D.; Krief, A. Angew. Chem., Int. Ed. 1974, 13, 279.
- 6 (a) Kakeya, H.; Morishita, M.; Kobinata, K.; Osono, M.; Ishizuka, M.; Osada, H. J. Antibiot.
 1998, 51, 1126; (b) Kakeya, H.; Morishita, M.; Koshino, H.; Morita, T.; Kobayashi, K.; Osada, H. J. Org. Chem. 1999, 64, 1052.
- 7 Mishra, R. K.; Revell, K. D.; Coates, C. M.; Turos, E.; Dickeyb, S.; Limb, D. V. Bioorganic & Medicinal Chemistry Letters, 2006, 16, 2081–2083.
- 8 (a) Baker, R.; Harrison, T.; Hollingworth, G. J.; Swain, C. J.; Williams, B. J. EP 0528 495A1, 1993; (b) Harrison, T.; Williams, B. J.; Swain, C. J.; Ball, R. G. *Bioorg. Med. Chem. Lett.* 1994, 4, 2545.
- 9 Anon, N. Z. *Drugs in R & D* 2005, *6*, 307.
- 10 Pryor, J. The Lancet 2006, 368, 929.
- (a) Katsuki, T.; Sharpless, K. B. J. Am. Chem. Soc. 1980, 102, 5974; (b) Martin, V. S.;
 Woodward, S. S.; Katsuki, T.; Yamada, Y.; Ikeda, M.; Sharpless, K. B. J. Am.
 Chem. Soc. 1981, 103, 6237.
- (a) Hassner, A.; Fowler, F. W. *J. Org. Chem.* **1968**, *33*, 2686; (b) Wasserman, H. H.; Brunner, R. K.; Buynak, J. D.; Carter, C. G.; Oku, T.; Robinson, R. P. *J. Am. Chem. Soc.* **1985**, *107*, 519; (c) Ranganathan, S.; Ranganathan, D.; Mehrotra, A. K. *Tetrahedron Lett.* **1973**, *14*, 2265. (d) Moorthy, S. N.; Devaprabhakara, D. *Tetrahedron Lett.* **1975**, *16*, 257.
- (a) Dewkar, G. K.; Narina S. V.; Sudalai, A. *Org. Lett.* 2003, *5*, 4501; (b) Emmanuvel, L.; Shaikh T. M. A.; Sudalai, A. *Org. Lett.* 2005, *7*, 5071; (c) Emmanuvel, L.; Shukla, R. K.; Sudalai, A.; Suryavanshi, G.; Sivaram, S. *Tetrahedron Lett.* 2006, *47*, 4793.
- (a) Kemp J. E. G. in *Comprehensive Organic Synthesis*, Vol. 7 (Eds.: B. M. Trost, I. Fleming), Pergamon, Oxford, **1991**, 469; (b) Lucet, D.; Gall, T. L.; Mioskowski, C. *Angew. Chem. Int.Ed.* **1998**, *37*, 2580; (c) Saibabu Kotti, S. R. S.; Timmons, C.; Li, G. *Chem. Biol. Drug Des.* **2006**, *67*, 101; (d) De Figueiredo, R. M. *Angew. Chem. Int.Ed.* **2009**, *48*, 1190.
- (a) Goldberg, K. I.; Goldman, A. S. Eds. Activation and Functionalization of C-H Bonds; ACS Symposium Series 885; American Chemical Society. Washington, DC, 2004. (b) Curci, R.; D'Accolti L.; Fusco, C. Acc. Chem. Res. 2006, 39, 1; (c) Godula K.; Sames, D. Science 2006, 312, 67; (d) Labinger J. A.; Bercaw, J. E. Nature 2002, 417, 507.
- 16 Eric, F. V.; Turnbull, K. Chem. Rev. 1988, 88, 297.
- (a) Ojima, I. "The Chemistry of Organic Silicon Compounds", Vol. 2, Patai, S.; Rappoport, Z. Wiley/Interscience, New York, 1989; (b) I. Ojima, Z. Li and J. Zhu, "Recent Advances in the Hydrosilylation Reaction: Chemisty of Organic Silicon Compounds", Vol. 2, Rappoport, Z.; Apeloig, Y.; John Wiley & Sons, Ltd, New York, 1998.
- 18 (a) Diez-Gondlez, S.; Nolan, S. P. Organic Preparations and Procedures Int. 2007, 39, 523; (b)

Marciniec, B. in Hydrosilylation: A Comprehensive Review on Recent Advances (Eds.: B. Marciniec), Springer, Netherlands, **2009**, chap. 9.

- (a) Wishka, D. G.; Graber, D. R.; Seest, E. P.; Dolak, L. A.; Han, F.; Watt, W.; Morris, J. J. Org. Chem. 1998, 63, 7851. (b) Uenishi, J.; Takagi, T.; Ueno, T.; Hiraoka, T.; Yonemitsu, O.; Tsukube, H. Synlett 1999, 41; (c) Collomb, P.; Zelewsky, A. V. Tetrahedron: Asymmetry 1998, 9, 3911; (d) Uenishi, J.; Ueno, T.; Hata, S.; Nishikawa, K.; Tanaka, T.; Watanabe, S.; Yonemitsu, O.; Oae, S. Heterocycles 1999, 50, 341.
- 20 Boekelheide, V.; Linn, W.; J. J. Am. Chem. Soc. 1954, 76, 1286.
- (a) Ellis, G. P.; Lockhart, I. M. *The Chemistry of Heterocyclic Compounds, Chromenes, Chromanones, and Chromones*; Ellis, G. P., Ed.; Wiley-VCH: New York, 2007; Vol. 31, pp 1. (b) Horton, D. A.; Bourne, G. T.; Smythe, M. L. *Chem. Rev.* 2003, 103, 893; (c) Kumar, S.; Malachowski, W. P.; DuHadaway, J. B.; LaLonde, J. M.; Carroll, P. J.; Jaller, D.; Metz, R.; Prendergast, G. C.; Muller, A. J. J. Med. Chem. 2008, 51, 1706.
- (a) Hashmi, A. S. K. *Gold Bull.* 2004, *37*, 51; (b) Arcadi, A.; Di Giuseppe, S. *Curr. Org. Chem.* 2004, *8*, 795; (b) Hashmi, A. S. K. *Chem. Rev.* 2007, *107*, 3180.
- (a) Olah, G. A. Friedel-Crafts and Related Reactions; Wiley: New York, 1973; (b) Bandini, M.;
 Melloni, A.; Umani-Ronchi, A. Angew. Chem., Int. Ed. 2004, 43, 550.

CHAPTER I

Cobalt-catalyzed Hydrolytic Kinetic Resolution of Azido Epoxides: A Short Enantioselective Synthesis of (+)-*Epi*-cytoxazone, (-)-Cytoxazone and (+)-2-Oxazolidone

Section I:


Cobalt-catalyzed hydrolytic kinetic resolution of azido epoxides 1.1.1 Introduction

The enantiomerically pure *syn-* or *anti-*azido epoxides and the corresponding diols are valuable 'building blocks' for asymmetric synthesis of bioactive pharmaceuticals and as chiral auxiliaries and ligands.¹ In principle, access to these building blocks may be provided by several routes including Sharpless' methods of epoxidation and dihydroxylation, and other tedious methods. However, they generally lead to multi-step reaction sequences including protection/deprotection of various functional groups, thereby limiting the overall yield and the enantioselectivity of the process particularly unsuitable for atom economic synthesis. Jacobsen's Hydrolytic Kinetic Resolution (HKR) that uses readily accessible Co-based chiral salen complexes as catalyst and water as the only reagent to afford chiral epoxides and diols of high ee in excellent yields, has been comprehensively studied in recent years to reveal its mechanistic and synthetic aspects.² In the present section, we have described a flexible, novel method that employs HKR of racemic azido epoxides to generate two stereocentres of high optical purities in a single step.


1.1.2 Hydrolytic kinetic resolution (HKR)

The importance of epoxides in organic synthesis arises partly from the occurrence of the strained three-membered ring unit in a number of interesting natural products³ but more so because the ring opening of epoxides allows straightforward elaboration to useful new functionality, often with generation of new carbon-carbon bonds. Indeed, reactions of epoxides with nucleophiles, Lewis acids, radicals, reducing agents, oxidizing agents, acids, and bases have all been well documented and utilized in synthesis.⁴ Thus epoxides

are versatile building blocks for organic synthesis. However, terminal epoxides are arguably the most important subclass of these compounds, and no general and practical method exists for their production in enantiomerically pure form. Terminal epoxides are available very inexpensively as racemic mixtures, and kinetic resolution is an attractive strategy for the production of optically active epoxides, given an economical and operationally simple method. Readily accessible synthetic catalysts (chiral cobalt-salen complexes)⁵ have been used for the efficient asymmetric hydrolysis of terminal epoxides. This process uses water as the only reagent, no added solvent, and low loadings of a recyclable catalyst (0.5 mol%), and it affords highly valuable terminal epoxides and 1,2diols in high yields with high enantiomeric enrichment. One of the most attractive features of kinetic resolution processes in general is the fact that the enantiomeric composition of unreacted substrate can be controlled by adjusting the degree of conversion, and virtually enantiopure material can be obtained at appropriately high conversions. This is an important consideration in the present case, since low-molecular weight terminal epoxides are typically liquids at room temperature and are not readily derivatized as salts, and therefore it is not a straightforward matter to upgrade their enantiomeric composition by crystallization. However, in the absence of straightforward substrate racemization protocols, kinetic resolutions have the significant disadvantage of a 50% maximum yield of substrate recovery. With a specific interest in devising a practical method for obtaining highly enantioenriched terminal epoxides, the following criteria must be met in order for a kinetic resolution approach to be viable.⁶ (1) The racemic epoxides must be inexpensive or easily accessible from inexpensive commercial starting materials. (2) The catalyst for the resolution must be readily available in both enantiomeric forms. In the optimal case, the catalyst would be used in small quantities in the resolution and would be recyclable. (3) The nucleophile used for the ring opening should be inexpensive and easily handled. (4) The resolved epoxides must be obtained in good yield and very high enantiopurity and must be easily separated from the ringopened products. (5) Ideally, although not necessarily, the ring-opened byproducts should also be valuable chiral building blocks and be obtainable in high enantiomeric excess.



1, M = Co



<u>Scheme 1:</u> Hydrolytic kinetic resolution (HKR) of racemic epoxide

The (salen)Co complex **1** catalyzed the efficient hydrolytic kinetic resolution (HKR) of a variety of terminal epoxides (**Scheme 1**).⁷ This new method appeared to hold considerable promise with regard to meeting all of the criteria outlined above. First, racemic 1,2-epoxides are generally available directly from commercial suppliers at low cost or are obtainable in one step from inexpensive olefins or aldehydes. In fact, certain racemic epoxides, such as propylene oxide, epichlorohydrin, styrene oxide, and butadiene

monoepoxide, are commodity chemicals and are no more expensive than common organic solvents. Second, the ligands for catalyst **1** had previously been commercialized and manufactured on a ton scale in the context of (salen)Mn epoxidation catalysts.⁸

The cobalt analogues (R,R)-1 and (S,S)-1 proved equally accessible, and these are also now available in bulk. Third, water is perhaps the ideal reagent for effecting the resolution reaction: it is inexpensive and safe, and the rate of the ring-opening reaction can be controlled simply by modulating the rate of addition of water to the epoxidecatalyst mixture. Fourth, for those examples that were described in the preliminary report, highly enantioenriched epoxides were recovered from the HKR. Finally, the HKR provided useful enantioenriched 1,2-diols, including many that are otherwise not readily accessible using existing asymmetric dihydroxylation methods.⁹ Two useful methods for the generation of complex 1.OAc have been developed. Method A involves isolation of 1.OAc as a crude solid prior to the HKR. The Co(II) complex 1 is dissolved in toluene to generate ~ 1 M solution, and acetic acid (2 equiv.) is added. The resulting solution is stirred open to air at room temperature for 30 min, during which time the color of the mixture changes from orange to dark brown. All volatile materials are removed in vacuo, affording **1.**OAc as a brown solid residue that can be used without further purification. Method B involves in situ generation of 1.OAc under HKR conditions by suspension of the Co(II) complex 1 in epoxide or epoxide/solvent and addition of HOAc under an aerobic atmosphere.1.1.3.


Review of Literature

Various syntheses of enantiomerically pure syn- or anti-azido epoxides and the corres-

ponding diols have been documented in the literature by several routes including Sharpless' methods of epoxidation and dihydroxylation, and other tedious methods. Some of the interesting and important synthetic routes are described below.

Kihlberg's approach (2003)¹⁰

Kihlberg et al. have reported synthesis of chiral azido epoxide **4** which was obtained with Katsuki-Sharpless asymmetric epoxidation of allylic alcohol **5** to furnish epoxy alcohol **6** in 82%, yield with 88% de. Regioselective opening of the epoxide in **6** by $Ti(OiPr)_2(N_3)_2$ then yielded azido diol **7**. Benzoylation of the primary hydroxyl group of **7** directly followed by mesylation of the secondary hydroxyl group gave **9**. Finally, treatment of **9** with sodium ethoxide resulted in removal of the benzoyl group and intramolecular ring closure to give azido epoxide **4** in 41% overall yield from **5** with 90% de (**Scheme 2**).




<u>Scheme 2:</u> (i) D-(-)-diisopropyl tartrate, $Ti(OiPr)_4$, *t*BuOOH in toluene, CH_2Cl_2 , -20 – 25 °C, 82%; (ii) $Ti(OiPr)_2(N_3)_2$, benzene, reflux, 92%; (iii) collidine, BzCl, -10 °C; (iv) MsCl, CH_2Cl_2 , 0 – 25 °C, 66%; (v) NaOEt in EtOH, THF, room temp, 83%.

Reddy's approach (2005)¹¹

Reddy et al. have reported synthesis of chiral azido epoxide **10** and azido diol **11** starting from anisaldehyde **12**, which was treated with vinyl magnesium bromide to give allyl alcohol **13**. The enantioselective epoxidation of the racemic allyl alcohol **13** gave, in the

presence of L-diisopropyl tartarate, the epoxy alcohol **14** in 46% yield. The epoxy alcohol **14** was then subjected to a Mitsunobu reaction, in which hydrazoic acid served as an azide nucleophile and gave the epoxy azide **10b** in 91% yield. Next, opening of the epoxide ring by treatment with aqueous sodium hydroxide in *tert*-butanol furnished the azido diol **11b** (**Scheme 3**).




Scheme 3: (i) 1M vinyl magnesium bromide in THF, dry ether, 0 °C, 4 h, 96%; (ii) diisopropyl L-tartarate, Ti(iPrO)₄, tert-butyl hydroperoxide, CH₂Cl₂, -20 °C, 14 h, 46%; (iii) PPh₃, diisopropyl azadicarboxylate, HN₃, benzene, 0 °C, 1 h, 91%; (iv) 0.5M aq. NaOH, *t*-BuOH, 75 °C, 5 h, 92%.

Kumar's approach (2007)¹²

Kumar et al. have described the synthesis of chiral *syn* azido epoxide **10a** and *anti* azido diol **11d**, which were with Sharpless asymmetric epoxidation of commercially available cinnamyl alcohol **15a** to furnish epoxide **16** in 89% yield with >99% ee. The regioselective epoxide opening of **16** with NaN₃ gave a single regioisomer **11d** in excellent yield. In order to establish the desired *syn* configuration, authors have planned a three-step sequence: (i) chemoselective pivalation **17** of diol **11d**; (ii) mesylation of secondary hydroxyl **17** using MsCl; (iii) final treatment of crude mesylate **18** with K₂CO₃

in methanol to furnish the appropriately oriented *syn* azido epoxide **10a** in 80% overall yield (**Scheme 4**).




<u>Scheme 4:</u> (1) (*S*,*S*)-(-)-DET, Ti(O-*i*Pr)₄, TBHP, MS 4A°, CH₂Cl₂, -20 °C, 3 h, 89%; (ii) NaN₃, NH₄Cl, MeOH/ H₂O (8: 1), 65 °C, 5 h, 98%; (iii) PivCl, Py/CH₂Cl₂ (1: 1), 0– 25 °C, 5 h; (iv) MsCl, Et₃N, DMAP, CH₂Cl₂, 0- 25 °C, 1 h; (v) K₂CO₃, MeOH, 25 °C, overnight, 80% (overall 3 steps).

Gravier-Pelletier's approach (2009)¹³

Gravier-Pelletier et al. have described synthesis of chiral *anti* azido epoxide **19** and *anti* azido diol **25** starting from ethyl 3,4-*O*-methylethylidene-L-threonate **20**, which is readily available from L-ascorbic acid. The carboxylic acid moiety of **20** was reduced to a primary alcohol **21** for stability reasons, which was then protected as its *tert*-butyldiphenylsilyl derivative **22**. The azido group was introduced with inversion of the configuration by two-step, one-pot protocol involving initial activation of the secondary alcohol function as a triflate **23** followed by nucleophilic substitution with tetramethylguanidinium azide, which furnished the azido compound **24** in 81% yield. Acetal hydrolysis of **24** [trifluoroacetic acid: H₂O: THF (3:3:1)] to give the corresponding diol **25**. Epoxidation was then efficiently achieved under Sharpless conditions gave the

anti azido epoxide 19 in 87% yield (Scheme 5).



<u>Scheme 5:</u> (i) LiAlH₄, THF, 95%; (ii) TBDPSCl, imid, DMF, 97%; (iii) Tf₂O, 2,6-lutidine, CH₂Cl₂, -78 °C; (iv) TMGA, -78 °C to 20 °C, 81%; (v) TFA, H₂O, THF, 0 °C, 65%; (vi) a) MeC(OMe)₃, PPTS (cat.), CH₂Cl₂; (b) AcBr, CH₂Cl₂; (c) K₂CO₃, MeOH, 87%.

1.1.4 Present Work

1.1.4.1 Objective

As can be seen from the above discussion, the literature methods for the synthesis of enantiomerically pure *syn-* or *anti-*azido epoxides and the corresponding diols employ either chiral starting materials, or involve multi-step reaction sequences including protection/deprotection of various functional groups, thereby limiting the overall yield and the enantioselectivity of the process. This is particularly unsuitable for atom economic synthesis. Despite achievements, HKR has only been applied to the resolution of simple terminal epoxides with one stereocentre.¹⁴ To the best our knowledge, study related to HKR of functionalized epoxides with two stereocentres is rare.¹⁵


1.1.5 Results and Discussion

In the present work, we have thus extended the scope of the applicable substrates for

HKR to cover multi-functionalized molecules with two stereocentres. The aim of such an investigation is to access enantiomerically enriched azido epoxides and diols by a direct and simple method from the respective racemic materials; thus complementing the other tedious routes. Due to its importance as 'building-blocks' for the synthesis of highly functionalized molecules, racemic azido epoxides are chosen for the study and subjected to HKR with chiral Co-catalysts. In this section, we have described a flexible, novel method that employs HKR of racemic azido epoxides to generate azido diols and azido epoxides with two stereocentres of high optical purities in a single step.

1.1.5.1 Synthesis of racemic azido epoxidews

The racemic *syn*-azido epoxides **10a-b** the substrates for HKR, were efficiently prepared in two step sequence, in a highly diastereoselective manner¹⁶ from the corresponding (E)-allylic alcohols (**15a-b**). Thus, cinnamyl alcohols **15a-b**, which were subjected to azidobromination in presence of NBS and NaN₃ to give *anti*-azido bromides, (\pm)-**26a-b** in 70-75% yields (**Schemes 6**).



<u>Scheme 6:</u> (i) NBS, NaN₃, CH₃CN: water (4: 1), 0- 25 °C, 3 h, 70-75%; (ii) LiOH, THF: water (4: 1), 0- 25 °C, 3 h 70-76%.

The formation of azido bromides, (\pm)-**26a-b** was confirmed by ¹H and ¹³C-NMR spectroscopy. The ¹H NMR spectrum of (\pm)-**26b** showed typical signals at δ 4.20-4.24 (m, 1H) and 4.85 (d, 1H) for bromo methine (-CH-Br) and azido methine (Ar-CH-N₃)

protons respectively. Its ¹³C-NMR showed a typical signal at δ 66.5 due to benzylic carbon attached to azide group (**Fig. 1**).




Fig. 1: ¹H and ¹³C NMR spectra of (\pm) -26b

Azido bromides, (±)-26a-b were then subjected to epoxidation [LiOH, THF: water (4:
1)] to give *syn*-azido epoxides, (±)-10a-b in 75-76% yield.

The formation of *syn*-azido epoxides, (\pm)-10a-b was confirmed by ¹H and ¹³C-NMR spectroscopy. The ¹H NMR spectrum of *syn*-azido epoxide, (\pm)-10a showed typical signals at δ 2.74-2.83 (m, 2H) and δ 3.25-3.28 (m, 1H) for methylene and methine protons respectively. Its ¹³C-NMR showed characteristic signals at δ 44.6 and 54.6 due to carbons of the epoxide ring (**Fig. 2**).






Fig. 2: ¹H and ¹³C NMR spectra of (\pm) -10a

Similarly, *anti*-azido epoxide, (\pm)-10c was readily prepared from *cis*- 1,4-butenediol 27 in two step. Thus compound 27 was subjected to azidobromination in presence of NBS and NaN₃ to give azido bromide, (\pm)-28 in 75% yield (Scheme 7).




<u>Scheme 7:</u> (i) NBS, NaN₃, CH₃CN: water (4: 1), 0- 25 °C, 3 h, 75%; (ii) NaOH powder, THF, 2 h; (iii) TBSCl, imid., CH_2Cl_2 , 25 °C, 2.5 h, 76%.

The formation of azido bromide, (\pm)-**28** was confirmed by ¹H and ¹³C-NMR spectroscopy. The ¹H NMR spectrum of (\pm)-**28** showed a typical signal at δ 4.12-4.16 (m, 1H) for methine (-CH-N₃) proton. Its ¹³C-NMR showed a typical carbon signal at δ 53.62 due to carbon attached to bromo group (**Fig. 3**).




The azido bromide (\pm)-**28** was then subjected to epoxidation (NaOH, THF), followed by protection of primary alcohol with TBS-ether to give TBS protected *anti*-azido epoxide, (\pm)-**10c** in 76% yield. The ¹H NMR spectrum of (\pm)-**10c** showed signals at δ 2.71-2.80 (m, 2H) and δ 3.23-3.26 (m, 1H) for methylene and methine protons respectively. Its ¹³C-NMR showed typical signals at δ 45.2 and 50.2 due to carbons of the epoxide ring (**Fig. 4**). The synthesis of *anti*-azido epoxide, (\pm)-**10d** was achieved following a reported procedure from racemic epoxy alcohol.¹² **16**, which was subjected to selective opening with NaN₃ followed by its mesylation and treatment with base. For the preparation of *anti*-azido epoxide, (\pm)-**10e**, see Section II. Thus in this strategy, the relative stereochemistry between the azido and epoxide groups is established prior to the HKR step itself and in this way a simple asymmetric reaction can be carried out to form the key enantiomerically pure azido epoxides with two stereocentres.



1.1.5.2 HKR of racemic azido epoxides

The HKR of racemic *syn*-azido epoxides, (\pm) -10a-b was performed with (R,R)-salen Co(OAc) complex (1) (0.5 mol%) and H₂O (0.5 equiv.) and the corresponding chiral epoxides 10a-b and diols 11a-b were isolated in high yields and optical purity (Table 1).


Table 1: Co-catalyzed HKR of syn-azido epoxides



^{*a*} Isolated yield after column chromatographic purification. ^{*b*}ee determined by chiral HPLC.

Both the racemic azido epoxides (\pm) -10a-b were subjected to hydrolytic kinetic resolution using catalytic amount (0.5 mol%) of (*R*,*R*)-salen Co(OAc) complex (1) to

give chiral *syn*-azido diols **11a** (48%) and **11b** (47%), with 98 % ee and 97% ee respectively along with chiral *syn*-azido epoxides in **10a** (48%) and **10b** (48%), with 96% ee and 98% ee respectively. The enantiomeric excess of *syn*-azido diol in **11** was determined by chiral HPLC analysis: Chiralpak OD-H (**Fig.5**).



The formation of *syn*-azido diols **11a-b** was confirmed by ¹H and ¹³C-NMR spectroscopy. For example, the ¹H NMR spectrum of **11b** exhibited signals at δ 3.35 (dd, 1H) and 3.55 (dd, 1H) due to methylene (-CH₂-OH) protons. Its ¹³C NMR spectrum showed characteristic signals at δ 62.7 and 75.0 due to the methine and methylene carbons attached to hydroxyl groups respectively (**Fig. 6**). The configuration of both

chiral azido epoxides and diols was further ascertained by comparing their optical rotations with those reported in the literature.¹⁰⁻¹³





Fig. 6: ¹H and ¹³C NMR spectra of **11b**

Similarly, *anti*-azido epoxides (\pm)-10c-e, when subjected to (*S*,*S*)-Co(salen)OAccatalyzed HKR, produced chiral *anti*-azido epoxides (\pm)-10c-e and *anti* diols 11c-e with high enantio purity (Table 2).






Ph	10d	48	97	11d	47	98 ^c
<i>p</i> -OMe- C ₆ H ₄	10e	47	96	11e	47	97

^{*a*} Isolated yield after column chromatographic purification; ^{*b*} ee determined by Mosher's ester analysis; ^{*c*} ee determined by chiral HPLC analysis.

The enantiomeric excess of *anti*-azido diol in **11d** was determined by chiral HPLC analysis: Chiralpak OD-H (**Fig 7**).



The formation of *anti*-azido diols **11c-e** was confirmed by ¹H and ¹³C-NMR spectroscopy. Example 1: The ¹H NMR spectrum of *anti*-azido diol **11c** showed a typical signal at δ 3.39-3.48 (m, 2H) for methylene (-CH₂-OH) protons. Its ¹³C NMR spectrum showed a characteristic signal at δ 71.4 due to the methine carbons attached to hydroxyl group (**Fig. 8**).




Fig. 8: ¹H and ¹³C NMR spectra of 11c

Example 2: The ¹H NMR spectrum of *anti*-azido diol **11d** showed signals at δ 3.56-3.71 (m, 2H) for methylene (-CH₂-OH) protons. Its ¹³C NMR spectrum showed characteristic signals at δ 62.8 and 74.0 due to the methine and methylene carbons attached to hydroxyl groups respectively (**Fig. 9**).




Fig. 9: 1 H and 13 C NMR spectra of 11d

1.1.6 Conclusion

In conclusion, the (salen) Co(III)-catalyzed HKR of racemic azido epoxides provides a highy practical route to enantiopure *syn-* or *anti-*azido epoxides, as the case may be and the corresponding 1,2-diols in a single step. The reaction is convenient to carry out under mild conditions. We believe that this HKR strategy will find applications in the field of asymmetric synthesis of bioactive molecules owing to the flexible nature of synthesis of racemic azido epoxides and the ready availability of cobalt salen catalysts in both enantiomeric forms.

1.1.7 Experimental section

A general experimental procedure for the preparation of racemic azido bromides (26a-b, 28):

A mixture of allyl alcohol (13 mmol) and NaN₃ (1.6 g, 26 mmol) was taken in CH₃CN: H_2O (30:10 mL) and NBS (2.3 g, 15.6 mmol) was added slowly *via* solid addition funnel, with stirring at 0 °C and progress of reaction was monitored by TLC. After completion of the reaction, it was diluted with EtOAc (30 mL) and washed with water and brine. The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give crude product, which was purified by column chromatography [silica gel (60-120 mesh) and petroleum ether: EtOAc (90:10) as an eluent] to afford pure product.

3-Azido-2-bromo-3-phenylpropane-1-ol (26a):

Yield: 70%; yellow liquid; IR (CHCl₃, cm⁻¹): 740, 1109, 1265, 1471, 2103, 2931, 3390;
¹H NMR (200 MHz, CDCl₃): δ 2.16 (brs, 1H), 3.98-4.10 (m, 2H), 4.20-4.29 (m, 1H),
4.68 (d, J = 8.5 Hz, 2H), 7.32-7.48 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ 57.7, 63.1,
67.1, 127.5, 128.7, 129.0, 131.6; Anal. Calcd for C₉H₁₀BrN₃O requires C, 42.21; H, 3.94;
N, 16.41; found: C, 42.30; H, 3.92; N, 16.41%.

3-Azido-2-bromo-3-(4-methoxyphenyl)propane-1-ol (26b):

Yield: 76%; yellow liquid; **IR** (CHCl₃, cm⁻¹): 740, 1106, 1263, 1473, 2106, 2931, 3393; ¹**H NMR** (200 MHz, CDCl₃): δ 2.30 (brs, 1H), 3.82 (s, 3H), 3.86-4.01 (m, 2H), 4.20-4.24 (m, 1H), 4.85 (d, *J* = 8.7, 1H), 6.92 (dd, *J* = 2.0, 8.7, 2H), 7.27 (dd, *J* = 2.0, 8.7, 2H); ¹³**C NMR** (50 MHz, CDCl₃): δ 55.1, 58.0, 63.8, 66.5, 114.0, 128.1, 128.8, 159.8; **Anal.** Calcd for C₁₀H₁₂BrN₃O₂ requires C, 41.98; H, 4.23; N, 14.69; found: C, 41.90; H, 4.20; N, 14.69%.

2-Azido-3-bromobutane-1,4-diol (28):

Yield: 76%; colorless solid **m.p.**: 52 °C; **IR** (CHCl₃, cm⁻¹): 740, 1109, 1265, 2104, 3395; ¹**H NMR** (200 MHz, CDCl₃): δ 3.74-3.95 (m, 5H), 4.12-4.20 (m, 1H), 4.43-4.54 (m, 2H); ¹³C NMR (50 MHz, CDCl₃): δ 54.3, 62.3, 63.3, 63.4; Anal. Calcd for C₄H₈BrN₃O₃ requires C, 22.87; H, 3.84; N, 20.01; found: C, 22.80; H, 3.82; N, 20.06%.

A general experimental procedure for the preparation of racemic *syn*-azido epoxides (10a-b):

Azido bromide (**26a-b**) (13 mmol) was taken in THF: H_2O (20: 5 mL) and LiOH powder (375 mg, 15.6 mmol) was added slowly with stirring at 0 °C for 2 h (monitored by TLC). The reaction mixture was diluted with EtOAc (25 mL) and water (30 mL). The organic layer was separated and the aq. layer was extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with brine and dried over anhyd. Na₂SO₄ and concentrated under reduced pressure to give crude products which were purified by column chromatography [silica gel (60-120 mesh) and petroleum ether: EtOAc (90:10) as an eluent] to give **10a-b** in 70-76% yields.

A general experimental procedure for the preparation of racemic *anti*-azido epoxide (10c):

Azido bromide **28** (10 mmol) was taken in THF (20 mL) and NaOH powder (0.4 g, 10 mmol) was added slowly with stirring at 0 °C for 2 h (monitored by TLC). The reaction mixture was diluted with EtOAc (25 mL) and water (30 mL). The organic layer was separated and the aq. layer was extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with brine and dried over anhyd. Na₂SO₄ and concentrated under reduced pressure to give crude product, which was dissolved in dry CH₂Cl₂ (20 mL) followed by the addition of imidazole (10 mmol) and *t*-butyl dimethyl silyl chloride (10 mmol). It was stirred for 0.5 h and quenched with aq. NaHCO₃ solution (20 mL). The aq. layer was extracted with CH₂Cl₂ (2 × 30 mL), dried over anhyd. Na₂SO₄ and concentrated

in vacuo to give the crude product, which was purified by column purified by column chromatography [silica gel (60-120 mesh) and petroleum ether:EtOAc (90:10) as an eluent] to give **10c** in 76% yield.

A general experimental procedure for the Hydrolytic Kinetic Resolution (HKR) of racemic azido epoxides:

To a solution of (R,R)-1 or (S,S)-1 (0.043 g, 0.07 mmol) in toluene (2.0 mL) was added acetic acid (0.04 g, 7.3 mmol). It was allowed to stir at 25 °C in open air for 30 min. over which time the color changed from orange-red to a dark brown and it was then concentrated in vaccuo to get the Co-salen complex as brown colored solid.

To a solution of Co-salen complex -1 (0.004 g, 0.5 mol%) and azido epoxide (1.41 mmol) in THF (0.5 mL) at 0 °C was added H₂O (0.012 g, 0.5 mmol) dropwise over 5 min. The reaction was allowed to warm to 25 °C and stirred for 14 h. After completion of reaction (monitored by TLC), solvent was removed *in vaccuo*. The crude product was purified by column chromatography over silica gel to give chiral azido epoxides **10a-e**, (solvent system; pet ether: EtOAc = 90:10) and chiral azido diols **11a-e** (solvent system; pet ether: EtOAc = 70:30) in pure form.

(2R,3S)-2-(Azidophenylmethyl)-oxirane (10a):

Yield: 48%; yellow liquid; [α]²⁵_D: +120 (*c* 1, CHCl₃); **IR** (CHCl₃, cm⁻¹): 758, 860, 1125, 1250, 1460, 1493, 1602, 2105, 2932, 3025; ¹H NMR (200 MHz, CDCl₃): δ 2.73-2.84 (m, 2H), 3.23-3.29 (m, 1H), 4.25 (d, *J* = 6.1, 1H), 7.35-7.47 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ 44.6, 54.6, 66.8, 127.2, 128.8, 128.9, 135.7; **Anal.** Calcd for C₉H₉N₃O requires C, 61.70; H, 5.18; N, 23.99; found: C, 61.79; H, 5.14; N, 23.90%.

(2R,3S)-2-(Azido-4-methoxyphenylmethyl)oxirane (10b):

Yield: 48%; yellow gum; $[\alpha]^{25}_{D}$: +82 (*c* 0.9, CHCl₃); **IR** (CHCl₃, cm⁻¹): 1039, 1250, 1516, 1609, 2106, 2932, 3025; ¹H NMR (200 MHz, CDCl₃): δ 2.72-2.73 (m, 1H), 2.78-2.80 (m, 1H), 3.21-3.24 (m, 1H), 3.82 (s, 1H), 4.21(d, *J* = 5.1 Hz, 1H), 6.91 (d, *J* = 8.6, Hz, 2H) 7.30 (d, *J* = 8.6 Hz, 2H); ¹³C NMR (50 MHz, CDCl₃): δ 44.6, 54.6, 55.1, 66.1, 114.2, 127.7, 128.5, 159.8; **Anal.** Calcd for C₁₀H₁₁N₃O₂ requires C, 58.53; H, 5.40; N, 20.48; found C, 58.48; H, 5.45; N, 20.56%.

(2S,3S)-3-Azido-4-tert-butyldimethylsilyloxy-1,2-epoxybutane (10c):

Yield: 48%; yellow liquid; $[\alpha]^{25}_{D}$: +26 (*c* 1, CHCl₃); **IR** (CHCl₃, cm⁻¹): 740, 839, 1127, 1250, 1463, 1493, 1602, 2106, 2932, 3025; ¹H NMR (200 MHz, CDCl₃): δ 0.09 (s, 6H), 0.90 (s, 9H), 2.73 (dd, *J* = 5.0, 2.6 Hz, 1H), 2.80 (dd, *J* = 5.0, 3.6 Hz, 1H), 3.01-3.07 (m, 1H), 3.21-3.29 (m, 1H), 3.74-3.90 (m, 2H); ¹³C NMR (50 MHz, CDCl₃): δ -5.5, 18.2, 25.7, 45.2, 50.2, 63.5, 63.9; **Anal.** Calcd for C₁₀H₂₁N₃O₂Si requires C, 49.35; H, 8.70; N, 17.27; found: C, 49.20; H, 8.75; N, 17.30%.

(2S,3S)-2-(Azido-phenylmethyl)oxirane (10d):

Yield: (48%); yellow liquid; $[\alpha]^{25}_{D}$: +170 (*c* 1.5, CHCl₃); **IR** (CHCl₃, cm⁻¹): 758, 862, 1127, 1250, 1463, 1493, 1602, 2106, 2932, 3025; ¹H NMR (200 MHz, CDCl₃): δ 2.82-2.84 (m, 1H), 2.86-2.88 (m, 1H), 3.21-3.23 (m, 1H), 4.59 (d, *J* = 4.5, 1H), 7.34-7.40 (m, 5H); ¹³C NMR (50 MHz, CDCl₃) δ : 44.5, 53.6, 64.9, 127.2, 128.6, 128.7, 135.7; **Anal.** Calcd for C₉H₉N₃O requires C, 61.70; H, 5.18; N, 23.99; found: C, 61.79; H, 5.14; N, 23.90%.

(2S,3S)-2-(Azido-4-methoxyphenyl-methyl)oxirane (10e):

Yield: 47%; yellow gum; $[\alpha]_{D}^{25}$: +90 (*c* 0.8, CHCl₃); **IR** (CHCl₃, cm⁻¹): 1039, 1250, 1516, 1609, 2106, 2932, 3025; ¹H NMR (200 MHz, CDCl₃): δ 2.83 (d, *J* = 5.0 Hz, 2H),

3.19-3.21 (m, 1H), 3.82 (s, 1H), 4.55 (d, J = 5.1 Hz, 1H), 6.91 (d, J = 8.6, Hz, 2H) 7.30 (d, J = 8.6 Hz, 2H); ¹³C NMR (50 MHz, CDCl₃): δ 44.9, 53.2, 55.10, 64.7, 114.2, 127.7, 128.7, 159.8; **Anal.** Calcd for C₁₀H₁₁N₃O₂ requires C, 58.53; H, 5.40; N, 20.48; found: C, 58.48; H, 5.45; N, 20.56%.

(2S, 3R)-3-Azido-3-phenylpropane-1,2-diol (11a):

Yield: 47%; gum; $[\alpha]^{25}{}_{\text{D}}$: -188 (*c* 1, CHCl₃); 98% ee by chiral HPLC analysis (Chiralpak OD-H, *n*-hexane/*i*PrOH, 90:10, 0.5 mL/min) retention time 13.020 (0.90%) and 13.512 (99.20%); **IR** (CHCl₃, cm⁻¹): 859, 828, 1039, 1100, 1384, 1454, 1493, 1602, 2099, 2932, 3052, 3392 (broad); ¹H NMR (200 MHz, CDCl₃): δ 3.30 (dd , *J* = 11.5, 6.0 Hz, 1H), 3.44 (d, *J* = 11.5 Hz, 1H), 3.80 (br s, 1H), 3.62-3.94 (m, 1H), 4.52 (d, *J* = 8.1 Hz, 1H), 7.28-7.35 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ 62.8, 68.1, 75.0, 127.5, 128.7, 128.9, 136.2; **Anal.** Calcd for C₉H₁₁N₃O₂ requires C, 55.95; H, 5.74; N, 21.75; found: C, 56.10; H, 5.65; N, 21.60%.

(2S, 3R)-3-Azido-3-(4-methoxyphenyl)propane-1,2diol (11b):

Yield: 48%; yellow liquid; $[α]^{25}$ _D: -190 (*c* 1, CHCl₃); 98% ee by chiral HPLC analysis (Chiralpak OD-H, *n*-hexane/*i*PrOH, 90:10, 0.5 mL/min) retention time 15.97 (1.50%) and 17.73 (98.50%); **IR** (CHCl₃, cm⁻¹): 1035, 1195, 1513, 1616, 2100, 2920, 3050, 3368; ¹H **NMR** (200 MHz, CDCl₃): δ 2.09 (br s , 1H), 2.81 (br s , 1H), 3.35 (dd, *J* = 11.2, 4.8 Hz, 1H), 3.55 (dd, *J* = 11.6, 2.3 Hz, 1H), 3.75-3.86 (m, 1H), 3.82 (s, 3H), 4.58 (d, *J* = 8.4 Hz, 1H), 6.92 (dd, *J* = 8.7, 2.1 Hz, 2H) 7.27 (dd, *J* = 6.0, 2.1 Hz, 2H); ¹³C **NMR** (50 MHz, CDCl₃): δ 55.1, 62.7, 67.8, 75.0, 114.3, 128.0, 128.8, 159.8; **Anal.** Calcd for C₁₀H₁₃N₃O₃ requires C, 55.95; H, 5.74; N, 21.75; found: C, 56.10; H, 5.65; N, 21.60%.

(2R,3R)-3-Azido-4-(tert-butyldimethylsilyloxy)butane-1,2-diol (11c):

Yield: 47%; yellow liquid; $[\alpha]^{25}{}_{D}$: -29 (*c* 1, CHCl₃); **IR** (CHCl₃, cm⁻¹): 740, 839, 1109, 1265, 1471, 2100, 2931, 3390; ¹H NMR (200 MHz, CDCl₃): δ 0.12 (s, 6H), 0.90 (s, 9H), 2.92 (br s, 1H), 3.39-3.48 (m, 2H), 3.61-3.81 (m, 3H), 3.81-3.97 (m, 2H); ¹³C NMR (50 MHz, CDCl₃): δ -5.5, 18.1, 25.7, 63.5, 63.6, 63.8, 71.4; **Anal.** Calcd for C₁₀H₂₃N₃O₃Si requires C, 45.95; H, 8.87; N, 16.08; found: C, 45.90; H, 8.92; N, 16.13%.

(2R, 3R)-3-Azido-3-phenylpropane-1,2-diol (11d):

Yield: 46%; yellow gum; $[a]^{25}_{D}$: -180 (*c* 0.35, CHCl₃); 98% ee by chiral HPLC analysis (Chiralpak OD-H, *n*-hexane/*i*PrOH, 90:10, 0.5 mL/min) retention time 14.68 (0.80%) and 15.89 (99.14%); **IR** (CHCl₃, cm⁻¹): 859, 828, 875, 1039, 1101, 1386, 1456, 1493, 1602, 2099, 2934, 3032, 3392; ¹H NMR (200 MHz, CDCl₃) : δ 2.59 (br s, 1H), 2.77 (br s, 1H), 3.58-3.71 (m, 2H), 3.72-3.86 (m, 1H), 4.57 (d, *J* = 7.0 Hz, 1H), 7.30-7.44 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ 62.8, 66.9, 74.0, 127.8, 128.7, 128.9, 136.1; **Anal.** Calcd for C₉H₁₁N₃O₂ requires C, 55.95; H, 5.74; N, 21.75%; found: C, 56.08; H, 5.66; N, 21.61%.

(2R, 3R)-3-Azido-3-(4-methoxyphenyl)propane-1,2-diol (11e)

Yield: 47%; yellow liquid; $[\alpha]^{25}{}_{D}$: -110 (*c* 0.35, CHCl₃); **IR** (CHCl₃, cm⁻¹): 1035, 1195, 1513, 1616, 2100, 2920, 3050, 3368 (broad); ¹H NMR (200 MHz, CDCl₃): 3.08 (br s , 2H), 3.56-3.68 (m, 2H), 3.70-3.78 (m, 1H), 3.80 (s, 3H), 4.47 (d, *J* = 6.9 Hz, 1H), 6.90 (d, *J* = 8.1, Hz, 2H), 7.24 (d, *J* = 8.0 Hz, 2H); ¹³C NMR (50 MHz, CDCl₃): δ 55.1, 62.9, 66.5, 73.9, 114.3, 127.9, 129.1, 159.8; **Anal.** Calcd for C₁₀H₁₃N₃O₃ requires C, 55.95; H, 5.74; N, 21.75; found: C, 56.10; H, 5.65; N, 21.60%.

Section II

Enantioselective synthesis of (+)-*epi*-Cytoxazone and (-)- Cytoxazone *via* hydrolytic kinetic resolution of azido epoxides

1.2.1 Introduction

In 1998, Osada and co-workers reported the isolation of (4R,5R)-5-(hydroxymethyl)-4-(4-methoxyphenyl)-1,3-oxazolidine-2-one [(-)-**29**, generic name cytoxazone],¹⁷ which was shown to possess high cytokine modulator activity by acting on the Th2 cells.¹⁸ Because of these biological properties, several total syntheses of (-)-**29** and its *trans*diastereoisomer (+)-*epi*-cytoxazone (**30**) (**Fig. 10**) have been reported.¹⁹




Fig. 10: Structures of (-)-cytoxazone (29) and (+)-*epi*-cytoxazone (30)

Prompted by the first positive biological results, many researchers have also reported the preparation of *cis-* and *trans*-isocytoxazones which are structural isomers of cytoxazone **29** and its *trans* epimer **30** (Fig 10).²⁰

1.2.2 Pharmacology of cytoxazone


It is well established that the induction of humoral or cellular response is influenced by the development of distinct subsets of CD4⁺ T cells.²¹ The Th1 cell subset produces predominantly IL-2, GM-CSF, INF- γ , and TNF- β , (type 1 cytokines) and is involved in delayed-type hypersensitivity reactions, whereas the Th2 cell subset secretes IL-4, IL-5,

IL-6, IL-10, and IL-13 (type 2 cytokines), which are important factors for β cell growth and differentiation to Ig secretion. The imbalance of cytokine production by CD4⁺ T cells leads to a wide variety of immunological disorders, i.e. allergy, progressive lymphoproliferation, and severe immunodeficiency.²² Skin and lung biopsies from allergic patients indicate that the pivotal cells in the allergic site are the Th2 cells.²³ Treatments effectively suppressing the function or the differentiation of these allergenspecific Th2 cells will most likely provide efficient ways to intervene in Ig-mediated allergic diseases. In the course of screening for chemical immunomodulators that inhibit the type 2 cytokine productions in Th2 cells, it was found that cytoxazone containing a 2oxazolidinone ring, which is rare in microbial metabolites, as a novel cytokine modulator produced by *Streptomyces* sp. Cytoxazones show a cytokine-modulating activity by inhibiting the signaling pathway of Th2 cells, but not Th1 cells.

1.2.3 Review of literature


Nakata's approach (1999)²⁴

Nakata *et al.* have achieved the synthesis of (-)-cytoxazone (**29**) using Sharpless asymmetric dihydroxylation of ester **31**. The cyclic sulfite **33** was obtained (in 99% yield and 97% ee) from ethyl *p*-methoxycinnamate **31** by a two-step process involving the Sharpless catalytic asymmetric dihydroxylation followed by treatment with SOCl₂. The cyclic sulfite **33** was then opened using LiN₃ and the alcohol obtained was protected as the corresponding carbonate **34**. Intramolecular cyclization of carbonate **34** with PPh₃ followed by the deprotection of TBDPS group gave (-)-cytoxazone (**29**) in 89% ee and 96% yield (**Scheme 8**).



Scheme 8: (i) (a) AD-mix-α, *tert*-BuOH: H₂O (1:1), 25 °C, 93 %, 99% ee; (b) NaBH₄, THF, 0 °C, 66%; (c) TBDPSCI, imid., DMF, 0 °C, 99%; (ii) SOCl₂, Et₃N, CH₂Cl₂, 0 °C, 99%; (iii) LiN₃, DMF, 70 °C, 74 %; iv) ClCO₂Ph, Py, CH₂Cl₂, 25 °C, 96%; (v) PPh₃, THF/ H₂O, 50 °C, 90%; (vi) n-Bu₄NF, THF, 0 °C, 89% ee, 96%.

The same group has achieved the synthesis of (-)-*epi*-cytoxazone **30** from the common intermediate **32** by using an efficient one-step process of stereoselective azidation (Scheme 9).




<u>Scheme 9:</u> (i) CICO₂Et, Py, CH₂Cl₂, 0 °C, 92%; (ii) TMSN₃, TMSOTf, MeCN, -43 °C, 99%; (iii) PPh₃, THF/H₂O, 50 °C, 100%; (iv) n-Bu₄NF, THF, 0 °C, 99%.

Thus, (4*S*,5*S*)-di(ethylcarbonate) **36**, prepared from diol **32**, was treated with TMSN₃ (6 eq.) in the presence of TMSOTf to afford a 6:1 mixture of the desired α -azide **37** and its β -isomer **38**. The α -azide **37** was then treated with PPh₃ in THF/H₂0 to give 2-oxazolidinone **39**, which was converted to *4-epi*-cytoxazone (**30**) in 99% yield using tetrabutylammonium fluoride.


Sunjic's approach (2001)²⁵

In this approach, synthesis of (-)-cytoxazone (\pm)-(29) was achieved starting from the glycidic ester (\pm)-40 using enzymatic kinetic resolution. Nucleophilic ring opening of the epoxide (\pm)-40 with NaN₃, followed by protection of the alcohol and intramolecular cyclization gave ester (\pm)-42. Reduction of the ester (\pm)-42 and the subsequent kinetic resolution of racemic (\pm)-29 using *Penicillium camemberti* lipase (PcamL) afforded (-)-cytoxazone (29) in 33% overall yield and 88.2% ee (Scheme 10).



<u>Scheme 10:</u> (i) aq. NaN₃, dioxane, 50 °C, 3 h, 56%; (ii) ClCO₂Ph, CH₂Cl₂, -5 °C, 1 h, 100%; (iii) (a) Ph₃P, aq THF, 50 °C, 1.5 h, 88%; (b) NaBH₄, CaCl₂, absolute EtOH, 25 °C, 20 min, 79%; (iv) PcamL, vinyl acetate, 30 °C; (v) KOH, MeOH, 25 °C, 1 h.

Also, (\pm) -*epi*-cytoxazone (\pm) -**30b** was synthesized from the common intermediate, oxazolidinone (\pm) -**42** (Scheme 11). Epimerization at C(5) in oxazolidinone (\pm) -**42** using potassium hydroxide followed by esterification with methyl iodide gave ester **44**. Reduction of ester **44** with calcium chloride/sodium borohydride and the subsequent kinetic resolution using CAL in SOL-Gel-AK afforded (+)-*epi*-cytoxazone **30** in 49% overall yield and 87.3% ee.




<u>Scheme 11:</u> (i) (a) KOH, EtOH, reflux, 1 h; (b) MeI, K_2CO_3 , DMF, 25 °C, 16 h, 46%; (ii) NaBH₄, CaCl₂, absolute EtOH, 25 °C, 20 min., 82%; (iii) CAL in SOL-Gel-AK, vinyl acetate, 30 °C; (iv) KOH, MeOH, 25 °C, 1 h.

Carter's approach (2003)²⁶

Carter *et al.* have made use of the Evans'aldol approach as the key reaction for the synthesis of (-)-cytoxazone **29** as well as (+)-*epi*-cytoxazone **30**. The reaction of dibutylboron enolate of **46** with the benzyloxyacetaldehyde provided the aldol **47** in good *syn*-diastereoselectivity. Removal of the chiral auxiliary from **47** provided the acid **48**, which was transformed into the oxazolidinone **51** in a one-pot 3 step procedure: (i) acyl azide formation, (ii) Curtius rearrangement and (iii) isocyanate trapping. Ether **51** was

debenzylated using Pearlman's catalyst to provide (-)-cytoxazone **29**. The synthesis of (+)-*epi*-cytoxazone required the use of an *anti*-selective aldol product **49**, which was obtained by the addition of a pre-complexed solution of benzyloxyacetaldehyde and 0.5 equiv. of SnCl₄ to the dibutylboryl enolate of **46**. The same sequence of reactions was used to synthesize (+)-*epi*-cytoxazone (**30**) starting from aldol product **49** (Scheme 12).




Scheme 12: (i) Bu₂BOTf, *i*-Pr₂EtN, -78 °C, 20 min.; BnOCH₂CHO, -78 °C to 0 °C, 1.5 h, 51%; (ii) 4:1 THF:H₂O, H₂O₂, LiOH, 0 °C, 1 h; NaHSO₃, 99%; (iii) (PhO)₂PON₃, PhCH₃, 23 °C, 40 min., 110 °C, 3h, 77%; (iv) H₂ (1 atm), Pd(OH)₂, MeOH, 23 °C, 24 h, 84%; (v) Bu₂BOTf, *i*-Pr₂EtN, 0 °C, 30 min., add BnOCH₂CHO precomplexed w/0.5 equiv SnCl₄, -78 °C, 3 h, 64%; (vi) (PhO)₂PON₃, CH₂Cl₂, 23 °C, 40 min., 45 °C, 12 h, 61%.


Saicic's approach (2004)²⁷

Saicic's approach was based on the Sharpless asymmetric aminohydroxylation reaction, starting from methyl *p*-methoxycinnamate, **53** in six steps and 31% overall yield (**Scheme 13**). The required *anti*-aminoalcohol **56** was synthesized using Sharpless asymmetric aminohydroxylation and subsequent inversion of configuration in

amidoalcohol 54 via an oxazoline 55.




Subjecting amidoalcohol **54** to the sequence of reactions already described for cytoxazone (hydrolysis/cyclization/esterification), gave the methyl ester **59**, which on reduction with sodium borohydride gave (+)-*epi*-cytoxazone **30** (Scheme 14).



<u>Scheme 14:</u> (i) 10% HCl, reflux, 4 h; (ii) ClCO₂CCl₃, NaOH, H₂O, 0 °C; (iii) CH₂N₂, THF, 63%; (iv) NaBH₄, THF, 0 °C, 80%.

Sudalai's approach (2006),(2007)^{28,29}


Sudalai *et al.* have developed a simple method for the enantioselective synthesis of (-)cytoxazone **29** using Sharpless asymmetric epoxidation as the key step. Thus, asymmetric epoxidation of allylalcohol **61** gave chiral epoxide **62**, which was further acylated to give acetate **63**. The nucleophilic opening of the epoxide **63** at the benzylic position with NaN₃ gave azido alcohol **64** in 88% yield. The protection of the alcohol followed by reductive cyclization with PPh₃ and deprotection of acetate group gave oxazolidinone **67**, which was directly subjected to methylation with methyl iodide in the presence of NaH to afford (-)-cytoxazone (**29**) in 65% yield and 83% ee (**Scheme 15**).



<u>Scheme 15:</u> (i) allyl alcohol, AgOAc, Pd(OAc)₂, PPh₃, DMF, 70 °C, 16 h, 81%. (ii) anhyd. 5.4 M TBHP in CH₂Cl₂, 4 Å molecular sieves, Ti(OiPr)₄, (+)-DIPT, CH₂Cl₂, -20 °C, 20 h, 78%. (iii) AcCl, Et₃N, DMAP, CH₂Cl₂, 25 °C, 87%. (iv) NaN₃, NH₄Cl, THF/H₂O (2:1), 50 °C, 3 h, 79%. (v) PhOCOCl, pyridine, CH₂Cl₂, -5 to 25 °C, 1 h, 93%. (vi) PPh₃, THF/H₂O (10:1), 50 °C, 2 h, 87%. (vii) aq NaHCO₃, MeOH, reflux, 1 h. (viii) NaH, MeI, THF, 0–25 °C, 3 h, 69%, 83% ee.

The same group has achieved the synthesis of (+)-*epi*-cytoxazone (**30**) using L-proline catalyzed asymmetric Mannich reaction. Thus, key intermediate *syn*-amino alcohol **71** was obtained from L-proline catalyzed asymmetric Mannich reaction of 4-methoxybenzaldehyde, **68** hydroxyacetone **69** and p-anisidine **70** in 76% yield with *syn/anti* ratio (2:1). Amino alcohol **71** was then protected with triphosgene to give


oxazolidinone **72** in 82% yield. *In situ* generated silyl enol ether **73** was subjected for ozonolysis without purification. Reductive work up of ozonide and PMP deprotection with CAN gave (+)-*epi*-cytoxazone (**30**) in 59% yield and 81% ee (**Scheme 16**).



<u>Scheme 16:</u> (i) *p*-anisidine, hydroxyacetone,. L-proline, DMSO, 25 °C, 24 h, 76%. (ii) triphosgene, Et₃N, CH₂Cl₂, -10 to 25 °C, 82%. (iii) Li-HMDS, TMSCl, THF, -78 °C. (iv) (a) O₃, PPh₃, CH₂Cl₂, -78 °C. (b) NaBH₄, MeOH, 25 °C. (c) CAN, CH₃CN, 5 h, 59% (in three steps), 81% ee.


Sudalai *et al.* have also developed a simple method for the enantioselective synthesis of (-)-cytoxazone **29** and (+)-epi-cytoxazone **30** commencing from the diol **74** and **80** respectively which were obtained by two different routes: hydrolytic kinetic resolution and proline-catalyzed α -aminooxylation. Diol **74** was converted to *bis*-TBS-protected silyl ether followed by selective deprotection of the primary OH group with camphorsulfonic acid to afford **75** which was converted into sulfamate ester **76** in 76% yield using HCO₂H and chlorosulfonyl isocyanate. The γ -C-H insertion of **76** was carried out with a catalytic amount of Rh₂(OAc)₄ (2 mol%), PhI(OAc)₂ and MgO in CH₂Cl₂ to give sulfamate ester **77** with *anti* (10:1) diastereoselectivity. The TBS deprotection, carbamoylation and ring opening of *N*-Boc protected oxathiazinane furnished the *anti*-

amino alcohol **79** in 84% which was converted to (-)-cytoxazone (**29**) by intramolecular cyclization using NaH in THF (**Scheme 17**).



<u>Scheme 17:</u> (i) (a) TBSCl, imidazole, DMF, 25 °C, 4 h, 98%; (b) camphorsulfonic acid, MeOH, 95%; (ii) HCO₂H, chlorosulfonyl isocyanate, 0 °C, 76%; (iii) 2 mol% Rh₂(OAc)₄, PhI(OAc)₂, MgO, CH₂Cl₂, 40 °C, 2 h, 82%, *anti:syn* (10:1); (iv) (a) camphorsulfonic acid, MeOH, 25 °C, 1 h, 97%; (b) (a) (Boc)₂O, DMAP, Et₃N, CH₂Cl₂, 25 °C, 1 h; (c) CH₃CN:H₂O (4:3), 60 °C, 4 h, 84%; (v) NaH, THF, 0 °C, 1 h, 96%.


In the case of (+)-epi-cytoxazone **30**, protection of the primary alcohol of diol **80** with TBSCl gave the secondary alcohol **81**, which was converted into carbamate **82** in 92% yield using reported conditions (trichloroacetyl isocyanate, CH_2Cl_2 , then K_2CO_3 , MeOH, H_2O). Carbamate **82** underwent C–H insertion on treatment with 2 mol % $Rh_2(OAc)_4$, $PhI(OAc)_2$ and MgO in CH_2Cl_2 at 40 °C to afford the corresponding oxazolidinone **83** with syn diastereoselectivity (5.5:1) (determined from ¹H NMR analysis) in 87% combined yield. The syn-diastereomer, oxazolidinone **83**, was readily separated by column chromatography. Finally, deprotection of the TBS group using TBAF in THF furnished (+)-epi-cytoxazone **30** in 92% yield (**Scheme 18**).



<u>Scheme 18:</u> (i) TBSCl, imidazole, CH_2Cl_2 , 25 °C, 98%; (ii) trichloroacetyl isocyanate, CH_2Cl_2 , 0 °C-25 °C, 2 h then K_2CO_3 , MeOH, H_2O , 0-25 °C, 12 h, 92%; (iii) 2 mol% $Rh_2(OAc)_4$, $PhI(OAc)_2$, MgO, CH_2Cl_2 , 40 °C, 87%, *syn: anti* (5.5: 1); (iv) TBAF, THF, 92%.

Kim's approach (2008)³⁰

Kim et al synthesis of (+)-epi-cytoxazone **30** the Mannich reaction between N-Boc-imine **84** and benzyloxyacetaldehyde **85** afforded the corresponding β -amino aldehyde 10 in high yield with excellent enantioselectivity. β -amino aldehyde **86** was reduced with sodium borohydride to afford β -amino alcohol **87** in 98 % yield. Deprotection of **87** by hydrogenolysis of the benzyl group afforded the desired diol **88** in 91% yield. Finally, treatment of compound **88** with sodium hydride in THF led to regioselective cyclization to give (+)-epi-cytoxazone **30** in 85% yield (**Scheme 19**).




<u>Scheme 19:</u> (i) (2*S*,5*S*)-5-Benzyl-3-methyl-2-pyrrole-imidazolidine-4-one (20 mol%), CHCl₃, -30 °C, 78%; (ii) NaBH₄, MeOH, 0 °C-25 °C, 98%; (iii) 10% Pd/C, H₂, EtOH, 91%; (iv) NaH, THF, 85%.

1.2.4 Present Work:

1.2.4.1 Objective

Literature search revealed that several methods such as classical resolution, chemoenzymatic or enantioselective synthesis have been reported for the synthesis of (-)cytoxazone **29** and its epimer (+)-*epi*-cytoxazone **30**. However, these methods suffer from many disadvantages such as low overall yields, the need for separation of diastereomers and the use of expensive chiral reagents. The synthetic precursors of (-)cytoxazone **29** and (+)-*epi*-cytoxazone **30** are 1,2-aminoalcohols, which have been the subject of thorough synthetic efforts in recent years.^{1a} Most of the syntheses for cytoxazone have made use of indirect methods to establish the *anti*-amino alcohol functionality. In this context, a more practical method for the synthesis of (+)-*epi*cytoxazone **30** and (-)-cytoxazone **29** is highly desirable. In this section, we describe a concise enantioselective synthesis of (+)-*epi*-cytoxazone **30** and (-)-cytoxazone **29** using HKR of racemic azido epoxides.

Retrosynthetic analysis (Scheme. 20) of (+)-*epi*-cytoxazone 30 reveals that *syn*-amino alcohol 88 could be visualized as the key intermediate.




Scheme 20: Retrosynthetic analysis of (+)-epi-cytoxazone 30

The *anti*-isomer **88** could be prepared from *syn*-azido diol **11b** obtained by the cobaltcatalyzed hydrolytic kinetic resolution of racemic azido epoxide (\pm)-**10b** (see Section I).

1.2.5 Results and Discussion

Our synthesis of (+)-*epi*-cytoxazone **30** has started from 4-methoxycinnamyl alcohol 1**5b**, which was transformed into *syn*-azido epoxide (\pm)-**10b** in two steps: (i) azidobromination; (ii) formation of epoxide to give *syn*-azido epoxide (\pm)-**10b** in 75% yield. The *syn*-azido epoxide (\pm)-**10b** was then subjected to HKR using (*R*,*R*)-Co(salen)OAc (**1**) to give chiral *syn*-azido diol in **11b** 48% yield with 97% ee along with chiral *syn*-azido epoxide in **10b** 48% yield with 98% ee (**Scheme 21**). The compound **10b** and **11b** were then readily separated by column chromatographic purification. The enantiomeric excess of *syn*-azido diol in **11b** was determined by chiral HPLC analysis; (Chirapalk OD-H, see **Section I**).



<u>Scheme 21:</u> (i) NBS, NaN₃, CH₃CN: H₂O (4:1), 0 °C, 75%; (ii) LiOH, THF: water (4: 1), 0- 25 °C, 3 h 76%; (iii) (R,R)-Co(salen)OAc (0.5 mol%), THF, H₂O (0.5 equiv), 0 °C, 12 h; (iv) polymethylhydrosiloxane (PMHS), 10% Pd/C, (Boc)₂O, EtOH, 25 °C, 4 h, 95%; (v) NaH, dry THF, 25 °C, 3 h, 96%.

Azido diol **11b** was then subjected to one pot azide reduction and Boc protection [10% Pd/C, polymethylhydrosiloxane (PMHS) and (Boc)₂O in EtOH] to give N-Boc amino diol **88** in 95 % yield, which was confirmed by ¹H and ¹³C-NMR spectroscopy. The ¹H NMR spectrum of **88** showed a typical signal at δ 1.43 (s, 9H) for *tert*-butyl protons. Its ¹³C NMR spectrum showed characteristic signal at δ 28.3 due to the methyl carbons of *tert*-butyl group (**Fig. 11**).




Fig. 11: ¹H and ¹³C NMR spectra of 88

Finally, the regioselective intramolecular cyclization of 88 using NaH in THF gave (+)*epi*-cytoxazone **30** (mp 158-160 °C; lit.³⁰ mp 159-160 °C) in 96 % yield and 98% ee. The formation of (+)-*epi*-cytoxazone **30** was confirmed by ¹H and ¹³C-NMR spectroscopy. The ¹H NMR spectrum of (+)-*epi*-cytoxazone **30** showed a typical signal at δ 8.0 (br s, 1H) for N-H proton of oxazolidinone ring. Its ¹³C NMR spectrum showed a characteristic signal at δ 159.2 due to the carbonyl carbons in oxazolidinone ring. The ¹H NMR and ¹³C NMR spectral data of (+)-*epi*-cytoxazone **30** matched very well with that of the reported values (**Fig. 12**).³⁰





Fig. 12: ¹H and ¹³C NMR spectra of (+)-*epi*-cytoxazone 30

Synthesis of (-)-cytoxazone **29**, has started from racemic azido epoxide (\pm)-10b, which was subjected to epoxide opening with 0.5M aq. NaOH, in *tert*-BuOH to furnish racemic azido diol **11b**. The selective protection of primary alcohol as pivolyl ester gave azido




pivalate ester (±)-89 in 96% yield (Scheme 22).

Scheme 22: (i) 0.5N aq. NaOH, *tert*-BuOH, 12 h, 70 °C, 90%; (ii) PivCl, Pyridine/CH₂Cl₂ (1: 1), 0 °C, 5 h, 96%; (iii) MsCl, Et₃N, DMAP, CH₂Cl₂, 25 °C, 10 h, 90%; (iv) K₂CO₃, MeOH, 25 °C, 6 h, 81% over two step; (v) (*S*,*S*)-Co(salen)OAc (0.5 mol%), THF, H₂O (0.5 equiv), 0 °C, 14 h; (vi) poly(methylhydrosiloxane) (PMHS), 10% Pd/C, (Boc)₂O, EtOH, 25 °C, 4 h, 90%; (vii) NaH, dry THF, 25 °C, 3 h, 89%.

The formation of pivalate (±)-89 was confirmed by ¹H and ¹³C-NMR spectroscopy. The ¹H NMR spectrum of pivalate (±)-89 showed a typical signal at δ 1.15 (s, 9H) for *tert*-butyl protons. Its ¹³C NMR spectrum showed a characteristic signal at δ 178.2 due to the ester carbonyl carbon (Fig. 13).

The secondary alcohol in pivalate (\pm)-89 was mesylated (pyridine, MsCl) followed by hydrolysis (K₂CO₃, MeOH) gave the *anti*-azido epoxide (\pm)-10e in 81% yield. Its formation was confirmed by ¹H and ¹³C-NMR spectroscopy.



The ¹H NMR spectrum of *anti*-azido epoxide (\pm)-10e showed signals at δ 3.17-3.22 (m, 1H) for methine proton. Its ¹³C-NMR spectrum showed a typical signal at δ 44.7 due to methylene carbon of the epoxide ring (Fig. 14).






Fig. 14: ¹H and ¹³C NMR spectra of (\pm) -10e

Racemic azido epoxide (\pm)-10e was then subjected to HKR using (*S*,*S*)-Co(salen)OAc to furnish the required chiral azido diol 11e in 48% chemical yield and 97% ee along with azido epoxide (+)-10e in 48% yield and 98% ee (Fig. 15).


Azido diol **11e**, obtained from **10e**, was then subjected to one pot azide reduction and Boc protection [10% Pd/C, polymethylhydrosiloxane (PMHS) and (Boc)₂O in EtOH] to give N-Boc amino diol **79** in 95% yield, which was confirmed by ¹H and ¹³C-NMR spectroscopy.



The ¹H NMR spectrum of N-Boc amino diol **79** showed a typical signal at δ 1.43 (s, 9H) for *tert*-butyl protons. Its ¹³C NMR spectrum showed characteristic signal at δ 28.2 due to the methyl carbons of *tert*-butyl group (**Fig. 16**). Finally, the regioselective intramolecular cyclization of **79** using NaH in THF gave (-)-cytoxazone **29** in 90 % yield and 97% ee. It is a colorless solid; **mp**: 118-121 °C (lit.²⁹ **mp**: 118-121 °C); $[\alpha]^{25}_{D}$: -70 (*c* 0.5, MeOH) {lit.²⁹ $[\alpha]^{25}_{D}$: -71 (*c* 1, MeOH)}; Its ¹³C NMR spectrum showed a characteristic signal at δ 160.0 due to presence of the oxazolidinone carbonyl carbon.



The ¹H NMR and ¹³C NMR spectral data of (-)-cytoxazone 29 matched very well with that of the reported values (Fig. 17).^{28, 29}



1.2.6 Conclusion

The enantioselective syntheses of (+)-*epi*-cytoxazone **30** (43.7% overall yield with 97% ee) and (-)-cytoxazone **29** (37.6% over all yield with 97% ee) have been achieved, starting from the respective racemic azido epoxides **10b** and **10e**. The method involved a cobalt-catalyzed hydrolytic kinetic resolution of azido epoxides as the key reaction.

1.2.7 Experimental section

For the preparation of (10b, 11b, 11e and 26b) see Section I of this chapter

(2S, 3R)-3-tert-Butoxycarbonylamino-3-(4-methoxyphenyl)propane-1,2-diol (88):

To a solution of azido diol **11b** (0.798 mg, 3.58mmol) in ethyl alcohol (25 mL) was added 10% Pd-C (0.15 mg), polymethylhydrosiloxane (0.64 mg, 10.76 mmol), and di*tert*-butyl dicarbonate (0.86 g, 3.94 mmol). After stirring for 4 h, the reaction mixture was filtered, and the filtrate was evaporated in vacuo. The residue was purified by column chromatography to give NHBoc diol **88** in 95% yield (1.0 g).

Yield: 95%; colourless solid **mp**: 141-143 °C {lit.³⁰ **mp**: 141-142 °C}; $[\alpha]^{25}_{D}$: -37.3 (*c* 1.0, CHCl₃) {lit.³⁰ $[\alpha]^{25}_{D}$: -36.1 (c 1.0, CHCl₃)}; **IR** (CHCl₃, cm⁻¹): 1035, 832, 1070, 1250, 1512, 1688, 2934, 3384; ¹H NMR (CDCl₃, 200MHz): δ 1.43 (s, 9H), 1.71 (br s, 1H), 2.98 (br s, 1H), 3.45-3.54 (m, 2H), 3.80 (s, 3H), 3.84.3.96 (m, 1H), 4.73 (br s, 1H), 5.28 (d, *J* = 8.1 Hz, 1H), 6.87 (d, *J* = 8.4 Hz, 2H), 7.23 (d, *J* = 8.4 Hz, 2H); ¹³C NMR (CDCl₃, 50MHz): δ 28.3, 55.1, 55.4, 63.6, 75.0, 80.1, 114.0, 127.9, 128.5, 156.6, 158.9; Anal. Calcd for C₁₅H₂₃NO₅ requires C, 60.59; H, 7.80; N, 4.71; found: C, 60.62; H, 7.83; N, 4.73%.

(4*S*,5*S*)-5-(Hydroxymethyl)-4-(4-methoxyphenyl)oxazolidin-2-one:(+)-*epi*cytoxazone (30): To a solution of NHBoc diol **88** (0.3g, 1.0 mmol) in dry THF (10 mL) was added sodium hydride (0.05 g, 60% w/w, 2.0 mmol) at room temperature, and the mixture was stirred under nitrogen atmosphere for 2.5 h. The reaction mixture was concentrated, ethyl acetate (10 mL) was added, and washed with saturated aq. NH₄Cl (5 mL) and brine solution (5 mL). The organic layer was separated, dried over Na₂SO₄, and concentrated. The crude product was purified by column chromatography to give **30** as a colorless solid (0.216 g, 96% yield).

Yield: 96%; colourless solid, **m.p.**:159-160 °C {lit.³⁰ **mp**: 161-162 °C}; $[\alpha]^{25}_{\mathbf{D}}$: +32.60 (*c* 1, MeOH) {lit.³⁰ $[\alpha]^{25}_{\mathbf{D}}$: +32.8 (c 0.6, MeOH)}; **IR** (CHCl₃, cm⁻¹): 772, 832, 1104, 1252, 1522, 1570, 1724, 3244; ¹H NMR (200 MHz, DMSO-d₆): δ 3.43-3.50 (m, 1H), 3.56-3.59 (m, 1H), 3.70 (s, 3H), 4.03-4.17 (m, 1H), 4.58(d, *J* = 5.8 Hz, 1H), 5.17 (t, *J* = 5.56 Hz, 1H), 6.91 (d, *J* = 8.6 Hz, 2H), 7.22(d, *J* = 8.6 Hz, 2H); ¹³C NMR (50 MHz, DMSOd₆) δ : 55.37, 56.43, 61.20, 84.44, 114.37, 127.72, 133.14, 158.41, 159.27; **Anal.** Calcd for C₁₁H₁₃NO₄ requires C, 59.19; H, 5.87; N, 6.27%; found: C, 59.20; H, 5.80; N, 6.23%.

3-Azido-2-hydroxy-3-(4-methoxyphenyl)propylpivalate (±)-89:

Racemic *syn*-azido diol (\pm)-11b (0.802 g, 3.6 mmol) was dissolved in dry pyridine (5 mL) and dry CH₂Cl₂ (5 mL) at 0 °C under argon and pivaloyl chloride (0.44 mL, 3.6 mmol) was added dropwise over a period of 30 min. The mixture was stirred at room temperature for 5 h. Concentration followed by azeotropic removal of pyridine gave a crude compound (\pm)-89, which was purified by column chromatography using petroleum ether/ethyl acetate (9:1) which afforded (\pm)-89 (1.06 g) as a colorless liquid.

Yield: 96%; colourless liquid; IR (CHCl₃, cm⁻¹): 669, 831, 1035, 1252, 1585, 1710, 2104, 3383; ¹H NMR (200 MHz, CDCl₃): δ 1.15 (s, 9H), 2.52 (br s, 1H), 3.70-3.79 (m, 1H),

3.75 (s, 3H), 3.84-3.92 (m, 1H), 4.02 (dd, J = 3.1, 8.1 Hz, 1H), 4.45 (d, J = 7.5 Hz, 1H), 6.84 (d, J = 8.7 Hz, 2H), 7.18 (d, J = 8.7 Hz, 2H); ¹³C NMR (50 MHz, CDCl₃): δ 27.2, 38.8, 55.1, 64.7, 67.9, 73.1, 114.4, 127.7, 128.7, 159.9, 178.2; **Anal.** Calcd for C₁₅H₂₁N₃O₄ requires C, 58.62; H, 6.89; N, 13.67; found: C, 58.65; H, 6.93; N, 13.60%.

2-(Azido-4-methoxyphenyl-methyl)oxirane (±)-10e:

To a solution of pivalate ester (\pm)-89 (1.105g, 3.6 mmol) in dry CH₂Cl₂ (10 mL) was added was methane sulfonyl chloride (0.28 mL, 3.6 mmol), Et₃N (0.6 mL, 4.3. mmol) and a catalytic amount of DMAP. The reaction mixture was stirred at room temperature for 1 h, and then quenched with water. The water layer was extracted with CH₂Cl₂ (3 x 20 mL) and the combined organic layers were washed with brine, dried over Na₂SO₄ and concentrated to give a crude product 90, which was dissolved in MeOH (10 mL) and treated with K₂CO₃ (0.5 g, 3.6 mmol). This mixture was stirred overnight at room temperature and then filtered through Celite. Removal of the volatiles under reduced pressure, followed by column chromatography on silica gel (eluent: petroleum ether/EtOAc 19:1) produced racemic *anti*-azido epoxide (\pm)-10e in 90% yield.

tert-Butyl(1*R*,2*R*)-2,3-dihydroxy-1-(4-methoxyphenyl)propylcarbamate (79)

To a solution of azido diol **11e** (0.798 mg, 3.58mmol) in ethyl alcohol (25 mL) was added 10% Pd-C (0.15 mg), polymethylhydrosiloxane (0.64 mg, 10.76 mmol), and di*tert*-butyl dicarbonate (0.86 g, 3.94 mmol). After stirring for 4 h, the reaction mixture was filtered, and the filtrate was evaporated in vacuo. The residue was purified by column chromatography to give NHBoc diol **79** in 90% yield (0.95 g).

Yield: 90%; colourless solid, **m.p.**: 116 °C; [*α*]²⁵_D: -51.0 (*c* 1, CHCl₃); **IR** (CHCl₃, cm⁻¹):669, 757, 831, 927, 1035, 1167, 1216, 1368, 1585, 1612, 1701, 2400, 2839, 2981,

3019, 3438, 3682; ¹**H NMR** (200 MHz, CDCl₃): δ 1.43 (s, 9H), 2.46 (br s, 1H), 3.05 (br s, 1H), 3.44-3.71 (m, 3H), 3.80 (s, 3H), 4.60 (t, *J* = 7.9 Hz, 1H), 5.08 (br s, 1H), 6.88 (d, *J* = 8.7 Hz, 2H), 7.24 (d, *J* = 8.2 Hz, 2H); ¹³**C NMR** (50 MHz, CDCl₃): δ 28.2, 55.2, 63.1, 74.0, 80.2, 114.2, 128.5, 131.0, 156.2, 159.2; Anal. Calcd for C₁₅H₂₃NO₅ requires C, 60.59; H, 7.80; N, 4.71; found: C, 60.31; H, 8.09; N, 4.60%.

(4*R*,5*R*)-5-(Hydroxymethyl)-4-(4-methoxyphenyl)oxazolidin-2-one (29)

To a solution of the amino alcohol **79** (0.15 g, 0.5 mmol) in dry THF (5 mL) was added NaH [0.024 g, 1 mmol (60% w/w in wax)] at room temperature and the mixture was stirred under nitrogen atmosphere for 2 h. The reaction mixture was concentrated, extracted with CH_2Cl_2 , washed with saturated NH_4Cl , brine and dried over anhyd. Na_2SO_4 . The organic layer was concentrated under reduced pressure and the residue was purified by column chromatography using petroleum ether/ethyl acetate (3:7) to afford (-)-cytoxazone, **29** (0.10 g) as a colorless solid.

Yield: 89%; colorless solid, **m.p.**: 118-121 °C (lit.²⁹ **mp**: 118-121 °C); $[α]^{25}_{D}$: -71 (*c* 0.5, MeOH) {lit.²⁹ $[α]^{25}_{D}$: -71 (*c* 1, MeOH)}; **IR** (CHCl₃, cm⁻¹): 1050, 1181, 1250, 1400, 1514, 1739, 2975, 3325, 3745; ¹H NMR (200 MHz, DMSO-*d*₆): δ 2.95-2.97 (m, 2H), 3.75 (s, 3H), 4.62–4.73 (m, 1H), 4.82 (t, *J* = 5.1 Hz, 1H), 4.90 (d, *J* = 4.3 Hz, 1H), 6.91 (d, *J* = 8.7 Hz, 2H), 7.15 (d, *J* = 8.46 Hz, 2H), 8.02 (br s, 1H); ¹³C NMR (50 MHz, DMSO-*d*₆): δ 55.1, 56.8, 61.9, 80.4, 113.7, 128.1, 129.4, 158.8, 160.0; **Anal.** Calcd for C₁₁H₁₃NO₄ requires C, 59.19; H, 5.87; N, 6.27; found: C, 58.88; H, 6.09; N, 6.14%.

Section III Formal synthesis of *N*-thiolated 2-oxazolidinone

1.3.1 Introduction

The problem of bacterial drug resistance has reached a crisis level such that successful treatment of antibiotic resistant infections in hospitals and health care centers can no longer be taken for granted. Infections caused by methicillin-resistant *Staphylococcus* aureus (MRSA) are becoming particularly difficult to treat with conventional antibiotics such as penicillin, leading to a sharp rise in clinical complications and deaths. The need for new antibacterial agents and protocols for treating MRSA infections is becoming extremely serious. Oxazolidinones are already recognized for their favorable pharmacological properties and are the only new class of antibacterial drugs introduced into clinical use in the last three decades.³¹ Recent studies have shown that *N*-thiolated 2-oxazolidinone **91** possesses antibacterial activity against methicillin-resistant *Staphylococcus* aureus and *Bacillus anthracis.*³²





Fig 18: Structure of N-thiolated 2-oxazolidinone 91

1.3.2 Pharmacology of N-thiolated 2-oxazolidinone

N-thiolated oxazolidinones, like their β -lactam counterparts,³³ react covalently with their biological target through transfer of the organothio side chain as shown in **Fig 19**. Further studies to assess the mode of action of this anti-MRSA, anti-Bacillus compounds, and to



identify their cellular target(s), are currently underway.


Fig 19: Pharmacology of N-thiolated 2-oxazolidinone

1.3.3 Review of literature

In section II, we have described several reports for the synthesis of oxazolidinones. Only one report for the racemic synthesis of anti-MRSA *N*-thiolated 2-oxazolidinone (91) and its precursor, 2-oxazolidinone 92 has been disclosed as can be seen below.

Turos's approach (2007)³⁴

Turos *et al.* have reported the synthesis of (\pm)-*N*-thiolated 2-oxazolidinone (**91**), starting from lactam **93.** This was hydrolyzed with Me₃SiCl in refluxing methanol to afford the *syn*-aminol **94** in 95% yield. Treatment of **94** with triphosgene and Hunig's base in CH₂Cl₂ led to isolation of oxazolidinone **95** (80% yield). The *N*-methoxyphenyl moiety on the oxazolidinone ring was then cleaved (ceric ammonium nitrate, CH₃CN and water) to give the *N*-protio oxazolidinone **96** in 70% yield. The ester functionality of oxazolidinone **96** was selectively reduced (NaBH₄, aq. THF) to furnish the alcohol **97** in 92% yield. Exchange of the hydroxyl group for an azide proceeded through mesylate **98**, which gave azide **92** in 72% yield after treatment with sodium azide in DMF (**Scheme 23**).



<u>Scheme 23:</u> (i) Me₃SiCl, MeOH, reflux, 95 %; (ii) triphosgene, DIPEA, CH₂Cl₂, 0- 23 °C, 80%; (iii) (NH₄)₂Ce(NO₃)₆, CH₃CN: H₂O, 0- 23 °C, 70%. (iv) NaBH₄, aq. THF, CH₂Cl₂, 0- 25 °C, 92%; (v) MsCl, Et₃N, CH₂Cl₂, 0- 25 °C, 98 %; (vi) NaN₃, DMF, reflux, 12 h, 72%.

1.3.4. Present Work


1.3.4.1. Objective

As can be seen from the above discussion, only one report is presently available for the synthesis of *anti*-MRSA *N*-thiolated 2-oxazolidinone **91** and its precursor, 2-oxazolidinone **92**. Hence, the enantioselective synthesis of *N*-thiolated 2-oxazolidinone **91** employing a simple catalytic enantioselective reaction is undertaken. This section describes a short synthesis of 2-oxazolidinone **92**, using hydrolytic kinetic resolution of racemic azido epoxide **10a** as the key step to induce chirality in the molecule.

1.3.5. Results and Discussion

The present synthetic route employed for the synthesis of *N*-thiolated 2-oxazolidinone **91** is shown in **Scheme 24**. Our synthesis starts with commercially available cinnamyl alcohol **16a**, which was transformed into the *syn*-azido epoxiode (\pm)-**10a** in two steps: (i) azidobromination of cinnamyl alcohol; (ii) formation of epoxide from **26a** to give *syn*-

azido epoxide (\pm) -10a in 70% yield.



Scheme 24: (i) NBS, NaN₃, CH₃CN: H₂O (4:1),0 °C, 70%; (ii) *tert*-BuOK, THF, 0 °C, 3 h; (iii) (*R*,*R*)-Co(salen)OAc (0.5 mol%), H₂O (0.5 equiv), 0 °C, 14 h; (iv) poly(methylhydrosiloxane), 10% Pd/C, (Boc)₂O, EtOH, 25 °C, 4 h, 96%; (v) NaH, dry THF, 25 °C, 3 h, 96%; (vi) (a) MsCl, Et₃N, CH₂Cl₂, 0 °C, 1 h then; (b) NaN₃, DMF, 60 °C, 12 h, 80%.

The *syn*-azido epoxide (\pm)-10a was then subjected to HKR using (*R*,*R*)-Co(salen)OAc (1) to give the chiral *syn*-azido diol 11a in 47% yield with 98% ee along with chiral *syn*-azido epoxide 10a in 48% yield with 96% ee. The compound 11a and 10a were then readily separated by column chromatographic purification. The enantiomeric excess of *syn*-azido diol in 11a was determined by chiral HPLC analysis; Chiralpak OD-H (Fig.20).




Fig. 20: HPLC chromatogram of azido diol 11a

Azido diol 11a was then subjected to one pot azide reduction and Boc protection [10%




Fig. 21: ¹H and ¹³C NMR spectra of 93

Pd/C, polymethylhydrosiloxane (PMHS) and (Boc)₂O in EtOH] to give N-Boc amino diol **93** in 96 % yield, which was confirmed by ¹H and ¹³C-NMR spectroscopy. The ¹H NMR spectrum of **93** showed a typical signal at δ 1.42 (s, 9H) for *tert*-butyl protons. Its ¹³C NMR spectrum showed a characteristic signal at δ 28.2 due to the methyl carbons of *tert*-butyl group (**Fig. 21**).

The regioselective intramolecular cyclization of **93** with NaH in THF gave oxazolidinone **94** (mp 106-107 °C; lit.³⁴ mp 105-107 °C) in 96 % yield. The formation of oxazolidinone **94** was confirmed by ¹H and ¹³C-NMR spectroscopy. The ¹H NMR spectrum of (+)-2oxazolidinone **94** showed a typical signal at δ 7.0 (br s, 1H) for N-H proton of oxazolidinone ring. Its ¹³C NMR spectrum showed a characteristic signal at δ 157.1 due to the carbonyl carbon of oxazolidinone ring (**Fig. 22**).




Fig. 22: ¹H and ¹³C NMR spectra of 94

Finally, mesylation of primary alcohol in oxazolidinone **94** gave the mesylate, which on subsequent treatment with NaN₃ in DMF at 60 °C afforded (+)-2-oxazolidinone **92** in 80% yield. The formation of (+)-2-oxazolidinone **92** was confirmed by ¹H and ¹³C-NMR spectroscopy. The ¹H NMR spectrum of (+)-2-oxazolidinone **92** showed a typical signal at δ 3.62 (dddd, J = 4.3, 9.5 Hz (each), 2H), for methylene protons. Its ¹³C NMR spectrum showed a characteristic signal at δ 51.9 due to the carbon attached to azide group (**Fig. 23**).




Fig. 23: ¹H and ¹³C NMR spectra of 92

The conversion of (+)-2-oxazolidone **92** to *N*-thiolated 2-oxazolidinone **91** has already been reported in the literature.³²

1.3.6 Conclusion

The enantioselective syntheses of (+)-2-oxazolidinone **92** (36% over all yield with 98% ee) have been achieved, starting from the racemic *syn*-azido epoxides **10a**. The method involved a cobalt-catalyzed hydrolytic kinetic resolution of azido epoxides as the key reaction.

1.3.7 Experimental section

tert-Butyl(1*R*,2*S*)-2,3-dihydroxy-1-phenylpropylcarbamate (93):

To a stirred solution of azido diol **11a** (0.69 mg, 3.58mmol) in ethyl alcohol (25 mL) was added 10% Pd-C (0.15 mg), polymethylhydrosiloxane (0.64 mg, 10.76 mmol) and di*-tert*-butyl dicarbonate (0.86 g, 3.94 mmol). After stirring for 4 h, the reaction mixture was filtered, and the filtrate was evaporated *in vacuo*. The residue was purified by column chromatography to give NHBoc diol **93** in 96% yield (0.91 g).

Yield: 96%; colourless oil; $[\alpha]^{25}_{D}$: -28.0 (*c* 0.7, CHCl₃); **IR** (CHCl₃, cm⁻¹): 832, 1035, 1070, 1250, 1512, 1699, 2934, 3363; ¹H NMR (CDCl₃, 200MHz): δ 1.42 (s, 9H), 3.15 (br s, 2H), 3.44-3.57 (m, 2H), 3.89 (br s, 1H), 4.70-4.88 (m, 1H), 5.45 (d, *J* = 5.0 Hz, 1H), 7.23-7.40 (m, 5H); ¹³C NMR (CDCl₃, 50 MHz): δ 28.2, 56.6, 63.6, 74.7, 79.9, 126.7, 127.3, 128.4, 140.2, 156.4; **Anal.** Calcd for C₁₄H₂₁NO₄ requires C, 62.90; H, 7.90; N, 5.24; found: C, 62.82; H, 7.88; N, 5.28%.

(4*S*,5*S*)-5-Hydroxymethyl-4-phenyloxazolidin-2-one (94):

To a stirred solution of NHBoc diol **93** (0.267g, 1.0 mmol) in dry THF (10 mL) was added sodium hydride (0.05 g, 60% w/w, 2.0 mmol) at room temperature and the mixture was stirred under nitrogen atmosphere for 2.5 h. The reaction mixture was concentrated, followed by the addition of ethyl acetate (10 mL), and washed with saturated aq. NH_4Cl

(5 mL) and brine solution (5 mL). The organic layer was separated, dried over anhyd. Na_2SO_4 and concentrated. The crude product was purified by column chromatography to give **94** as a colourless solid (0.185 g, 96% yield).

Yield: 96%; colourless solid m.p.:106-107 °C {lit.³⁴ m.p.: 105-107 °C}; $[\alpha]^{25}_{D}$: +24.6 (*c* 0.5, MeOH); **IR** (CHCl₃, cm⁻¹): 772, 832, 1104, 1252, 1522, 1570, 1724, 3244; ¹H NMR (200 MHz, DMSO-D₆): δ 2.12 (br s, 1H), 3.60 (dddd, *J* = 3.1, 9.1 Hz, 2H), 4.35-4.43 (m, 1H), 4.70 (d, *J* = 6.3 Hz, 1H), 7.01 (br s, 1H), 7.30-7.40 (m, 5H); ¹³C NMR (50 MHz, DMSOd₆) δ : 55.6, 59.7, 82.8, 124.7, 126.5, 127.2, 139.7, 157.1; Anal. Calcd for C₁₀H₁₁NO₃ requires C, 62.17; H, 5.74; N, 7.25%; found: C, 62.20; H, 5.80; N, 7.23%.

(4*S*,5*S*)-5-Azidomethyl-4-phenyloxazolidin-2-one (92):

To a stirred solution of alcohol **94** (0.791 g, 4.1 mmol) in CH_2Cl_2 (5 mL) was added Et₃N (0.82 g, 8.2 mmol) at 0 °C. After 5 min of stirring, methane sulfonyl chloride (0.47 g, 4.1 mmol) was added drop-wise over a period of 5 min. The reaction mixture was then stirred for another 1 h at 0 °C and brought to room temperature. After the completion of the reaction, as monitored by TLC, it was extracted with CH_2Cl_2 (3x 20 ml) washed with water, brine and dried over anhyd. Na₂SO₄. The combined organic layer was concentrated under reduced pressure to get crude methane sulfonate ester **95** in almost quantitative yield. To a solution of the reaction mixture was heated at 60 °C for 7 h. After the completion of the reaction, as monitored by TLC, it was extracted by TLC, it was extracted with CH_2Cl_2 (3x 20 mL) washed with water, brine and dried over annot by TLC, it was be extracted with CH_2Cl_2 (3x 20 mL) washed with water, brine and dried over annot by TLC, it was extracted with CH_2Cl_2 (3x 20 mL) washed with water, brine and dried over annot by TLC, it was extracted with CH_2Cl_2 (3x 20 mL) washed with water, brine and dried over annot by TLC, it was extracted with CH_2Cl_2 (3x 20 mL) washed with water, brine and dried over annot by TLC, it combined organic layer was organic layer was concentrated under reduced pressure to give the crude 2-oxazolidinone

92, which was purified by column chromatography using pet. ether: ethyl acetate (9: 2) to produce **92** as colourless solid.

Yield: 80% (0.715 g); colourless solid **m.p.**: 82-85 °C {lit.³⁴ **mp**: 82-84 °C}; $[α]^{25}$ _D: +30.0 (*c* 1, CHCl₃); **IR** (CHCl₃, cm⁻¹): 772, 832, 1104, 1252, 1522, 1570, 1724, 2106, 3244; ¹**H NMR** (200 MHz, CDCl₃): δ 3.62 (dddd, *J* = 4.3, 9.5 Hz, 2H), 4.30-4.43 (m, 1H), 4.71 (d, *J* = 6.3 Hz, 1H), 6.79 (br s, 1H), 7.30–7.41 (m, 5H); ¹³**C NMR** (50 MHz, CDCl₃): δ 51.9, 58.7, 73.0, 82.5, 126.1, 129.9, 129.27, 138.8, 128.3, 158.4; **Anal.** Calcd for C₁₀H₁₀N₄O₂ requires C, 55.04; H, 4.62; N, 25.68; found: C, 55.01; H, 4.60; N, 25.65%.

1.3.8 References

- 1 (a) Grajewska, A.; Rozwadowska, M. D.; *Tetrahedron: Asymmetry*, **2007**, *18*, 803; (b) Gravier-Pelletier, C.; Milla, M.; Merrer, Y. L.; Depezay, J-C. Eur. J. Org. Chem. **2001**, 3089.
- 2 Tokunaga, M.; larrow, J. F.; Kakiuchi, F.; Jacobsen, E. N. Science, **1997**, 277, 936.
- 3 (a) Wilkinson, R. G.; Shepherd, R. G.; Thomas, J. P.; Baughn, C. J. Am. Chem. Soc. 1961, 83, 2212; (b) Shepherd, R. G.; Wilkinson, R. G. J. Med. Chem. 1962, 5, 823; (c) Wilkinson, R. G.; Cantrall, M. B.; Shepherd, R. G. J. Med. Chem. 1962, 5, 835.
- Some, among many, notable examples: (a) Fumagillin: Tarbell, D. S.; Carman, R. M.; Chapman, D. D.; Cremer, S. E.; Cross, A. D.; Huffman, K. R.; Kuntsmann, M.; McCorkindale, N. J.; McNally, J. G.; Rosowsky, A.; Varino, F. H. L.; West, R. L. J. Am. *Chem. Soc.* 1961, 83, 3096. (b) Ovalicin: Sigg, H. P.; Weber, H. P. *Helv. Chim. Acta* 1968, 51, 1395. (c) Coriolin: Takeuchi, T.; Iinuma, H.; Iwanaga, J.; Takahashi, S.; Takita, T.; Umezawa, H. J. Antibiot. 1969, 22, 215. (d) Disparlure: Bierl, B. A.; Beroza, M.; Collier, C. W. Science 1970, 170, 87.
- For reviews and lead references, see: (a) Winstein, S.; Henderson, R. B. *Heterocyclic Compounds*, Vol. 1; Elderfield, R. C., Ed.; Wiley: New York, 1950; Chapter 1; (b) Parker, R. E.; Isaacs, N. S. *Chem. Rev.* 1959, *59*, 737; (c) Barto'k, M.; La'ng, K. L. *Small Ring Heterocycles In The Chemistry of Heterocyclic Compounds*, Vol. 42, Part 3; Hassner, A., Ed.; Wiley: New York, 1985; Chapter 1.
- 6 Furrow, M. E.; Schaus, S. E.; Jacobsen, E. N. J. Org. Chem. 1998, 63, 6776.

- For an in depth discussion of practical considerations in kinetic resolution reactions, see: Keith, J. M.; Larrow, J. F.; Jacobsen, E. N. Adv. Synth., Catal. 2001, 343, 5.
- a) Larrow, J. F.; Jacobsen, E. N.; Gao, Y.; Hong, Y.; Nie, X.; Zepp, C. M. J. Org. Chem. **1994**, 59, 1939; (b) Larrow, J. F.; Jacobsen, E. N. Org. Synth. **1997**, 75, 1.
- For the most effective catalyst developed thus far for the asymmetric dihydroxylation of terminal olefins, see: (a) Becker, H.; Sharpless, K. B. *Angew. Chem., Int. Ed. Engl.* 1996, 35, 448. For a general review of the AD reaction, see: (b) Kolb, H. C.; Vannieuwenhze, M. S.; Sharpless, K. B. *Chem. Rev.* 1994, 94, 2483.
- Yuan, Z. Q.; Blomberg, D.; Sethson, I.; Brickmann, K.; Ekholm, K.; Johansson, B.; Nilsson,
 A.; Kihlberg, J. J. Med. Chem. 2002, 45, 2512.
- 11 Smitha, G.; C. Reddy, S. Synth. Commn. 2006, 36,1795.
- 12 Cherian, S. K.; Kumar, P. Tetrahedron: Asymmetry, 2007, 18,982.
- 13 Monasson, O.; Ginisty, M.; Mravljak, J.; Bertho, G.; Gravier-Pelletier, C.; Merrer Y. L. *Tetrahedron: Asymmetry*, **2009**, *20*, 2320.
- (a) Kumar, P.; Naidu, S. V.; Gupta, P. *Tetrahedron*, 2007, 63, 2745; (b) Kumar, P.; Gupta, P. *Synlett*, 2009, 9, 1367; (c) Yu, Q.; Wu, Y.; Xia, L. J.; Tang M. H.; Wu, Y. L. J. Chem. Soc. Chem. Commun., 1999, 129.
- 15 Kim, Y. J.; Tae, J. Synlett, 2006, 61.
- 16 Ende, D. V.; Krief, A. Angew. Chem, Int. Ed. Engl., 1974, 13, 279.
- Kakeya, H.; Morishita, M.; Kobinata, K.; Osono, M.; Ishizuka, M.; Osada, H. J. Antibiot.
 1998, 51, 1126.
- 18 Kakeya, H.; Morishita, M.; Koshino, H.; Morita, T.; Kobayashi, K.; Osada, H. J. Org. Chem. 1999, 64, 1052.
- 19 Hamersak, Z.; Sepac, D.; Ziher, D.; Sunjic, V. Synthesis 2003, 375.
- 20 List, B. J. Am. Chem. Soc. 2000, 122, 9336.
- (a) Seder, R. A.; Paul, W. E. Annu. Rev. Immunol. 1994, 12, 635. (b) Finkelman, F. D.; Shea-Donohue, T.; Goldhill, J.; Sullivan, C. A.; Morris, S. C.; Madden, K. B.; Gause, W. C.; Urban, J. F. Annu. Rev. Immunol. 1997, 15, 505.
- Stirling, R. G.; Chung, K. F. *Eur. Respir. J.* 2000, *16*, 1158. (b) Renauld, J. C. *J. Clin. Pathol.* 2001, *54*, 577.
- (a) Gazzinelli, R. T.; Makino, M.; Chattopadhyay, S. K.; Snapper, C. M.; Sher, A.; Hugin, A. W.; Morise, H. C. III *J. Immunol.* 1992, *148*, 182. (b) Romagnani, S. *Immunol. Today* 1990, *11*, 316. (c) Secrist, H.; Chelen, C. J.; Wen, Y.; Marshell, J. D.; Umetsu, D. T. *J. Exp. Med.* 1993, *178*, 2123.
- 24 Sakamoto, Y.; Shiraishi, A.; Seonhee, J.; Nakata, T. Tetrahedron Lett. 1999, 40, 4203.

- 25 Hamerak, Z.; Ljubovic, E.; Mercep, M.; Mesic, M.; Sunjic V. Synthesis 2001, 1989.
- 26 Carter, P. H.; LaPorte, J. R.; Scherle, P. A.; Decicco, C. P. *Bioorg. Med. Chem. Lett.* 2003, 13, 1237.
- 27 Milicevic, S.; Matovic, R.; Saicic, R. N. Tetrahedron Lett. 2004, 45, 955.
- 28 Paraskar, A. S.; Sudalai, A. Tetrahedron 2006, 62, 5756.
- 29 Narina, S. V.; Siva Kumar, T.; George, S.; Sudalai, A. Tetrahedron Lett. 2007, 48, 65.
- 30 Sung-Gon Kim, S-G.; Park, T. H. *Tetrahedron: Asymmetry*, **2008**, *19*, 1626.
- Brickner, S. J. *Curr. Pharm. Des.* 1996, 2, 175; (b) Phillips, O. A. *Curr. Opin. Invest. Drugs* 2003, 4, 117; (c) Brickner, S. J.; Hutchinson, D. K.; Barbachyn, M. R.; Manninen, P. R.; Ulanowicz, D. A.; Garmon, S. A.; Grega, K. C.; Hendges, S. K.; Toops, D. S.; Ford, C. W.; Zurenko, G. E. *J. Med. Chem.* 1996, *39*, 673.
- 32 Mishra, R. K.; Revell, K. D.; Coates, C. M.; Turos, E.; Dickeyb, S.; Limb, D. V. Bioorganic & Medicinal Chemistry Letters, 2006, 16, 2081–2083.
- 33 Turos, E.; Coates, C.; Shim, J.-Y.; Wang, Y.; Leslie, J. M.; Long, T. E.; Reddy, G. S. K.; Ortiz, A.; Culbreath, M.; Dickey, S.; Lim, D. V.; Alonso, E.; Gonzalez, *J. Bioorg. Med. Chem.* 2005, 13, 6289.
- 34 Mishra, R. K.; Coates, C. M.; Revell, K. D.; Turos, E. Org. Lett., 2007, 9, 4.

CHAPTER II

Enantioselective Synthesis of (+)-L-733,060 *via* Hydrolytic Kinetic Resolution of Azido epoxide and Synthesis of (S)-Dapoxetine *via* Sharpless Asymmetric Epoxidation

Section I

A short enantioselective synthesis of (+)-L-733,060 *via* hydrolytic kinetic resolution of azido epoxide

2.1.1. Introduction

Substance P (SP), a peptide neurotransmitter, is a member of the tochynin family of peptides, which include neurokinins A and B (NKA, NKB). These peptides bind to a series of three neurokinin receptors, NK1, NK2, and NK3, which have selective affinity for SP, NKA and NKB respectively.¹ For example SP has been shown to elicit a IL-I production in macrophages, sensitize neutrophils and enhance dopamine release in the *substantia nigra* region in cat brain. The neurokinin substance P has also been associated with a variety of biological effects including smooth muscle contraction, neurogenic inflammation and pain transmission. Recently, (+)-L-733,060 (1)² and (+)-CP-99,994 (2)³ possessing 2-alkyl-3-hydroxypiperidine and 2-alkyl-3-aminopiperidine structural units respectively, have proven to be selective and potent non-peptide neurokinin substance P receptor antagonists (**Fig. 1**). Also, they have been implicated in a variety of disorders including migraine, rheumatoid arthritis and pain.⁴ Recent studies shown that (+)-L-733,060 (1) can act both as an antitumor agent and as a promising new target for the treatment of retinoblastoma.⁵




Fig. 1: Structures of 2-aryl-3-hydroxypiperidine and 2-aryl-3-aminopiperidine derivatives


In view of these potential pharmacological applications, several reports on the synthesis of **1** and **2** both in racemic and optically active forms, have been published.⁶

2.1.2. Review of Literature

Various syntheses of non-peptidic neurokinin NK1 receptor antagonist namely (+)-L-733,060 (1) and (2*S*, 3*S*)-3-hydroxy-2-phenyl piperidine (**3**) have been documented in the literature.^{2,6} Some of the interesting and important synthetic routes to (+)-L-733,060 (1) are described below.

Rao's approach (2003)⁷

Rao *et al.* have achieved the synthesis of (+)-L-733,060 (1) starting from *N*-Boc protected amino alcohol **4**, which was subjected to Swern oxidation conditions [(COCl)₂, DMSO, Et_3N] followed by addition of vinyl magnesium bromide to give allylic alcohol **5** (Scheme 1).




<u>Scheme 1:</u> (i) DMSO, (COCl)₂, *i*-Pr₂NEt, CH₂Cl₂; then CH₂=CHMgBr, THF, 2 h, 90%; (ii) TBDMS-Cl, imid., CH₂Cl₂, 24 h, 90%; (iii) allyl bromide, NaH, DMF, 0- 25 °C, 24 h, 90%; (iv) TBAF-AcOH, THF, 0- 25 °C, 24 h, 85%; (v) Grubbs' catalyst, CH₂Cl₂, 25 °C, 6 h, 82%; (vi)10% Pd/C, H₂, EtOH, 4 h, 65%; (vii) 3,5-bis(trifluoromethyl)benzyl bromide, NaH, DMF, 80%; (viii) TFA, CH₂Cl₂, 79%.

Protection of allylic alcohol **5** as silyl ether followed by *N*-allylation of the amine resulted in diene **6**, which upon ring closing metathesis using Grubbs' catalyst gave the unsaturated piperidine moiety **7**. The catalytic hydrogenation of olefin **8** furnished the intermediate **8** in 65% yield. Etherification of alcohol group in **8** with 3,5bis(trifluromethyl)benzyl bromide followed by deprotection of the Boc-group provided (+)-L-733,060 (**1**).

Chang's approach (2005)⁸


Chang *et al.* have employed a new method of addition of Grignard reagent onto glutarimide **9** for the synthesis of racemic 3-hydroxy-2-phenyl piperidine **3**. Accordingly, addition of phenyl magnesium bromide to glutarimide **9** followed by trapping the resulted –OH group with Ac₂O proceeded regioselectively to provide the enol ether **10** in 82% yield. Removal of the sulfonate ester group was achieved using Na/Hg to obtain enol ether **11**, which was hydrolysed by using BBr₃ that afforded ketolactam **12**. The reduction of ketolactam **12** with LiAlH₄ gave piperidine **13**. Benzyl group was deprotected to produced racemic 3-hydroxy-2-phenyl piperidine **3** (Scheme 2).



<u>Scheme 2:</u> (i) NaH, PhMgBr, THF, 25 °C, 1 h, 82%; (ii) Na-Hg, MeOH, 25 °C, 90%; (iii) BBr₃, CH₂Cl₂, -78 °C, 90%; (iv) LiAlH₄, THF, reflux, 87%; (v) Pd(OH)₂, H₂, MeOH, 25 °C, 90%.

Ham's approach (2005)⁹

This approach describes the synthesis of (+)-L-733,060 starting from chiral oxazoline 14 prepared from the corresponding amino alcohol. Ozonolysis of double bond in 14 followed by Horner-Wittig reaction of the resulting aldehyde furnished α , β -unsaturated ester 15 in 87% yield. 1,4-Reduction of 15 with copper bromide, Red-Al[®] and 2-butanol gave the saturated methyl ester 16 in 83% yield. Reduction of oxazoline was achieved using Pd(OH)₂/H₂ (70 psi) during which process intramolecular lactamization took place to give lactam 17. Reduction of lactam 17 with BH₃·SMe₂ and protection of amine gave the required intermediate **8**. Etherification of alcohol **8** with 3,5-bis(trifluromethyl)benzyl bromide followed by deprotection afforded (+)-L-733060 (1) (Scheme 3).




Scheme 3: (i) O₃, MeOH, -78 °C, then $(CH_3)_2S$; (ii) $(MeO)_2POCH_2CO_2Me$, LiCl. ^{*i*}Pr₂NEt, CH₃CN, 87%; (iii) CuBr, Red-Al[®], 2-butanol, THF, 83%; (iv) 20% Pd(OH)₂/C, H₂, (70 psi), MeOH:AcOH (10:1), 76%; (v) (a) BH₃·SMe₂, MeOH, THF; (b) (Boc)₂O, CH₂Cl₂, 62%; (vi) (a) 3,5bis(trifluoromethyl)benzyl bromide, NaH, DMF, 76%; (b) trifluoroacetic acid, 93%.

Oshitari's approach (2006)¹⁰

Oshitari et al. have achieved the synthesis of (+)-L-733,060 starting from optically active

amino alcohol **18**. Protection of amine functionality in **18** with $(Boc)_2O$ followed by esterification of the free alcohol group with benzoyl chloride gave the protected amino alcohol **19**. One carbon extension and ring closure to obtain enamine **20** was achieved in one-pot *via* Rh(acac)(CO)₂-catalyzed hydroformylation of olefin **19**. Hydrogenation of C=C bond in **20** followed by hydrolysis gave the intermediate **8** which was converted to (+)-L-733,060 (**1**) *via* standard reaction sequences (**Scheme 4**).




<u>Scheme 4:</u> (i) BzCl, pyridine, 25 °C, 10 h; (ii) Rh(acac)(CO)₂ (3 mol%), biphephos (6 mol%), CO/H₂ (5 atm), THF, 65 °C, 5 h; (iii) 10% Pd/C, H₂ (1 atm), EtOH, 25 °C, 20 h; (iv) 1M NaOH, MeOH: 1,4-dioxane (1:2), 25 °C, 1 h; (v) 3,5-(CF₃)₂C₆H₃CH₂Br, NaH, THF: DMF (1: 3), 0 °C, 6 h; (vi) TFA, 25 °C, 1.5 h, NaHCO₃.

Kumar's approch (2007)¹¹

Kumar *et al.* have achieved the synthesis of (+)-L-733,060 using Sharpless asymmetric epoxidation of cinnamyl alcohol **21** to get epoxy alcohol **22** in 99%ee. Regioselective opening of epoxide with NaN₃ resulted in *tran*-azido diol **23**, which was converted to the *cis* azido epoxide **24** *via* standard reaction sequences. Among the several reagents screened, allyltrimethyl silane opened azido epoxide **24** regioselctively to give the azido alcohol in moderate yield, which was protected as silyl ether **25**. One carbon degradation

of **25** was achieved *via* one-pot dihydroxylation followed by diol cleavage to get the crucial azido aldehyde **26**. Azido aldehyde **26** underwent aza-Wittig reaction in the presence of PPh₃ to provide six-membered imine, which upon reduction with NaBH₄ gave piperidine moiety **8**. Etherification of alcohol **8** with 3,5-bis(trifluromethyl)benzyl bromide followed by deprotection afforded (+)-L-733,060 (1) (Scheme 5).




<u>Scheme 5:</u> (i) Ti(OPr-*i*)₄, (*S*,*S*)-(-)-DET, TBHP, MS 4 Å, CH₂Cl₂, -20 °C, 3 h, 89%; (ii) NaN₃, NH₄Cl, MeOH:H₂O (8:1), 65 °C, 5 h, 98%; (iii) PivCl, Pyridine, CH₂Cl₂ (1:1), 0 °C–25 °C, 5 h; (iv) MsCl, Et₃N, DMAP, CH₂Cl₂, 0 –25 °C, 1 h; (v) K₂CO₃, MeOH, 25 °C, 10 h, 80% (3 steps); (vi) allyltrimethylsilane, TiCl₄, CH₂Cl₂, -78 °C, 1 h, 65%; (vii) TBSOTf, 2,6-lutidine, 0 °C, 1 h, 95%; (viii) OsO₄, NaIO₄, 1,4-dioxane:H₂O (3:1), 0 °C, 3 h; (ix) PPh₃, THF, 25 °C, 16 h; (x) NaBH₄, MeOH, 0 °C, 30 min., 65%; (xi) (Boc)₂O, Et₃N, CH₂Cl₂, 2 h, 95%; (xii) TBAF, THF, 0 °C–25 °C, 10 h, 90%; (xiii) NaH, 3,5-bis(trifluoromethyl)benzyl bromide, DMF, 80 °C, 12 h, 78%; (xiv) TFA, MeOH, 25 °C, 12 h, 70%.

Wang's approach (2008)¹²

Wang et al. employed the reductive coupling of 4-pivaloxybutanal 27 with (R)-phenyl N-

tert-butanesulfinyl imine 28 in the presence of SmI_2 to afford amino alcohol 29 with


required stereochemistry. Removal of the chiral auxiliary followed by selective *N*-acylation with 4-methoxybenzoic anhydride afforded amide **30**. Mesylation of free alcohol group in **30** furnished oxazoline **31** in 85% yield, with complete inversion of configuration at C-2. Reductive ring-opening of oxazoline **31** (NaBH₃CN, HOAc, 40 °C) gave *syn*-1,2-amino alcohol **32** in excellent yield. Selective *O*-alkylation with 3,5-bis(trifluromethyl)benzyl bromide provided **33** in 82% yield. The intermediate **33** was converted to (+)-L-733,060 (**1**) by standard reaction sequences (**Scheme 6**).



<u>Scheme 6:</u> i) SmI₂, ^{*t*}BuOH, -78 °C, 78%; (ii) HCl, MeOH; (iii) (PMPCO)₂O, Et₃N, CH₂Cl₂, 88%; (iv) MsCl, Et₃N, CH₂Cl₂, 85%; (v) NaCNBH₃, AcOH, 90%; (vi) NaH, 3,5-bis(trifluoromethyl)benzyl bromide, TBAI, DMF, 82%; (vii) NaOMe, MeOH; (viii) MsCl, Et₃N, CH₂Cl₂, 78%; (ix) DDQ, CH₂Cl₂, 0 °C.

Sudalai's approach (2008)¹³


This approach describes the synthesis of (+)-L-733,060 starting from allylic alcohol **34**, which was subjected to Johnson–Claisen [3,3]- sigmatropic rearrangement to give homoallylic ester **35** in 82% yield. Alkaline hydrolysis of ester **35** using aq. KOH furnished potassium alkenoate **36**, which was subjected to Shi-epoxidation using D-fructose-derived ketone as the chiral catalyst (30 mol%) and Oxone as the stoichiometric oxidant to afford hydroxylactone **37** in 62% yield. Mesylation of hydroxylactone **37** gave the corresponding mesylate **38**, which was subjected to S_N2 displacement with NaN₃ to afford azidolactone **39**. Reduction of azide **39** under Staudinger conditions produced lactam **40** which was converted to (+)-L-733,060 (**1**) *via* standard reaction sequences (**Scheme 7**).



<u>Scheme 7</u>: i) CH₃C(OMe)₃, propanoic acid, 135 °C, 6 h, 82%; ii) aq. KOH, reflux; iii) pH 10-11, Oxone, chiral ketone, KOH, CH₃CN, -5 °C, 1 h then 15 °C, 5 h, 62%; iv) MsCl, Et₃N, CH₂Cl₂, 0 °C, 2 h, 96%; v) NaN₃, DMF, 60 °C, 12 h, 94%; vi) PPh₃, THF, 25 °C, 2 h then H₂O refluxed 3 h, 91%; vii) a) BH₃.SMe₂, THF, reflux, 6 h; b) (Boc)₂O, Et₃N, DMAP (cat.), CH₂Cl₂, 0–25°C, 73% over two steps; viii) 3,5-bis(trifluoromethyl)benzyl bromide, NaH, DMF: THF (3:1), 0 °C, 6 h; ix) TFA, CH₂Cl₂, 18 h, 81% over two steps.

O'Brien's approach (2008)¹⁴

O'Brien *et al.* have reported synthesis of (+)-L-733,060 using catalytic asymmetric deprotonation of *N*-Boc pyrrolidine **41** as a key step. Accordingly *N*-Boc pyrrolidine **41** was subjected to asymmetric deprotonation by using *s*-BuLi, (-)-sparteine to give the organolithium reagent, which was subsequently trapped with benzaldehyde to afford alcohol **42** with dr = 3:1 (*syn: anti*). Deprotection of Boc group in alcohol **42** followed by its treatment with allyl bromide in presence of K₂CO₃ gave *N*-allylated alcohol **43** in 58% yield. The *N*-allylated alcohol **43** was subjected to ring-expasion with TFAA followed by hydrolysis to give piperidine derivative **44** in 83% yield. *O*-Benzylation of **44** was achieved by using NaH and the corresponding benzyl bromide. Finally, *N*-deallylation was achieved with Pd(0) and *N*,*N'*-dimethylbarbituric acid to give (+)-L-733,060 (**1**) (**Scheme 8**).




Scheme 8: i) a) BuLi, (-)-spareine, LiDMAE, Et₂O, -78 °C; b) PhCHO, 64% (3:1 dr). ii) TFA, CH₂Cl₂, 25 °C, 16; iii) K₂CO₃, AllylBr, MeCN, 25 °C, 6 h, 58%; iv) (CF₃CO)₂O, Et₃N, THF, reflux, 72 h, then aq NaOH, 83%; v) 3,5-bis(trifluoromethyl)benzyl bromide, NaH, THF, 0 °C, 30 min; vi) Pd(PPh₃)₄, *N*,*N*'-dimethylbarbituric acid CH₂Cl₂, 25 °C, 24 h.

2.1.3. Present Work

2.1.3.1. Objective

As can be seen from the above discussion, the literature methods for the synthesis of (+)-L-733,060 (1), either employ chiral starting material, expensive reagents, involve longer reaction sequences or lack of selectivity. Hence, the synthesis of (+)-L-733,060 using catalytic enantioselective reactions is desirable. This section describes a short synthesis of (+)-L-733,060 (1), using hydrolytic kinetic resolution¹⁵ of azido epoxide **47** as the key step to induce chirality in the molecule.

The retrosynthetic analysis of (+)-L-733,060 (1) is shown in **Scheme 9**. It reveals that *syn* 1,2-amino alcohol **8** could be considered as a key intermediate. We have thus planned to employ intramolecular reductive cyclization of (*E*)- α , β -unsaturated azidoester **45** under hydrogenation conditions for the construction of the 6-membered heterocyclic nucleus **8**.




<u>Scheme 9</u>: Retrosynthesis of (+)-L-733, 060 (1)

The azidoester **45** can be readily made from the corresponding azido diol **46** by a twostep reaction sequence of Dess-Martin periodinane oxidation¹⁶ of primary alcohol followed by Wittig olefination.¹⁷ We envisaged further that introduction of chirality in **46** with *syn* stereochemistry could be realized *via* hydrolytic kinetic resolution of racemic azido epoxide **47**.

2.1.4. Results and Discussion

The present synthetic route employed for the synthesis of L-773,060 **1** is shown in **Scheme 10**.



Scheme 10: (i) (*S*,*S*)-salen-Co(III)OAc (0.5 mol%), H₂O (0.5 equiv), 0 °C, 14 h; (ii) TBSCl, imid., CH₂Cl₂, 25 °C, 98%; (iii) CSA, MeOH:CH₂Cl₂ (1:1), 0 °C 6 h, 95%; (iv) Dess-Martin periodinane, CH₂Cl₂, 25 °C, 98%;v) Ph₃P=CHCO₂Et, THF, 25 °C, 14 h, 94%; (vi) 10% Pd/C, H₂, MeOH, 25 °C, then reflux in EtOH, 85%; (vii) TBAF, THF, 25 °C, 96%; (viii) a) Me₂S. BH₃, THF, reflux, 10 h; b) (Boc)₂O, Et₃N, cat. DMAP, CH₂Cl₂, 0 – 25°C, 73% over two steps; (ix) 3, 5-bis (trifluoromethyl)benzyl bromide, NaH, DMF: THF (3:1), 0 °C, 6 h; (x) TFA, CH₂Cl₂, 18 h, 82% over two steps.

Racemic azido epoxide (\pm)-47 was subjected to hydrolytic kinetic resolution using catalytic amount (0.5 mol%) of (*S*,*S*)-salen-Co(III)OAc complex to give chiral azido diol

46 in 48% yield and 97% ee along with chiral azido epoxide (-)-**47** in 47% yield and 96% ee. The compounds **46** and **47** were then readily separated by column chromatographic purification. The enantiomeric excess of azido diol **46** was determined by chiral HPLC analysis; Chiralpak OD-H.

The formation of azido diol **46** was confirmed by its ¹H NMR spectrum wherein the appearence of a multiplet at δ 3.80 and a doublet of doublet at δ 3.30 and 4.25 are due to methine (C-H) and methylene (CH₂) protons respectively. Its ¹³C NMR spectrum showed characteristic signals at δ 62.8 and 75.0 for the methine and methylene carbons attached to hydroxyl groups respectively (**Fig. 2**).




Fig. 2: ¹H and ¹³C NMR spectra of azido diol 46

The azidodiol **46** was then protected as its *bis*-TBS ether (TBS chloride and imid.) to give **48** in 98% yield. The formation of coupound **48** was confirmed by its ¹H NMR spectrum,

which showed the appearance of singlets at δ 0.84 and 0.90 due to *tert*-butyl protons. The other proton signals at δ -0.22, -0.08, 0.03 and 0.05 are assigned to methyl protons attached to silyl group (**Fig. 3**).




Fig. 3: 1 H and 13 C NMR spectra of bis-TBS ether 48

The selective deprotection of the primary silyl ether in **48** was then achieved with camphorsulfonic acid (5 mol%) in MeOH¹⁸ to produce alcohol **49** in 95% yield. The formation of alcohol **49** was confirmed by its ¹H NMR spectrum, which showed the appearance of only one singlet at δ 0.78 for *tert*-butyl protons. The alcohol group in **49** was then oxidized under Dess-Martin periodinane condition to produce azido aldehyde **50** in 98% yield. The ¹H NMR spectrum of aldehyde **50** displayed a typical doublet at δ

9.7 due to aldehydic proton. Its ¹³C NMR spectrum showed a typical signal at δ 201.3 for the aldehydic carbonyl function (**Fig. 4**).






Fig. 4: ¹H and ¹³C NMR spectra of azidoaldehyde 50

Then the resulting aldehyde was subjected to Wittig olefination to give α,β -unsaturated azidoester **45** in 94% yield. The formation of α,β -unsaturated azidoester **45** was confirmed by its ¹H NMR spectrum, which showed the appearance of doublets of doublets at δ 5.88 (dd, J = 1.0, 15.6 Hz, 1H) and 6.63 (dd, J = 4.3, 15.6 Hz, 1H) due to olefinic protons. Its ¹³C NMR spectrum showed typical signals at δ 122.62 and 146.15 due to the olefinic carbons (**Fig. 5**).



Reduction of azide group along with double bond (C=C) was achieved under hydrogenation condition (H₂ and 10% Pd/C). Subsequently, on refluxing with EtOH, TBS protected lactam **51** was obtained in 85% yield. The formation of lactam **51** was confirmed by its ¹H NMR spectrum, which showed the appearance of multiplets at 1.99-2.83 due to methylene protons and the absence of signals in the olefinic region. Its ¹³C NMR spectrum showed a typical signal at δ 172.1 corresponding to amide carbonyl (-CO-NH) group (**Fig. 6**). The presence of amide group was further evidenced by the exhibition of two characteristic absorption bands at 1346 and 1664 cm⁻¹ in its IR spectrum.



The TBS group in **51** was deprotected (TBAF in THF) to give hydroxylactam **40** in 96% yield. The formation of hydroxylactam **40** was confirmed from its ¹H NMR spectrum, which displayed signals at δ 4.48 and 3.85 corresponding to the methine protons (-CH-NHCO and -CHOH). Its ¹³C NMR spectrum showed carbon signals at δ 73 and 67.1 corresponding to the methine carbons (-CH-NHCO and -CHOH). The other signal at δ 177.4 corresponds to amide carbonyl carbon (-CONH-) and signals at δ 30.99 and 28.65 are due to methylene carbons (-CH₂- and -CH₂CO-) respectively.

Reduction of lactam **40** was achieved using $BH_3 \cdot SMe_2$ in THF to give the amino alcohol whose N-H bond protection with $(Boc)_2O$ gave the *syn*- amino alcohol **8** in 73% yield over two steps. The ¹H NMR spectrum of **8** indicated the presence of Boc methyl protons

at δ 1.43 as a singlet (**Fig. 7**). The proton signals at δ 5.30 and 4.44 correspond to the methine protons (CH-N and CH-O) of the substituted piperidine moiety of aminoalcohol **8**. Its ¹³C NMR spectrum displayed signals at δ 156.72 and 80.12 indicating the presence of Boc carbonyl (-NCO-) and *tert*-butyl carbon (Me₃C-O) groups respectively.





Fig. 7: ¹H and ¹³C NMR spectra of *syn*- amino alcohol 8

Having constructed the piperidine ring with the desired *syn*-stereochemistry, *O*-alkylation of **8** with 3,5-bis(trifluoromethyl)benzyl bromide in the presence of NaH was performed to give **52** { $[\alpha]^{25}_{D}$ +30.9 (*c* 0.8, CHCl₃); lit.^{5h} $[\alpha]^{25}_{D}$ +30.38 (*c* 1.55, CHCl₃)}. Finally, deprotection of the Boc group under acidic conditions afforded (+)-L-733,060 (**1**) { $[\alpha]^{25}_{D}$ +35.2 (*c* 0.5, CHCl₃); [lit.^{5h} $[\alpha]^{25}_{D}$ +34.29 (*c* 1.32, CHCl₃]}. The ¹H, ¹³C NMR and other spectral data were in complete agreement with the reported values (**Fig. 8**).⁷



2.1.5. Conclusion

In summary, the enantioselective synthesis of (+)-L-733, 060 (1) has been achieved in 98% ee using hydrolytic kinetic resolution of azido epoxide **46** as the chiral inducing step. The intramolecular reductive cyclization of (*E*)- α , β -unsaturated azido ester **45** was the important step used for the construction of piperidine ring. The synthetic strategy described herein has significant potential for further extension to piperidine-based bioactive molecules as well as other NK1 receptor antagonists.

2.1.6. Experimental Section

(2R, 3S)-3-Azido-3-phenyl-propane-1,2diol (46)

To solution of (*S*,*S*)-salen-cobalt(III)OAc complex (see chapter I) (0.066 g, 1 mol%) and racemic azido epoxide **47** (1.75 g, 10 mmol) at 0 °C was added H₂O (86.4 g, 4.8 mmol) drop wise over 5 min then the resulting reaction mixture was stirred at 0 °C for 14 h. The reaction mixture was filtered through a pad of silica gel and washed with 50% EtOAc/hexanes (40 mL) and the filtrate was concentrated *in vacuo* to give the crude products, which were purified by column chromatography packed with silica gel using petroleum ether/EtOAc (9:1) to give chiral azido epoxide (-)-47 (0.83 g, 48%) and using petroleum ether/EtOAc (7:3) to give chiral azido diol 46 (0.90 g, 47%). The ee of the diol was determined to be 98% ee by chiral HPLC analysis.

Yield: (0.90 g) 47%; yellow colored liquid; $[\alpha]^{25}_{D}$: +188 (*c* 1, CHCl₃); 98% ee by chiral HPLC analysis (Chiralpak OD-H, *n*-hexane/*i*-PrOH, 90:10, 0.5 mL/min) retention time 14.848 (0.90%) and 16.876 (99.20%); **IR** (CHCl₃, cm⁻¹): 859, 828, 1039, 1100, 1384, 1454, 1493, 1602, 2099, 2932, 3052, 3392 (broad); ¹H NMR (200 MHz, CDCl₃) δ : 3.30 (dd, *J* = 11.5, 6.0 Hz, 1H), 3.44 (d, *J* = 11.5 Hz, 1H), 3.80 (br s, 1H), 3.62-3.94 (m, 1H), 4.52 (d, *J* = 8.1, 1H), 7.28-7.35 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ 62.8, 68.1, 75.0, 127.5, 128.7, 128.9, 136.2; **Anal.** Calcd for C₉H₁₁N₃O₂ requires C, 55.95; H, 5.74; N, 21.75%; found: C, 56.10; H, 5.65; N, 21.60%.

(2R, 3S)-3-Azido-1,2-bis(*tert*-butyldimethylsilyloxy)-3-phenyl-propane-1,2-diol (48)

To a solution of azido diol **46** (0.77 g, 4.0 mmol) in CH_2Cl_2 (20 mL) at 25 °C was added TBSCl (1.50 g, 10 mmol) and imidazole (0.680 g, 10 mmol). The resulting solution was stirred at 25 °C for 24 h, then quenched with water and extracted with CH_2Cl_2 . The

combined organic extracts were washed with brine, dried over anhyd. Na_2SO_4 and concentrated *in vacuo* to give the crude product, which was purified by column chromatography packed with silica gel using pet. Ether: EtOAc (9.5:0.5) to give pure bis-TBS ether **48** as colorless oil.

Yield: (1.65g) 98%; colourless oil; $[α]^{25}_{D}$: +56.20 (*c* 1, CHCl₃); **IR** (CHCl₃, cm⁻¹): 668, 765, 835, 1111, 1250, 1464, 1513, 1585, 1612, 2103, 2931, 2955, 3017; ¹H NMR (200 MHz, CDCl₃): δ -0.22 (s, 3H), -0.08 (s, 3H), 0.03 (s, 3H), 0.05 (s, 3H), 0.84 (s, 9H), 0.90 (s, 9H), 3.42 (dd, *J* = 10.0, 4.4 Hz, 1H), 3.62 (dd, *J* = 10.0, 6.4 Hz, 1H), 3.73 (m, 1H), 4.66 (d, *J* = 4.6 Hz, 1H), 7.27-7.35 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ -5.4, -5.2, -4.7, 18.1, 18.3, 25.8, 26.0, 64.1, 66.8, 76.8, 127.5, 127.97, 128.4, 138.1; **Anal.** Calcd for C₂₁H₃₉N₃O₃Si₂ requires C, 59.81; H, 9.32; N, 9.96; found: C, 59.90; H, 9.20; N, 10.0 %.

(2R, 3S)-3-Azido-2-(tert-butyldimethylsilyloxy)-3-phenyl-1-propanol (49)

To a solution of *bis*-TBS ether **48** (1.263g, 3 mmol) in MeOH (10 mL) was added camphorsulfonic acid (0.070g, 10 mole%) at 0 °C and the mixture stirred for 5 h. After completion of the reaction (monitored by TLC), it was neutralized with NaHCO₃ and concentrated to give the crude product, which was purified by column chromatography packed with silica gel using pet. ether: EtOAc (9:1) as eluent to furnish TBS-protected azido alcohol **49** as colorless liquid.

Yield: (0.875 g) 95%; colourless liquid; [α]²⁵_D: +120.21 (*c* 1, CHCl₃); IR (CHCl₃, cm⁻¹):
668, 765, 835, 1115, 1250, 1515, 1585, 1610, 2101, 2955, 3470; ¹H NMR (200 MHz, CDCl₃): δ -0.04 (s, 3H), 0.01 (s, 3H), 0.78 (s, 9H), 1.75 (br s, 1H), 3.02 (m, 1H), 3.27 (m, 1H), 3.57 (m, 1H), 4.45 (d, J = 8.2 Hz, 1H), 7.12-7.21 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ -4.7, -4.6, 18.2, 25.6, 63.2, 68.3, 76.6, 127.6, 128.4, 128.7, 137.2; Anal. Calcd

for C₁₅H₂₅N₃O₂Si requires C, 58.60; H, 8.20; N, 13.67; found: C, 58.50; H, 8.35; N, 13.50%.

(2R, 3S)-3-Azido-2-(tert-butyldimethylsilyloxy)-3-phenyl-1-propanal (50)

To a stirred solution of TBS-protected azido alcohol **49** (0.614g, 2 mmol) in dry CH_2Cl_2 (10 mL) was added Dess-Martin periodinane (1.017g, 2.4 mmol) at room temperature. After the completion of the reaction, it was quenched with water. The precipitate formed was filtered through a sintered funnel and the filtrate was concentrated and subjected to column chromatographic purification using ethyl acetate and pet. ether (1:9) as eluent to give azido aldehyde **50** as yellow liquid.

Yield: (0.60 g) 98%; yellow coloured liquid; $[\alpha]^{25}{}_{D}$: +110.41 (*c* 1, CHCl₃); **IR** (CHCl₃, cm⁻¹): 668, 765, 835, 1110, 1250, 1515, 1585, 1610, 1730, 2106, 2850, 2955; ¹H NMR (200 MHz, CDCl₃): δ -0.17 (s, 3H), -0.10 (s, 3H), 0.86 (s, 9H), 4.07 (dd, *J* = 4.6, 1.4 Hz, 1H), 4.80 (d, *J* = 4.4 Hz, 1H), 7.32-7.39 (m, 5H), 9.60 (d, *J* = 1.5 Hz, 1H); ¹³C NMR (50 MHz, CDCl₃): δ -5.4, -5.2, 18.2, 25.6, 67.1, 80.7, 127.6, 128.7, 135.6, 201.3; **Anal.** Calcd for C₁₅H₂₃N₃O₂Si requires C, 58.98; H, 7.59; N, 13.76; found: C, 59.10; H, 7.50; N, 13.70 %.

(4*R*,5S)-5-Azido-4-(*tert*-butyldimethylsilyloxy)-5-phenylpent-2-enoicacidethylester (45):

To a solution of azido aldehyde **50** (1.0 g, 3.27 mmol) in dry THF (20 mL), was added ylide $Ph_3P=CHCO_2Me$ (1.30 g, 3.92 mmol) at 25 °C. The reaction mixture was stirred at 25 °C for 10 h, and then quenched with water (5 mL). The product was extracted with EtOAc (3 x 20 mL). The combined organic phase was dried over anhyd. Na₂SO₄ and concentrated under *vacuum*. The crude product was purified by column chromatography

on silica gel using ethyl acetate and pet. ether (1:9) as eluent to give (*E*)- α , β -unsaturated azidoester **45** as yellow liquid.

Yield: (1.152 g) 94%; yellow colored liquid; $[\alpha]^{25}_{D}$: +66.11 (*c* 1, CHCl₃); **IR** (CHCl₃, cm⁻¹): 668, 765, 835, 1110, 1250, 1515, 1585, 1610, 1740, 2106, 2955; ¹H NMR (200 MHz, CDCl₃): δ 0.02 (s, 3H), 0.06 (s, 3H), 0.94 (s, 9H), 1.26 (t, *J* = 7.0 Hz, 1H), 4.09-4.17 (m, 1H), 4.34-4.39 (m, 1H), 5.88 (dd, *J* = 15.9, 1.0 Hz, 1H), 6.63 (dd, *J* = 15.9, 4.2 Hz, 1H), 7.20 (dd, *J* = 7.8, 1.5 Hz, 2H), 7.29-7.25 (m, 3H); ¹³C NMR (50 MHz, CDCl₃): δ -5.0, -4.5, 14.3, 18.30, 25.9, 60.2, 70.9, 75.8, 122.6, 127.7, 128.6, 136.2, 14.15, 165.39; **Anal.** Calcd for C₁₉H₂₉N₃O₃Si requires C, 60.77; H, 7.78; N, 11.19; found: C, 60.40; H, 7.85; N, 11.25 %.

(4R, 5S)-5 -(tert-Butyldimethylsilyloxy)-6-phenylpipridine-2-one (51)

To a solution of (E)- α , β -unsaturated azidoester **45** (1.0 g, 2.66 mmol) in methanol (20 mL), was added 10% Pd/C (60 mg) and the mixture stirred under hydrogen (20 psi) atmosphere at 25 °C. The reaction mixture was stirred at 25 °C for 5 h, and the progress monitored by TLC. After completion of reaction, it was filtered through a Celite pad and washed with EtOAc (3 x 20 mL). The combined organic phase was concentrated under *vacuum*. The crude product thus obtained was refluxed in ethanol (20mL) for 4h. Ethanol was concentrated under *vacuum*. The crude product was purified by column chromatography on silica gel using ethyl acetate and pet. ether (4:6) as eluent to give TBS protected lactam **51** (0.431 g) as yellow gum.

Yield: (0.431 g) 85%; yellow colored gum; **[α]**_D +29.32 (*c* 0.5, CHCl₃); **IR** (CHCl₃, cm⁻¹): 700, 748, 1190, 1321, 1450, 1654, 2930, 3282; ¹H-NMR (200 MHz, CDCl₃): δ -0.60 (s, 3H), -0.21 (s, 3H), 0.76 (s, 9H), 1.99-2.07 (m, 1H), 2.40 (m, 2H), 2.65-2.83 (m, 1H),

4.02-4.05 (m, 1H), 4.60 (d, J = 2.7 Hz), 5.68 (brs, 1H), 7.29-7.36 (m, 5H); ¹³C-NMR (50 MHz, CDCl₃): δ -6.0, -5.4, 17.9, 25.7, 26.1, 28.4, 62.5, 67.3, 127.6, 127.9, 128.2, 138.9, 172.1; **Anal.** Calcd for C₁₇H₂₇NO₂Si requires C, 66.84; H, 8.91; N, 4.59; found: C, 66.50; H, 9.02; N, 4.65%.

5-Hydroxy-6-phenylpiperidin-2-one (40)

To a stirred solution of TBS protected lactam **51** (0.610 g, 2 mmol) in THF was added a solution of tetrabutylammonium fluoride (TBAF) (0.528 g, 1M in THF, 2 mmol) at 0 °C and stirred for 6 h. The reaction mixture was quenched by the addition of water and the organic phase was separated. The aqueous layer was extracted with ethyl acetate (3x 50 mL) washed with water, brine and dried over anhydrous Na₂SO₄. The combined organic layer was concentrated under reduced pressure to give the crude lactam **40**, which was purified by column chromatography using petroleum ether: ethyl acetate (3: 7) to obtain lactam **40**.

Yield: (0.366 g) 96%; yellow colored gum; $[α]^{25}$ _D +32.48 (*c* 0.8, CHCl₃); **IR** (CHCl₃, cm⁻¹): 700, 748, 1196, 1321, 1452, 1654, 2930, 3282; ¹H-NMR (200 MHz, CDCl₃): δ 1.97-2.04 (m, 1H), 2.11-2.17 (m, 1H), 2.35-2.41 (m, 1H), 2.68-2.75 (m, 1H), 4.06-4.07 (m, 1H), 4.66 (d, *J* = 3.0 Hz, 1H), 7.32-7.42 (m, 5H); ¹³C-NMR (50 MHz, CDCl₃): δ 26.2, 26.6, 61.8, 66.2, 127.0, 127.6, 129.1, 137.8, 172.9; **Anal.** Calcd for C₁₁H₁₃NO₂ requires C, 69.09; H, 6.85; N, 7.32; found: C, 69.98; H, 6.02; N, 7.55%.

(2S, 3S)-1-(3-Hydroxy-2-phenyl piperidin-1-yl)-2,2-dimethyl propan-1-one (8)

To a solution of the lactam **40** (191 mg, 1 mmol) in dry THF (10 mL) at 25 $^{\circ}$ C was added BH₃.SMe₂ (152 mg, 2 mmol) drop-wise and the mixture was then refluxed for 6 h. After the completion of the reaction, the solvent was removed under reduced pressure and the

residue was extracted with ethyl acetate to give the corresponding amino alcohol. Without purification, amino alcohol was dissolved in CH_2Cl_2 (5 mL) and Et_3N (2 mmol) followed by catalytic amount of DMAP were added. After stirring for 5 min at 0 °C, $(Boc)_2O$ (1 mmol) was added drop-wise and the reaction mixture was allowed to stir for another three hours. After the completion of the reaction, it was extracted with ethyl acetate, washed with water, brine and dried over anhydrous Na₂SO₄ to get crude product. Chromatographic purification of the crude product using petroleum ether: ethyl acetate gave the pure **8** as viscous liquid.

Yield: (202 mg) 73% (over two steps); viscous liquid; $[\alpha]^{25}{}_{D}$ +37.80 (*c* 1.0, CHCl₃) {lit.⁷ $[\alpha]_{D}^{25}$ +38.3 (*c* 1.92, CHCl₃)}; **IR** (CHCl₃, cm⁻¹): 756, 851, 876, 984, 1137, 1168, 1326, 1365, 1417, 1495, 1602, 1675, 2955, 3015, 3447; ¹H- **NMR** (200 MHz, CDCl₃): δ 1.41 (s, 9H), 1.55–2.01 (m, 5H), 2.74–2.89 (ddd, *J* = 3.2, 9.7, 12.9 Hz, 1H), 4.45–4.49 (m, 1H), 4.0–4.09 (m, 1H), 5.32 (m, 1H), 7.13–7.35 (m, 5H); ¹³C-NMR (50 MHz, CDCl₃): δ 23.98, 25.92, 28.36, 39.90, 60.24, 67.48, 80.11, 126.86, 126.89, 138.15, 156.70; **Anal.** Calcd for C₁₆H₂₃NO₃ requires C, 69.29; H, 8.36; N, 5.05; found: C, 69.43; H, 8.13; N, 4.92%.

(2*S*,3*S*)-1-(*tert*-Butyoxycarbonyl)-2-phenyl-3-[(3,5-bis(trifluoromethyl)benzyloxy] piperidine (52)

To a stirred solution of **8** (99 mg. 0.36 mmol) in dry DMF (1 mL) at 0 °C was added sodium hydride (10 mg, 60% dispersion in mineral oil, and 0.43 mmol) in one portion. After 5 min of stirring at the same temperature, 3,5-bis(trifluoromethyl)benzyl bromide (110 mg, 0.36 mmol) in dry DMF (1 mL) was added *via* syringe. The reaction mixture was stirred for 12 h at 80 °C and it was then quenched with water (3 mL) and extracted

with Et_2O (5 mL). The combined organic layers were washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated. The residue was purified by flash chromatography on silica gel column using petroleum ether: ethyl acetate (7: 3) to provide **52** as colorless oil.

Yield: (0.14 g) 78%; colorless oil; $[\alpha]_D^{25}$ +30.90 (*c* 1.0, CHCl₃) {lit.⁷ $[\alpha]_D^{25}$ +30.4 (*c* 1.55, CHCl₃)}; **IR** (neat, cm⁻¹): 665, 875, 1172, 1253, 1345, 1381, 1644, 2945; ¹**H-NMR** (CDCl₃, 200 MHz): δ 1.42 (s, 9H), 1.32-1.66 (m, 2H), 1.78-2.12 (m, 2H), 2.76 (ddd, *J* = 11.2, 9.8, 4.6 Hz, 1H), 3.79-3.98 (m, 2H), 4.66 (d, *J* = 11.4 Hz, 1H), 4.74 (d, *J* = 12.2 Hz, 1H), 5.67 (d, *J* = 4.6 Hz, 1H), 7.22-7.38 (m, 3H), 7.42-7.52 (m, 2H), 7.66 (s, 2H), 7.78 (s, 1H); ¹³**C-NMR** (CDCl₃, 50 MHz): δ 20.2, 25.3, 26.3, 27.2, 44.4, 63.2, 71.2, 77.0, 120.2, 123.1, 126.7, 127.3, 127.8, 132.4, 141.2, 142.4, 159.0; **Anal.** Calcd for C₂₅H₂₇F₆NO₃ requires C, 59.64; H, 5.41; N, 2.78; found: C, 59.61; H, 5.38; N, 2.76%.

Preparation of (+)-L-733,060 (1)

To an ice-cooled solution of **52** (100 mg, 0.2 mmol) in dry CH_2Cl_2 (4 mL) was added trifluoroacetic acid (228 mg, 2 mmol). The reaction mixture was stirred at room temperature for 12 h and then quenched with saturated NaHCO₃ and extracted with dichloromethane (3x5 mL). The combined organic layers were washed with brine and dried over anhyd. Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography using CH₃OH: CHCl₃ (1: 9) as eluent to give pure **1** as colorless viscous liquid.

Yield: (79 mg) 89%; colorless viscous liquid; $[\alpha]_D^{25} + 35.2$ (*c* 0.66, CHCl₃) {lit.⁷ $[\alpha]_D^{25} + 34.29$ (*c* 1.32, CHCl₃)};)}; **IR** (neat, cm⁻¹): 663, 877, 1123, 1170, 1277, 1370, 2950; ¹**H-NMR** (CDCl₃, 200 MHz) : δ 1.42-204 (m, 3H), 2.22 (br d, *J* = 13.0 Hz, 1H), 2.62 (s, 1H), 2.76-2.81 (m,1H), 3.23-3.38 (m, 1H), 3.66 (s, 1H), 3.84 (br s, 1H), 4.12 (d, J = 12.0 Hz, 1H), 4.54 (d, J = 12.2 Hz, 1H), 7.20-7.50 (m, 7H), 7.78 (s, 1H); ¹³C-NMR (CDCl₃, 50 MHz): 20.6, 27.5, 47.1, 64.0, 70.5, 77.2, 120.9, 124.1, 127.7, 128.5, 128.7, 131.2, 141.6, 142.3; **Anal.** Calcd for C₂₀H₁₉F₆NO₃ requires C, 59.55; H, 4.75; N, 3.47; found. C, 59.52; H, 4.81; N, 3.56%.

Section II

Enantioselective synthesis of (S)-dapoxetine *via* Sharpless asymmetric epoxidation

2.2.1. Introduction

Discovery of (S)-dapoxetine (53) is credited to David T. $Wong^{19}$ of *Eli Lilly and company*. (S)-Dapoxetine 53 is found to be a potent selective serotonin re-uptake inhibitor (SSRIs) but is slightly different from the SSRIs (such as (S)-Fluoxetine, (-)-Paroxetine and Sertraline) widely prescribed for depression and other psychiatric disorders as bulimia or anxiety. It is very much structurally related to Fluoxetine 54 (Prozac) with antidepressant activity (Fig 9).




Fig. 9: Structures of (S)-dapoxetine and (S)-Fluoxetine

Dapoxetine is the D-enantiomer of LY 243917 and found to be 3.5 times more potent as a serotonin reuptake inhibitor than the L-enantiomer of LY 243917. It would make it join the ranks of sildenafil (Viagra®), tadalafil (Cialis®), vardenafil (Levittra®), the erectile dysfunction drugs and cabergoline (Dostinex ®) as a drug invented to improve male sexual health.²⁰

2.2.2 Dapoxetine and Pharmacology

Delay in ejaculation is one of the side effects of serotonine-specific reuptake inhibitors (SSRIs) and TCAs that make them useful in the treatment of premature ejaculation (PE)


with physiological rather than physical etiologies.²¹ Although it has been found in the literature that PE is more common among men with higher levels of education because of their interest in the sexual satisfaction of their partner.²² SSRI antidepressants have been shown to delay ejaculation in men treated for different psychiatry disorders. These are considered to be the most effective treatment currently available for PE. The use of these drugs that require chronic therapy is limited by the neuropsychiatric side effects. New SSRI drugs specifically targeted to treat premature ejaculation (e.g. dapoxetine) can be taken on as needed basis and have recently shown positive results in large phase III studies. Nevertheless dapoxetine is not yet approved by any regulatory authority around the world. There is a speculation that some of the associated effects are caused by lowered libido and blood pressure as well as lowered anxiety levels. Other pharmaceutical products known to delay male orgasm are; opioids, cocaine, and diphenhydramine.²³2.2.3.

Review of Literature

Various asymmetric syntheses of (*S*)-dapoxetine (**53**) and (*R*) and (*S*)-3-amino-3-phenyl-1-propanol have been documented in the literature.²⁴ Some of the interesting and important synthetic routes to dapoxetine are described below.

Koizumi's approach (1982)²⁵


Koizumi *et al.* have reported the synthesis of (*R*)-amino alcohol **55** (intermediate for (R)dapoxetine) starting from optically active (*R*)-(+)-*p*-tolyl vinyl sulfoxide **56** which on 1,3dipolar cycloaddition with nitrones **57** in refluxing benzene gave sulfinyl isoxazolidines **58** in 40% yield. The isoxazolidines **58** was then converted to (*R*)-amino alcohol **55** by using sequence of reactions such as *N*-methylation, reductive cleavage of N-O bond followed by desulfurization (Scheme 11).



<u>Scheme 11:</u> i) benzene, reflux, 20 h, 40%; ii) (a) MeI; (b) Zn-AcOH, rt; iii) TiCl₄-AcOH-AcONa, rt; iv) Raney Ni-EtOH, rt.

Gotor approach (2006)²⁶


This approach describes the synthesis of (*S*)-dapoxetine starting from benzaldehyde **60** which on reaction with malonic acid, ammonium acetate in refluxing ethanol followed by the reduction with LiAlH₄ in THF at 65 °C to give amino alcohol **61** in 77% yield. The alcohol group was protected by *tert*-butyl dimethyl silyl chloride (TBDMSCl) using imidazole in CH_2Cl_2 which gave amine **62** in 95% yield. The amine **62** on enzymatic resolution using ethyl methoxyacetate as acyl donor, *antarctica lipase* type A as enzyme in TBME solvent after 47 h at 30 °C gave **64** in 93% ee along with the hydrolyzed intermediate **63**. The intermediate **64** on treatment with 6M HCl at 50 °C gave amino alcohol **65** in 84% yield. The primary amine function in **65** was converted into tertiary amine **66** in 83% yield using formaldehyde and formic acid as hydrogen source. This on reaction with 1-napthol, triphenyl phosphine, DEAD in THF gave (*S*)-dapoxetine **53** in good yield with 93% ee (**Scheme 12**).



<u>Scheme 12:</u> i) $CH_2(CO_2H)_2$, NH_4OAc , EtOH, 80 °C,12 h, 68%; ii) LiAlH₄, THF, 65 °C, 3 h, 77%; iii) TBDMSCl, imid., CH_2Cl_225 °C, 95%; iv) Acyl donor, enzyme, solvent, 30 °C, 250 rpm; v) HCl 6M, 50 °C, 84%; vi) (CH₂O)n, HCO₂H, 25 °C, 83%; vii) PPh₃, DEAD, 1-napthol, THF, 25 °C, 72%.

Fadnavis approach (2006)²⁷

Fadnavis et al. have achieved the synthesis of (R) and (S)-3-amino-3-phenyl-1-propanol,




<u>Scheme 13:</u> i) Baker's yeast, diisopropyl ether, 48 h, 90%; ii) NH₄OAc, NaBH₃CN, EtOH, 25 °C, 36 h, 65%. iii) PhCH₂COCl, NaOH, 25 °C, 4 h, 80%. iv) *penicillin G acylase*, 4 h, water.

a prominent intermediate of (*S*)-dapoxetine, starting from ethyl 2,4-dioxo-4phenylbutyrate **67** which was converted to 3-oxo-3-phenyl-1-propanol **68** in 90% yield by reaction with baker's yeast. Reductive amination with sodium cyanoborohydride in the presence of ammonium acetate gave the racemic 3-amino-3-phenyl-1-propanol **61** in 65% yield. The enzymatic resolution of the corresponding *N*-phenyl acetyl derivative **69** with *penicillin G acylase*, immobilized on an epoxy resin gave (*S*)-amide **70** and (*R*)amino alcohol **71** in high enantiomeric purity (99% ee) (**Scheme 13**).


Srinivasan approach (2007, 2008)^{28,29}


Srinivasan *et al.* have achived the synthesis of (*S*)-dapoxetine using Sharpless asymmetric dihydroxylation of *trans*-cinnamyl ester, **72** to get diol **73** in 80% yield with 99% ee (Scheme 14).



<u>Scheme 14</u>: (i) (DHQ)₂PHAL (5 mol %), OsO₄, NMO, *tert*-BuOH, , 25 °C, 16 h, 80%; (ii) CH₂Cl₂, Et₃N, SOCl₂, 0 °C to , 25 °C, 1 h; (iii) NaN₃ (5 equiv), DMF, , 25 °C, 48 h, 85%; (iv) H₂/Pd-C, EtOAc, , 25 °C, 24 h, (Boc)₂O, Et₃N; (v) MeI, CS₂, MsCl, Et₃N, CH₂Cl₂, 0 °C to , 25 °C, 12 h; (vi) n-Bu₃SnH, AIBN, toluene, reflux, 75% after two steps; (vii) LiAlH₄, THF, , 25 °C, 12 h; (viii) TFA, CH₂Cl₂, 25 °C; (ix) HCHO, HCO₂H; (x) Ph₃P, DEAD, 1-naphthol, THF, 25 °C.

Srinivasan *et al.* have also achieved the synthesis of (*S*)-amino alcohol **65** using Sharpless asymmetric epoxidation of cinnamyl alcohol (**78**) to get epoxy alcohol **79** in 98%ee. Regioselective opening of epoxide with NaN₃ resulted in *trans* azido diol **80**, which was converted to (S)-amino alcohol **65** *via* deoxygenation of xanthate **83** followed by deprotection (Scheme 15).






Scheme 15: (i) (R,R)-(+)-DET, Ti(O-*i*Pr)₄, TBHP, MS 4 Å, CH₂Cl₂, -20 °C, 3 h, 88%; (ii) NaN₃, MeOH:H₂O (8:1), 65 °C, 5 h, 97%; (iii) TBSCl, imid., 0-25 °C, 5 h, 96%; (iv) 10% Pd/C, H₂, (Boc)₂O, EtOAc, 25 °C, 12 h, 88%; (v) CS₂, NaH, MeI, THF, 0-25 °C, 84%; (vi) n-Bu₃SnH, AIBN, 0-25 °C, 84%. (vii) TFA, CH₂Cl₂, 0 °C, 5 h, 81%.

Deshmukh approach (2009)³⁰

Deshmukh *et al.* have achieved the synthesis of (S)-amino alcohol **66** from optically active hydroxyl β -lactam **85**, which was converted to its xanthate derivatives [NaH, CS₂, and methyl iodide] followed by reduction with n-Bu₃SnH, and AIBN to furnish PMP protected β -lactam **86**. The oxidative removal of PMP using CAN to give β -lactam **87** in

60% yield. N-Boc protection of amine functionality in **87** with $(Boc)_2O$ followed by reduction with LiAlH₄ gave Boc protected amino alcohol **77**, which was converted to amine **66** *via* standard reaction sequences (**Scheme 16**).




<u>Scheme 16</u>: (i) NaH, CS₂, CH₃I, THF, 0- 25 °C, 6 h, 75%; (ii) Bu₃SnH, AIBN, toluene, reflux, 3-4 h, 92%; (iii) CAN, CH₃CN/ H₂O, 0 °C, 1 h, 60%; (iv) (Boc)₂O, DMAP, CH₂Cl₂, 0- 25 °C, 6 h, 70%; (v) LiAlH₄, THF, 0- 25 °C, 4 h, 80%; (vi) TFA, CH₂Cl₂, 0- 25 °C, 2 h, 89%; (vii) HCHO, NaBH₃CN, CH₃CO₂H, CH₃CN, 25 °C, 2 h, 80%.

2.2.4. Present Work

2.2.4.1. Objective

As can be seen from the above discussion, literature methods for the synthesis of (*S*)dapoxetine (**53**), employ chiral starting materials and expensive reagents, involve longer reaction sequences or require radical reaction conditions. This section describes a short synthesis of (*S*)-dapoxetine (**53**), using Sharpless asymmetric epoxidation³¹ and regioselective reductive ring opening³² of chiral epoxy alcohol **79** as key reactions. The retrosynthetic analysis for the synthesis of (*S*)-dapoxetine (**53**) is shown in (**Scheme 17**). Retrosynthetic analysis of (*S*)-dapoxetine (**53**) shows that amino alcohol **66** emerges as the key intermediate, which could be obtained from 1,3-diol **88** by azide displacement and reductive N-alkylation. The precursor **88** can be prepared from epoxy alcohol **79**, which in turn could be readily obtained from cinnamyl alcohol **78** by the Sharpless asymmetric epoxidation protocol.




Scheme 17: The retrosynthesis of (S)-dapoxetine (53)

2.2.4.2 Sharpless asymmetric epoxidation

Asymmetric epoxidation of allylic alcohols is one of the leading areas of investigation in synthetic organic chemistry, mainly due to the fact that very high enantioselective induction for a wide range of substrates is possible using several classes of reagents. Today, the most successful asymmetric epoxidation reaction is the titanate-mediated epoxidation of allylic alcohols, or Sharpless epoxidation,³¹ which enables the achievement of an enantiomeric excess of more than 90% in most cases. The Sharpless epoxidation is a popular laboratory and industrial process due to its both enantioselective and catalytic nature. The reaction mixture includes a titanium tetraalkoxide, a chiral tartrate diester, an allylic alcohol substrate, and an alkyl hydroperoxide as the oxidant. The consistency of the reaction is remarkable, excellent enantiofacial selectivity is realized for allylic alcohol substrates of widely varying structure. In addition to being

able to asymmetrically oxidize prochiral substrates to products of predictable absolute configuration, the reaction is extremely sensitive to preexisting chirality in selected positions of the allylic alcohols. For example, kinetic resolution of racemic secondary allylic alcohols is very efficient since it can be used for generating chiral allylic alcohols as well as *trans*-epoxyalcohols in high enantiomeric excess.

Selection of the proper chirality in the starting tartrate esters and proper geometry of the allylic alcohols allows one to establish both the chirality and relative configuration of the product (**Scheme 18**).



Scheme 18: The Sharpless epoxidation reaction

Since its discovery in 1980, the Sharpless expoxidation of allylic alcohols has become a benchmark classic method in asymmetric synthesis. One factor that simplifies the standard epoxidation reaction is that the active chiral catalyst is generated *in situ*, which means that the pre-preparation of the active catalyst is not required. It is believed that the species containing equal moles of Ti and tartrate is the most active catalyst. It promotes the reaction much faster than Ti(IV) tetraalkoxide alone and exhibits selective ligand-accelerated reaction.³³





Fig. 10: Structure of dinuclear Ti-tartrate complex

Sharpless suggested that epoxidation was catalyzed by a single Ti center in a dimeric complex with a C_2 symmetric axis (Fig. 10).³⁴

2.2.5. Results and Discussion

The present synthetic route employed for the synthesis of (S)-dapoxetine (53) is shown in





<u>Scheme 19</u>: (i) (+)-Diethyl tartarate, Ti(O^{*i*}Pr)₄, anhyd. TBHP, CH₂Cl₂, -33 °C, 83%; (ii) Red Al[®], DME, 0 -25 °C, 85%; (iii) NaH, benzyl bromide, DMF, -70 °C, 80%. (iv) a) MsCl, Et₃N, CH₂Cl₂, 0 °C, 1h ; (b) NaN₃, DMF, 60 °C, 5 h, 98%; (v) 10% Pd/C, H₂, MeOH, AcOH, 25 °C ; (vi) HCHO, HCO₂H, reflux, 8 h, 80%; (vii) PPh₃, DEAD, 1-naphthol, THF, 25 °C, 71%.

Cinnamyl alcohol **78** was subjected to Sharpless asymmetric epoxidation using (+)diethyl tartarate, [(+)-DET] to furnish the corresponding chiral epoxide **79** as a yellow crystal {m.p. : 53.5–54 °C and $[\alpha]^{25}_{D} = -49.4$ (*c* 1, CHCl₃)} in 83% yield with 98% ee. Its optical purity was determined from ¹H NMR analysis of the corresponding Mosher's ester **79b** (Fig. 11).





Fig. 12: ¹H NMR spectra of Mosher's ester 79b


The ¹H NMR spectrum of **79b** showed. characteristic proton signals at δ 3.90 (d, *J* = 2.0 Hz, 1H) and 3.18-3.22 (m, 1H) for the epoxide protons. Its ¹³C NMR spectrum displayed typical peaks at δ 55.5 and 62.4 corresponding to methine carbons of epoxide moiety.


Our next task was to make 1,3-diol **88** from epoxide **79**. In order to achieve this transformation with high regioselectivity and yield, a strategy involving Red-Al[®], originally published by Sharpless *et al.* was undertaken.³² Thus, epoxide **79** was treated with Red-Al[®] in DME at 0 -25 °C to give 1,3-diol **88** in 85% yield. Its ¹H NMR spectrum showed typical signals at δ 3.82 (t, 2H) and δ 4.92 (dd, 1H) due to methylene (-CH₂OH) and methine (-CHOH) protons respectively. Its ¹³C NMR spectrum displayed a typical



carbon signals at δ 60.5 and 73.1 due to methylene and methine carbons attached to hydroxyl group (**Fig. 12**).


1,3-Diol **88** was then selectively monobenzylated³⁵ (BnBr, NaH, DMF at -70 °C) to give the monobenzylated 1,3-diol **89**. Its ¹H NMR spectrum showed a typical singlet at δ 4.45 for the benzyloxy methylene proton (PhCH₂O-) while its ¹³C NMR spectrum displayed characteristic signals at δ 68.44 and 73.28 for alkoxy and benzyloxy (PhCH₂-O-CH₂-) methylene carbons respectively (**Fig. 13**). The nucleophilic displacement of mesylate, obtained from alcohol **89**, with NaN₃ in DMF at 80 °C yielded the corresponding azide **90** in 98% yield.







Its ¹H NMR spectrum showed a typical signal at δ 4.70 (dd, J = 6.6, 8.1 Hz) due to methine proton (Ph-CH-N₃) while its ¹³C NMR spectrum displayed a characteristic signal at δ 63.10 for carbon attached to azido group (Ph-CH-N₃) (**Fig. 14**). The presence of azide group was further evidenced by the characteristic absorption band exhibited at 2106 cm⁻¹ in its IR spectrum. Reduction of azide group with simultaneous deprotection of OBn was achieved by using H₂ (60 psi) and 10% Pd/C to give amino alcohol **65**. The presence of primary amine group was confirmed by the two characteristic absorption bands at 3387 and 3348 cm⁻¹ in its IR spectrum. Subsequently the primary amine **65** was reductive

alkylated using Clarke-Eschweiler protocol (formaldehyde, excess of formic acid and reflux) to give **66** in 85% yield.³⁶




The ¹H NMR spectrum of **66** showed a singlet of six protons at δ 2.21 corresponding to methyl groups. The ¹³C NMR spectrum of **66** showed a signal at δ 32.0 for two methyl groups attached to nitrogen atom (**Fig. 15**). The final reaction in the sequence was the coupling between the hydroxyl group of **66** with α -naphthol. We ultimately opted for Mitsunobu reaction³⁷ of nucleophilic substitution conditions, with α -naphthol in the presence of DEAD, PPh₃ and THF as solvent that produced (+)-(*S*)-dapoxetine **53** in 72% yield, {[α]²⁵_D+64.6 (*c* 1.0, CHCl₃); [lit.²⁸ [α]²⁵_D +64.2 (*c* 0.3, CHCl₃]}.





The ¹H, ¹³C NMR and other spectral data of (+)-(S)-dapoxetine **53** were in complete agreement with the reported values (**Fig. 16**).²⁸



2.2.6 Conclusion

We have achieved, a short synthesis of (*S*)-dapoxetine with 98% ee, using Sharpless asymmetric epoxidation and regioselective reductive ring opening of chiral epoxy alcohol as a key reactions.

2.2.7. Experimental Section

(2*S*,3*S*)-(3-Phenyl-oxiranyl)methanol (79)

To a stirred solution of (R,R)-(+)-diethyl tartarate (0.80 g, 3.91 mmol) in CH₂Cl₂ (45 mL) at -20 °C, (2.8 g) activated powdered 4A° molecular sieves, Ti(O-*i*Pr)₄ (0.78 mL, 0.74 g, 2.61 mmol) and 3 M solution of TBHP in toluene (34.78 mL, 104.34 mmol) were added sequentially. The mixture was allowed to stir at -20 °C for 1 h and then a solution of freshly distilled (E)-3-phenyl-2-propenol (7.0 g, 52.17 mmol) in 10 mL of CH₂Cl₂ was added drop wise over 30 min. After 3 h at -20 °C, the reaction was quenched at -20 °C with 10% aqueous solution of NaOH saturated with NaCl (4.2 mL). After diethyl ether (60 mL) was added, the cold bath was allowed to warm to 10 °C, stirring was maintained at 10 °C while MgSO₄ (5 g) and Celite (500 mg) were added. After another 15 min of stirring, the mixture was allowed to settle and clear solution was filtered through a pad of celite and washed with diethyl ether. Azeotropic removal of TBHP with toluene at a reduced pressure and subjection to high vacuum gave **79** as yellow oil. Recrystallization from petroleum ether/diethyl ether gave yellow crystals of **79** (6.5 g, 83%, >98% ee determined by spectroscopic analysis of the ester derived from (+)-MTPA chloride).

Yield: 83% (5.6 g); yellow crystals mp = 53.5–54 °C; $[\alpha]^{25}_{D}$: -49.4 (*c* 1, CHCl₃) {lit.³² $[\alpha]_{D}^{25}$ -49.6, (*c* 2.40, CHCl₃)}; **IR** (CHCl₃, cm⁻¹): 758, 840, 863, 881, 1027, 1068, 1108, 1256, 1392, 1462, 1606, 2871, 2927, 3017, 3428; ¹H NMR (200 MHz, CDCl₃): δ 2.77 (br s, 1H), 3.18–3.32 (m, 1H), 3.70–3.81 (m, 1H), 3.90 (d, J = 2.1 Hz, 1H), 3.97–4.12 (m, 1H), 7.23–7.34 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ 55.4, 61.1, 62.4, 125.5, 127.8, 128.1, 136.4; **Anal.** Calcd for C₉H₁₀O₂ requires C, 71.98; H, 6.71; found: C, 71.92; H, 6.86%.

(R)-3-Phenyl-1,3-dihydroxypropane (88)

(2S,3S)-2,3-Epoxycinnamyallc alcohol **79** (1.5 g, 10.0 mmol) in dimethoxyethane (50 mL) was added a 3.4 M solution of sodium *bis*-(2-methoxyethoxy)aluminum hydride (Red-Al[®]) in toluene (3.1 mL, 10.5 mmol) dropwise under nitrogen at 0 °C. After stirring at room temperature for 3 h, the solution was diluted with ether and quenched with 5% HCl solution. After further stirring at room temperature for 30 min, the white precipitate formed was removed by filtration and boiled with ethyl acetate and filtered again. The combined organic extracts were dried with magnesium sulfate. The solution was concentration and the crude compound was purified by column chromatography using petroleum ether/EtOAc (6:3) to give (*R*)-3-phenyl-1,3-dihydroxypropane, (**88**).

Yield: 98% (1.5 g); colourless viscous liquid; $[\alpha]^{25}_{D}$: +53.8 (*c* 1, CHCl₃); **IR** (CHCl₃, cm⁻¹): 758, 840, 863, 881, 1027, 1068, 1108, 1256, 1392, 1462, 1606, 2871, 2927, 3017, 3428; ¹H NMR (200 MHz, CDCl₃): δ 1.89-2.09 (m , 2H), 2.85 (br s, 2H), 3.82 (t, *J* = 5.1, 10.9 Hz, 2H), 4.92 (dd, *J* = 4.4, 8.2 Hz, 1H), 7.24–7.34 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ 40.4, 60.5, 73.1, 125.6, 127.3, 128.3, 144.3; **Anal.** Calcd for C₉H₁₂O₂ requires C, 71.03; H, 7.95; found: C, 71.48; H, 7.80%.

(R)-3-(Benzyloxy)-1-phenylpropan-1-ol (89)

To a solution of NaH (0.40 g, 10 mmol) in dry DMF (12 mL) at -70 °C was added 1,3diol **88** (1.52 g, 10 mmol) in (2 mL) dry DMF over 10 min. The resulting mixture was stirred for an additional 15 min and then benzyl bromide (1.2 mL, 10 mmol) was added drop wise. The reaction was stirred for 5 h at the same temperature. After completion, the reaction mixture was quenched with cold water (5 mL) and the aq. phase was extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with water followed by brine and dried over anhyd. Na₂SO₄. The solvent was removed under reduced pressure and the crude compound was purified by column chromatography using petroleum ether/EtOAc (6: 2) to afford mono protected alcohol **89** as a colorless liquid.

Yield: 80% (1.93 g); colourless liquid; $[\alpha]^{25}{}_{D}$: +29.4 (*c* 1, CHCl₃); **IR** (CHCl₃, cm⁻¹): 750, 881, 1027, 1068, 1100, 1108, 1250, 1463, 1601, 2871, 2927, 3017, 3428; ¹H NMR (200 MHz, CDCl₃): δ 1.85-2.01 (m, 2H), 2.54 (br s, 1H), 3.54–3.62 (m, 2H), 4.45 (s, 2H), 4.83 (dd, *J* = 4.4, 7.5 Hz, 1H), 7.16–7.28 (m, 10H); ¹³C NMR (50 MHz, CDCl₃): δ 38.6, 68.4, 73.1, 73.2, 125.6, 127.1, 127.6, 127.7, 128.2, 128.4, 137.8, 144.3; **Anal.** Calcd for C₁₆H₁₈O₂ requires C, 79.31; H, 7.49; found: C, 79.20; H, 7.60%.

1-(S)-3-Azido-3-phenylpropoxymethyl)benzene (90)

To a solution of alcohol **89** (0.99 g, 4.1 mmol) in CH_2Cl_2 (5 mL) was added Et_3N (0.82 g, 8.2 mmol) at 0 °C. After 5 min of stirring, methane sulfonyl chloride (0.47 g, 4.1 mmol) was added drop-wise over a period of 5 min. The reaction mixture was then stirred for another 1 h at 0 °C and brought to room temperature. After the completion of the reaction, as monitored by TLC, it was extracted with CH_2Cl_2 (3x 20 ml) washed with water, brine and dried over anhydrous Na_2SO_4 . The combined organic layer was concentrated under reduced pressure to get crude methane sulfonate ester in almost quantitative yield. To a solution of mesylate in DMF (10 mL) was added sodium azide (0.53g, 8.2 mmol) and the reaction mixture was heated at 60 °C for 7 h. After the

completion of the reaction, as monitored by TLC, it was extracted with CH_2Cl_2 (3x 20 mL) washed with water, brine and dried over anhydrous Na_2SO_4 . The combined organic layer was concentrated under reduced pressure to give the crude azidobenzyloxyether **90**, which was purified by column chromatography using petroleum ether: ethyl acetate (9:1) to produce **90** as pale yellow oil.

Yield: 98% (1.07 g); pale yellow oil; $[\alpha]^{25}_{D}$: -65.6 (*c* 2, CHCl₃); **IR** (CHCl₃, cm⁻¹): 750, 1108, 1250, 1463, 1601, 2106, 2871, 2927, 3017; ¹H NMR (200 MHz, CDCl₃): δ 1.98-2.10 (m, 2H), 3.46-3.53 (m, 1H), 3.54-3.59 (m, 1H), 4.48 (s, 2H), 4.70 (dd, *J* = 6.6, 8.1 Hz, 1H), 7.27–7.40 (m, 10H); ¹³C NMR (50 MHz, CDCl₃): δ 36.5, 62.9, 66.3, 73.0, 126.8, 127.6, 127.7, 128.1, 128.3, 128.7, 138.1, 139.5; **Anal.** Calcd for C₁₆H₁₇N₃O requires C, 71.89.31; H, 6.41; N, 15.72; found: C, 72.01; H, 6.50; N, 15.55%.

(S)-3-Amino-3-phenylpropan-1-ol (65)

To a solution of azidobenzyloxyether **90** (0.27 g, 1 mmol) in methanol (5 mL), was added 10% Pd/C (10 mg) and glacial acetic acid (0.5 mL) at 25 °C. The reaction mixture was stirred under hydrogen (60 psi) for 20 h, and the progress of the reaction monitored by TLC. After completion of reaction, it was filtered through a celite pad and washed with EtOAc (3 x 20 mL). The combined organic phase was concentrated under *vacuum*. The crude product was obtained, purified by column chromatography on silica gel using ethyl acetate / MeOH (1:1) as eluents to give amino alcohol **65**.

Yield: 92% (0.14 g); white hygroscopic solid m.p.: 76-77 °C; $[\alpha]^{25}_{D} = -11.6$ (c 1, CHCl₃); IR (CHCl₃, cm⁻¹): 758, 840, 1050, 1460, 1575, 2940, 3280, 3386; ¹H NMR (200 MHz, CDCl₃): δ 1.77-2.32 (m, 2H), 3.63–3.69 (m, 3H), 3.86 (brs, 3H), 7.15–7.38 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ 35.9, 55.1, 58.9, 126.2, 127.0, 128.6, 138.9;

Anal. Calcd for C₉H₁₃NO requires C, 71.49; H, 8.67; N, 9.26; found: C, 71.40; H, 8.60; N, 9.30%.

(S)-3-(N, N-Dimethylamino)-3-phenylpropan-1-ol (66)

To a solution of (S)-3-amino-3-phenylpropan-1-ol **65** (0.05g, 0.19 mmol) in formic acid (39 μ L), was added a 30% aqueous solution of formaldehyde (78 μ L, 1.05 mmol) and the mixture refluxed over 8 h when the reaction is complete as monitored by TLC. After that the solution was acidified with conc. HCl to pH = 1 and basified with 4 N NaOH. The organic phases were combined, dried over MgSO₄ and the solvent evaporated under reduced pressure. The crude product was purified by flash column chromatography.

Yield: (28.9 mg) 85%; hygroscopic solid (turned in to semisolid immediately); $[\alpha]^{25}_{D}$: +39.8 (*c* 0.4, CHCl₃); **IR** (CHCl₃, cm⁻¹): 733, 847, 914, 1047, 1162, 1455, 2780, 2868, 2948, 3384; ¹H NMR (200 MHz, CDCl₃): δ 1.66-1.79 (m, 1H), 2.21 (s, 6H), 2.32-2.48 (m, 1H), 3.69-3.90 (m, 3H), 5.20 (br s, 1H), 7.15-7.32 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ 32.1, 36.4, 63.1, 67.5, 127.1, 127.8, 128.3, 128.8, 128.9, 136.1; **Anal.** Calcd for C₁₁H₁₇NO requires C, 73.70; H, 9.56; N, 7.81; found C, 73.65; H, 9.50; N, 7.90%.

(S)-N, N-Dimethyl-3-(naphthalen-1-yloxy)-1-phenylpropan-1-amine (53)

To a solution of **66** (40mg, 0.22 mmol) in dry THF (5 mL) under nitrogen atmosphere was added 1-naphthol (64 mg, 0.44 mmol). The mixture was cooled to 0 °C and PPh₃ (118 mg, 0.44 mmol) and DEAD (71 mg, 0.44 mmol) were successively added. The solution was allowed to warm till room temperature and stirred further for 15 h. After reaction was completed, the solution was evaporated and the crude product was purified by flash column chromatography using EtOAc/ MeOH (10:1) mixture which afforded (*S*)-dapoxetine as colorless oil in 74% yield.

Yield: 74% (49.6 mg); colorless oil; $[\alpha]^{25}_{D}$ = +64.8 (*c* 0.4, CHCl₃) {lit.²⁸ $[\alpha]_{D}^{25}$ +64.2 (*c* 0.3, CHCl₃); **IR** (CHCl₃, cm⁻¹): 733, 847, 914, 1047, 1167, 1265, 1345, 1727, 2950, 2960; ¹H NMR (200 MHz, CDCl₃): δ 2.22 (s, 6H), 2.34-2.45 (m, 1H), 2.59-2.71 (m, 1H), 3.55-3.63 (m, 1H), 3.93-4.12 (m, 2H), 7.19-7.52 (m, 9H), 7.70-7.74 (m, 1H), 7.95-8.21 (m, 2H); ¹³C NMR (50 MHz, CDCl₃): δ 32.0, 36.4, 63.1, 67.5, 104.5, 120.1, 127.1, 127.4, 127.8, 128.3, 128.9, 136.0, 138.1, 155.2; **Anal.** Calcd for C₂₁H₂₃NO requires C, 82.58; H, 7.59; N, 4.59; found: C, 82.30; H, 7.65; N, 4.70%.

2.2.8 References

- (a) von Euler, V. S.; Gaddum, J. H. J. Physiol. 1931, 72, 577; (b) Chang, M. M.; Leeman, S. E. J. Biol. Chem. 1970, 245, 4784; (c) Pernow, B. Pharmacol. Rev. 1983, 35, 85; (d) Naanishi, S. Physiol. Rev. 1987, 67, 1117; (e) Vaught, J. Life Sci. 1988, 43, 1419; (f) Lotz, M.; Vaughan, J. H.; Carson, D. A. Science 1988, 241, 1218;
- 2 (a) Baker, R.; Harrison, T.; Hollingworth, G. J.; Swain, C. J.; Williams, B. J. EP 0528 495A1, 1993; (b) Harrison, T.; Williams, B. J.; Swain, C. J.; Ball, R. G. *Bioorg. Med. Chem. Lett.* 1994, *4*, 2545.
- 3 Desai, M. C.; Lefkowitz, S. L.; Thadeio, P. F.; Longo, K. P.; Snider, R. M. J. Med. Chem. 1992, 35, 4911.
- (a) Perianan, A.; Snyderman, R.; Malfroy, B. *Biochem. Biophy. Res. Commun.* 1989, 161, 520; (b) Snijdelaar, D. G.; Dirksen, R.; Slappendd, R.; Crul, B. J. P. *Eur. J. Pain* 2000, 4, 121; (c) Datar, P.; Srivastava, S.; Coutinho, E.; Govil, G. *Curr. Top. Med. Chem.* 2004, 4, 75; (d) Lotz, M.; Vaughan, J. H.; Carson, D. A. *Science* 1987, 235, 893; (e) Moskowitz, M. A. *Trends Pharmacol. Sci.* 1992, 13, 307; (f) Takeuchi, Y.; Shands, E. F. B.; Beusen, D. D.; Marshall, G. R. *J. Med. Chem.* 1998, 41, 3609; (g) Swain, C. J. *Prog. Med. Chem.* 1998, 35, 57.
- (a) Muñoz, M.; Rosso, M.; Pérez, A.; Coveñas, R.; Rosso, R.; Zamarriego, C.; Soult, J, A.; Montero, I. *Invest. Ophthalmol. Vis. Sci.* 2005, 46, 2567; (b) Miguel, M.; Marisa, R.; Rafael, C. *Lett. Drug Des. Discov.* 2006, *3*, 323.
- (a) Takahashi, K.; Nakano, H.; Fujita, R. *Tetrahedron Lett.* 2005, 46, 8927; (b) Lee, J.; Hoang, T.; Lewis, S.; Weissman, S. A.; Askin, D.; Volante, R. P.; Reider, P. J. *Tetrahedron Lett.* 2001, 42, 6223; (c) Liu, R. H.; Fang, K.; Wang, B.; Xu, M. H.; Lin, G, Q. J. Org. Chem. 2008, 73, 3307; (d) Huang, P, Q.; Liu, L, X.; Wei, B, G.; Ruan, Y, P. Org. Lett. 2003, 5, 1927; (e) Davis, F. A.; Ramachandar, T.; *Tetrahedron Lett.* 2008, 49, 870.

- 7 Bhaskar G.; Rao, B. V.; Tetradedron Lett. 2003, 44, 915.
- 8 Tsai, M.-R., Chen, B.-F., Cheng, C.-C., Chang, N.-C. J. Org. Chem. 2005, 70, 1780.
- 9 Yoon, Y.-J.; Joo, J.-E.; Lee, K.-Y.; Kim, Y.-H.; Oh, C.-Y.; Ham, W.-H. Tetrahedron Lett. 2005, 46, 739
- 10 Oshitari, T.; Mandai, T. Synlett 2006, 3395.
- 11 Cherian, S. K.; Kumar, P. Tetrahedron: Asymmetry 2007, 18, 982.
- 12 Liu, R.-H., Fang, K., Wang, B., Xu, M.-H., Lin, G.-Q. J. Org. Chem. 2008, 73, 3307
- 13 Emmanuvel, L.; Sudalai, A. Tetrahedron Lett. 2008, 49, 5736.
- 14 Bilke, J, L.; Moore, S, P.; O'Brien, P.; Gilday, J. Org. Lett. 2009, 11, 1935.
- (a) Tokunaga, M.; Larrow, J. F.; Kakiuchi, F.; Jacobsen, E. N. *Science* 1997, 277, 936. (b)
 Schaus, S. E.; Brandes, B. D.; Larrow, J. F.; Tokunaga, M.; Hansen, K. B.; Gould, A. E.;
 Furrow, M. E.; Jacobsen, E. N. *J. Am. Chem. Soc.* 2002, *124*, 1307.
- (a) Zhdankin, V. V.; Stang, P, J. Chem. Rev. 2002, 102, 2523. (b) Stang, P, J.; Zhdankin, V,
 V.; Chem. Rev. 1996, 96, 1123.
- 17 Maryanoff, B. E.; Reitz, A. B. Chem. Rev. 1989, 99, 863.
- 18 Pattenden, G.; Plowright, A. T.; Tornos, J. A.; Ye, T. Tetrahedron Lett. 1998, 39, 6099.
- 19 Anon, N. Z. Drugs in R & D 2005, 6, 307.
- 20 Pryor, J. The Lancet 2006, 368, 929.
- Sadock, B. J.; Sadock, V. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Vol.
 2, Philadelphia, Pa.: Lippincott Williams and Wilkins; 2000, 1577.
- 22 Sadock, B. J.; Sadock, V. *Kaplan & Sadock's Synopsis of Psychiatry*, Philadelphia, Pa.: Lippincott Williams and Wilkins; **2003**, 710.
- 23 Waldinger, M. D.; Quinn, P.; Dilleen, M.; Mundayat, R.; Schweitzer, D. H.; Boolell, M. J. Sex Med. 2005, 2, 492.
- 24 Yang, J. W.; Chandler, C.; Stadler, M.; Kampen, D.; List, B. Nature 2008, 452, 453.
- 25 Koizumi, T.; Hirai, H.; Yoshii, E. J. Org. Chem. 1982, 47, 4005.
- 26 Torre, O.; Gotor-Fernandez, V.; Gotor, V. Tetrahedron: Asymmetry 2006, 17, 860.
- 27 Fadnavis, N. W.; Radhika, K. R.; Devi, A. V. Tetrahedron: Asymmetry 2006, 17, 240.
- 28 Siddiqui, S. A.; Srinivasan, K. V. Tetrahedron: Asymmetry 2007, 18, 2099.
- 29 Venkatesan, K.; Srinivasan, K. V. ARKIVOC 2008, xvi, 302.
- 30 Chincholkar, P. M.; Kale, A. S.; Gumaste, V. K.; Deshmukh, A. R. A. S. *Tetrahedron* 2009, 65, 2605.
- 31 (a) Katsuki, T.; Sharpless, K. B. J. Am. Chem. Soc. 1980, 102, 5974; (b) Martin, V. S.; Woodward, S. S.; Katsuki, T.; Yamada, Y.; Ikeda, M.; Sharpless, K. B. J. Am. Chem. Soc. 1981, 103, 6237.
- 32 Gao, Y.; Sharpless, K. B. J. Org. Chem. 1988, 53, 4081.
- 33 Woodward, S. S.; Finn, M. G.; Sharpless, K. B. J. Am. Chem. Soc. 1991, 113, 106.

- 34 (a) Finn, M. G.; Sharpless, K. B. J. Am. Chem. Soc. 1991, 113, 113; (b) Potvin, P. G.;
 Bianchet, S. J. J. Org. Chem. 1992, 57, 6629.
- 35 Fukuzawa, A., Sato, H., Masamune, T. Tetrahedron Lett. 1987, 28, 4303.
- 36 (a) Eschweiler, W. Chem. Ber. 1905, 38, 880. (b) Clarke, H. T. J. Am. Chem. Soc. 1933, 55, 4571.
- 37 Mistunobu, O. Synthesis 1981, 1.


CHAPTER III

NalO₄-mediated Azidoiodination of Olefins, 1,2-Diazidation of Olefins and α,α-Diazidation of Aryl Ketones and C-H Functionalization of Hydrocarbons

Section I

NaIO₄–KI-NaN₃–mediated regioselective azidoiodination of alkenes 3.1.1 Introduction

The 1,2-functionalization of olefins by the selective addition of two different functional groups in a single step provides access to wide range of functional group manipulation in organic synthesis. Variety of reactions such as aminohydroxylation, halohydration, haloamination, azidohydroxylation, and haloazidation are some of the examples of this class of synthetic transformation. Among these, the vicinal azidoiodination of alkenes in particular is an important organic transformation for simultaneous introduction of iodo and azido functionalities into a carbon skeleton (**Scheme 1**).



Scheme 1: azidoiodination of olefins

The resulting azidoiodides can be subjected to further synthetic manipulations to achieve a variety of compounds such as vinyl azide,¹ amines,² aziridines³ and tetrazoles.⁴ Since the pioneering work of Hassner *et al.*,⁵ azidoiodination of alkenes involves the use of iodine azide reagent, which is generated insitu from sodium azide and iodine chloride in polar solvents. However, its explosive character is regarded to be a major disadvantage.


3.1.2 Review of literature

Literature survey revealed that there are various methods available for the azidoiodination of alkenes, using a variety of reagents such as I₂/NaN₃/Adogen,⁶ PhI(OAc)₂/Et₄NI/TMSN₃, CAN/NaI/NaN₃, IPy₂BF₄/TMS-N₃ and Oxone/wet

Al₂O₃/KI/NaN₃ reagent combination. Some of the recent developments on this reaction are discussed in the following section.

Hassner's approach (1965)⁷


Hassner *et al*. have reported in *situ* preparation of I-N₃ from reaction of I-Cl with NaN₃ in polar solvent and addition of this on to alkenes **4** to give the corresponding azidoiodides **5** (Scheme 2).



<u>Scheme 2</u>: (i) ICl, NaN₃, CH₃CN, 25 °C.


Krisching's approach^{8,9}

Krisching *et al.* have developed a new reagent system consisting of reagents such as $PhI(OAc)_{2,}$ tetraalkylammonium halide and TMSN₃. This reagent system is equivalent to I-N₃ system. The treatment of these reagents with indene **6** and cyclohexene **4f** gave the corresponding azidoiodides 62% and 50% yields respectively (**Scheme 3**).



Scheme 3: (i) PhI(OAc)₂, TMSN₃, Et₄NI, CH₂Cl₂, 25 °C.


Same authors have also developed a new polymer-supported azide source, which was employed for the azidoiodination of alkenes to give the corresponding vicinal azidoiodides in 38-98% yield (**Scheme 4**).



Scheme 4: (i) polystyrene-NMe₃I, PhI(OAc)₂, TMSN₃, CH₂Cl₂, 25 °C .

Nair's approach¹⁰


In this approach, NaN₃/NaI/CAN (3equiv) reagent combination was used for the azidoiodination of alkenes. The addition followed *anti*-Markovnikov fashion (**Scheme 5**).



<u>Scheme 5</u>: (i) CAN (2.1 equiv.), NaN₃, NaI, MeOH, 0 °C.

Barluenga's approach (2000)¹¹


Barluenga *et al.* used IPy_2BF_4 and Me_3SiN_3 reagent combination for the azidoiodination of alkenes **10** in the presence of $BF_3.OEt_2$ to furnish the corresponding azidoiodides **11** in 45-95% yield (**Scheme 6**).



Scheme 6: (i) IPy_2BF_4 , TMSN₃, $BF_3.OEt_2$, CH_2Cl_2 , 0 °C, 3h.

Marcolullio's approach¹²


In this approach, $NaN_3/KI/Oxone^{\ensuremath{\mathbb{R}}}$ supported on wet alumina was used for the azidoiodination of alkenes. Here again the addition followed an *anti*-Markovnikov fashion with moderate yields (**Scheme 7**).



Scheme 7: (i) Oxone-wet (5 equiv.), Al_2O_3 , KI (5 equiv.), NaN_3 , CHCl₃, 25 °C.

Terent'ev's approach ¹³

Terent'ev et al. have reported a new synthesis of vicinal azidoiodides in 62-77% yields by the reaction of sodium azide and iodine with unsaturated olefinic compounds in aqueous methanol solvent system (**Scheme 8**).



<u>Scheme 8</u>: (i) I₂, NaN₃ , MeOH/H₂O 25 °C, 62-77%


3.1.3. Present Work

3.1.3.1 Objective

From the above discussion, it is clear that most of the reported methods suffer from certain drawbacks such as use of expensive reagents and large excess of oxidants or halide sources. Hence, a practical method that involves less toxic yet readily available reagents is of paramount importance. This section describes one such process, in which an excellent regiospecific azidoiodination of alkenes takes place using NaIO₄ as the stoichiometric oxidizing agent and NaN₃ and KI as the azide and iodine sources respectively, in acetic acid as solvent.

3.1.4. Results and Discussion

In connection with our interest on NaIO₄-mediated oxidative functionalization of alkenes,¹⁴ we thought of providing a cheaper method of azidoiodination of alkenes using NaIO₄-KI-NaN₃ combination. We noticed that NaIO₄-KI-NaN₃ combination was found to be an excellent system for the regiospecific azidoiodination of styrene in acetic acid as solvent. This prompted us to explore the effectiveness of the NaIO₄-KI-NaN₃ combination in the azidoiodination of alkenes. Thus, when styrene **4a** was treated initially with NaIO₄, KI and NaN₃ (all equimolar) in acetic acid at 25 °C, the corresponding 2-azido-1-iodo-ethylbenzene **5a** was obtained in 33% yield. However, this yield could be increased to 95% when stoichiometry of NaN₃ was altered to increase of 3 equiv. (**Scheme 9**). This prompted us to explore the effectiveness of the NaIO₄-KI-NaN₃ system in the 1, 2- azidoiodination of several alkenes. This new azidoiodination procedure was indeed found to be quite general for a variety of olefins and the results of this study are summarized in **Table 1**



<u>Scheme 9</u>: styrene (1 equiv.), KI (1 equiv.), NaIO₄ (1 equiv.), NaN₃(3 equiv.), glacial AcOH, 25 °C, 2 h.

As can be seen from **Table 1**, a variety of alkenes **4a-1** (aliphatic, styrenic, allylic and disubstituted) underwent azidoiodinations to give the corresponding β -iodoazides **5a-1** in excellent yields. It is interesting to note that the regiochemistry of the addition, for all the cases examined, proceeded in an *anti*-Markovnikov fashion, indicating a possible radical pathway. Internal olefins such as β -methylstyrene, cyclohexene and cinnamyl alcohol have proceeded to give products in excellent yields with diastereoselectivities reaching up to 1: 4 (**5c**, **5f** and **5k**) as confirmed by their ¹H-NMR spectra. Terminal functionalized olefin such as allyl acetate also underwent regiospecific azidoiodination in 92% yield. However, no reaction took place in the case of conjugated alkenes with electron-withdrawing groups, which may be a limitation of this method.


Entry	Alkenes (4a-l)	Products (5a-l)	Yield (%) ^b
a	Styrene	I N ₃	95
b	4-Methylstyrene	I N ₃	70
c	β-Methylstyrene	I N ₃	95 ^c

Table 1: NaIO₄-mediated azidoiodination of alkenes.^a

d	4-Chlorostyrene		92
e	4-Chloromethylstyrene	Cl	85
f	Cyclohexene		93 ^d
g	Vinylcyclohexane	N ₃	88
h	1-Hexene	I N ₃	93
i	1-Heptene		94
j	1-Decene	$\sim \sim $	90
k	trans-Cinnamyl alcohol	И ОН	90 ^c
1	Allyl acetate	OAc N ₃	92

^a Reaction conditions: alkene (5 mmol), KI (5 mmol), NaIO₄ (5 mmol), NaN₃ (15 mmol), glacial AcOH (15 mL), 25 °C, 2 h; ^bisolated yield. ^csyn: anti = 1: 1; ^d syn: anti = 1: 4.


The formation of azidoiodides **5a-1** was confirmed by ¹H, ¹³C-NMR and IR spectroscopy. For example, the ¹H-NMR spectrum of 2-azido-1-iodoethyl-4-chloromethylbenzene (**5e**) showed a doublet at δ 3.92 and a triplet at δ 5.12 due to -CHI and -CH₂N₃ protons respectively. Its ¹³C-NMR spectrum showed typical signals at δ 26.8 and 58.5 for carbons




attached to iodo and azido groups respectively (Fig. 1).

Fig. 1: ¹H and ¹³C NMR spectra of **5e**


In the case of 1-azido-2-iodocyclohexane (**5f**), *anti: syn* ratio (4:1) was confirmed by ¹H-NMR spectrum (**Fig. 2**).





3.1.5. Mechanism

Mechanistically, we have proved that NaIO₄ oxidizes both KI and NaN₃ simultaneously to liberate I_2^{15} and an azide radical¹⁶ respectively; combination of which probably results in the formation of IN₃.¹⁷ Homolysis of IN₃¹⁸ provides an azide radical, which then adds onto alkenes to produce a more stable alkyl radical species **12**, thus controlling the regiochemistry of the process. The combination of alkyl radical either I_2 or iodine radical results in the formation of β -iodoazides **5a-I** (**Scheme 10**).



Scheme 10: Proposed mechanism for the azidoiodination of alkenes

3.1.6. Conclusion

In conclusion, we have developed a simple procedure with NaIO₄-KI-NaN₃ as a new combination for the 1, 2- azidoiodination of alkenes that provides a mild, efficient entry to vicinal azidoiodoalkanes in high yields under ambient conditions. The azidoiodination reaction proceeds to give β -iodoazides **5a-1** in a regiospecific manner.

3.1.7. Experimental section

General experimental procedure for azidoiodination of alkenes: To a suspension of NaN₃ (0.975 g, 15 mmol) and KI (0.830 g, 5 mmol) in acetic acid (20 ml) at 25 °C was added NaIO₄ (1.069 g, 5 mmol) and the reaction mixture was stirred for 5 min. when a dark brown color was observed. This was followed by the addition of alkenes **4a-1** (5 mmol) and the entire reaction mixture was stirred at the same temperature for 2h. After the reaction was complete as monitored by TLC, it was poured into water (100 mL) and extracted with CH_2Cl_2 (3×50 mL). The combined organic layers were washed with a saturated solution of NaHCO₃ (50 mL), washed with aq. Na₂S₂O₃ (5%, 50 mL), dried over anhyd. Na₂SO₄ and concentrated under reduced pressure to give the crude product, which was then purified by column chromatography (packed with silica gel 60-120 mesh) using pet. ether as eluents to afford the pure product **5a-1**.

2-Azido-1-iodoethylbenzene (5a)

Yield: 95%; pale yellow oil; **IR** (CHCl₃, cm⁻¹): 693, 1257, 1446, 1605, 2100, 2921, 3027; ¹**H NM**R (200 MHz, CDCl₃) δ 3.94 (d, *J* = 7.7 Hz, 2H), 5.14 (t, *J* = 7.7 Hz, 1H), 7.30-7.45 (m, 5H); ¹³**C NM**R (50 MHz, CDCl₃): δ 27.8, 58.5, 127.4, 128.7, 128.9, 140.1; **Anal.** Calcd for C₈H₈IN₃ requires C, 35.19; H, 2.95; N, 15.39; found: C, 35.10; H, 2.90; N, 15.44%.

2-Azido-1-iodoethyl-4-methylbenzene (5b)

Yield: 70%; pale yellow oil; **IR** (CHCl₃, cm⁻¹): 1257, 1446, 2101, 2920, 3027; ¹**H NMR** (200 MHz, CDCl₃) δ 2.30 (s, 3H), 3.87 (d, *J* = 7.7 Hz, 2H), 5.09 (t, *J* = 7.7 Hz, 1H), 7.10 (d, *J* = 7.8 Hz, 2H), 7.27 (d, *J* = 7.8 Hz, 2H); ¹³**C NMR** (50 MHz, CDCl₃): δ 21.2, 28.1, 58.6, 127.3, 129.5, 137.2, 138.5; **Anal**. Calcd for C₉H₁₀IN₃ requires C, 37.65; H, 3.51; N, 14.64; found: C, 37.70; H, 3.48; N, 14.60%.

2-Azido-1-iodopropylbenzene (5c)

Yield: 95%; pale yellow oil; mixture of *anti:syn* (1:1); **IR** (CHCl₃, cm⁻¹): 1258, 1605, 1458, 2101, 2990; ¹H **NMR** (200 MHz, CDCl₃) δ 1.23 (d, J = 6.4 Hz, 3H), 1.52 (d, J = 6.4 Hz, 3H), 3.74-3.99 (m, 2H), 4.91(d, J = 7.0 Hz, 1H), 4.96 (d, J = 8.0 Hz, 1H), 7.26-7.40 (m, 10H); ¹³C **NMR** (50 MHz, CDCl₃): δ 21.2, 28.1, 58.6, 127.3, 129.5, 137.2, 138.5; **Anal**. Cald for C₉H₁₀IN₃ requires C, 37.65; H, 3.51; N, 14.64; found: C, 37.70; H, 3.48; N, 14.62%.

2-Azido-1-iodoethyl-4-chlorobenzene (5d)

Yield: 92%; pale yellow oil; **IR** (CHCl₃, cm⁻¹): 693, 1257, 1489, 1589, 2100; ¹**H NMR** (200 MHz, CDCl₃) δ 3.88-3.94 (m, 2H), 5.10 (dd, J = 8.2, 7.0 Hz, 1H), 7.30-7.40 (m, 4H); ¹³**C NMR** (50 MHz, CDCl₃): δ 26.0, 58.5, 128.8, 129.1, 134.4, 138.7; **Anal.** Calcd for C₈H₇ClIN₃ requires C, 31.25; H, 2.29; N, 13.66; found: C, 31.30; H, 2.25; N, 13.68%.

2-Azido-1-iodoethyl-4-chloromethylbenzene (5e)

Yield: 85%; pale yellow oil; **IR** (CHCl₃, cm⁻¹): 1257, 1489, 2101, 2920, 3027; ¹H NMR (200 MHz, CDCl₃) δ 3.92 (d, *J* = 6.9 Hz, 2H), 4.55 (s, 2H), 5.12 (t, *J* = 7.2 Hz, 1H), 7.32 -7.43 (m, 4H); ¹³C NMR (50 MHz, CDCl₃): δ 26.8, 45.3, 58.5, 127.9, 129.0, 137.9, 140.4; **Anal.** Calcd for C₉H₉CIIN₃ requires C, 33.62; H, 2.82; N, 13.07; found: C, 33.55; H, 2.85; N, 13.01%.

1-Azido-2-iodocyclohexane (5f)

Yield; 93%; pale yellow oil; mixture of *anti:syn* (4:1); **IR** (CHCl₃, cm⁻¹): 669, 769, 923, 1217, 1257, 1448, 2100, 2860, 2939; ¹H NMR (200 MHz, CDCl₃) δ 1.31-1.57 (m, 4H), 1.99-2.50 (m, 4H), 3.46-3.58 (m, 1H), 3.90-4.03 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 23.7, 26.9, 31.8, 33.2, 38.3, 67.1; **Anal**. Calcd for C₆H₁₀IN₃ requires C, 28.70; H, 4.01, N, 16.74; found: C, 28.64; H, 4.10, N, 16.78%.

2-Azido-1-iodoethylcyclohexane (5g)

Yield: 88%; pale yellow oil; **IR** (CHCl₃, cm⁻¹): 669, 769, 923, 1217, 1257, 1448, 2102, 2860, 2939; ¹H NMR (200 MHz, CDCl₃) δ 1.02-1.45 (m, 6H), 1.63-1.93 (m, 5H), 3.63-3.82 (m, 2H), 4.07-4.15 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 25.6, 25.8, 26.0, 30.5, 32.8, 41.0, 42.1, 56.5; **Anal**. Calcd for C₆H₁₄IN₃ requires C, 34.42; H, 5.06, N, 15.05; found: C, 34.50; H, 5.01, N, 14.98%.

1-Azido-2-iodohexane (5h)

Yield: 93%; pale yellow oil; **IR** (CHCl₃, cm⁻¹): 667, 769, 925, 1258, 1446, 2103, 2939; ¹**H NMR** (200 MHz, CDCl₃) δ 0.9 (t, J = 6.9 Hz, 3H), 1.27-1.52 (m, 4H), 1.73 1.84 (m, 2H), 3.60-3.83 (m, 2H), 4.04-4.17 (m, 1H); ¹³**C NMR** (50 MHz, CDCl₃): δ 13.8, 22.3, 28.4, 31.5, 37.1, 58.9; **Anal.** Calcd for: C₆H₁₂IN₃ requires C, 28.47; H, 4.78, N, 16.60; found: C, 28.50; H, 4.69, N, 16.65%.

1-Azido-2-iodoheptane (5i)

Yield: 94%; pale yellow oil; **IR** (CHCl₃, cm⁻¹): 669, 769, 923, 1257, 1448, 2102, 2939; ¹**H NMR** (200 MHz, CDCl₃) δ 0.9 (t, *J* = 6.6 Hz, 3H), 1.27-1.50 (m, 6H), 1.69 1.84 (m, 2H), 3.57-3.80 (m, 2H), 4.04-4.17 (m, 1H); ¹³**C NMR** (50 MHz, CDCl₃): δ 13.9, 22.3, 28.8, 30.7, 32.2, 37.0, 58.9; **Anal.** Calcd for: C₇H₁₄IN₃ requires C, 31.48; H, 5.28, N, 15.73; found: C, 31.40; H, 5.33, N, 15.65%.

1-Azido-2-iododacane (5j)

Yield: 90%; pale yellow oil; IR (CHCl₃, cm⁻¹): 668, 770, 923, 1257, 1448, 2103, 2939;
¹H NMR (200 MHz, CDCl₃) δ 0.9 (t, J = 6.1 Hz, 3H), 1.28-1.51 (m, 12H), 1.72 1.82 (m, 2H), 3.59-3.80 (m, 2H), 4.01-4.11 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 14.1, 22.6, 25.8, 28.7, 29.2, 29.3, 31.8, 32.0, 37.1, 59.0; Anal. Calcd for C₁₀H₂₀IN₃ requires C, 38.85; H, 6.52, N, 13.59; found: C, 38.75; H, 6.60, N, 13.65 %.

2-Azido-3-iodo-3-phenylpropan-1-ol (5k)

Yield: 90%; pale yellow oil; mixture of *anti:syn* (1:1); **IR** (CHCl₃, cm⁻¹): 757, 1153, 1217, 1258, 1458, 2096, 2927, 3004, 3330; ¹H NMR (200 MHz, CDCl₃) δ 2.36 (br s, 2H), 3.40-3.49 (m, 1H), 3.59-3.66 (m, 1H), 3.75-3.94 (m, 2H), 4.02-4.17 (m, 2H), 5.13 (d, *J* = 8.5 Hz, 1H), 5.16 (d, *J* = 9.2 Hz, 1H), 7.28-7.48 (m, 10H); ¹³C NMR (50 MHz, CDCl₃): δ 28.9, 32.1, 63.1, 64.8, 68.6, 70.0, 127.8, 128.2, 128.6, 128.9, 129.0, 140.1, 140.2; **Anal.** Calcd for C₉H₁₀ION₃ requires C, 35.66; H, 3.33; N, 13.86; found: C,35.70; H, 3.30; N, 13.85%.

3-Azido-2-iodopropylacetate (5l)

Yield: 92%; pale yellow oil; **IR** (CHCl₃, cm⁻¹): 669, 769, 923, 1257, 1448, 1735, 2101, 2940; ¹**H NMR** (200 MHz, CDCl₃) δ 2.10 (s, 3H), 3.74-3.82 (m, 2H), 4.15-4.37 (m, 3H); ¹³**C NMR** (50 MHz, CDCl₃): δ 20.5, 23.8, 55.3, 65.9, 169.3; **Anal.** Calcd for C₅H₈IN₃O₂ requires C, 22.32; H, 3.0; N, 15.62; found: C, 22.38; H, 2.98; N, 15.73%.

Section II

NaIO₄–NaN₃–mediated diazidation of olefins and α,α-diazidation of aryl ketones

3.2.1 Introduction


Vicinal diazides are important precursors for the synthesis of 1,2-diamines, which have become important synthetic targets in a variety of natural products, various biologically active molecules and are also used as ligands or catalysts in organo- and transition –metal catalyzed reactions.¹⁹⁻²³ Despite their extensive utility, the development of new method allowing efficient preparation of 1,2-diamine remains a stimulating challenge. The general methods of diamine synthesis usually involves vicinal diazides *via* diazidation, epoxides²⁴ or 1,2 diols²⁵ *via* dimesylation. In contrast, the direct oxidative diazidation of alkenes to diazides presents an attractive strategy.

3.2.2 Review of literature

Literature search revealed that there are only few reports available for direct diazidation of alkenes, which involve the use of stoichiometric amounts of $Mn(OAc)_2$, oxidants and azide sources, the details of which are presented below.


Fristad's approach (1985)²⁶

Fristad *et al.* have reported the 1,2-diazidation of alkenes with stoichiometric amounts of $Mn(OAc)_2$ and NaN_3 to give the corresponding mixture of *syn-* and *anti-*diazides products **13** in 51-68% yield (**Scheme 11**).




Moriarty's approach (1986)²⁷

Moriarty *et al.* have reported 1,2-diazidation of a variety of alkenes **14** with PhIO-AcOH-NaN₃ reagent system to give vicinal diazides **15** in 34-85% yields, along with α -azidoketone **16** in 14% yields (**Scheme 12**).




Arimoto's approach (1989)²⁸

In this approach, β -substituted allyltrimethylsilane were converted into the corresponding vic-diazides **18** with (PhIO)_n (iodosylbenzene) and TMSN₃ in moderate yields (**Scheme 13**).



Austin's approach (2004)²⁹


Austin *et al.* have studied the diazidation of pyrazinone **19** to give the corresponding *syn* and *anti* diazidopyrazinone, **20** which is intermediate of dibromophakellstatin (**Scheme 14**).



<u>Scheme 14:</u> (i) ICl, NaN₃, MeCN, -10 °C; (ii) PhI(OAc)₂, TMSN₃, -10 °C.

Ohba's approach (2005)³⁰


In this approach, the authors have described vic-diazidation of α -pinene **21** to give the corresponding mixtures of diazides **22** by using Mn(OAc)₂ and NaN₃ in acetic acid (Scheme 15).



<u>Scheme 15:</u> (i) Mn(OAc)₂, NaN₃, AcOH, 50 °C.

Pfaendler's approach (2004)³¹


Pfaendler *et al.* have reported a mild and two step procedures for the vic-diazidation of olefins. The sequence includes azidoiodination followed by substitution with azide ion (Scheme 16).



However the direct α, α -diazidation of ketones was not known in the literature.

Moore's approach (1976)³²

Moore *et al.* have reported gem-diazidation of carbonyl derivatives from the corresponding gem-dihalo **26** derivatives by using sodium azide in water to give the corresponding gem-diazides **27** in high yields (**Scheme 17**).



Scheme 17: (i) NaN₃, H₂O, 140 °C, 90-98%.

3.2.3 Present Work

3.2.3.1 Objective


There are only five methods available in the literature for the direct diazidation of alkenes. However, some of them suffer from certain drawbacks like low yields, multistep reaction sequences, expensive metal salts and oxidants. This section describes a new method of diazidation of alkenes and aryl ketones that provided the corresponding vicinal and geminal diazide derivatives using NaIO₄ as the oxidant and sodium azide as the azide source.

3.2.4 Results and Discussion

3.2.4.1: 1,2-Diazidation of alkenes

In our earlier section, we have described a method of $NaIO_4$ -mediated azidoiodination of alkenes that afforded the corresponding azidoiodides. During the course of this study of $NaIO_4$ -mediated oxidative functionalization of alkenes, we observed that the treatment of alkenes **4a-h** with stoichometric amount of $NaIO_4$ and sodium azide in AcOH : DMSO


(1: 4) as solvent at 75 °C, gave 1,2-diazides **28a-h** in good yields. In particular when styrene **4a** was subjected to oxidative functionalization with NaIO₄ (1 equiv) in the presence of NaN₃ (3 equiv.) in AcOH: DMSO (1: 4) as solvent at 75 °C, gave diazide **28a** in 75% yield (**Scheme 18**).



To study the generality of the reaction, a variety of alkenes were subjected to diazidation with NaIO₄-NaN₃ reagent combination and the results are presented in (**Table 2**). Aromatic olefins as well as aliphatic olefins gave good yields of the corresponding 1,2diazides. Internal olefins such as indene and cinnamyl alcohol have proceeded to give products in excellent yields with 1:1 diastereoselectivity (**28c** and **28d**) as confirmed by their ¹H-NMR spectra. However, no reaction took place in the case of α , β -unsaturated carbonyl compounds, which may be a limitation of this method.

No	Substrate (4)	Products (28)	Yield $(\%)^b$	anti : syn
a	Styrene	N ₃ N ₃	75	
b	4-Methylstyrene	N ₃ N ₃	74	
c	Indene	N ₃ N ₃	75	1:1


 Table 2: NaIO₄-mediated diazidation of alkenes^a




Reaction conditions: ^a alkenes (5 mmol), NaIO4 (5 mmol), NaN₃ (15 mmol), 20ml DMSO: AcOH (4:1), 75 °C, 2 h; ^b yields refer to isolated yield after column chromatography.

The formation of diazides **28a-h** was confirmed by ¹H-NMR, ¹³C-NMR and IR spectroscopy. The ¹H NMR spectrums of **28a** showed a doublet of doublet at δ 4.65 for benzylic proton and a typical signal at δ 3.37-3.55 (m, 2H) for homobenzylic protons. Its ¹³C NMR spectrum showed a typical signal at δ 65.4 and 55.8 for the homobenzylic and benzylic carbons respectively (**Fig. 3**). Its IR spectrum showed a strong absorption at 2103 cm⁻¹ confirming the formation of azide function. The diasteromeric ratios (*anti: syn*) for internal olefins were determined from ¹H-NMR spectroscopic studies.

The probable mechanism for the direct diazidation of alkenes to the corresponding diazides is proposed, that involves a radical pathway. Accordingly, the NaIO₄ is able to oxidize NaN₃ to give the corresponding azide radical,¹⁴ which is then added onto alkene to give the secondary radical **12**.



Subsequently, the secondary radical is further believed to be trapped with another azide radical to give diazides (**Scheme 19**).



Scheme 19: Proposed mechanism for the 1,2-diazidation of alkenes

3.2.4.2: a,a-Diazidation of aryl ketones

We further extended the scope of this reagent system to aryl ketones 29 and alcohols 30 for the direct azidation and the results are presented in (Table 3). As can be seen from Table 3, aryl ketones with α -methylene group (-CO-CH₂-) underwent selective oxidative

diazidation with NaIO₄ and sodium azide in AcOH:DMSO (1:4) as solvent at 75 °C, to give α, α -diazido aryl ketones **31** in 91-95% yields. Moreover, when benzylic alcohols were subjected to α, α -diazidation condition, the corresponding α, α -diazido aryl ketones were obtained in good yields, occurring probably *via* oxidation of alcohol followed by diazidation of ketones.




Table 3: NaIO₄-mediated α , α -diazidation of aryl ketones and benzylic alcohols^a

Reaction conditions: ^a aryl ketone (5 mmol), NaIO₄ (5 mmol), NaN₃ (15 mmol), 20ml DMSO:AcOH (4:1), 75 °C, 2 h ; ^b yields refer to isolated yield after column chromatographic purification.

The structures of α,α -diazido aryl ketones **31** were established by ¹H-NMR, ¹³C-NMR and IR spectroscopy. The ¹H NMR spectrum of **31a** showed a typical singlet at δ 1.86 for methyl proton. Its 13 C NMR spectrum showed characteristic signals at δ 83.10 and 191.72 due to the geminal diazido and carbonyl (-C=O) quaternary carbons respectively. Its IR spectrum showed a strong band at 2109 cm⁻¹ due to the presence of azide functional group in the molecule (Fig. 4).




Fig. 4: 1 H, 13 C NMR and IR spectra of **31a**

3.2.5. Conclusion

In conclusion, we have developed a new reagent system consisting of NaIO₄-NaN₃ as a new efficient system suitable for direct diazidation of alkenes and aryl ketones into their corresponding vicinal and geminal diazides. The reaction is believed to proceed *via* radical pathway.

3.2.6. Experimental

General experimental procedure for 1,2-diazidation of alkenes: To a suspension of NaN₃ (0.975 g, 15 mmol) and NaIO₄ (1.069 g, 5 mmol) in 20 mL of DMSO: glacial AcOH (4: 1) was added alkenes 4 (5 mmol) and the reaction mixture was stirred at 75 °C for 2 h until the mixture became dark brown in color. Then the reaction mixture was poured into water (100 ml) and extracted with EtOAc (3×50 ml)). The combined organic layers were washed with a saturated solution of NaHCO₃ (50 ml) followed by aqueous Na₂S₂O₃ (5%, 50 ml), dried over anhyd. Na₂SO₄. Concentration of the organic layer gave diazides, which was subjected to column purification using hexane/ethyl acetate (19:1) as eluent to obtain pure 1,2-diazides **28a-h**.

1,2-Diazido-1-phenylethane (28a)

Yield: 75%; pale yellow liquid; IR (neat, cm⁻¹): 700, 759, 1257, 1454, 2100, 2926; ¹H-NMR (200 MHz, CDCl₃): δ 3.37-3.55 (m, 2H), 4.65 (dd, *J*= 5.4, 7.8 Hz, 1H), 7.29-7.55 (m, 5H); ¹³C-NMR (50 MHz, CDCl₃): δ 55.8, 65.4, 126.8, 128.9, 129.0, 136.3; Anal. Calcd for. C₈H₈N₆: C, 51.06; H, 4.28; N, 44.66; Found: C, 51.30; H, 4.08; N, 44.50%.

1,2-Diazido-1-(4-methylphenyl)ethane (28b)

Yield: 74%; pale yellow liquid; **IR** (neat, cm⁻¹): 701, 765, 1254, 1454, 2101, 2926; ¹**H-NMR** (200 MHz, CDCl₃): δ 2.36 (s, 3H), 3.42-3.49 (m, 2H), 4.64 (dd, *J* = 5.9, 7.9 Hz, 1H), 7.22 (s, 4H); ¹³C-NMR (50 MHz, CDCl_.): δ 21.1, 55.7, 65.2, 126.8, 129.6, 133.2, 138.8; Anal. Calcd for. C₈H₈N₆: C, 51.06; H, 4.28; N, 44.66; Found: C, 51.30; H, 4.08; N, 44.50%.

1,2-Diazidoindane(28c)

Yield: 70%; pale yellow liquid; mixture of *anti:syn* (1:1); **IR** (neat, cm⁻¹): 704, 738, 1265, 2104, 2926; ¹**H-NMR** (200 MHz, CDCl₃): δ 2.94 (dd, J = 6.7, 16 Hz, 1H), 3.17 (d, J = 6.7 Hz, 2H), 3.35 (dd, J = 6.8, 16 Hz, 1H), 4.16 (dd, J = 6.7, 12 Hz, 1H), 4.29 (dd, J = 6.7, 12 Hz, 1H), 4.76 (d, J = 5.6 Hz, 1H), 4.82 (d, J = 5.7 Hz, 1H), 7.23-7.42 (m, 8H); ¹³**C-NMR** (50 MHz, CDCl₃): δ 35.4, 35.9, 63.9, 66.8, 67.5, 124.41, 124.7, 125.0, 125.2, 127.5, 127.6, 129.3, 129.5, 137.4, 137.6, 138.9, 139.6; **Anal.** Calcd for. C₁₀H₁₀N₆: C, 56.07; H, 4.71; N, 39.23; Found: C, 55.60; H, 4.88; N, 39.50%.

1,2-Diazido-1-phenylpropanol (28d)

Yield: 78%; pale yellow liquid; mixture of *anti:syn* (1:1); **IR** (neat, cm⁻¹): 702, 763, 1049, 1261, 1454, 1492, 2104, 2935, 3034, 3416; ¹**H-NMR** (200 MHz, CDCl₃): δ 1.91 (br s, 2H), 3.32-3.42 (m, 1H), 3.54-3.81 (m, 5H), 4.67 (d, J = 8.1 Hz, 2H) 7.32-7.48 (m, 10H); ¹³C-NMR (50 MHz, CDCl₃): δ 61.9, 65.3, 66.5, 66.6, 67.5, 127.2, 127.6, 128.9, 12.0, 135.4, 135.6; **Anal.** Calcd for C₈H₈N₆: C, 51.06; H, 4.28; N, 44.66; Found: C, 51.30; H, 4.08; N, 44.50%.

1,2-Diazido-1-cyclohexylethane (28e)

Yield: 80%; pale yellow liquid; **IR** (neat, cm⁻¹): 1252, 2102, 2937; ¹**H-NMR** (200 MHz, CDCl₃): δ 0.96-1.35 (m, 5H), 1.45-1.17 (m, 6H), 3.21-3.30 (m, 1H), 3.36-3.49 (m, 2H); ¹³**C-NMR** (50 MHz, CDCl₃): δ 25.7, 25.8, 28.5, 29.6, 40.0, 52.9, 67.5; **Anal** Calcd for. C₈H₁₄N₆: C, 49.47; H, 7.26; N, 43.27; Found: C, 49.25; H, 7.50; N, 43.20%.

1,2-Diazidohexane (28f)

Yield: 70%; pale yellow liquid; IR (neat, cm⁻¹): 1253, 2103, 2930; ¹H-NMR (200 MHz, CDCl₃): δ 0.93 (t, J = 6.7, 3H), 1.25-1.41 (m, 4H), 1.51-1.58 (m, 2H), 3.25-3.53 (m, 3H);
¹³C-NMR (50 MHz, CDCl₃): δ 13.7, 22.2, 27.8, 31.3, 54.7, 61.9; Anal. Calcd for. C₆H₁₂N₆: C, 42.84; H, 7.19; N, 49.96; Found: C, 42.50; H, 7.31; N, 49.90%.

1,2-Diazidoheptane (28g)

Yield: 68%; pale yellow liquid; **IR** (neat, cm⁻¹): 1253, 2104, 2945; ¹**H-NMR** (200 MHz, CDCl₃): δ 0.91 (t, J = 6.5, 3H), 1.32-1.59 (m, 8H), 3.25-3.37 (m, 2H), 3.41-3.49 (m, 1H); ¹³**C-NMR** (50 MHz, CDCl₃): δ 13.7, 22.3, 25.4, 31.3, 31.6, 54.7, 61.9; **Anal.** Calcd for. C₇H₁₄N₆: C, 46.14; H, 7.74; N, 46.12; Found: C, 46.01; H, 7.80; N, 46.20%.

1,2-Diazidodecane (28h)

Yield: 63%; pale yellow liquid; **IR** (neat, cm⁻¹): 1254, 2103, 2940; ¹**H-NMR** (200 MHz, CDCl₃): δ 0.89 (t, J = 6.6, 3H), 1.28-1.58 (m, 14H), 3.25-3.37 (m, 2H), 3.42-3.47 (m, 1H); ¹³**C-NMR** (50 MHz, CDCl₃): δ 13.9, 22.5, 25.7, 29.0, 29.2, 29.3, 31.6, 37.7, 54.7, 62.0; **Anal.** Calcd for. C₁₀H₂₀N₆: C, 53.55; H, 8.99; N, 37.47; Found: C, 53.65; H, 8.89; N, 37.40%.

General experimental procedure for diazidation of α , α -diazidation of aryl ketones and alcohols:

To a suspension of NaN₃ (0.975 g, 15 mmol) and NaIO₄ (1.069 g, 5 mmol) in 20 mL DMSO: glacial AcOH (4: 1) was added aryl ketones 29 /alcohols 30 (5 mmol) and the reaction mixture was stirred at 75 °C for 2 h until the mixture became dark brown in color. Then the reaction mixture was poured into water (100 ml) and extracted with EtOAc (3×50 ml). The combined organic layers were washed with a saturated solution of NaHCO₃ (50 ml) followed by aq. Na₂S₂O₃ (5%, 50 ml), dried over anhyd. Na₂SO₄. Concentration of the organic layer

gave crude gem-diazides, which were subjected to column chromatographic purification using hexane/ethyl acetate (19: 1) as eluent to obtain pure gem-diazides **31a-d**.

2,2-Diazido-1-phenyl-propane-1-one (31a)

Yield: 96%; pale yellow liquid; **IR** (Neat, cm⁻¹): 739, 1230, 1456, 1602, 1690, 2104, 2937; ¹**H-NMR** (200 MHz, CDCl₃): δ 1.86 (s, 3H), 7.44-7.53 (m, 2H), 7.57-7.66 (m, 1H), 8.11 (t, J = 1.5 Hz, 1H), 8.14 (t, J = 1.3 Hz, 1H); ¹³**C-NMR** (50 MHz, CDCl₃): δ 20.0, 83.1, 128.3, 130.1, 132.5, 133.6, 191.7; **Anal.** Calcd for. C₉H₆N₆O: C, 50.00; H, 3.73; N, 38.87 Found: C, 50.62; H, 3.24; N, 38.72 %.

2,2-Diazido-3,4-dihydronapthalen-1-one (31b)

Yield: 91%; pale yellow liquid; **IR** (Neat, cm⁻¹): 738, 1228, 1456, 1602, 1693, 2104, 2937; ¹**H-NMR** (200 MHz, CDCl₃): δ 2.33 (t, J = 6.4 Hz, 1H), 3.06 (t, J = 6.0 Hz, 1H), 7.28 (d, J = 7.5 Hz, 1H), 7.39 (t, J = 7.3 Hz, 1H), 7.57 (ddd, J = 1.5, 7.4, 15 Hz, 1H), 8.12 (d, J = 7.8 Hz, 1H); ¹³**C-NMR** (50 MHz, CDCl₃): δ 25,3, 32.9, 80.2, 127.3, 128.6, 129.17, 128.9, 134.8, 143.0, 187.5; **Anal**. Calcd for. C₁₀H₈N₆O: C, 52.63; H, 3.53; N, 36.83 Found: C, 52.32; H, 3.60; N, 36.93 %.

2,2-Diazido-1,3-diphylpropane-1-one (31c)

Yield: 94%; pale yellow liquid; **IR** (Neat, cm⁻¹): 738, 1230, 1456, 1602, 1695, 2103, 2937; ¹**H-NMR** (200 MHz, CDCl₃): δ 3.39 (s, 2H), 7.15-7.30 (m, 5H), 7.41-7.49 (m,2H), 7.55-7.63 (m, 1H), 7.98-8.03 (m, 2H); ¹³**C-NMR** (50 MHz, CDCl₃): δ 43.0, 32.9, 85.5, 127.9, 128.5, 128.8, 130.1, 130.6, 132.2, 133.5, 133.6, 192.7; **Anal**. Calcd for. C₁₅H₁₂N₆O: C, 61.64; H, 4.14; N, 28.75 Found: C, 61.60; H, 4.10; N, 28.83 %.

2,2-Diazido-3,4-dihydronapthalen-1-one (31d)

Yield: 95%; pale yellow liquid; **IR** (Neat, cm⁻¹): 738, 1228, 1456, 1602, 1698, 2105, 2937; ¹**H-NMR** (200 MHz, CDCl₃): δ 3.29 (s, 2H), 7.46 (dd, *J* = 6.0, 7.5 Hz, 2H), 7.71 (t, *J* = 7.6 Hz, 1H), 7.86 (d, *J* = 7.5, 1H); ¹³**C-NMR** (50 MHz, CDCl₃): δ 39,5, 80.1, 125.9, 126.4, 128.7, 132.1, 136.9, 149.1, 194.6; **Anal**. Calcd for. C₉H₆N₆O: C, 50.47; H, 2.82; N, 39.24 Found: C, 50.55; H, 2.78; N, 39.30 %.

Section III

NaIO₄-KI-NaN₃ as a new reagent system for C-H functionalization in hydrocarbons

3.3.1 Introduction

Direct and selective replacement of C-H bonds in hydrocarbons with C-C, C-O, C-N and C-X groups is an important and long-standing goal in chemistry.³³ Generally, for monofunctionalization of unactivated C-H bonds, such catalytic systems as organometallic compounds,^{34a} metallo-porphyrin complexes,^{34b} superacids,^{34c} Gif and Gif-Orsay systems,^{34d} MeReO₃/H₂O₂,^{34e} OsO₄,^{34f} polyoxometallates,^{34g} and other systems³³ have been reported. In particular, a new, effective method for 1,2-functionalization of unactivated C-H bonds in a single step which represents a major challenge for chemist. In addition, free-radical iodinations of hydrocarbons with iodine, despite its endothermic nature, have emerged as useful route for the activation of C-H bonds in hydrocarbons. During the course of our study on NaIO₄-mediated oxidative halogenations,¹⁴⁻¹⁵ (see the Section I for details) we noticed that regiospecific addition of I-N₃, generated *in situ*, onto styrenes took place in an *anti*-Markovnikov fashion, suggesting a probable radical pathway.³⁵ This prompted us to explore the effectiveness of the NaIO₄-KI-NaN₃ combination in the C-H activation of alkanes.


3.3.2 Review of literature

Literature search reveals that while there are several reports available for the iodination of hydrocarbons, very few methods are reported for the direct 1,2-difunctinalization and benzylic azidation of hydrocarbons. Some of these methods are briefly discussed below.

(a) Direct C-H activation

Gidley's approach (1968)³⁶


Gidley *et al.* have reported a photochemical free radical method for C-H activation of primary, secondary and benzylic C-H bonds of hydrocarbons to the corresponding iodides **33** in 20-60% yields (**Scheme 20**).



<u>Scheme 20</u>: (i) *t*-BuCOI, Feron 113 (1.2 M), hydrocarbon (4.2 M), *hv*, NaN₃, 40 °C.

Schreiner's approach (1999, 2000)^{37, 38}

Schreiner *et al.* have used CHI₃ and NaOH reagent combination for iodination of alkanes to give the corresponding alkyl iodides **35**, in 27-92% yield (**Scheme 21**). The procedure is simple yet efficient and even normally completely unreactive straight chain alkanes can be iodinated readily.




Scheme 21: (i) CHI₃, NaOH, hydrocarbon , CH₂Cl₂ 25 °C.

Writh's approach (2003)³⁹

Writh *et al.* have reported iodination of hydrocarbons by using *in situ* generated *tert*-butyl hypoiodite from iodine and sodium *tert*-butoxide to give the iodides in 62-77% yields


(Scheme 22). However this iodination procedure gave less yield and poor selectivity for straight chain alkanes.



<u>Scheme 22</u>: (i) I_2 , hydrocarbons (excess), *t*-BuONa, 25 °C , 15 h.


Barluenga's approach (2002, 2005)^{40, 17}

Barluenga *et al.* have reported the photochemical iodination of alkanes and thermally vic-acetoxyiodination of cycloalkanes **39** by using $PhI(OAc)_2$ and molecular I_2 to gave corresponding iodoalkanes **40** and acetoxyiodo compounds **41** in 85-98% and 65-92% yields respectively. The reported examples leading to the synthesis of 1,2-difunctional derivatives constitute the first diastereoselective vic-activation of the hydrocarbons (Scheme 23).



The same group have used the following reagents: (i) 1-acetoxy-1,2-benziodoxole-3(1H)-


one (42), I_2 and TMSN₃; (ii) H_2O_2 , I_2 , and NaN₃. These reagent combinations were found to be effective for the iodination of various hydrocarbons giving the corresponding alkyl iodides in good yields (Scheme 24).



<u>Scheme 24</u>: (i) I_2 (1.1 equiv.), hydrocarbons (25 mL), TMSN₃, 60 °C , 15 h; (ii) I_2 , H_2O_2 , NaN₃, Ac₂O, H_2O , 40 °C, 13 h.

Yu's approach (2005)⁴¹

Yu *et al.* have reported palladium catalyzed an auxiliary approach for the chemoselective and asymmetric iodination of methyl group located at the α -position of oxazolines **43** (**Scheme 25**). The combination of Pd(OAc)₂, I₂, and PhI(OAc)₂ was shown to be a powerful protocol for the catalytic and asymmetric iodination of methyl, cyclopropyl and aryl groups under mild conditions.




<u>Scheme 25</u>: (i) Pd(OAc)₂ (10 mol%), I₂, PhI(OAc)₂ (1 equiv), CH₂Cl₂, 24 °C, 48-72 h.

(b) Direct benzylic azidation

Kita's approach (1994)⁴²


Kita *et al.* have reported direct benzylic azidation of *p*-alkyl anisole **45** with hypervalent iodine reagent such as $PhI(OCOCF_3)_2$ and trimethylsilyl azide to give the corresponding benzyl azides **46** in 34-73% yields (**Scheme 26**).



Scheme 26: (i) *p*-alkyl anisole , PhI(OCOCF₃)₂, TMSN₃, CH₃CN, 40 °C.


Bols's approach (2001, 2005)^{43, 18}

In this approach, Bols *et al.* have used iodine azide (IN₃) for the direct azidation of benzyl ether **47** to the corresponding benzyl azides **48** in high yields (**Scheme 27**).



Scheme 27: (i) ICl, NaN₃, CH₃CN, -10 °C, then benzyl ether, reflux, 3-4 h.

The same authors have also reported a direct azidation of benzyl ether **49** with polymer supported diazidoiodate to give the corresponding benzyl azides **50** in high yields **(Scheme 28)**.



Scheme 28: (i) polystyrene-NMe₃I, PhI(OAc)₂, TMSN₃, CH₃CN, 83 °C.

3.3.3. Present Work

3.3.3.1 Objective


From the above discussion, it is clear that most of the reported methods for iodination of alkanes suffer from certain drawbacks like low yields and poor selectivity, molecular iodine as the iodine source and other expensive oxidants. The effective method for the 1,2-functionalization of unactivated C-H bonds in a single step represents a major challenge for chemists. Hence, a practical method for mono- and 1,2-difunctionalization of hydrocarbons which should involve less toxic and easily available reagents are desirable. This section describes the use of NaIO₄-KI-NaN₃ combination to selectively functionalize the C-H bonds of hydrocarbons to produce iodoalkanes **33**, 1-acetoxy- or 1-azido-2-iodocycloalkanes **51** or benzyl azides **52**, in excellent yields upon reaction with the respective hydrocarbons.

3.3.4. Results and Discussion

3.3.4.1 Direct iodination of alkanes

During the course of our study on NaIO₄-mediated oxidative azidoiodination, we noticed that regiospecific addition of I-N₃, generated *in situ*, onto alkenes took place in an *anti*-Markovnikov fashion, suggesting a probable radical pathway (for details, see Section I of this chapter). This prompted us to explore the effectiveness of the NaIO₄-KI-NaN₃

combination in the C-H activation of alkanes. We describe in this section the use of NaIO₄-KI-NaN₃ combination that selectively functionalizes the C-H bonds of hydrocarbons to produce iodoalkanes **33a-g**, 1-acetoxy- or 1-azido-2-iodocycloalkanes **51a-d** or benzyl azides **52a-g**, in excellent yields depending upon reaction condition with the respective hydrocarbons **32**. Thus, when cyclohexane **32a** was treated with NaIO₄, KI and NaN₃ (all 1 equiv.) in acetic acid at 25 °C, iodocyclohexane **32a** was isolated in 32% yield. However, the yield could be increased dramatically to 99% when 3 equiv. of NaN₃ was used (**Scheme 29**).⁴⁴



<u>Scheme29</u>: (i) cyclohexane (excess), NaIO₄ (1 equiv.), KI (1 equiv.), NaN₃ (3 equiv), glacial AcOH, 25 °C.

This novel iodination process is successful for a variety of alkanes including cyclic and acyclic and its completion is readily ascertained by a distinct colour change observed in the reaction from dark brown to colourless. The presence of both NaIO₄ and NaN₃ was essential for obtaining high yields of iodoalkanes **33a-g**. Interestingly, for linear alkanes, an improved selectivity was observed as only the methylene positions were iodinated (**Table 4**).

Table 4: NaIO₄-mediated iodination of alkanes.^a

Entry	R-H (32a-g)	t (h)	Yield of $(33a-g) (\%)^b$
a	Cyclohexane	8	99
b	Cyclopentane	6	98
с	Cycloheptane	8	99

d	Cyclooctane	4	99 ^c
e	<i>n</i> -Pentane	9	99 (2:1) ^d
f	<i>n</i> -Hexane	6	98 (1.1:1) ^e
g	<i>n</i> -Heptane	8	97 (2.5:2.2:1) ^f

Reaction conditions: (a) alkane (5 mL), NaIO₄ (5 mmol), KI (5 mmol), NaN₃ (15 mmol), glacial AcOH (15 mL), 25 °C; ^b Yield was calculated based on KI; ^c 2 equiv. each of NaIO₄ and NaN₃ used; ^d 2-I:3-I pentane; ^e 2-I:3-I hexane; ^f 2-I:3-I:4-I heptane; (ratios determined by ¹H-NMR and GC).

The formation of iodoalkanes **33a-g** was confirmed by ¹H-NMR and ¹³C-NMR spectroscopy. For example, the ¹H-NMR spectrum of iodocycloheptane (**33c**) showed a multiplet at δ 4.40-4.51 corresponding to methine proton (-CH-I). Its ¹³C-NMR showed a typical signal at δ 35.6 for methine carbon attached to iodo group (**Fig. 5**). In the case of linear alkanes, the ratios were confirmed by GC and ¹H-NMR spectrum.




Fig. 5: ¹H and ¹³C NMR spectra of 33c

Surprisingly, for cyclooctane under the same reaction condition, the reaction took a different course to furnish **51a** in 60% yield along with **33d** in 15% yield (**Table 5**).

Entry	R-H (32)	NaN ₃	t	Т	Yield of 51 (%)^b
(equiv.) (h) (°C)					
1					$\bigcup_{N_3}^{I} \bigcup_{I}^{I}$
					51a 33d
		3	4	25	60 15
		6	4	25	85 [°] -
2	\bigcirc				$N_3^{(1)}$ $N_3^{(1)}$
					51b 51c
		3	24	45	10 5 ^d
		6	24	45	62 35
		3	10	75	- 70 ^e
		3	10	75	- 94 ^f
3	\bigcirc				OH O -O 51d
		3	10	45	g
		6	30	45	50 ^{h,i}

Table 5: NaIO₄-mediated 1, 2-difunctionalization of cycloalkanes with KI and NaN₃^a

^a Reaction conditions: cycloalkane (5 mL), NaIO₄ (5 mmol), KI (5 mmol), gl. AcOH (15 mL); ^bYield was calculated based on KI; ^c*syn:anti* = 2:1 by ¹H NMR;

^d**33a** was formed in 81% yield; ^e**33a** was also formed in 25% yield; ^f2 equiv. of NaIO₄ was used; ^gcyclopentyl acetate was formed in 95% yield; ^hcyclopentyl acetate was also formed in 46% yield; ⁱ Stereochemistry was not assigned.

However, with 6 molar equiv. of NaN₃, **51a** was obtained in 85% yield with syn: anti ratio of 2:1. It was also observed that both NaIO₄ and NaN₃, in appropriate concentrations, were critical in determining product selectivities. Thus, for cyclohexane, at 45 °C, with 3 molar equiv. of NaN₃, 33a (81%) was obtained along with 51b (10%) and 51c (5%), while use of 6 molar equiv of NaN_3 resulted in improved product selectivity: 51b (62%) and 51c (35%). At 75 °C, an excellent yield of 51c (94%) was realized with NaIO₄ (2 equiv.; 10 mmol). For cyclopentane, at 45 °C, only cyclopentyl monoacetate was obtained in 95% yield whereas an increase of azide concentration (6 molar equiv.) gave an unusual 1, 2-dihydroxyiodo derivative **51d** in 50% yield along with cyclopentyl monoacetate (46%). In the case of cycloheptane, an increase of either the temperature or azide concentration resulted in only cycloheptyl monoacetate in 96% vield. Overall, increasing the temperature facilitates oxidative elimination of the iodoalkane to furnish an alkene, thereby giving higher yields of difunctionalized products. However, in the case of cycloheptane and cyclopentane, nucleophilic substitution becomes a favorable process.⁴⁵

The formation of 1-acetoxy- or 1-azido-2-iodocycloalkanes **51a-d** was confirmed by ¹H-NMR and ¹³C-NMR spectroscopy. For example, the ¹H-NMR spectrum of 1-acetoxy-2-iodocyclohehanes (**51c**) showed multiplets at δ 3.98-4.11 and 4.82-4.94 corresponding to methine protons. Its ¹³C-NMR spectrum showed a typical signal at δ 169.5 for carbonyl carbon of acetoxy group (**Fig. 6**)





Fig. 6: ¹H and ¹³C NMR spectra of 51c

3.3.4.2 Direct azidation at benzylic position

Direct azidation *via* functionalization at Ar-C-H bonds is an atom economical route in organic synthesis.⁴⁶ A recent report on direct azidation of activated arenes using polymer-supported iodine azide has established that a certain electron-donating capacity is needed at the benzylic position for the reaction to occur. With the NaIO₄- KI-NaN₃ system (1:1:3 molar ratio), we found that toluene **37a** was functionalized smoothly at the benzylic position to give benzyl azide **52a** (85%) along with benzyl acetate **53** (10%). Further, on

increasing the concentration of azide (6 equiv), exclusive formation of monobenzyl azide **52a** (95%) was realized (**Scheme 30**).



Scheme30: : (i) toluene (excess), NaIO₄ (1 equiv.) KI (1 equiv.), NaN₃ (6 equiv.), glcial AcOH, 25 °C.

To study the generality of the reaction, a variety of toluene derivatives were subjected to azidation with NaIO₄-KI-NaN₃ reagent combination, and the results are presented in **Table 6**.

Table 6: NaIO₄-mediated azidation at the benzylic C-H bond of alkyl arenes^a

Entry	Arene (37)	t (h)	Benzyl azide (52)	Yield (%) ^b
а	Toluene	8	benzyl azide	95
b	o-Xylene	8	2-methylbenzyl azide	
c	<i>m</i> -Xylene	7	3-methylbenzyl azide	90
d	<i>p</i> -Xylene	8	4-methylbenzyl azide	93
e	mesitylene	7	3,5-dimethylbenzyl azide	89
f	Ethylbenzene	15	1-azidoethylbenzene	20 ^c
g	Indane	15	1-azidoindane	50 ^c

Reaction conditions: ^a arene (5 mL), NaIO₄ (5 mmol), KI (5 mmol), NaN₃ (30 mmol), glacial AcOH (20 mL), 25 °C; ^b Yield was calculated based on KI; ^c reaction was carried out without KI at 75 °C in DMSO-AcOH (4:1).

Notably, no polyazidation took place for other alkylarenes even if higher equivalents of NaN_3 were used (**Table 6**). In similar reaction condition, no reaction took place in the case of secondary alkyl arenes such as ethyl benzene and indane. However, when ethyl

benzene and indane were subjected to oxidative functionalization in the absence of KI, with NaIO₄ (1 equiv) in the presence NaN₃ (3 equiv) in AcOH: DMSO (1: 4) as solvent at 75 °C, the corresponding secondary benzyl azides could be obtained in 20% and 50% yields respectively. The formation of benzyl azides **52a-g** was confirmed by ¹H-NMR, ¹³C-NMR and IR spectroscopy. The ¹H NMR spectrum of **52d** showed a singlet at δ 4.28 for benzylic methylene proton attached to azide group (Ar-CH₂-N₃). Its ¹³C NMR spectrum showed a typical signal at δ 45.4 due to methylene carbon attached to azide group (**Fig. 7**).




Fig. 7: ¹H and ¹³C NMR spectra of 52d

The ¹H NMR spectrum of **52g** showed a doublet of doublet at δ 4.85 for benzylic methine proton attached to azide group (Ph-CH.N₃). Its ¹³C NMR spectrum showed a typical signal at δ 65.7 for methine carbon attached to azide group (**Fig. 8**).





Fig. 8: ¹H and ¹³C NMR spectra of 52g

3.3.5. Mechanism for C-H activation of alkanes

Mechanistically, we have proved that $NaIO_4$ oxidizes KI as well as NaN_3 simultaneously, to liberate I_2^{15} and an azide radical¹⁶ respectively; combination of which results in the formation of I-N₃. To confirm the formation of I₂, alkane was treated with molecular iodine instead of KI. We found in this study that similar results were indeed obtained.

Homolysis of I-N₃¹⁸ provides an azide radical, which abstracts a proton from alkane to produce alkyl radical **A**. Combination of radical **A** with I₂ followed by oxidative elimination of the resulting alkyl iodide⁴⁷ generates alkene (confirmed by GC analysis). Addition of either I-N₃ or I-OAc across the double bond produces **51b** and **51c**, respectively (**Scheme 31**). Evidence for the radical pathway is deduced from the following experiment: no reaction took place in the presence of *N-tert*-butyl- α -phenylnitrone, a radical scavenger.¹⁸ In the case of direct azidation of alkyl arenes, the involvement of a benzyl radical followed by a benzyl cation is similarly proposed.⁴³



<u>Scheme 31</u>: Proposed mechanistic pathway for the C-H activation of alkanes

3.3.6. Conclusion

In conclusion, we have described NaIO₄-KI-NaN₃ as a new efficient system suitable for mono and 1,2-difunctionalization of hydrocarbons *via* C-H bond activation. In particular, reaction invoving vicinal azido- and acetoxy iodinations of cyclic hydrocarbons in high yields and selectivity are unique and unprecedented. A high yield direct azidation at the benzylic position in less activated alkyl arenes has been demonstrated under ambient conditions.

3.3.7. Experimental section

General experimental procedure for iodination of alkane: To a suspension of NaN₃ (0.975 g, 15 mmol) and KI (0.830 g, 5 mmol) in glacial acetic acid (20 ml) at 25°C was added NaIO₄ (1.069 g, 5 mmol) and the reaction mixture was stirred for 5 minutes so that the dark-brown color was formed. Alkanes **32** in excess (5 mL) were then added and the colored reaction mixture was stirred at the same temperature for 8h until the dark-brown was changed to colorless. The reaction mixture was poured into water (100 mL) and extracted with CH_2Cl_2 (3×50 mL)). The combined organic layers were washed with saturated solution of NaHCO₃ (50 mL) and washed with aq. Na₂S₂O₃ (5%, 50 ml) dried over anhyd. Na₂SO₄, concentrated and unreacted alkane recovered by simple distillation under reduced pressure to give the crude product, which was then purified by column chromatography (packed with silica gel 60-120 mesh) using petroleum ether as eluents to afford the pure products **33a-g**

Iodocyclohexane (33a)

Yield: 99%; colorless oil; **IR** (CHCl₃, cm⁻¹): 2933, 2854, 1448, 1215, 1172, 1095, 987, 759, 669; ¹H NMR (200 MHz, CDCl₃) δ 1.37-1.49 (m, 3H), 1.64-1.74 (m, 3H), 1.93-2.05 (m, 2H), 2.13-2.20 (m, 2H), 4.30-4.43 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 25.1, 27.2, 32.6, 39.5; **Anal.** Calcd for C₆H₁₁I requires C, 34.31; H, 5.28; found: C, 34.30; H, 5.30 %.

Iodocyclopentane (33b)

Yield: 98%; colorless oil; **IR** (CHCl₃, cm⁻¹): 2935, 2855, 1450, 1216, 1174, 1098, 988, 760, 670; ¹**H NMR** (200 MHz, CDCl₃): δ 1.56-1.73 (m, 2H), 1.76-1.94 (m, 2H), 2.03-

2.12 (m, 4H), 4.25-4.39 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 23.9, 28.1, 39.7; Anal. Calcd for C₅H₉I requires C, 30.63; H, 4.63; found: C, 30.62; H, 4.65 %.

Iodocycloheptane (33c)

Yield: 99%; colorless oil; **IR** (CHCl₃, cm⁻¹): 2925, 2854, 1446, 1215, 1184, 1120, 939, 757, 646; ¹**H NMR** (200 MHz, CDCl₃): δ 1.39-1.64 (m, 8H), 2.08-2.35 (m, 4H), 4.40-4.53 (m, 1H); ¹³**C NMR** (50 MHz, CDCl₃): δ 27.0, 27.3, 35.6, 41.9; **Anal.** Calcd for C₇H₁₃I requires C, 37.52; H, 5.85; found: C, 37.50; H, 5.86%.

Iodocyclooctane (33d)

Yield: 99%; colorless oil; **IR** (CHCl₃, cm⁻¹): 2922, 2852, 1442, 1214, 1185, 1122, 935, 756, 644; ¹**H NMR** (200 MHz, CDCl₃): δ 1.44-1.70 (m, 10H), 2.20-2.29 (m, 4H), 4.54-4.67 (m, 1H); ¹³**C NMR** (50 MHz, CDCl₃): δ 25.0, 26.5, 27.3, 37.8, 38.2; **Anal.** Calcd for C₈H₁₅I requires C, 40.35; H6.35; found: C, 40.34; H, 6.38 %.

Mixture of 2-iodopentane and 3-iodopentane ≈ 2:1 (33e)

Yield: 99%; colorless oil; **IR** (CHCl₃, cm⁻¹): 2928, 2847, 1461, 1216, 758, 668; ¹H NMR (200 MHz, CDCl₃): δ 0.85-1.06 (m, 4H), 1.38-1.68 (m, 2H), 1.70-1.94 (m, 4H), 3.99-4.23 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 13.1, 14.1, 22.9, 28.9, 29.7, 33.3, 43.9,44.9; **Anal.** Calcd for C₅H₁₁I requires C, 30.32; H, 5.60; found: C, 30.34; H, 5.57 %.

Mixture of 2-iodohexane and 3-iodohexane ≈ 1:1 (33f)

Yield: 98%; colorless oil; **IR** (CHCl₃, cm⁻¹): 2930, 2850, 1461, 1215, 757, 669; ¹H NMR (400 MHz, CDCl₃): δ 0.81-0.99 (m, 4H), 1.22-1.33 (m, 3H), 1.48-1.59 (m, 2H), 1.69-1.89 (m, 3H), 3.99-4.15 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 13.2, 13.9, 14.0, 21.8, 22.7, 28.91, 30.6,31.8, 33.6, 42.1, 42.3, 42.6; **Anal.** Calcd for C₆H₁₃I requires C, 33.98; H, 6.18; found: C, 33.95; H, 6.20 %.

Mixture of 2-iodoheptane and 3-iodoheptane and 4-iodoheptane ≈ 2.5:2.2:1 (33g)

Yield: 98%; colorless oil; **IR** (CHCl₃, cm⁻¹): 2931, 2873, 1461, 1216, 757, 669; ¹H NMR (400 MHz, CDCl₃): δ 0.85-1.08 (m, 4H), 1.23-1.98 (m, 10H), 4.03-4.22 (m, 1H); ¹³C **NMR** (50 MHz, CDCl₃): δ 13.3, 14.0, 14.1, 14.1, 22.0, 22.5, 22.8, 29.0, 29.4, 30.1, 30.9, 31.72, 33.7, 39.2, 40.0, 41.9, 42.7, 42.9; **Anal.** Calcd for C₇H₁₅I requires C, 37.19; H, 6.69; found: C, 37.21; H, 6.70 %.

1-Azido-2-iodocyclooctane (syn: anti = 2:1) (51a)

Yield: 85%; pale yellow oil; **IR** (CHCl₃, cm⁻¹): 2926,2854, 2094, 1444, 1259, , 779; ¹**H NMR** (200 MHz, CDCl₃) δ 1.38-1.82 (m, 10H), 1.93-2.40 (m, 2H), 3.41-3.49 (qd, J = 3.9, 2.8, Hz, 1H), 4.54-4.64 (qd, J = 2.8, 6.2 Hz, 1H); ¹³**C NMR** (50 MHz, CDCl₃): δ 23.1, 23.9, 25.1, 25.6, 26.1, 26.2, 27.1, 27.1, 31.5, 31.7, 34.2, 36.9, 38.6, 39.0, 64.1, 71.0; **Anal.** Calcd for C₈H₁₄IN₃ requires C, 34.42; H, 5.06, N, 15.05; found: C, 34.46; H, 5.00, N, 15.04 %.

Typical experimental procedure for 1-Azido-2-iodocyhexane (51b): To a suspension of NaN₃ (1. 950 g, 30 mmol) and KI (0.830 g, 5 mmol) in glacial acetic acid (20 ml) at 25°C was added NaIO₄ (1.069 g, 5 mmol) and the reaction mixture was stirred for 5 minutes so that the dark-brown color was formed, followed by the addition of cyclohexane (5 mL). The colored reaction mixture was stirred at the same temperature for 4 h followed by and at 45 °C for 24 h. During heating, the color of the reaction mixture has disappeared and again reappeared. The reaction mixture was then poured into water (100 mL) and extracted with CH_2Cl_2 (3×50 mL)). The combined organic layers were washed with saturated aq. solution of NaHCO₃ (50 mL), aq. Na₂S₂O₃ (5%, 50 mL) and dried over anhyd. Na₂SO₄, concentrated and unreacted alkanes recovered by simple

distillation under reduced pressure to give the crude product, which was then purified by column chromatography (packed with silica gel 60-120 mesh) using petroleum ether as eluent to afford the pure product **51b**.

Yield: 65%; pale yellow oil; **IR** (CHCl₃, cm⁻¹): 2939 2860, 2100, 1448, 1257,1217, 923, 769, 669; ¹H NMR (200 MHz, CDCl₃): δ 1.31-1.57 (m, 4H), 1.99-2.50 (m, 4H), 3.46-3.58 (m, 1H), 3.90-4.03 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 23.7, 26.9, 31.8, 33.2, 38.3, 67.1; **Anal.** Calcd for C₆H₁₀IN₃ requires C, 28.70; H, 4.01, N, 16.74; found: C, 28.72; H, 4.00, N, 16.73 %.

2-Iodocyclohexylacetate (51c)

Yield: 94%; pale yellow oil; **IR** (CHCl₃, cm⁻¹): 2939 2861, 1735, 1448, 1236,1047, 756, 667; ¹H NMR (200 MHz, CDCl₃): δ 1.25-1.52 (m, 3H), 1.57-1.85 (m, 2H), 1.98-2.16 (m, 2H), 2.09 (s, 3H), 2.40-2.51 (m, 1H), 3.98-4.11 (m, 1H), 4.82-4.94 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 21.1, 23.5, 27.0, 31.5, 37.7, 76.5, 169.5; **Anal.** Calcd for C₈H₁₃IO₂ requires C, 35.84; H, 4.89; found: C, 35.86; H, 4.86 %.

2-Hydroxycyclopentyl 2-iodoacetate (51d)

Yield: 50%; pale yellow oil; **IR** (CHCl₃, cm⁻¹): 3446, 2976, 1730, 1417, 1215, 923, 757, 668; ¹H NMR (200 MHz, CDCl₃): δ 1.53-2.17 (m, 8H), 1.70-1.90 (br s, 1H) 3.73-3.4 (d, J = 1.7 Hz, 2H), 4.18-4.26 (m, 1H), 4.96-5.04 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ - 5.1, 19.2, 27.6, 30.6, 73.0, 78.2, 168.4; **Anal.** Calcd for C₇H₁₁O₃ requires C, 31.13; H, 4.11; found: C, 31.10; H, 4.12 %.

General experimental procedure for azidation of alkyl arenes: To a suspension of NaN₃ (1.950 g, 30 mmol) and KI (0.830 g, 5 mmol) in glacial acetic acid (20 ml) at 25°C was added NaIO₄ (1.069 g, 5 mmol) and the reaction mixture was stirred for 5 minutes so

that the dark-brown color was formed. Alkyl arenes **37** in excess (5 mL) were then added and the reaction mixture was stirred at the same temperature for 8 h. The reaction mixture was poured into water (100 mL) and extracted with CH_2Cl_2 (3×50 mL)). The combined organic layers were washed with saturated solution of NaHCO₃ (50 mL) followed by washed with aq. Na₂S₂O₃ (5%, 50 mL), dried over anhyd. Na₂SO₄, concentrated and unreacted alkane recovered by simple distillation under reduced pressure to give the crude product **52a-e**, which was then purified by column chromatography (packed with silica gel 60-120 mesh) using pet. ether as eluents to afford the pure products **52a-e**.

1-(Azidomethyl) benzene (52a)

Yield: 95%; colorless liquid; **IR** (CHCl₃, cm⁻¹): 3032, 3015, 2930, 2877, 2097, 1605, 1586, 1496, 1455, 1255, 1217, 758, 699, 668; ¹H NMR (200 MHz, CDCl₃): δ 4.33 (s, 2H), 7.34-7.43 (m 5H); ¹³C NMR (50 MHz, CDCl₃): δ 54.7, 128.1, 128.2, 128.76, 135.3; **Anal.** Calcd for C₇H₇N₃ requires C, 63.14; H, 5.30; N, 31.56; found: C, 63.00; H, 5.40; N, 31.20%.

1-(Azidomethyl)-2-methylbenzene (52b)

Yield: 85%; colorless liquid; **IR** (CHCl₃, cm⁻¹): 3019, 2974, 2934, 2105, 1553, 1456, 1215, 757, 668; ¹H NMR (200 MHz, CDCl₃): δ2.37 (s, 3H), 4.35 (s, 2H), 7.21-7.28 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ 18.8, 52.8, 126.0, 128.5, 129.2, 130.5, 133.2, 136.6; **Anal.** Calcd for C₈H₉N₃ requires C, 65.29; H, 6.16; N, 28.55; found: C, 65.18; H, 6.24; N, 28.45%.

1-(Azidomethyl)-3-methylbenzene (52c)

Yield: 90%; colorless liquid; **IR** (CHCl₃, cm⁻¹): 3024, 2924, 2873, 2098, 1592, 1490, 1455, 1264,1237, 864, 778, 742, 702; ¹**H NMR** (200 MHz, CDCl₃): δ2.37 (s, 3H), 4.29

(s, 2H), 7.09-7.16(m 3H) 7.23-7.28 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 21.1, 54.7, 125.1, 128.6, 128.8, 128.9, 135.2, 138.4; Anal. Calcd for C₈H₉N₃ requires C, 65.29; H, 6.16; N, 28.55; found: C, 65.22; H, 6.20; N, 28.35%.

1-(Azidomethyl)-4-methylbenzene (52d)

Yield: 93%; colorless liquid; **IR** (CHCl₃, cm⁻¹): 3017, 2926, 2100, 1515, 1450, 1254, 1216, 804,757, 668; ¹**H NMR** (200 MHz, CDCl₃): δ2.36 (s, 3H), 4.28 (s, 2H), 7.20 (s, 4H); ¹³**C NMR** (50 MHz, CDCl₃): δ 21.0, 54.4, 128.1, 129.3, 132.2, 137.9; Anal. Calcd for C₈H₉N₃ requires C, 65.29; H, 6.16; N, 28.55; found: C, 65.19; H, 6.09; N, 28.44%.

1-(Azidomethyl)-3,5-dimethylbenzene (52e)

Yield: 89%; colorless liquid; **IR** (CHCl₃, cm⁻¹): 3017, 2921, 2870, 2097, 1605, 1464, 1245, 841,725; ¹H NMR (200 MHz, CDCl₃): δ 2.33 (s, 6H), 4.26 (s, 2H), 6.93 (s, 2H), 6.97 (s, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 21.1, 54.7, 125.9, 129.8, 135.1, 138.3; **Anal.** Calcd for C₉H₁₁N₃ requires C, 67.06; H, 6.88; N, 26.07; found: C, 67.15; H, 6.92; N, 26.10%.

Typical experimental procedure for azidation of ethylbenzene and indane: To a suspension of NaN₃ (0.975 g, 15 mmol) and NaIO₄ (1.069 g, 5 mmol) in (20 mL) DMSO: glacial AcOH (4: 1) was added ethyl benzene or indane (**37f** or **37g**) 5 mL as the case may be, and the reaction mixture was stirred at the 75 °C for 6 h until the mixture became dark brown in color. Then the reaction mixture was poured into water (100 mL) and extracted with EtOAc (3×50 mL). The combined organic layers were washed with a saturated solution of NaHCO₃ (50 mL) and aq. Na₂S₂O₃ (5%, 50 mL), dried over anhyd. Na₂SO₄. Concentration of the organic layer gave benzyl azide, which was subjected to column purification using hexane/ethyl acetate (20:1) as eluent to obtain pure benzyl azides **52f-g**.

1-Azidoethylbenzene (52f)

Yield: 20%; colorless liquid; IR (CHCl₃, cm⁻¹): 3040, 2960, 28880, 2106, 1607, 1494, 1250, 775, 730; ¹H NMR (200 MHz, CDCl₃): δ 1.53 (d, *J* = 6.8 Hz, 3H), 4.62 (q, *J* = 6.8, 1H), 7.30-7.38 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ 23.1, 66.0, 126.1, 127.8, 128.6, 139.3; Anal. Calcd for C₈H₉N₃ requires C, 65.29; H, 6.16; N, 28.55; found: C, 65.20; H, 6.10; N, 28.63%.

1-Azidoindane (52g)

Yield: 50%; colorless liquid; **IR** (CHCl₃, cm⁻¹): 3020, 2925, 2871, 2097, 1601, 1463, 1250, 843; ¹H NMR (200 MHz, CDCl₃): δ 2.03-2.19 (m, 1H), 2.36-2.52 (m,1H), 2.79-2.94 (m, 1H), 3.01-3.16 (m, 1H), 4.85 (dd, *J* = 4.7, 7.0 Hz, 1H), 7.23-7.30 (m, 3H), 7.37-7.41 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 30.2, 32.6, 65.7, 124.3, 126.6, 128.6, 140.5, 143.4; **Anal.** Calcd for C₉H₉N₃ requires C, 67.90; H, 5.70; N, 26.40; found: C, 67.85; H, 5.72; N, 26.44%.

3.3.8 References

- 1 Hassner, A.; Fowler, F. W. J. Org. Chem. 1968, 33, 2686.
- 2 Wasserman, H. H.; Brunner, R. K.; Buynak, J. D.; Carter, C. G.; Oku, T.; Robinson, R. P. J. Am. Chem. Soc. 1985, 107, 519.
- 3 (a) Van Ende, D.; Krief, A. Angew. Chem. Int. Ed. 1974, 13, 279. (b) Denis, J. N.; Krief, A. *Tetrahedron* 1979, 35, 2901.
- 4 (a) Ranganathan, S.; Ranganathan, D.; Mehrotra, A. K. *Tetrahedron Lett.* **1973**, *14*, 2265. (b) Moorthy, S. N.; Devaprabhakara, D. *Tetrahedron Lett.* **1975**, *16*, 257.
- 5 (a) Fowler, F. W.; Hassner, A.; Levy, A. J. Am. Chem. Soc. 1967, 89, 2077; (b) Hassner, A. Acc. Chem. Res. 1971, 4, 9.
- 6 Woodgate, P. D.; Lee, H. H.; Rutledge, P. S.; Cambie, R. C. Synthesis, 1977, 462
- 7 Hassner, A.; Levy, L. A. J. Am. Chem. Soc. 1965, 87, 4203.
- 8 Kirschning, A.; Hashem, M. A.; Monenschein, H.; Rose, L.; Schoning, K.-U. J. Org. Chem. 1999, 64, 6522.
- 9 Kirschning, A.; Monenschein, H.; Schmeck, C. Angew. Chem. Int. Ed. 1999, 38, 2594.

- 10 Nair, V.; George, T. G.; Sheeba, V.; Augustine, A.; Balagopal, L.; Nair, L. G. Synlett 2000, 1597.
- 11 Barluenga, J.; Alvarez-Perez, M.; Fananas, F. J.; Gonzalez, J. M. Adv. Synth. Catal. 2001, 343, 335.
- 12 Curini, M.; Epifano, F.; Marcotullio, M. C.; Rosati, O. Tetrahedron Lett. 2002, 43, 1201.
- 13 Alexander, O.; Terent'ev, I. B. K.; Vladimir, A. K.; Gennady, I. N. Syn. Commun. 2008, 38, 3797.
- (a) Dewkar, G. K.; Narina S. V.; Sudalai, A. Org. Lett. 2003, 5, 4501; (b) Emmanuvel, L.; Shaikh T. M. A.; Sudalai, A. Org. Lett. 2005, 7, 5071.
- 15 Emmanuvel, L.; Shukla, R. K.; Sudalai, A.; Suryavanshi, G.; Sivaram, S. *Tetrahedron Lett.* **2006**, 47, 4793.
- (a) Tingoli, M.; Tiecco, M.; Chianelli, D.; Balducci, R.; Temperini, A. J. Org. Chem. 1991, 56, 6809. (b) Fontana, F.; Minisci, F.; Yan, Y. M.; Zhao, L. Tetrahedron Lett. 1993, 34, 2517.
- 17 Barluenga, J.; Campos-Gomez, E.; Rodriguez, D.; Gonzalez-Bobes F.; Gonzalez, J. M. Angew. Chem., Int. Ed. 2005, 44, 5851.
- 18 Marinescu, L.G.; Pedersen C. M.; Bols, M. Tetrahedron 2005, 61, 123.
- 19 Kemp J. E. G. in *Comprehensive Organic Synthesis*, Vol. 7 (Eds.: B. M. Trost, I. Fleming), Pergamon, Oxford, **1991**, 469.
- 20 Lucet, D.; Gall, T. L.; Mioskowski, C. Angew. Chem. Int.Ed. 1998, 37, 2580.
- 21 Mortensen, M. S.; O_Doherty, G. A. Chemtracts: Org. Chem. 2005, 18, 555.
- 22 Saibabu Kotti, S. R. S.; Timmons, C.; Li, G. Chem. Biol. Drug Des. 2006, 67, 101.
- 23 De Figueiredo, R. M. Angew. Chem. Int. Ed. 2009, 48, 1190.
- a) Swift, G.; Swern, D. J. Org. Chem. 1966, 31, 4226; b) Swift, G.; Swern, D. J. Org. Chem. 1967, 32, 511.
- 25 Skarzewski, J.; Gupta, A. Tetrahedron Asymmetry, 1997, 8, 1861.
- 26 Fristad, W. E.; Brandvold, T. A.; Peterson, J. R.; Thompson, S. R.; J. Org. Chem. 1985, 50, 3647.
- 27 Moriarty, R. M.; Khosrowshahi, J. S. Tetrahedron Lett. 1986, 27, 2809.
- 28 Arimoto, M.; Yamaguchi, H.; Fujita, E.; Nagao, Y.; Ochiai, M. Chem. Pharm. Bull. 1989, 37, 3221.
- 29 Chung, R.; Yu, E.; Incarvito, C. D.; Austin, D. J. Org. Lett. 2004, 6, 3881.
- 30 Suzuki, T.; Shibata, A.; Morohashi, N.; Ohba, Y. Chem. Lett. 2005, 34, 1476.
- 31 Pfaendler, H. R.; Klingl, A. Helv. Chim. Act. 2005, 88, 1486.
- 32 Moore, H. W.; Landen, G. Tetrahedron Lett. 1976, 29, 2515.
- (a) Goldberg, K. I.; Goldman, A. S. Eds. Activation and Functionalization of C-H Bonds; ACS Symposium Series 885; American Chemical Society. Washington, DC, 2004. (b) Curci, R.; D'Accolti L.; Fusco, C. Acc. Chem. Res. 2006, 39, 1; (c) Godula K.; Sames, D. Science 2006, 312, 67; (d) Labinger J. A.; Bercaw, J. E. Nature 2002, 417, 507.
- 34 (a) Crabtree, R. H. Chem. Rev. 1995, 95, 987; (b) Mansuy, D. Pure Appl. Chem. 1987, 59, 759; (c) Sommer J.; Bukala, J. Acc. Chem. Res. 1993, 26, 370; (d) Barton, D. H. R. NATO ASI Ser., Ser. E: Appl. Sci. 1996, 320, 589; (e) Murray, R. W.; Iyanar, K.; Chen J.; Wearing, J. T. Tetrahedron Lett. 1995, 36, 6415; (f) Bales, B. C.; Brown, P.; Dehestani A.; Mayer, J. M. J. Am. Chem. Soc. 2005,

127, 2832; (g) Hill, C. L. Catal. Met. Complexes 1992, 9, 253.

- (a) Abbe, L.; Hassner, A. Angew. Chem. Int. Ed. 1971, 10, 98; (b) Workentin, M. S.; Wagner, B. D.; Lusztyk, J.; Wayner, D. D. M. J. Am. Chem. Soc. 1995, 117, 119.
- 36 Tanner D. D.; Gidley, G. C. J. Am. Chem. Soc. 1968, 90, 808.
- 37 Schreiner, P. R.; Lauenstein, O.; Butova E. D.; Fokin, A. A. Angew. Chem. Int. Ed. 1999, 38, 2786.
- 38 Fokin, A. A.; Lauenstein, O.; Gunchenko P. A.; Schreiner, P. R. J. Am. Chem. Soc. 2001, 123, 1842.
- 39 Montoro R.; Wirth, T. Org. Lett. 2003, 5, 4729.
- 40 Barluenga, J.; Gonzalez-Bobes F.; Gonzalez, J. M. Angew. Chem. Int. Ed. 2002, 41, 2556; (b)
- 41 Giri, R.; Chen X.; Yu, J.-Q. Angew. Chem. Int. Ed. 2005, 44, 2112.
- 42 Kita, Y.; Tohma, H.; Takada, T.; Mitoh, S.; Fujita, S.; Gyoten, M. Synlett, 1994, 427.
- 43 Viuf, C.; Bols, M. Angew. Chem. Int. Ed. 2001, 40, 623.
- Cambie, R. C.; Hayward, R. C.; Rutledge, P. S.; Smith-Plalmer, T.; Swelland, B. E.; Woodgate, P. D. J. Chem. Soc. Perkin Trans. 1 1979, 180.
- 45 Liu, B.; Shine, H. J. J. Phys. Org. Chem. 2001, 14, 81.
- 46 Eric, F. V.; Turnbull, K. Chem. Rev. 1988, 88, 297.
- 47 Patai, S.; Rappoport, Z. *The Chemistry of Functional Group, Supplement D*; John Wiley & Sons, 1983, chapt. 18, pp. 744.

CHAPTER IV

Palladium-catalyzed Hydrosilylation of Aryl Ketones and Enantioselective Rearrangement of 2-Alkyl Pyridine *N*-oxides and Synthesis of 4-Substituted Chromanes *via* Gold-catalyzed Intramolecular Friedel-Crafts Reaction

Section I

Palladium-catalyzed hydrosilylation of aryl ketones with triethylsilane 4.1.1 Introduction


Reduction of carbonyl and pseudo-carbonyl functions represents a ubiquitous protocol in organic synthesis. Transition-metal catalysis has been successfully applied to the reduction of olefins, alkynes and many carbonyl compounds via hydrogenation or hydrosilvlation.¹ Hydrogenation reactions often proceed in good yields but only under high pressure or elevated temperature. In contrast, since the first report of metal-catalyzed hydrosilvlation of ketones in the presence of Wilkinson's catalyst,² smooth reaction conditions have been devised and in consequence over-reduced products are rarely detected. Recently, hydrosilylation reactions using various metals such as Zn, Fe, Rh, Cu, Re, etc have been reported. Furthermore, asymmetric hydrosilylations with high enantioselectivities have also been well-documented.³ In industry, hydrosilylation has become an appropriate method to produce organosilicon compounds, in particular with respect to the functionalization of polymers.⁴ A general sequence involving hydrosilylation of carbonyl compounds followed by hydrolysis leads to the formation of alcohols, but the silvl group may also be retained as a protecting group, a process that can be of great interest in organic synthesis.⁵ Moreover, a great majority of hydrosilanes employed in this reaction are easy to handle and are economical.

4.1.2 Review of Literature

In literature a wide variety of catalytic systems in combination with different hydrosilanes have been employed to selective reduction of carbonyl functional groups attached to aliphatic and aromatic structures. The discovery of more active catalysts and its asymmetric version has made this process more popular. Some of the recent developments on this reaction are discussed below.

Ojima's approach (1972)⁶


Ojima et al. have reported hydrosilylation of aldehydes and ketones 1 with various hydrosilane and Rhodium(I) complex to give silyl ethers 2 in very high yields (Scheme 1). In case of α,β -unsaturated ketones and aldehydes the corresponding saturated derivatives were obtained in fairly high yields.



<u>Scheme 1</u>: (i) hydrosilane, (Ph₃P)₃RhCl (1 mol %), n-hexane, 25 °C, 93-98%.

Pregosin's approach (1988)⁷


In this approach, the catalyst $PtCl_2(PhCH=CH_2)_2$ was shown to catalyze the hydrosilylation of various ketones **3** with dichloromethylsilane in the presence of pyridine or aniline as co-catalyst to give silyl ethers **4** in 51-98% yield (**Scheme 2**). The authors have observed that the completion of this reaction required more than 24 h.



Scheme 2: (i) $PtCl_2(PhCH=CH_2)$ (aniline), MeCl_2SiH, 25 °C, 24-41 h.

Samuel's approach (1999)⁸


Samuel et al. have reported bis (benzene) chromium as a pre-catalyst for the hydrosilylation of α -aryl carbonyl compounds to give the corresponding silyl ethers in 39-50% yield (**Scheme 3**).



Scheme 3: (i) Bis(benzene)chromium (0.06 mmol), Me₂OEtSiH, PhH, 45 °C, 3 h.

Lee's approach (2002)⁹


Lee et al. have described a catalytic method for the synthesis of silyl ether **8** using Grubbs' Ist generation catalyst ($Cl_2(PCy_3)_2Ru=CHPh$). Silyl ether **8** is thus obtained from the reaction of a variety of silanes by the hydrosilylation of carbonyl compound **7** under neat conditions (**Scheme 4**).



<u>Scheme 4</u>: (i) $Cl_2(PCy_3)_2Ru=CHPh$ (0.5 mol%), Ph_2SiH_2 , neat, 50-80 °C.

Dioumaev's approach (2003)¹⁰


Dioumaev et al. have reported tungsten and molybdenum N-heterocyclic carbene complexes **11** for the hydrosilylation of carbonyl compounds **9** under mild condition accompanied by precipitation of catalysts at the end of reaction. The reaction exhibits good rates, high conversion and excellent selectivity for hydrosilylation (**Scheme 5**).



<u>Scheme 5</u>: (i) ketone, cat,11 (0.2 mol%), Et₃SiH, neat, 23 °C.

Lipshutz's approach (2003)¹¹


Lipshutz *et al.* have developed a simple protocol for the single-flask conversion of dialkyl ketones **12** to the corresponding TES or TBS ethers **13** based on *in situ* generated catalyst i.e. hydrido copper complex (**Scheme 6**).




<u>Scheme 6</u>: (i) CuCl (0.5 mol%), NaOMe, DM-SEGPHOS, (1 mol%), Et₃SiH, Et₂O, 25 °C.

Yun's approach (2004)¹²

Yun *et al.* have used air and moisture stable copper(II) salts to catalyze the hydrosilylation of aromatic ketones **15**.






The combination of catalytic amounts of copper(II) acetate or copper(II) acetate monohydrate and BINAP in the presence of organosilanes as the stoichiometric reducing agent generates an active catalyst for the asymmetric hydrosilylation of ketones (**Scheme 7**).

Gade's approach (2004)¹³

Gade *et al.* have described Rh-catalyzed asymmetric hydrosilylation of ketones by using chiral *N*-heterocyclic carbene as a ligand to give the corresponding alcohol **17** up to 96% ee (**Scheme 8**).




<u>Scheme 8</u>: (i) Rh-cat.18 (1 mol%), $AgBF_4$ (1.2 mol%), Ph_2SiH_2 , CH_2Cl_2 , -60 °C. then K_2CO_3 , MeOH

Andrus's approach (2005)¹⁴

Andrus *et al.* have reported new chiral *bis*-paracyclophane *N*-heterocyclic carbene (NHC)

ligands for ruthenium catalyzed asymmetric hydrosilylation of ketones **19** using diphenyl




<u>Scheme 9</u>: (i) $RuCl_2(PPh_3)_3$ (0.5 mol%), ligand-**21** (1.2 mol %), AgBF₄, Ph₂SiH₂, THF, 25 °C. then HCl, H₂O.

silane to give enantioenriched alcohols **20**. These ligands provide for efficient asymmetric reduction in the presence of silver(I) triflate (1 mol %) at room temperature with high reactivity and selectivity. Acetophenone was reduced with 1 mol % catalyst in 96% isolated yield, 97% ee (**Scheme 9**).

Beller's approach (2008)¹⁵


Beller *et al.* have reported Fe-catalyzed enantioselective hydrosilylation of ketones **22** with various phosphine ligands. Good to excellent enantioselectivities were obtained for electronically rich and sterically hindered aryl ketones. For example, diaryl and dialkyl ketones were converted into the corresponding alcohols **23** in good to excellent enantioselectivities (up to 99% ee) (**Scheme 10**).



Scheme 10: (i) Fe(OAc)₂ (5 mol%), chiral phosphenes (10 mol%), PMHS, THF, 25-100 °C. then NaOH, MeOH


Berke's approach (2009)¹⁶

Berke *et al.* have reported the easily available $[Re(CH_3CN)_3Br_2(NO)]$ rhenium(I) complex that catalyzes the homogeneous hydrosilylation of a great variety of organic carbonyl compounds (ketones and aldehydes). Various aliphatic and aromatic silanes were tested as hydride source. Excellent yields were achieved at 85 °C in chlorobenzene using triethylsilane. The reaction proceeded with TOF values of up to 495 h⁻¹ (Scheme 11).



Nishiyama's approach (2009)¹⁷

Nishiyama *et al.* have reported zinc acetate as an efficient catalyst for hydrosilylation of ketones and aldehydes in combination with (EtO)₂MeSiH to give the corresponding alcohols in 91-99% yield (**Scheme 12**).



<u>Scheme 12</u>: (i) $Zn(OAc)_2$ (5 mol%), (EtO)₂MeSiH, THF, 65 °C then H_3O^+ .

4.1.3 Present Work


4.1.3.1 Objective

In recent years, has been made considerable progress in hydrosilylation of various organic carbonyl compounds. It has become a major tool of synthetic organic chemistry and organosilicon chemistry, thus providing an efficient and versatile access to new organo silicon compounds. There are many methods available in the literature for hydrosilylation of carbonyl compounds using a variety of metal catalysts and hydrosilanes. Moreover, metals such as palladium have not been studied extensively for the hydrosilylation of ketones.¹⁸ In this section, we describe an efficient and selective

method for the hydrosilylation of various aryl ketones catalyzed by palladium using triethylsilane as the hydride source.

4.1.4 Results and Discussion

It has been reported in the literature that the reaction of aryl carbonyl compounds with PdCl₂ as catalyst and triethylsilane in ethanol led to the formation of reduction product namely alkyl arenes.¹⁹ We found however, that when the same reaction was carried out on acetopenone **28a** using DMF as solvent, in the presence of PdCl₂ as catalyst, it took a different course to give the hydrosilylation product **29a** in excellent yield (**Scheme 13**).



<u>Scheme 13</u>: (i) acetophenone (1 equiv), $PdCl_2$ (0.5 mol%) Et₃SiH (1.2 equiv.), DMF, 25 °C, 2 h.

In order to study this catalytic reaction in a systematic manner, several palladium catalysts have been screened with acetophenone as an aryl ketone and the results of such a study are shown in **Table 1**.

effect of c Entry	Catalyst	Yield of 29a (%)
1	Pd(OAc) ₂	98
2	PdCl ₂	90
3	Pd(PhCN) ₂ Cl ₂	94
4	$Pd(dba)_2$	60
5	$Pd(Ph_3P)_4$	95
6	Sulfimine palladacycle (30)	96
7	Saccharine palladium complex	95

Table 1: Palladium-catalyzed hydrosilylation of acetophenone:effect of catalysts^a

	(31)	
9	10%Pd/C	89
10	Pd [(R , R)-BINAP]Cl ₂	80 ^b
11	Pd[(-)-sparteine](OAc) ₂	82 ^b

Reaction conditions: ^a acetophenone (1 mmol), Pd-catalyst (0.5 mol%), Et₃SiH (1.2 mmol), DMF (2 ml), 25 °C, 1 h; ^b no ennantiomeric excess.

All the palladium catalysts screened gave excellent yields of hydrosilylated product **29a**. The maximum yield of silyl ether obtained was with $Pd(OAc)_2$ (98%) whereas $Pd(dba)_2$ (60%) gave the lowest yield. Sulfilimine palladacycle²⁰ **30** and water soluble palladium saccharine compex²¹ **31** (**Fig. 1**) also gave high yields of silyl ethers.




Fig. 1: Structures of palladium catalysts 30 and 31

We also made an attempt to induce chirality in the molecule using different chiral palladium catalysts (entries 10 and 11); unfortunately the reaction did not give any asymmetric induction. The results in **Table 2** show that out of a variety of solvents screened, DMF was found to be more suitable for palladium-catalyzed hydrosilylation of acetophenone. However, when DMF-water (4: 1) or water was employed as solvent,²² phenyl ethanol was obtained as the only product in good yields.

Entry	Solvent	Time (h)	Yield of 29a (%) ^b
1	CH ₂ Cl ₂	20	0
2	CH ₃ CN	6	60
3	Toluene	20	0
4	Water	6	40 ^c
5	DMF- water (4:1)	1	85°
6	DMF	1	98
7	DMF	20 ^d	0
8	DMF	20 ^e	0

Table 2: Palladium acetate catalyzed hydrosilylation ofacetophenone: effect of solvents^a

Reaction condition: ^aacetophenone (1 mmol), $Pd(OAc)_2$ (0.5 mol%), Et_3SiH (1.2 mmol), solvent (2 ml), 25 °C, 1 h; ^bisolated yield; ^c phenylethanol was obtained; ^dPMHS is used as as hydride source; ^e diphenyl silane is used .


When other hydrosilanes such as Ph₂SiH₂, PMHS etc were used as a hydride sources with DMF as solvent, we observed that the reaction failed to give any product.

In order to understand the scope and generality of the reaction, a wide range of aryl ketones was subjected to hydrosilylation under this reaction condition. As can be seen, the method worked exceedingly well with all the aryl ketones employed (**Table 3**). Substrates containing bulky groups, such as tetralone, 9-fluorenone and 2, 2-dimethyl-1-phenylpropan-1-one were converted to the corresponding silyl ethers with excellent yields (entries **e**, **f**, and **i**). In case of chloro substituted aryl ketone (entry **k**), the corresponding dehaloganated silyl ether was obtained in 50% yield. However, we observed that the reaction failed in case of aliphatic ketones **281-m**. This indicates that the

present catalytic system is suitable for selectively hydrosilylating aryl ketones in presence of aliphatic ketones.

Entry	Substrates (28)	Products (29)	Yield (%) ^b
a	O C	OSiEt ₃	98
b	°	OSiEt ₃	95
С		OSiEt ₃	96
d		Et ₃ SiO	96
e		OSiEt ₃	90
f		OSiEt ₃	91
g	MeO	MeO OSiEt ₃	88
h		OSiEt ₃	95
i		OSiEt ₃	95
j	O C	OSiEt ₃	96

Table: 3. Palladium acetate catalyzed hydrosilylation of aryl ketones.^a




Reaction condition: a ketones (1 mmol), Pd(OAc)_2 (0.5mol%), Et_3SiH (1.2 mmol), DMF (2 ml), 25 °C, 1 h ; b isolated yield.

However in case of α,β -unsaturated ketones, reduction of C=C took place giving the corresponding saturated ketones in high yields. A noteworthy feature of this protocol is that when reaction was carried out in DMF-water (4:1) solvent system, the corresponding alcohols **32** were produced in high yields (**Table 4**). Thus, both hydrosilylation and deprotection of the silyl ether were achieved in a single step by using a simple modification of solvent system.

Entry	Substrate	Product (32)	Yield (%) ^b	
			Pd(OAc) ₂	Saccharine- Pd complex
a	o	OH	85	76
b	°	OH	80	75
С	0 I	OH	79	77

Table: 4. Pd-catalyzed hydrosilylation using DMF: H₂O as solvent system.^a



Reaction condition: ^a ketones (1 mmol), Pd-catalyst (0.5 mol%), Et₃SiH (1.2 mmol), DMF: water (1.5:0.5 ml), 25 °C, 2 h ; ^bisolated yield.

The formation of silyl ethers **29a-j** was confirmed by ¹H and ¹³C-NMR spectroscopy. Ex.1: The ¹H NMR spectrum of **29e** showed signals at δ 0.50 (q) and 4.30 (d) for methine (Ph-CH-OSi) and methylene (CH₃-CH₂-Si) protons respectively. Its ¹³C-NMR spectrum showed a typical signal at δ 80.5 due to carbon attached to silyloxy group (**Fig. 2**).




Fig. 2: ¹H and ¹³C NMR spectra of 29e

Example 2: The ¹H NMR spectrum of **29i** displayed signals at δ 0.60 (q) and 5.62 (d) for methine (Ar-CH-OSi) and methylene (CH₃-CH₂-Si) protons. Its ¹³C-NMR spectrum showed a typical signal at δ 75.6 due to carbon attached to silyloxy group (**Fig. 3**).





Fig. 3: ¹H and ¹³C NMR spectra of 29i

4.1.5 Mechanism

The catalytic cycle for the oxidative process is shown in **Scheme 14.** The first step corresponds to the reaction of palladium acetate with Et_3SiH leading to the formation of active metallic Pd(0) entity in the catalyzed reaction.²³ Oxidative addition of Et_3SiH to Pd(0) leads to the formation of Et_3SiPdH complex, which is co-ordinating with aryl carbonyl. Then hydride transfer to aryl carbonyl followed by reductive elimination generate the desired silylated product with liberation of Pd(0).



Scheme 14: Proposed mechanism for Pdcatalyzed hydrosilylation of ketones

4.1.6. Conclusion

In conclusion, we have demonstrated, for the first time, that palladium is a highly effective catalyst for selective hydrosilylation of aryl ketones in DMF at room temperature using triethylsilane as a hydride source. Also we found that benzyl alcohol was obtained in excellent yields, when reaction was performed in DMF: H_2O (4:1) as solvent system in a single step.

4.1.7 Experimental Section

General experimental procedure for the hydrosilylation of aryl ketones

To a 10 mL two-neck round-bottomed flask with a magnetic stir bar was added palladium catalyst (0.5 mol%) in DMF (2.0 mL). To this was added ketones (1.0 mmol) followed by triethylsilane (1.2 mmol). The resulting solution was stirred for 2 h. It was subsequently quenched with water and extracted with EtOAc (3x10 mL) and the organic layer dried over anhyd. Na₂SO₄. The solvent was concentrated under reduced pressure to give the crude product, which was purified by column chromatography (petroleum ether) as eluent to afford the pure **29a-j**.

1-Phenylethoxytriethylsilane (29a)

Yield: 98%; colorless liquid; **IR** (CHCl₃, cm⁻¹): 740, 1094, 1238, 1600, 2952; ¹H NMR (200 MHz, CDCl₃): δ 0.50 (q, J = 8.0 Hz, 6H), 0.85 (t, J = 8.0 Hz, 9H), 1.36, (d, J = 6.6 Hz, 3H), 4.79 (q, J = 6.6 Hz, 1H), 7.12-7.31 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ 4.8, 7.0, 27.5, 70.7, 125.2, 126.8, 128.1, 146.9; **Anal.** Calcd for C₁₄H₂₄OSi requires C, 71.12; H, 10.23. Found: C, 71.18; H, 10.20%.

Benzhydryloxytriethylsilane (29b)

Yield: 95%; colorless liquid; IR (CHCl₃, cm⁻¹): 700, 740, 1064, 1091, 1240, 1276, 1599, 2955; ¹H NMR (200 MHz, CDCl₃): δ 0.55 (q, J = 8.1 Hz, 6H), 0.87 (t, J = 8.1 Hz, 9H), 5.72 (s, 1H), 7.12-7.39 (m, 10H); ¹³C NMR (50 MHz, CDCl₃): δ 5.1, 6.84, 76.6, 126.4, 127.0, 128.1, 145.3; Anal. Calcd for C₁₉H₂₆OSi requires C, 76.45; H, 8.78; Found: C, 76.40; H, 8.88%.

1-p-Tolylethoxytriethylsilane (29c)

Yield: 96%; colorless liquid; ¹**H NMR** (200 MHz, CDCl₃): δ 0.62 (q, J = 7.8 Hz, 6H), 0.89 (t, J = 7.8 Hz, 9H), 1.47 (d, J = 6.3 Hz, 3H), 2.40 (s, 3H), 4.88 (q, J = 6.6 Hz, 1H), 7.15 (d, J = 7.8 Hz, 2H), 7.27 (d, J = 8.1 Hz, 2H); ¹³**C NMR** (50 MHz, CDCl₃): δ 4.8, 6.7, 20.9, 27.2, 70.4, 125.0, 126.6, 135.9, 143.8; **Anal.** Calcd for C₁₅H₂₆OSi requires C, 71.93; H, 10.46; Found: C, 71.88; H, 10.53%.

1-Naphalene-4-ylethoxytriethylsilane (29d)

Yield: 96%; colorless liquid; ¹H NMR (200 MHz, CDCl₃): δ 0.40 (q, J = 7.3 Hz, 6H),
0.73 (t, J = 8.0 Hz, 9H), 1.40, (d, J = 6.6 Hz, 3H), 5.40 (q, J = 6.6 Hz, 1H), 7.22-7.31 (m,
3H), 7.51 (t, J = 7.4 Hz, 2H), 7.65 (d, J = 7.4 Hz, 1H), 7.88 (d, J = 8.3 Hz, 1H); ¹³C
NMR (50 MHz, CDCl₃): δ 4.8, 6.9, 26.7, 68.2, 122.6, 123.2, 125.1, 125.5, 127.3, 128.9,

129.8, 142.5; **Anal.** Calcd for C₁₈H₂₆OSi requires C, 75.46; H, 9.15; Found: C, 75.40; H, 9.16%.

2-Methyl-1-phenylpropoxytriethylsilane (29e)

Yield: 90%; colorless liquid; ¹H NMR (200 MHz, CDCl₃): δ 0.50 (q, J = 7.4 Hz, 6H), 0.75-0.95 (m, 15H), 1.76 (m, 1H), 4.30 (d, J = 6.2 Hz, 1H), 7.19-7.28 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ 5.1, 6.8, 18.3, 19.0, 36.7, 80.5, 126.8, 126.9, 127.7, 144.5; **Anal.** Calcd for C₁₆H₂₈OSi: C, 72.66; H, 10.67; Found: C, 72.60; H, 10.72%.

1,2,3,4-Tetrahydronaphalene-1-yloxytriethylsilane (29f)

Yield: 91%; colorless liquid; ¹H NMR (200 MHz, CDCl₃): δ 0.60 (q, J = 8.1 Hz, 6H),
0.93 (t, J = 8.0 Hz, 9H), 1.58-2.01 (m, 4H), 2.57-2.82 (m, 2H), 4.72 (t, J = 4.3 Hz, 1H)
6.92-7.07 (m, 3H), 7.26-7.29 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 5.4, 7.0, 19.5, 29.1,
33.1, 69.2, 125.1, 126.9, 127.9, 128.5, 136.6, 139.8; Anal. Calcd for C₁₆H₂₆OSi C, 73.22;
H, 9.98; Found: C, 73.28; H, 9.82%.

1-(4-Methoxyphenyl)ethoxytriethylsilane (29g)

Yield: 96%; colorless liquid; **IR** (CHCl₃, cm⁻¹): 740, 1097, 1240, 1597, 2968; ¹**H NMR** (200 MHz, CDCl₃): δ 0.55 (q, J = 8.1 Hz, 6H), 0.91 (t, J = 8.1 Hz, 9H), 1.40 (d, J = 6.3 Hz, 3H), 3.70 (s, 3H), 4.80 (q, J = 6.3 Hz, 1H), 6.82 (d, J = 8.8 Hz, 2H), 7.22 (d, J = 8.8 Hz, 2H); ¹³**C NMR** (50 MHz, CDCl₃): δ 5.1, 6.8, 25.0, 55.6, 69.9, 113.8, 126.6, 137.9, 158.9; **Anal.** Calcd for C₁₅H₂₆O₂Si requires C, 67.61; H, 9.84; Found: C, 67.59; H, 9.90%.

2,3-Dihydro-1H-inden--3-yloxytriethylsilane (29h)

Yield: 95%; colorless liquid; ¹**H NMR** (200 MHz, CDCl₃): δ 0.70 (q, *J* = 8.0 Hz, 6H), 1.03 (t, *J* = 8.0 Hz, 9H), 1.83-2.02 (m, 1H), 2.33-2.48 (m, 1H), 2.67-2.79 (m, 1H), 2.943.06 (m, 1H), 5.24 (t, *J* = 6.8 Hz, 1H) 7.18-7.23 (m, 3H), 7.29-7.37 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 5.4, 7.0, 19.5, 33.1, 69.3, 125.1, 126.9, 127.9, 128.5, 136.6, 139.8; **Anal.** Calcd for C₁₅H₂₄OSi requires C, 72.52; H, 9.74. Found: C, 72.48; H, 9.78%.

9H-Fluoren-9-yloxytriethylsilane (29i)

Yield: 95%; colorless liquid; ¹H NMR (200 MHz, CDCl₃): δ 0.60 (q, J = 7.8 Hz, 6H), 0.93 (t, J = 8.1 Hz, 9H), 5.62 (s, 1H), 7.17-7.31 (m, 4H), 7.52 (dd, J = 9.7, 6.6 Hz, 4H); ¹³C NMR (50 MHz, CDCl₃): δ 5.5, 6.9, 75.6, 119.8, 124.9, 127.4, 128.5, 139.9, 146.1; Anal. Calcd for C₁₉H₂₄OSi requires C, 76.97; H, 8.16. Found: C, 76.90; H, 8.20%.

1-Phenylpropoxytriethylsilane (29j)

Yield: 96%; colorless liquid; ¹**H NMR** (200 MHz, CDCl₃): δ 0.55 (q, J = 7.4 Hz, 6H), 0.87-0.94 (m, 12H), 1.63-1.81 (m, 2H), 4.58 (t, J = 6.5 Hz, 1H), 7.12- 7.51 (m, 5H); ¹³**C NMR** (50 MHz, CDCl₃): δ 5.1, 6.8, 9.9, 33.7, 76.3, 126.0, 126.9, 128.0, 145.6; **Anal.** Calcd for C₁₅H₂₆OSi requires C, 71.93; H, 10.46. Found: C, 71.98; H, 10.40%.

General experimental procedure for the hydrosilylation of aryl ketones in DMFwater:

To a 10 mL two-neck round-bottomed flask with a magnetic stir bar was added palladium catalyst (0.5 mol%) in DMF: water (1.5: 0.5 mL). To this was added ketones (1.0 mmol) followed by triethylsilane (1.2 mmol). The resulting solution was stirred for 2 h. It was subsequently quenched with water, extracted with EtOAc (3x10 mL) and dried over anhyd. Na₂SO₄. The solvent was concentrated under reduced pressure to give the crude product, which was purified by column chromatography (silica gel, pet. ether) as eluent to afford the pure alcohols **32a-e**.

1-Phenylethanol (32a)

Yield: 85%; colorless liquid; **IR** (Neat, cm⁻¹): 669, 761, 907, 1078, 1204, 1461, 1493, 2973, 3029, 3365; ¹**H-NMR** (200 MHz, CDCl3): δ 1.42 (d, *J* = 6.31 Hz, 3H); 2.55 (br s, 1H); 4.79 (q, *J* = 6.31 Hz, 1H); 7.21- 7.3 (m, 5H); ¹³**CNMR** (50 MHz, CDCl₃): δ 24.9, 69.8, 125.2, 127.0, 128.1, 145.8; **Anal.** Calcd for C₈H₁₀O requires C, 78.65; H, 8.25; found: C, 78.62, H, 8.38 %.

1-(4-Methylphenyl)ethanol (32b)

Yield: 80%; colorless liquid; **IR** (CHCl₃, cm⁻¹): 895, 1010, 1070, 1360, 1435, 1510, 2920, 3150, 3500; ¹H-NMR (200 MHz, CDCl₃): δ 1.47 (d, J = 7.4 Hz, 3H), 2.1 (br s, 1H), 2.41 (s, 3H), 4.84 (q, J = 7.4 Hz, 1H), 7.15 (d, J = 9.2 Hz, 2H), 7.25 (d, J = 9.2 Hz, 2H); ¹³C-NMR (50 MHz, CDCl₃): δ 20.9, 24.8, 69.9, 125.2, 128.94, 136.7, 142.8; **Anal.** Calcd for C₉H₁₂O requires C, 79.37; H, 8.88 %; found: C, 79.32; H, 8.81%.

1-Phenylpropanol (32c)

Yield: 89%; colorless liquid; **IR** (CHCl₃, cm⁻¹): 764, 975, 1014, 1097, 1454, 1494, 2877, 2934, 2966, 3030, 3339; ¹**H-NMR** (200 MHz, CDCl₃): δ 0.89 (t, *J* = 7.3 Hz, 3H), 1.64 – 1.85(m, 2H), 2.22 (br s, 1H), 4.55 (t, *J* = 6.8 Hz, 1H), 7.31 (m, 5H); ¹³**C-NMR** (50 MHz, CDCl₃): δ 9.8, 31.5, 75.4, 125.8, 127.0, 128.0, 144.4; **Anal.** Calcd for C₉H₁₂O requires C, 79.37; H, 8.88%; found: C, 79.47; H, 8.90%.

1-Naphthylethanol (32d)

Yield: 90%; colorless solid mp: 50 °C; **IR** (CHCl₃, cm⁻¹): 1010, 1056, 1108, 1168, 1218, 1256, 1328, 1374, 1445, 1509, 1597, 3011; ¹**H-NMR** (200 MHz, CDCl₃): δ 1.48 (d, J = 6.2 Hz, 3H); 3.01 (s, 1H); 5.40 (q, J = 6.2 Hz, 1H); 7.31- 7.90 (m, 7H); ¹³CNMR (50

MHz, CDCl₃): δ 24.1, 66.2, 121.7, 122.9, 124.9, 125.1, 125.3, 127.2, 128.4, 129.9, 133.4,

141.2; Anal. Calcd for C₁₂H₁₂O requires C, 83.69; H, 7.02; found: C, 83.60, H, 7.10%.

Diphenylmethanol (32e)

Yield: 86% ; **IR** (CHCl₃, cm⁻¹): 705, 750, 770, 1020, 1190, 1280, 1380, 1460, 3200 - 3300; ¹**H-NMR** (200 MHz, CDCl₃): δ 2.11 (br s, 1H), 5.79 (s, 1H), 7.22-7.35 (m, 10H); ¹³**C-NMR** (50 MHz, CDCl₃): δ 76.0, 126.5, 127.4, 128.3, 143.8; **Anal.** Calcd for C₁₃H₁₂O requires C, 84.75; H, 6.57 %; found: C, 84.70; H, 6.67%.

Section II Enantioselective rearrangement of 2-alkyl pyridine *N*-oxides

4.2.1 Introduction

Optically active pyridyl alcohols are useful key compounds, not only as pharmaceutical intermediates,²⁴ but also as chiral ligands²⁵ and auxiliaries in asymmetric synthesis.²⁶ Although there have been many reports on the synthesis of this important class of compounds by means of asymmetric alkylation to pyridyl aldehydes, stoichiometric or catalytic asymmetric reduction of acetyl pyridines and enzymatic resolution of racemic pyridyl alcohols. An interesting and productive way to improve synthetic efficiency, which can give access to a multitude of Csp3 chiral compounds, is to take a new look at poorly exploited and old pioneer reactions using current knowledge of organic chemistry. In this manner, we re-investigated the so-called Boekelheide rearrangement with the aim of obtaining an asymmetric version of the reaction, and in this way expand the available tools for accessing at enantiomerically enriched 1-(2-pyridinyl) alkyl alcohol derivatives.


4.2.2 Review of Literature

Literature search revealed that there are various methods available for the preparation of optically active pyridyl alcohols. These methods involve the reduction of acetyl pyridines, asymmetric alkylation to pyridyl aldehydes and enzymatic resolution. Some of the important developments for the synthesis of optically active pyridyl alcohols are discussed below.

Soai's approach (1987)²⁷

Soai *et al.* have reported an enantioselective reduction of acetyl pyridines using chiral lithium borohydride (LiBH₄) modified with N,N'-dibenzoylcystine and ethanol. When


2,3,4-acetylpyridine 33 was reduced with LiBH₄-(*R*,*R*)-(*N*,*N*'-dibenzoylcystine)-EtOH,
(*R*)-1,2,3-pyridy ethanols 34 was obtained in 56-87% ee (Scheme 15).



<u>Scheme 15</u>: (i) *N*,*N*'-dibenzoylcystine, LiBH₄, EtOH, THF, -78 °C.

Bolm's approach (1990)²⁸


Bolm *et al* have found that (-)- β -chlorodiisopinocampheylborane as an extremely efficient reducing reagent for the conversion of pyridyl ketone **35** to the corresponding pyridyl alcohol **36** (**Scheme 16**).



<u>Scheme16</u>: (i) (-)- β -chlorodiisopinocampheylborane, EtOH, THF, 25 °C then imino diehanol, Et2O, 3 h.

Hosino's approach (1994)²⁹

Hosino et al have developed an asymmetric addition of dialkylzinc to pyridine-2-, 3-, and




<u>Scheme 17</u>: (i) Et₂Zn (1.5 equiv), L* **38** (5 mol%), toluene: hexane (1:1), 25 °C.

4-carboxaldehydes and 6-bromo-2-carboxaldehyde **37** in the presence of tridentate chiral pyridylalkanol **38.** Optically active pyridylpropanol **39** were synthesized in good to high ee (**Scheme 17**).

Norin's approach (1994)³⁰


Norin *et al* have described the preparation of chiral 1,2,3-pyridinylethanols **40** with high enantiomeric purity (up to 99%) by lipase catalyzed transesterification of racemic 1, 2,3-pyridinylethanols **41** with ethylthiooctanoate **42** (**Scheme 18**).



Scheme 18:(i) ethyl thiooctanoate, lipase (component B), 39 °C.

Uenishi's approach (1998)³¹


Uenishi *et al* have reported the resolution of racemic 1-(2-pyridyl)ethanols **44** by lipasecatalyzed asymmetric acetylation with vinyl acetate. The reactions were carried out in diisopropyl ether at either room temperature or 60 °C using *Candida Antarctica* lipase (CAL) to give (R)-acetate **45** and unreacted (S)-alcohol **46** with excellent enantiomeric purities in good yields (**Scheme 19**).



<u>Scheme 19</u>: (i) vinyl acetate, *Candida Antarctica* lipase (CAL), *i*-Pr₂O, 25 °C.

Ikariya's approach (2000)³²


Ikariya *et al* have reported chiral Ru(II) complex, RuCl[(S,S)-N-(p-toluenesulfonyl)-1,2diphenylethylenediamine](p-cymene), **47** serves as an efficient catalyst for asymmetric transfer hydrogenation of 2-acetylpyridine **48** with HCO₂H as a hydrogen source to give (S)-1-(2-pyridyl)ethanol **49** in an almost quantitative yield and with 95% ee (**Scheme 20**).



Scheme 20: (i) (*S*,*S*)-Ru cat (47), HCO₂H, Et₃N, 27 °C.

Sheldrake's approach (2002)³³

Sheldrake *et al* have used *Pseudomonas putida* UV4 biocatalyst for the reduction of 2-, 3- and 4-acylpyridines **48** to afford the corresponding (*S*)-1-pyridyl alkanols **49**, with moderate to high ee (**Scheme 21**). In contrast, the toluene dioxygenase enzyme in the same organism catalyses the hydroxylation of 2- and 3-alkylpyridines **50** to (*R*)-1-(2-pyridyl) and (*R*)-1-(3-pyridyl)alkanols **49**.




Scheme 21: (i) Pseudomonas putida UV4

This combination of oxidative and reductive biotransformation thus provides a method for preparing both enantiomers of chiral 1-pyridyl alkanols using one biocatalyst.

Pfaltz's approach (2006)³⁴

In this approach, Cu(II)(borabox)-catalyst **51** has been used for kinetic resolution of pyridyl alcohols **52**. Both the optically active pyridyl alcohol derivative **53** and **54** were synthesized in good to high ee (**Scheme 22**).




<u>Scheme 22</u>: (i) CuCl₂ (1 mol%), L* **51** (1 mol%), PhCOCl (0.51 equiv), *i*-PrNEt₂, CH₂Cl₂, 0 °C, 16 h.

The rearrangement of 2-alkyl pyridine *N*-oxides (Boekelheide reaction) using an acylating agent followed by saponification which gave pyridyl alcohol has also been reported in the literature as described below.


Boekelheide reaction

The modification of the Katada reaction,³⁵ first reported by Boekelheide,³⁶ is a well established and frequently used procedure in heterocyclic chemistry for the introduction of oxygen on an alkyl group α to a ring nitrogen atom (Scheme 23).




Scheme 23: (i) acetic anhydride, reflux; ii) con. HCl, reflux, 10 h.

Under the classical conditions, the heterocyclic N-oxide **55** is heated with a large excess of acetic anhydride to give, after hydrolysis, the desired pyridyl alcohol **56** in good yield. In 1985, McKillop *et al.*³⁷ have reported a detailed study of the different parameters that control the product distribution in this reaction. They demonstrated that the use of a mixture of acetyl chloride and acetic anhydride in the Boekelheide reaction provides a convenient acylating agent. Fontenas *et al*³⁸ have reported Boekelheide reaction using trifluoroacetic anhydride (TFAA) as an acylating agent followed by saponification which gave pyridyl alcohol in good yield at room temperature (**Scheme 24**).



Quite recently Spada et al³⁹ have reported the first example of asymmetric Boekelheide rearrangement applied to a set of 2-alkylpyridine N-oxide derivatives **59** using (*R*) Mosher's acyl chloride as activator of the rearrangement to give, after hydrolysis, enantiomerically enriched 1-(2-pyridinyl)alkyl alcohol **61**. Diastereoselectivity of the process was studied at low temperatures in different solvents, and was supported by a preliminary in silico modeling.



Scheme 25: (i) (*R*)-Mosher's acyl chloride (2 equiv), ethyl acetate, -78 °C, 8 h; ii) LiOH, THF/water, 70 °C.


4.2.3 Present Work

4.2.3.1 Objective

From the above discussion, it is clear that most of the reported methods for the synthesis of chiral pyridyl alcohols involve enzymatic resolution and reduction of 2-acetyl pyridine with expensive metal complexes. The asymmetric version of Boekelheide reaction is an alternative method for the synthesis of chiral pyridyl alcohols. Hence, a practical rearrangement of 2-alkyl pyridine N- oxides (Boekelheide reaction), which should involve inexpensive and easily available reagents is desirable. Therefore, we have decided to explore rearrangement of 2-alkyl pyridine N-oxides (Boekelheide reaction) using acid chloride as an acylayting agent with chiral bases.

4.2.4 Results and Discussion

Initially, 2-benzylpyridine N-oxide **57b** was treated with acetyl chloride (1.0 equiv) in presence of (-)- sparteine (1.0 equiv) that produced 2-alkylpyridyl ester, which underwent in situ hydrolysis to give chiral 2-benzylpyridyl alcohol **58b**, in 80% yield with 6% ee (**Scheme 26**).



Scheme 26: (i) CH₃COCl (1 equiv), (-)- sparteine, CH₂Cl₂, 0 $^{\circ}$ C, 4h; (ii) LiOH, THF: water (4: 1), 25 $^{\circ}$ C.

This prompted us to explore the effectiveness of chiral bases in the rearrangement of 2alkyl pyridine N- oxides. To increase the enantiomeric excess, we have screened a variety

No.	R (57a-b)	Acylating	Base	Yield (%) ^b	ee(%) ^c
		agent			
1	Ph	CH ₃ COCl	(-)- sparteine	80	06 (<i>R</i>)
2	Ph	C ₆ H ₁₁ COCl	(-)- sparteine	81	17 (<i>R</i>)
3	Ph	C ₆ H ₅ COCl	(-)- sparteine	70	16 (<i>R</i>)
4	Ph	Me ₃ CCOCl	(-)- sparteine	80	14 (<i>R</i>)
5	Ph	$(CH_3CO)_2O$	(-)- sparteine	75	0
6	Ph	(CF ₃ CO) ₂ O	(-)- sparteine	87	0
7	Ph	CH ₂ =CHCOCl	(-)- sparteine	80	10 (<i>R</i>)
8	CH ₃	C ₆ H ₁₁ COCl	(-)- sparteine	70	5 (<i>R</i>)
9	Ph	C ₆ H ₁₁ COCl	(DHQ) ₂ PYR	50	10 (<i>S</i>)
10	Ph	C ₆ H ₁₁ COCl	(-) - nicotine	65	4 (<i>S</i>)
11	Ph	C ₆ H ₁₁ COCl	hydroquinidine	46	0
12	Ph	(R)-CH ₃ CH-	Et ₃ N	70	5 (<i>S</i>) (15) ^d
		(OCH ₂ Ph)COCl			

of acid chlorides and chiral bases. The results of which are presented in **Table 5**.

Table 5: Rearrangement of 2-alkyl pyridine N-oxides: effect of acid chloride and base^a

Reaction condition: ^a Pyridine N-oxide (1 mmol), RCOCl (1.2 mmol), Base (1 mmol), CH₂Cl₂ (4 mL) 0 °C, (ii) LiOH (2.0 mmol) THF: water (4 :1), 25 °C, 4 h, ^b isolated yield; ^c optical rotation is compared with literature values ^d reaction was carried out at -60 °C.

The results in **Table 5** show that out of a variety of acylating reagents (entry **1-8**) screened, we have found that cyclohexylcarboxyl chloride (17%) and benzoyl chloride (16%) gave highest enantiomeric excess when carried out in presence of (-)-sparteine as a chiral base at 0 °C. With the cyclohexylcarboxyl chloride as acylating reagent, we have screened various chiral bases such as $(DHQ)_2PYR$ (10% ee), (-)-nicotine (4% ee) and hydroquinidine, (poor % ee) (entries **9-12**). Alternatively, chiral acid chloride (entry **12**)

was also studied in presence of triethyl amine as a base but low induction (5% ee only) was observed at 0 °C. Hence, in order to improve % ee, we have carried out the same reaction at -60 °C which gave % ee upto 15. Hence, we thought of lowering of the temperature of the system to see its effects on % ee (**Table 6**).

Accordingly, 2-alkyl pyridine N- oxide was subjected to Boekelheide reaction at -78 °C by using cyclohexylcarboxyl chloride and (-)-sparteine as acylating agent and chiral base respectively. We found that a slight improvement in % ee was observed (entry 1). Finally, in order to increase the ee, we have carried out the same reaction in presence various Lewis acids (20%) at -78 °C and the results are shown in **Table 6** (entry **3-12**). As can be seen from **Table 6**, when the Lewis acids such as BF₃.OEt₂ (26% ee), LiCl (27% ee), LaCl₃-7 H₂O (36% ee), TBSCl (25% ee) and TiCl₄ (34% ee), pyridyl alcohol was produced in 50-79% yield with reasonably good ee. However, when TMSCl was employed as Lewis acid (entries **4** and **7**), 2-benzyl and 2-ethyl pyridyl alcohols were obtained in 80 and 70% yields with 50% ee and 18% ee respectively.

Table 6: Rearrangement of	f 2-alkyl pyridine	N-oxides:screening of Lewis acids at -7	$78 ^{\circ}\mathrm{C}^{\mathrm{a}}$
---------------------------	--------------------	---	---------------------------------------

Entry	R	Lewis Acid	Yield(%) ^b	ee(%) ^c
1	Ph	-	80	25 (R)
2	Ph	-	80	$23(R)^d$
3	Ph	BF ₃ -OEt ₂	65	26 (R)
4	Ph	TMSCl	80	50 (R)
5	Ph	TMSCl	65	$34(R)^{e}$
6	Ph	TMSCl	75	$44(R)^{d}$
7	CH_3	TMSCl	70	18(R)
8	Ph	LiCl	60	27 (R)
9	Ph	LaCl ₃ -7H ₂ O	50	36 (R)

10	Ph	TBSCl	79	25(R)
11	Ph	$B(OCH_3)_3$	60	38(R)
12	Ph	TiCl ₄	66	34(R)

Reaction condition: ^a (i) pyridine N-oxide (1 mmol), cyclohexyl carboxyl chloride (1.2 mmol), (-)-sparteine (1 mmol), Lewis acid (20 mol%), CH₂Cl₂ (4 mL) -78 °C; (ii) LiOH (2.0 mmol) THF: water (4 :1), 25 °C, 4 h, ^b isolated yield; ^c optical rotation compared with literature; ^d benzoyl chloride was used; ^e acroyl chloride was used.

The starting materials namely 2-alkyl pyridine N-oxides **57a-b** were prepared by known procedure.³⁶ The formation of 2-alkyl pyridine N-oxides **57a-b** was confirmed by ¹H and ¹³C-NMR spectroscopy. The ¹H NMR spectrum of **57b** showed a typical signal at δ 4.25 (s) for methylene (Py-CH₂-Ph) proton. Its ¹³C-NMR showed a typical signal at δ 151.6 due to quaternary carbon attached to nitrogen atom in pyridine ring (**Fig. 4**)




Fig. 4: ¹H and ¹³C NMR spectra of N-oxide 57b

The formation of the products namely 2-alkyl pyridyl alcohols **58a-b** was confirmed by ¹H and ¹³C-NMR spectroscopy. The ¹H NMR spectrum of **58b** showed a signal at δ 5.72 (s) for methine (Py-CH -OH) proton. Its ¹³C-NMR showed a typical signal at δ 74.9 due to carbon attached to hydroxyl group (**Fig. 5**)





Fig. 5: ¹H and ¹³C NMR spectra of pyridyl alcohol 58b

4.2.5 mechanism

Despite much research, the mechanism of the rearrangement has not been fully understood and remains controversial.⁴⁰ The most common and accepted explanation is that of an ion-pair mechanism (**Scheme 27**) proposed by Oae⁴¹ and Katritzky.⁴² However, we cannot exclude the possibility that other mechanisms such as a hetero-Claisen

rearrangement, in relation to the nature of the substrate, could contribute to the Boekelheide rearrangement.



<u>Scheme 27</u>: Mechanism for rearrangement of pyridine N-oxide (Boekelheide reaction).

4.2.6. Conclusion

We have made an attempt to develop an enantioselective rearrangement of 2-alkyl pyridine N-oxide to give 2-pyridyl alcohols. However the best result obtained was up to 50% enantiomeric excess achieved using (-)-sparteine as the base in the presence of trimethyl silyl chloride as Lewis acid at -78 °C.

4.2.7 Experimental Section

General experimental procedure for synthesis of 2-alkyl pyridine N-oxide (57a-b):

The mixture containing 2-alkyl pyridine (0.13 mole), hydrogen peroxide (33.5 mL, 30%) and glacial acetic acid (90 mL) was heated at 70-80 °C for 24 h. After reaction was complete acetic acid was distilled off under reduced pressure. The residue was taken in chloroform (150 mL), washed with aq. sodium carbonate (4x100 mL) and the solvent concentrated under reduced pressure to give the crude product. It was then purified by column chromatography (packed with silica gel 60-120 mesh) using ethyl acetate/ methanol as eluents to afford the pure products **57a-b**.

2-Ethylpyridine N-oxide (57a)

Yield: 93%; yellow gum; **IR** (CHCl₃, cm⁻¹): 799, 1441, 1477, 1601, 2848, 2958, 3007; ¹**H NM**R (200 MHz, CDCl₃) δ 1.32 (t, *J* = 6.0 Hz, 3H), 2.95 (q, *J* = 7.0 Hz, 2H), 7.17-7.24 (m, 3H), 8.25 (d, *J* = 8.0 Hz, 1H); ¹³**C NMR** (50 MHz, CDCl₃): δ 10.5, 23.65, 123.5, 124.6, 126.0, 139.3, 153.4; **Anal.** Calcd for C₇H₉NO requires C, 68.27; H, 7.37; N, 11.37; found: C, 68.30; H, 7.40; N, 11.30%.

2-Benzylpyridine N-oxide (57b)

Yield: 95%; pale yellow solid **m.p.:** 98-100 °C; **IR** (CHCl₃, cm⁻¹): 790, 1445, 1475, 1601, 2849, 2958, 3008; ¹H NMR (200 MHz, CDCl₃) δ 4.25 (s, 2H), 6.86-6.94 (m, 1H), 7.08-7.15 (m, 2H) 7.26-7.40 (m, 5H), 8.26-8.30 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 26.2, 123.2, 124.8, 125.4, 126.7, 128.5, 129.4, 136.0, 139.0, 151.6; **Anal.** Calcd for C₁₂H₁₁NO requires C, 77.81; H, 5.99; N, 7.56; found C, 77.72; H, 6.01; N, 7.50%.

General experimental procedure for rrearrangement of 2-alkyl pyridine N-oxide:

To a solution of 2-alkyl pyridine N-oxide (1.0 mmol) and chiral base (1.0 mmol) in dry dichloromethane (4 mL) under nitrogen at -78 °C was added Lewis acid (20 mol%) followed by acyl chloride (1.0 mmol) drop-wise. The resulting reaction mix was stirred at the same temperature for 4 h. After completion of reaction (monitored by TLC), it was concentrated to dryness and the solid residue is dissolved in THF: water (8: 2 mL) and hydrolyzed with LiOH (2.0 mmol) after vigorously stirring for 4 h. Reaction mixture was subsequently extracted with ethyl acetate then dried over anhyd. Na₂SO₄ and concentrated under reduced pressure to give the crude product, which was purified by column chromatography (ethyl acetate, pet. ether) as eluent to afford the alcohols **58a-b**.

1-Pyridin-2-yl-ethanol (58a)

Yield: 93%; colorless oil; $[\alpha]^{25}{}_{D} = -5.2 (c \ 1, CHCl_3) \{ \text{lit.}^{32} [\alpha]_{D}^{25} -27.6, (c \ 0.71, CHCl_3) \};$ IR (CHCl₃, cm⁻¹): 796, 1077, 1403, 1440, 1588, 2857, 2978, 3067 3230; ¹H NMR (200 MHz, CDCl₃) δ 1.50 (d, J = 6.4 Hz, 3H), 3.97 (br s, 1H), 4.85 (q, J = 6.4 Hz, 1H), 7.17–7.25 (m, 1H), 7.28 (d, J = 8.4 Hz, 1 H), 7.63–7.71 (m, 1 H), 8.51 (d, J = 4.0 Hz, 1 H); ¹³C NMR (50 MHz, CDCl₃): δ 22.2, 70.8, 121.0, 122.1, 138.7, 143.8, 162.1; Anal. Calcd for C₇H₉NO requires C, 68.27; H, 7.37; N, 11.37; found: C, 68.30; H, 7.40; N, 11.30%.

1-Phenyl(pyridin-2-yl)methanol (58b)

Yield: 95%; white solid **m.p**: 70-73 °C; $[\alpha]^{25}{}_{D} = -80.0 (c \ 1, \text{CHCl}_3) \{\text{lit.}^{43} \ [\alpha]_{D}^{22} - 158.0, (c \ 0.51, \text{CHCl}_3)\};$ **IR** $(CHCl_3, cm⁻¹): 795, 1078, 1405, 1445, 1585, 1601, 2857, 2978, 3070, 3232; ¹H$ **NM** $R (200 MHz, CDCl_3) <math>\delta$ 5.29 (br s, 1H), 5.73 (s, 1H), 7.11-7.39 (m, 7H), 7.60 (td, J = 7.2, 1.6 Hz,1H), 8.55 (d, J = 5.0 Hz, 1H); ¹³C **NMR** (50 MHz, CDCl_3): δ 74.9, 121.2, 122.2, 126.9, 127.6, 128.4, 136.7, 143.1, 147.6, 161.1; **Anal.** Calcd for C₁₂H₁₁NO requires C, 77.81; H, 5.99; N, 7.56; found: C, 77.73; H, 6.06; N, 7.53%.

Section III

Synthesis of 4-substituted chromanes *via* gold-catalyzed intramolecular Friedel-Crafts reaction of 3-aryloxy benzyl alcohols

4.3.1 Introduction


The structures of chromane and benzopyrane are abundant in natural products that possess a broad array of biological activities such as antimicrobial, antiviral, mutagenicity, antiproliferative, sex pheromone, antitumor, and central nervous system activity.⁴⁴ Organic transformations catalyzed by gold have been the focus of attention recently.⁴⁵ Generally gold(I) and gold(III) show unique activity in mediating reactions involving alkynes. In contrast, gold-catalyzed arene functionalization has been given scant attention. Such processes could provide efficient ways to construct C-C bonds from simple arene substrates. Alkylation of aromatic groups is typically achieved with Friedel-Crafts reactions.⁴⁶ In this section we have described a new method of synthesis of 4-aryl substituted chromanes by using gold (III) chloride-catalyzed intramolecular Friedel-Crafts reaction of 3-aryloxy benzyl alcohol.

4.3.2 Review of Literature

Literature search reveals that there are several reports available for the synthesis of chromane derivatives. Some of these methods are briefly discussed below.

Rindfusz's approach (1920)⁴⁷


Rindfusz *et al.* have reported a dehydration of hydroxyl or bromo -alkyl-aryl ether **64** by using $ZnCl_2$ or P_2O_5 to give chromane **65** with 10-50% yield. This method requires high temperature and stoichiometric amount of Lewis acids (**Scheme 28**).



Scheme 28: (i) ZnCl₂ or P₂O₅, 235 °C, 10- 50%.

Bradsher's approach (1981)⁴⁸


Bradsher *et al.* have found that the addition of butyl lithium at -100 °C to 3-(obromophenoxy) propyl bromides **66** led to preferential exchange of the aryl bromine at the ortho position. The resulting organolithium reagent, under suitable conditions, cyclized to afford 3,4-dihydro-2H-1-benzopyrans **67** in 79-80% yields (**Scheme 29**).



<u>Scheme29</u>: (i) BuLi (2 equiv), THF, -100 °C, 2 h, 79-80%.

Yamamoto's approach (1995)⁴⁹

Yamamoto *et al.* have reported AlCl₃–tetralkylammonium halide complex as a catalyst in Friedel-Crafts alkylation using trimethylhydroquinone **68** and myrcene **69** to give the




<u>Scheme 30</u>: (i) AlCl₃, Bu₄NBr, 25 °C, 94%.

chromane compound **70** as a major product (**Scheme 30**). This reagent system may expand the use of Lewis acid catalyst in a non polar solvent system and may be applicable to a wide range of reaction.

Trost's approach (2003)⁵⁰


Trost *et al.* have described the application of Pd-catalyzed asymmetric allylic alkylation reaction of phenol allylic carbonates **71** to the synthesis of chiral chromans **72**. The authors have observed the remarkable influence on enantioselectivity by acetic acid as an additive and by the olefin geometry of the substrates (**Scheme 31**).



 $\underline{\textbf{Scheme 31}}{:}(i) \ Pd_2dba_3 \ (2 \ mol\%), \ L* \ \textbf{73} \ (6 \ mol\%), \ AcOH, \ CH_2Cl_2.$

He's approach (2004)⁵¹

He *et al.* have found that chromanes can be synthesized in good yields with the use of gold(III)-catalyzed functionalization of aromatic C-H with primary alcohol triflate or methanesulfonate esters **74** to construct C-C bonds (**Scheme 32**).




<u>Scheme 32</u>: (i) AuCl₃/3Ag(OTf) (5 mol%), ClCH₂CH₂Cl, 128 °C, 48 h, 15-93%.

The mechanistic studies indicate the involvement of the aryl gold(III) species as the reaction intermediate. This intermediate then reacts with the sulfonate ester to give the final product.

Zanda's approach (2005)⁵²


Zanda *et al.* have developed two step approach for synthesis of 4-arylbenzopyrans, **77** exploiting the synthetic potential of ortho-*N*-methylformamidophenylsulfoxides **76**. The authors have observed that the synthesis of ortho-*N*-methylformamidophenylsulfoxides requires more number of steps (**Scheme 33**).



<u>Scheme 33</u>: (i) Tf₂O, TMP, CH₂Cl₂, -78 °C.

Kim's approach (2010)⁵³

Kim *et al.* have reported a novel synthetic method using ionic liquids (ILs) for a sixmembered ring closure cyclization (Scheme 34).



Scheme 34: (i) [bmim][BF₄], 150 °C, 24-48 h.

The ring closure cyclization by nucleophilic C-alkylation was achieved with various halo and alkanesulfonyloxyalkyl aromatic compounds **74** in high yields with minimal byproducts using ILs as the reaction media in the absence of any catalyst.

4.3.3 Present Work

4.3.3.1 Objective

From the above discussion, it is clear that most of the reported methods are run under harsh conditions with high concentration of Lewis acids, which can hardly be tolerated by many functional groups. Given the importance of these valuable chromanes as well as the lack of efficient methods for the preparation of these important active agents, development of a new catalytic synthesis of these compounds appears to be of great importance. In this section, we describe a novel AuCl₃-catalyzed synthesis of 4substituted chromanes from 3-aryloxy benzyl alcohol by the Friedel-Crafts type intramolecular cyclization of 3-aryloxy benzyl alcohols.

4.3.4. Results and Discussion

3-Aryloxy benzyl alcohols **78**, precursors for the synthesis of 4-substituted chromanes, were readily prepared by employing nucleophilic substitution of phenols on 3-hydroxy-3-phenyl propyltosylate **79** using sodium hydride as a base (**Table 7**).⁵⁴ As can be seen from **Table 7**, a variety of phenols underwent nucleophilic substitution with tosylates **79** to give the corresponding 3-aryloxy benzyl alcohols **78a-g** in excellent yields. The formation of 3-Aryloxy benzyl alcohols **78a-g** was confirmed by ¹H and ¹³C-NMR spectroscopy.

OH


Ph	∕OTs + ArOH	→ Ph O
79	(i) NaH (1 mmol), DMF, 8	78 Ar 0 °C, 5h
Entry	Ar	Yield of 78 (%) ^b
a	α-Naphthyl	98
b	4-Methylphenyl	98
c	Phenyl	96
d	β-Naphthyl	97
e	4-Chlorophenyl	93
f	4-Cyanophenyl	90
g	cesamoyl	93

 Table 7: Synthesis of 3-aryloxy benzyl alcohols (78)^a

OH

Reaction conditions: ^a 3-hydroxy-3-phenyl propyltosylate (1 mmol), NaH (1 mmol), phenol (1 mmol), DMF (10 mL) 80 °C, 5h; ^b yields refer to isolated yields after column chromatography.

The ¹H NMR spectrum of **78a** showed signals at δ 4.09-4.23 (m, 1H) and 4.28-4.39 (m, 1H), for methylene (-CH₂-OAr) proton. Its ¹³C-NMR showed a typical signal at δ 65.1 due to carbon attached to naphthoxy group (**Fig.6**). We have then subjected 3- α -naphthoxybenzyl alcohol **78a** to gold(III)chloride-catalyzed Friedel-Crafts intramolecular cyclization in dichloromethane as a solvent at room temperature, which proceeded to give 4-aryl substituted chromanes **80a** in 98% yields (**Scheme 35**).



<u>Scheme 35</u>: (i) $3-\alpha$ -Naphthoxybenzyl alcohol (1 mmol), AuCl₃ (1 mol%), CH₂Cl₂, 25 °C, 6 h.




Fig. 6: ¹H and ¹³C NMR spectra of **78a**

To study the generality of the reaction, several 3-aryloxy benzyl alcohols **78a-g** were subjected to AuCl₃-catalyzed Friedel-Crafts intramolecular cyclization the results of which are presented in **Table 8**. 3-Phenoxy benzyl alcohols as well as 3-naphthoxy benzyl alcohols gave good yields. In the case of both electron-donating (**78b**) as well as electron-withdrawing (**78f**) substituted 3-aryloxy benzylalcohols gave the corresponding chromanes in 98% and 90% yields respectively. Notably, substrate cesamoyloxy benzyl alcohol gave the corresponding cyclized product **80g** in 93% yield. However, when chiral 3-phenoxy benzyl alcohol⁵⁴ was employed as substrate, we found no optical induction.

Entry	Substrate (78) Ar	Product (80)	Yield (%) ^b	
a	α-Naphthyl	Ph	98	
b	4-Methylphenyl	Ph Me	98	
c	Phenyl	Ph	96°	
d	β-Naphthyl	Ph	97	
e	4-Chlorophenyl	Cl Ph	93	
f	4-Cyanophenyl	NC Ph	90	
g	Cesamoyl	Ph O O O	93	

Table 8: Synthesis	of 4-phenyl	substituted	chromanes ((80) ^a
	or i phonyi	Substituted	enn onnanes (

The formation of chromanes **80a-g** was confirmed by ¹H and ¹³C-NMR spectroscopy. The ¹H NMR spectrum of **80b** showed signals at δ 4.08-4.16 (m, 3H) for methylene (CH₂-O-*p*-tolyl) and methine (*p*-tolyl-CH-) protons. Its ¹³C-NMR showed a typical signal at δ 41.0 due to carbon attached to phenyl and *p*-tolyl ring (**Fig. 7**).

Reaction conditions: ^a 3-aryloxy benzyl alcohols (1 mmol), AuCl₃ (1 mol%), CH₂Cl₂ (5 mL) 25 °C, 5h; ^b yields refer to isolated yields after column chromatography. ^c Also reaction was carried out with chiral 3-phenoxy benzyl alcohol, however no chiral induction was observed.





Fig. 7: ¹H and ¹³C NMR spectra of 80b

4.3.5 Mechanism

A simplified catalytic cycle shown in **Scheme 36** consists of the following three steps: (1) coordination of oxygen atom of the benzyl alcohol to Au-catalyst; (2) transfer of the hydroxyl group to the metal with concomitant generation of the intermediate carbocation;⁵⁵ (3) trapping of the carbocation by the electron-rich aryloxy ring to produce cyclized product with generation of 1 mole of water.



Scheme 36: Proposed catalytic cycle for gold (III)-catalyzed cyclization of 3-aryloxy benzylalcohols.

4.3.6 Conclusion

In conclusion we have demonstrated that gold (III) chloride is highly effective catalyst for intramolecular Friedel-Crafts reaction of 3-Aryloxy benzyl alcohols to gave 4-aryl substituted chromanes in 90-98% yields.

4.3.7 Experimental Section

General experimental procedure for the preparation of 3-aryloxy benzyl alcohols 78a-g

To a solution of phenol (1.0 mmol) in DMF (5 mL) was added 60% of sodium hydride (0.04 g, 1.0 mmol) dispersed in mineral oil at 25 °C. After five minutes of stirring, 3-hydroxy-3-phenylpropyltosylate **79** (0.309 g 1.0 mmol) in DMF (2 mL) was added via syringe. The reaction mixture was warmed to 70 °C and stirred at the same temperature for 5 h. After completion of reaction (monitored by TLC), it was quenched with aq. NH₄Cl (5 mL) and extracted with ethyl acetate (3×10 ml)). The combined organic layers were washed with saturated solution of brine (10 ml), dried over anhyd. Na₂SO₄, concentrated under reduced pressure to give the crude product, which was then purified

by column chromatography (packed with silica gel 60-120 mesh) using petroleum ether/ ethyl acetate (9:1) as eluents to afford the pure product **78a-g**.

3-Naphthalen-1-yloxy-1-phenylpropan-1-ol (78a)

Yield: 98%; colorless solid m.p.: 88-93 °C; IR (CHCl₃, cm⁻¹): 700, 768, 1068, 1100, 1216, 1269, 1459, 1508, 1580, 2849, 2930, 3019, 3401, 3541; ¹H NMR (200 MHz, CDCl₃): δ 2.24-2.42 (m, 2H), 2.35 (brs, 1H), 4.09-4.23 (m, 1H), 4.28-4.39 (m, 1H), 5.12 (dd, J = 2.6, 5.1 Hz, 1H), 6.78 (d, J = 1.1, 7.1 Hz 1H), 7.27-7.52 (m, 9H), 7.75-7.81 (m, 1H) 8.20-8.25 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 38.4, 65.1, 71.8, 104.6, 120.3, 121.8, 125.1, 125.5, 125.7, 125.8, 126.3, 127.4, 127.5, 128.4, 134.4, 144.1, 154.3; Anal. Calcd for C₁₉H₁₈O₂ requires C, 81.99; H, 6.52; found: C, 81.95; H, 6.60%.

3-p-Tolyloxy-1-phenylpropan-1-ol (78b)

Yield: 98%; colorless liquid; **IR** (CHCl₃, cm⁻¹): 768, 1068, 1100, 1216, 1265, 1459, 1508, 1580, 2849, 2950, 3019, 3401, 3500; ¹H NMR (200 MHz, CDCl₃): δ 2.0-2.22 (m, 2H), 2.26 (s, 3H), 2.96 (brs, 1H), 3.85-3.95 (m, 1H), 3.99-4.10 (m, 1H), 4.86-4.93 (m 1H), 6.74 (d, *J* = 8.6 Hz, 2H), 7.02 (d, *J* = 8.6 Hz, 2H), 7.27-7.31 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ 20.5, 38.5, 65.5, 72.5, 114.4, 125.7, 127.6, 128.5, 129.9, 130.0, 144.2, 156.5; **Anal.** Calcd for C₁₆H₁₈O₂ requires C, 79.31; H, 7.49; found: C, 79.40; H, 7.51%.

3-Phenyl-1-phenylpropan-1-ol (78c)

Yield: 96%; pale yellow liquid; IR (CHCl₃, cm⁻¹): 768, 1063, 1101, 1216, 1263, 1459, 1508, 1580, 2849, 2955, 3015, 3401; ¹H NMR (200 MHz, CDCl₃): δ 2.22-2.49 (m, 2H), 2.50 (brs, 1H), 4.0-4.17 (m, 2H), 4.95-5.03 (m, 1H), 6.87-6.94 (m, 3H), 7.27-7.36 (m, 7H); ¹³C NMR (50 MHz, CDCl₃): δ 39.0, 65.3, 72.6, 114.4, 122.4, 125.3, 127.2, 128.1,

129.3, 138.6, 156.5; **Anal.** Calcd for C₁₅H₁₆O₂ requires C, 78.92; H, 7.06; found: C, 78.95; H, 7.10%.

3-Naphthalen-2-yloxy-1-phenylpropan-1-ol (78d)

Yield: 95%; colorless solid **m.p**.: 90 °C; **IR** (CHCl₃, cm⁻¹): 700, 768, 1068, 1102, 1217, 1269, 1459, 1508, 1580, 2845, 2930, 3019, 3401, 3540; ¹**H NM**R (200 MHz, CDCl₃): δ 2.11 (brs, 1H), 2.29-2.38 (m, 2H), 4.09-4.20 (m, 1H), 4.23-4.34 (m, 1H), 5.04 (dd *J* = 2.8, 5.0 Hz, 1H), 7.11-7.17 (m, 2H), 7.26-7.45 (m, 7H), 7.66-7.76 (m, 3H); ¹³C **NMR** (50 MHz, CDCl₃): δ 38.3, 65.0, 71.7, 106.6, 118.7, 123.6, 125.7, 126.3, 126.7, 127.5, 127.6, 128.4, 128.9, 129.3, 134.5, 144.1, 156.5; **Anal.** Calcd for C₁₉H₁₈O₂ requires C, 81.99; H, 6.52; found: C, 81.90; H, 6.55%.

3-(4-Chlorophenyl)-1-phenylpropan-1-ol (78e)

Yield: 98%; yellow liquid; **IR** (CHCl₃, cm⁻¹): 1070, 1100, 1216, 1265, 1459, 1510, 1582, 2849, 2950, 3019, 3403, 3510; ¹H NMR (200 MHz, CDCl₃): δ 2.12-2.25 (m, 2H), 2.38 (brs, 1H), 3.92-4.0 (m, 2H), 4.05-4.18 (m, 1H), 6.81 (d, *J* = 9.0 Hz, 2H), 7.16-7.39 (m, 7H); ¹³C NMR (50 MHz, CDCl₃): δ 38.1, 65.2, 71.5, 115.6, 116.6, 125.7, 127.6, 128.4, 129.2, 143.9, 157.2; **Anal.** Calcd for C₁₅H₁₅ClO₂ requires C, 68.57; H, 5.75; found: C, 68.50; H, 5.81%.

4-(3-Hydroxy-3-phenylpropoxy)benzonitrile (78f)

Yield: 90%; colorless solid m.p.: 82 °C; IR (CHCl₃, cm⁻¹): 1070, 1100, 1217, 1264, 1459, 1510, 1582, 2211, 2254, 2849, 2950, 3019, 3403; ¹H NMR (200 MHz, CDCl₃): δ
2.09 (brs, 1H), 2.14-2.35 (m, 2H), 4.0-4.11 (m, 1H), 4.17-4.28 (m 1H), 4.93-5.01 (m, 1H), 6.94 (d, J = 8.9 Hz, 2H), 7.28-7.39 (m, 5H), 7.58 (d, J = 8.9 Hz, 2H); ¹³C NMR (50

MHz, CDCl₃): δ 38.0, 65.1, 70.8, 103.6, 115.0, 118.9, 125.5, 127.5, 128.4, 133.7, 143.9, 162.0; **Anal.** Calcd for C₁₆H₁₅NO₂ requires C, 75.87; H, 5.97; N, 5.53; found: C, 75.80; H, 6.02; N, 5.50%.

3-Benzo-1,3-dioxol-6-yloxy-1-phenylpropan-1-ol (78g)

Yield: 93%; brown colored gum; **IR** (CHCl₃, cm⁻¹): 768, 1070, 1100, 1216, 1265, 1455, 1508, 1580, 2849, 2950, 3019, 3430; ¹H NMR (200 MHz, CDCl₃): δ 2.03-2.19 (m, 2H), 2.47 (brs, 1H), 3.92-4.08 (m, 2H), 4.97 (dd, *J* = 2.6, 5.0 Hz 1H), 5.90 (s, 2H), 6.30 (dd, *J* = 2.6, 5.9 Hz 1H), 6.47 (d, *J* = 2.4 Hz, 1H), 6.68 (d, *J* = 8.8 Hz, 1H), 7.27-7.36 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): δ 38.3, 65.9, 71.6, 97.9, 100.9, 105.6, 107.8, 125.6, 127.4, 128.3, 141.6, 144.1, 148.1, 154.0; **Anal.** Calcd for C₁₆H₁₆O₄ requires C, 70.57; H, 5.92; found: C, 70.63; H, 5.81%.

General experimental procedure for the preparation of chromenes (80a-g)

To a solution of gold(III) chloride (3 mg, 1 mol%), in CH_2Cl_2 (5 mL) was added 3aryloxy benzyl alcohols **78a-g** (1.0 mmol) in (2 mL, CH_2Cl_2) at room temperature. The resulting mixture was stirred for 6 h at room temperature. After starting for 5 h, 3-aryloxy benzyl alcohols were consumed. The reaction mixture was then quenched with water and extracted with CH_2Cl_2 (10 mL× 2). The organic layer was washed with brine and dried over anhydrous Na₂SO₄. The solvent was removed and the residue was purified by column chromatography (pet. ether: ethyl acetate = 9: 1) to afford the desired cyclized products in pure form (**80a-g**).

3,4-Dihydro-4-phenyl-2*H*-benzo[*h*]chromene (80a)

Yield: 90%; colorless solid **m.p.:** 82 °C; **IR** (CHCl₃, cm⁻¹): 701, 768, 1023, 1105, 1216, 1262, 1403, 1404, 1491, 1507, 1576, 2882, 2954, 3019, 3057; ¹H **NM**R (200 MHz,

CDCl₃): δ 2.07-2.22 (m, 1H), 2.37-2.53 (m, 1H), 4.26-4.38 (m, 3H), 6.92 (d *J* = 8.1 Hz, 1H), 7.11-7.32 (m, 6H), 7.40-7.50 (m, 2H), 7.68-7.74 (m, 1H), 8.18-8.22 (m, 1H); ¹³C **NMR** (50 MHz, CDCl₃): 31.8, 40.9, 63.6, 117.4, 119.7, 121.8, 125.2, 126.0, 126.4, 127.4, 128.2, 128.4, 128.7, 133.5, 145.9, 150.3; **Anal.** Calcd for C₁₉H₁₆O requires C, 87.66; H, 6.19; found: C, 87.60; H, 6.25%.

3,4-Dihydro-(6-methyl-4-phenyl)-2*H*-chromene (80b)

Yield: 90%; colorless gum; **IR** (CHCl₃, cm⁻¹): 768, 1023, 1107, 1218, 1266, 1403, 1404, 1491, 1508, 1576, 2884, 2954, 3019, 3050; ¹H NMR (200 MHz, CDCl₃): δ 1.97-2.12 (m, 1H), 2.16 (s, 3H), 2.22-2.37 (m, 1H), 4.08-4.16 (m, 3H), 6.61-6.62 (m, 1H), 6.74 (d, *J* = 8.3 Hz, 1H), 6.89-6.94 (m, 1H), 7.10-7.33 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): 20.5, 31.8, 41.0, 63.4, 116.5, 123.8, 126.4, 128.4, 128.5, 128.6, 129.2, 130.7, 145.8, 153.0; **Anal.** Calcd for C₁₆H₁₆O requires C, 85.68; H, 7.19; found: C, 85.70;H, 7.25%.

3,4-Dihydro-4-phenyl-2*H*-chromene (80c)

Yield: 90%; gum; **IR** (CHCl₃, cm⁻¹): 768, 1030, 1107, 1220, 1266, 1406, 1404, 1491, 1508, 1576, 2882, 2950, 3019, 3051; ¹H NMR (200 MHz, CDCl₃): δ 2.04-2.14 (m, 1H), 2.27-2.36 (m, 1H), 4.13-4.20 (m, 3H), 6.73-6.86 (m, 3H), 7.07-7.33 (m, 6H); ¹³C NMR (50 MHz, CDCl₃): 20.5, 31.8, 41.0, 63.4, 116.5, 123.8, 126.4, 128.4, 128.5, 128.6, 129.2, 130.7, 145.8, 153.0; **Anal.** Calcd for C₁₅H₁₄O requires C, 85.68; H, 6.71; found: C, 85.72; H, 6.67%.

3,4-Dihydro-4-phenyl-2*H*-benzo[*h*]chromene (80d)

Yield: 90%; colorless solid **m.p.**: 85 °C; **IR** (CHCl₃, cm⁻¹): 701, 768, 1023, 1105, 1216, 1262, 1403, 1404, 1491, 1507, 1576, 2882, 2954, 3019, 3057; ¹H NMR (200 MHz,

CDCl₃): δ 2.10 (qd, J = 2.2, 6.9 Hz, 1H), 2.43-2.61 (m, 1H), 4.07 (td, J = 2.0, 10.4 Hz, 1H), 4.19-4.28 (m, 1H), 5.11 (d, J = 5.2 Hz, 1H), 7.08-7.28 (m, 8H), 7.44-7.99 (m, 1H), 7.66-7.74 (m, 2H); ¹³C NMR (50 MHz, CDCl₃): 30.9, 36.8, 61.3, 114.1, 119.0, 123.0, 123.1, 126.3, 126.4, 128.4, 128.5, 128.8, 129.2, 133.0, 145.8, 153.0; **Anal.** Calcd for C₁₉H₁₆O requires C, 87.66; H, 6.19; found: C, 87.60; H, 6.25%.

6-Chloro-3,4-dihydro-4-phenyl-2*H*-chromene (80e)

Yield: 90%; pale yellow gum; **IR** (CHCl₃, cm⁻¹): 766, 1030, 1100, 1218, 1260, 1403, 1404, 1491, 1508, 1576, 2884, 2952, 3010, 3045; ¹H NMR (200 MHz, CDCl₃): δ 1.99-2.14 (m, 1H), 2.21-2.36 (m, 1H), 4.09-4.19 (m, 3H), 6.76-6.82 (m, 2H), 7.03-7.13 (m, 3H), 7.16-7.36 (m, 4H); ¹³C NMR (50 MHz, CDCl₃): 31.3, 41.0, 63.8, 118.2, 125.1, 126.0, 127.9, 128.5, 128.6, 130.0, 144.8, 153.7; **Anal.** Calcd for C₁₅H₁₃ClO requires C, 73.62; H, 5.35; found: C, 73.60; H, 5.40%.

3,4-Dihydro-4-phenyl-2*H*-chromene-6-carbonitrile (80f)

Yield: 90%; colorless gum; IR (CHCl₃, cm⁻¹): 768, 1023, 1103, 1218, 1266, 1403, 1410, 1491, 1510, 1576, 2210, 2253, 2884, 2954, 3019, 3054; ¹H NMR (200 MHz, CDCl₃): δ 2.01-2.14 (m, 1H), 2.21-2.39 (m, 1H), 4.06-4.18 (m, 1H), 4.26 (t, J = 5.1 Hz, 2H), 6.90 (d, J = 8.3 Hz, 1H), 7.05-7.15 (m, 3H), 7.26-7.43 (m, 5H); Anal. Calcd for C₁₆H₁₃NO requires C, 81.68; H, 5.57; N, 5.95; found: C, 81.60; H, 5.60; N, 5.91%.

7,8-Dihydro-8-phenyl-6*H*-1,3-dioxalo-4,5-chromene (80g)

Yield: 90%; colorless gum; **IR** (CHCl₃, cm⁻¹): 765, 1023, 1107, 1218, 1266, 1403, 1409, 1491, 15108, 1576, 2884, 2954, 3019, 3057; ¹H NMR (200 MHz, CDCl₃): δ 1.99-2.09 (m, 1H), 2.23-2.35 (m, 1H), 4.03-4.13 (m, 3H), 5.91 (s, 2H), 6.24 (s, 1H), 6.38 (s,

1H), 7.11-7.33 (m, 5H); ¹³C NMR (50 MHz, CDCl₃): 38.4, 66.1, 71.7, 98.1, 101.0, 105.7, 108.0, 125.8, 127.6, 128.5, 141.7, 144.3, 148.2, 154.2; **Anal.** Calcd for C₁₆H₁₄O₃ requires C, 75.57; H, 5.55; found: C, 75.50; H, 5.65%.

4.3.8 References

- (a) Ojima, I. *"The Chemistry of Organic Silicon Compounds"*, Vol. 2, Patai, S.; Rappoport, Z. Wiley/Interscience, New York, **1989**; (b) I. Ojima, Z. Li and J. Zhu, *"Recent Advances in the Hydrosilylation Reaction: Chemisty of Organic Silicon Compounds"*, Vol. 2, Rappoport, Z.; Apeloig, Y.; John Wiley & Sons, Ltd, New York, **1998**.
- 2 Ojima, I.; Nihonyanagi, M.; Nagai, Y. J. Chem. Soc., Chem. Commun.1972, 938.
- 3 (a) Han, J. W.; Tokunaga, N.; Hayashi, T. J. Am. Chem. Soc. 2001, 123, 12915; (b) Jensen, J.
 F.; Svendsen, B. Y.; Cour, T. V.; Pedersen, H. L.; Johannsen, M. J. Am. Chem. Soc. 2002, 124, 4558; (c) Corma, A.; Gonzalez-Arellano, C.; Iglesias, M.; Sanchez, F. Angew. Chem. Int. Ed. 2007, 46, 7820; (d) Shaikh, N. S.; Enthaler, S.; Junge, K.; Beller, M. Angew. Chem. Int. Ed. 2008, 47, 2497.
- 4 Sprengers, J. W.; de Greef, M.; Duin, M. A.; Elsevier, C. J. *Eur. J. Inorg. Chem.* **2003**, 3811.
- 5 (a) Carpentier, J.-F.; Bette, V. *Curr. Org. Chem.* **2002**, *6*, **913**; (b) Riant, O. Mostefa, N.; Courmarcel, J. *Synthesis* **2004**, 2943.
- 6 Ojima, I.; Kogure, T.; Nihonyanagi, M.; Nagai, Y. Bull. Chem. Soc. Jpn. 1972, 45, 3506.
- 7 Caseri, W.; Pregosin, P. S. Organometallics, 1988, 7, 1373.
- 8 Bideau, F. L.; Henique, J.; Samuel, E.; Elschenbroich, C. *Chem. Commun.* 1999, 1397.
- 9 Maifeld, S. V.; Miller, R. L.; Lee, D. Tetrahedron Lett. 2002, 43, 6363.
- 10 Dioumaev, V. K.; Bullock, R. M. Nature, 2003, 424, 530.
- 11 Lipshutz, B. H.; Caires, C. C.; Kuipers, P.; Chrisman, W. Org. Lett. 2003, 5, 3085.
- 12 Lee, D.-W.; Yun, J. Tetrahedron Lett. 2004, 45, 54 I5.
- 13 Gade, L. H.; Cesar, V.; Bellemin-Laponnaz, S. Angew. Chem. Int. Ed. 2004, 43, 1014.
- 14 Song, C.; Ma, C.; Ma, Y.; Feng, W.; Ma, S.; Chai, Q.; Andrus, M. B. Tetrahedron Lett. 2005, 46, 3241.
- 15 Shaikh, N. S.; Enthaler, S.; Junge, K.; Beller, M. *Angew. Chem. Int. Ed.* **2008**, *47*, 2497.
- 16 Dong, H.; Berke, H. Adv. Synth. Catal. 2009, 351, 1783.
- 17 Inagaki, T.; Yamada, Y.; Phong, L. T.; Furuta, A.; Ito, J-I.; Nishiyama, H. Synlett. 2009, 253.

- (a) Diez-Gondlez, S.; Nolan, S. P. *Organic Preparations and Procedures Int.* 2007, *39*, 523;
 (b) Marciniec, B. in Hydrosilylation: A Comprehensive Review on Recent Advances (Eds.: B. Marciniec), Springer, Netherlands, 2009, chap. 9.
- (a) Mirza-Aghayan, M.; Boukherroub, R.; Rahimifard, M. J. Organomet. Chem. 2008, 693, 3567.
- 20 Thakur, V. V.; Ramesh Kumar, N. S. C.; Sudalai, A. Tetrahedron Lett. 2004, 45, 2915.
- 21 Ramesh Kumar, N. S. C.; Victor Paul Raj, I.; Sudalai, A. J. Mol. Cat. A: Chemical, 2007, 269, 218.
- 22 Mirza-Aghayan, M.; Boukherroub, R.; Bolourtchian, M. J. Organomet. Chem. 2005, 690, 2372.
- (a) Kunai, A.; Sakurai, T.; Toyoda, E.; Ishikawa, M.; Yamamoto, Y. Organometallics 1994, 13, 3233; (b) Ferreri, C.; Costantino, C.; Chatgilialoglu, C.; Boukherroub, R.; Manuel, G. J. Organomet. Chem. 1998, 554, 135.
- (a) Wishka, D. G.; Graber, D. R.; Seest, E. P.; Dolak, L. A.; Han, F.; Watt, W.; Morris, J. J. Org. Chem. 1998, 63, 7851. (b) Uenishi, J.; Takagi, T.; Ueno, T.; Hiraoka, T.; Yonemitsu, O.; Tsukube, H. Synlett 1999, 41.
- 25 Gärtner, H.; Salz, U.; Rüchardt, C. Angew. Chem. Int. Ed. Engl. 1984, 23, 162.
- (a) Collomb, P.; Zelewsky, A. V. *Tetrahedron: Asymmetry* 1998, 9, 3911; (b) Uenishi, J.;
 Ueno, T.; Hata, S.; Nishikawa, K.; Tanaka, T.; Watanabe, S.; Yonemitsu, O.; Oae, S. *Heterocycles* 1999, 50, 341.
- 27 Soai, K.; Niwa, S.; Kobayashi, T. J. Chem. SOC., Chem. Commun. 1984, 413.
- 28 Bolm, C.; Zehnder, M.; Bur, D. Angew. Chem. Int. Ed. 1990, 29, 205;
- 29 Hoschino, O.; Ishizaki, M. Chem. Lett. 1994, 1337.
- 30 Orrenius, C.; Mattson, A.; Norin, T. Tetrahedron Asymmetry 1994, 5, 1363.
- 31 Uenishi, J.; Hiraoka, T.; Hata, S.; Nishiwaki, K.; Yonemitsu, O.; Nakamura K.; Tsukube, H. . J. Org. Chem. 1998, 63, 2481.
- 32 Okano, K.; Murata, K.; Ikariya, T. Tetrahedron Lett. 2000, 41, 9277.
- 33 Garrett, M. D.; Scott, R.; Sheldrake, G. N. Tetrahedron Asymmetry 2002, 13, 2201.
- 34 Mazet, C.; Roseblade, S.; Ko1hler, V.; Pfaltz, A. Org. Lett. 2006, 8, 1879.
- 35 Katada, M. J. Pharm. Soc. Jpn., 1947,67, 51.
- 36 Boekelheide, V.; Linn, W.; J. J. Am. Chem. Soc. 1954, 76, 1286.
- 37 McKillop, A.; Bhagrath, M.; K. Heterocycles, 1985, 23, 1697.
- 38 Fontenas, C.; Bejan, E.; Haddou, H. A.; Balavoine, G. G. A. Synth. Commn. 1995, 25, 629.
- Andreotti, D.; Miserazzi, E.; Nalin, A.; Pozzan, A.; Profeta, R.; Spada, S. *Tetrahedron Lett.* 2010, 51, 6526.
- 40 Li, J. Name Reactions in Heterocyclic Chemistry; John Wiley & Sons: NJ, 2005.
- 41 (a) Oae, S.; Kitao, Y. J. Am. Chem. Soc. 1962, 84, 3359; (b) Oae, S.; Kozuka, S. Tetrahedron

1964, *20*, 2671;

- 42 Bodalski, R.; Katritzky, A. R. J. Chem. Soc. (B) 1968, 831.
- Heller, B.; Redkin, D.; Gutnov, A.; Fischer, C.; Bonrath, W.; Karge, R.; Hapke, M. Synthesis
 2008, 69.
- (a) Ellis, G. P.; Lockhart, I. M. *The Chemistry of Heterocyclic Compounds, Chromenes, Chromanones, and Chromones*; Ellis, G. P., Ed.; Wiley-VCH: New York, 2007; Vol. 31, pp 1.
 (b) Horton, D. A.; Bourne, G. T.; Smythe, M. L. *Chem. Rev.* 2003, 103, 893. (c) Geen, G. R.; Evans, J. M.; Vong, A. K. *Comprehensive Heterocyclic Chemistry II: Pyrans and their Benzo Derivatives: Applications*; Katritzky, A. R., Rees, C.W., Scriven, E. F. V., Eds.; Pergamon Press: Oxford, UK, 1996; Vol. 5, pp 469. (d) Neugebauer, R. C.; Uchiechowska, U.; Meier, R.; Hruby, H.; Valkov, V.; Verdin, E.; Sippl, W.; Jung, M. J. Med. Chem. 2008, 51, 1203–1213. (e) Posakony, J.; Hirao, M.; Stevens, S.; Simon, J. A.; Bedalov, A. J. Med. Chem. 2004, 47, 2635–2644. (f) Wilkinson, J.; Foretia, D.; Rossington, S.; Heagerty, A.; Leonard, J.; Hussain, N.; Austin, C. *Eur. J. Pharmmacol.* 2007, 561, 160. (g) Maloney, D. J.; Deng, J. Z.; Starck, S. R.; Gao, Z.; Hecht, S. M. J. Am. Chem. Soc. 2005, 127, 4140. (h) Kumar, S.; Malachowski, W. P.; DuHadaway, J. B.; LaLonde, J. M.; Carroll, P. J.; Jaller, D.; Metz, R.; Prendergast, G. C.; Muller, A. J. J. Med. Chem. 2008, 51, 1706.
- (a) Hashmi, A. S. K. *Gold Bull.* 2004, *37*, 51; (b) Arcadi, A.; Di Giuseppe, S. *Curr. Org. Chem.* 2004, *8*, 795; (c) Zhang, L.; Sun, J.; Kozmin, S. A. *Adv. Synth. Catal.* 2006, *348*, 2271; (d) Bond, G. C.; Louis, C.; Thompson, D. T. *Catalysis*; Gold Imperial College Press: London, 2006; (e) Fu[¬]rstner, A.; Davies, P. W. *Angew. Chem., Int. Ed.* 2007, *46*, 3410; (f) Gorin, D. J.; Toste, F. D. *Nature* 2007, *446*, 395; (g) Hashmi, A. S. K. *Chem. Rev.* 2007, *107*, 3180.
- (a) Olah, G. A. Friedel-Crafts and Related Reactions; Wiley: New York, 1973; (b) Bandini,
 M.; Melloni, A.; Umani-Ronchi, A. Angew. Chem., Int. Ed. 2004, 43, 550.
- 47 Rindfusz, R. E.; Ginnings, P. M.; Harnack, V. L. J. Am. Chem. Soc. 1920, 42, 157.
- 48 Bradsher, C. K.; Reames, D. C. J. Org. Chem. 1981, 46, 1384.
- 49 Matsui, M.; Yamamoto, H. Bull. Chem. Soc. Jpn. 1995, 68, 2663.
- 50 Trost, B. M.; Shen, H. C.; Dong, L.; Surivet, J-P. J. Am. Chem. Soc. 2003, 125, 9276.
- 51 Shi, Z.; He, C. J. Am. Chem. Soc. 2004, 126, 13596.
- 52 Volonterio, A.; Zanda, M. Tetrahedron Lett. 2005, 46, 8723.
- 53 Hong , D. J.; Kim, D. W.; Chi, D. Y. Tetrahedron Lett. 2010, 51, 54.
- Ali, I. S.; Sudalai, A. *Tetrahedron Letters*, **2002**, *43*, 5435.
- 55 Cuenca, A. B.; Mancha, G.; Asensio, G.; Medio-Sim, M. Chem. Eur. J. 2008, 14, 1518.

PUBLICATIONS

- 1 NaIO₄-KI-NaN₃ as a new reagent system for C-H functionalization in hydrocarbons. **Chouthaiwale, P. V.**; Suryavanshi, G.; Sudalai, A. *Tetrahedron Lett.* **2008**, *49*, 6401.
- 2 Cu(OTf)₂-catalyzed α-halogenation of ketones with 1,3-dichloro 5,5'dimethylhydantoin and *N*-bromosuccinimide. Jagdale, A. R.; Chouthaiwale P. V.; Sudalai, A. *Ind. J. Chem. Section B*, **2009**, *48*, 1424-1430.
- 3 Formal synthesis of (-)-anisomycin *via* organocatalysis. Chouthaiwale, P. V.; Kotkar S. P.; Sudalai, A. *ARKIVOC* 2009, (*ii*), 88-94.
- 4 A concise enantioselective synthesis of (+)-decarestrictine L via proline-catalyzed sequential α-aminooxylation and Horner–Wadsworth–Emmons olefination. Rawat, V.; Chouthaiwale, **P. V.**; Suryavanshi, G.; Sudalai, A. *Tetrahedron: Asymmetry* **2009**, *20*, 2173–2177.
- 5 Co(III)(salen)-catalyzed HKR of two stereocentered alkoxy- and azido epoxides: a concise enantioselective synthesis of (S,S)-reboxetine and (+)-epi-cytoxazone. Reddy, R. S.; Chouthaiwale, P. V.; Suryavanshi, G.; Chavan, V. B.; Sudalai, A. *Chem. Commun.* 2010, 46, 5012–501.
- 6 NaIO₄/LiBr-mediated aziridination of olefins using chloramine-T. Karabal, P.; **Chouthaiwale, P. V.**; Shaikh, T. M. S.; Suryavanshi, G.; Sudalai, A. *Tetrahedron Lett.* **2010**, *51*, 6460-6462.
- 7 A facile enantioselective synthesis of (S)-N-(5-chlorothiophene-2-sulfonyl)- β , β -diethylalaninol via proline-catalyzed asymmetric α -aminooxylation and α -amination of aldehyde. Rawat, V.; Chouthaiwale, P. V.; Suryavanshi, G.; Chavan, V. B.; Sudalai, A. *Tetrahedron Letters* 2010, *51*, 6565–6567.
- 8 Regiospecific Azidoiodination of Alkenes with Sodium Periodate, Potassium Iodide, and Sodium Azide: A High-Yield Synthesis of β-Iodoazides. Chouthaiwale, P. V.; Karabal, P.; Suryavanshi, G.; Sudalai, A. Synthesis 2010, 22, 3879–3882.
- 9 Cobalt-Catalyzed HKR of Alkoxy- and Azido Epoxides: Reddy, R. S.; Chouthaiwale, P. V.; Suryavanshi, G.; Chavan, V. B.; Sudalai, A. Highlights in current synthetic organic chemistry: Synfacts 2010, 10, 1146.
- 10 Palladiun-Catalyzed Selective Hydrosilylation of Aryl ketones and Aldehyde: Chouthaiwale, P. V.; Rawat, V.; Sudalai, A. (Manuscript under preparation).
- 11 Enantioselective synthesis of (+) -L-733,060 *via* Hydrolytic Kinetic Resolution of Azido epoxide: **Chouthaiwale, P. V.;** Sudalai, A. (Manuscript under preparation)
- 12 NaIO₄-NaN₃-mediated 1,2-Diazidation of Olefins and α,α -Diazidation of Aryl ketones: Chouthaiwale, P. V.; Sudalai, A.(Manuscript under preparation).
- 13 Synthesis of 4-Substituted Chromanes *via* Gold-catalyzed Intramolecular Friedel-Crafts Reaction: Chouthaiwale, P. V.; Sudalai, A. (Manuscript under preparation).